---
document_datetime: 2024-06-14 12:21:57
document_pages: 181
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/qalsody-epar-public-assessment-report_en.pdf
document_name: qalsody-epar-public-assessment-report_en.pdf
version: success
processing_time: 101.8079315
conversion_datetime: 2025-12-23 04:56:37.07646
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 February 2024 EMA/276404/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Qalsody

International non-proprietary name: tofersen

Procedure No. EMEA/H/C/005493/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................8                                   |                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8        |                                                                                                          |
| 1.2. Legal basis, dossier content...................................................................................8        |                                                                                                          |
| 1.3. Information on Paediatric requirements...................................................................8              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................8                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................8 |                                                                                                          |
| 1.5. Applicant's request(s) for consideration...................................................................9            |                                                                                                          |
| 1.5.1. Marketing authorisation under exceptional circumstances                                                               | .......................................9                                                                 |
| 1.5.2. New active Substance status...............................................................................9           |                                                                                                          |
| 1.6. Protocol assistance                                                                                                     | ...............................................................................................9         |
| 1.7. Steps taken for the assessment of the product.........................................................9                 |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ..............................................................................11                         |
| 2.1. Problem statement                                                                                                       | .............................................................................................11          |
| 2.1.1. Disease or condition.........................................................................................11       |                                                                                                          |
| 2.1.2. Epidemiology and risk factors............................................................................12           |                                                                                                          |
| 2.1.3. Aetiology and pathogenesis                                                                                            | ..............................................................................12                         |
| 2.1.4. Clinical presentation, diagnosis and prognosis                                                                        | .....................................................12                                                  |
| 2.1.5. Management...................................................................................................13       |                                                                                                          |
| 2.2. About the product                                                                                                       | ..............................................................................................13         |
| 2.3. Type of Application and aspects on development....................................................13                    |                                                                                                          |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................14     |
| 2.4.1. Active Substance.............................................................................................14       |                                                                                                          |
| 2.4.2. Finished Medicinal Product                                                                                            | ................................................................................18                       |
| 2.4.3. Discussion on chemical and pharmaceutical aspects.............................................21                      |                                                                                                          |
| 2.4.4. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................22                                                                                 |
| 2.4.5. Recommendation(s) for future quality development.............................................22                       |                                                                                                          |
| 2.5. Non-clinical aspects                                                                                                    | ............................................................................................22           |
| 2.5.1. Introduction....................................................................................................22    |                                                                                                          |
| 2.5.2. Pharmacology                                                                                                          | .................................................................................................22      |
| 2.5.3. Pharmacokinetics.............................................................................................29       |                                                                                                          |
| 2.5.4. Toxicology                                                                                                            | ......................................................................................................31 |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................35                                              |
| 2.5.6. Discussion on non-clinical aspects......................................................................36            |                                                                                                          |
| 2.5.7. Conclusion on the non-clinical aspects................................................................38              |                                                                                                          |
| 2.6. Clinical aspects                                                                                                        | ..................................................................................................38     |
| 2.6.1. Introduction....................................................................................................38    |                                                                                                          |
| 2.6.2. Clinical pharmacology                                                                                                 | ......................................................................................40                 |
| 2.6.3. Discussion on clinical pharmacology...................................................................47              |                                                                                                          |
| 2.6.4. Conclusions on clinical pharmacology.................................................................47               |                                                                                                          |
| 2.6.5. Clinical efficacy                                                                                                     | ...............................................................................................47        |
| 2.6.6. Discussion on clinical efficacy..........................................................................             | 117                                                                                                      |
| 2.6.7. Conclusions on the clinical efficacy...................................................................               | 130                                                                                                      |
| 2.6.8. Clinical safety................................................................................................       | 131                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.6.9. Discussion on clinical safety ............................................................................      | 149                                                                                              |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| 2.6.10. Conclusions on the clinical safety...................................................................          | 155                                                                                              |
| 2.7. Risk Management Plan ......................................................................................       | 156                                                                                              |
| 2.7.1. Safety concerns.............................................................................................    | 156                                                                                              |
| 2.7.2. Pharmacovigilance plan ..................................................................................       | 156                                                                                              |
| 2.7.3. Risk minimisation measures............................................................................          | 157                                                                                              |
| 2.7.4. Conclusion....................................................................................................  | 158                                                                                              |
| 2.8. Pharmacovigilance............................................................................................     | 158                                                                                              |
| 2.8.1. Pharmacovigilance system..............................................................................          | 158                                                                                              |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                          | ................................... 158                                                          |
| 2.9. Product information ..........................................................................................    | 159                                                                                              |
| 2.9.1. User consultation...........................................................................................    | 159                                                                                              |
| 2.9.2. Labelling exemptions .....................................................................................      | 159                                                                                              |
| 2.9.3. Additional monitoring.....................................................................................      | 159                                                                                              |
| 3. Benefit-Risk Balance............................................................................159                 |                                                                                                  |
| 3.1. Therapeutic Context .........................................................................................     | 159                                                                                              |
| 3.1.1. Disease or condition.......................................................................................     | 159                                                                                              |
| 3.1.2. Available therapies and unmet medical need.....................................................                 | 160                                                                                              |
| 3.1.3. Main clinical studies                                                                                           | ....................................................................................... 160      |
| 3.2. Favourable effects                                                                                                | ............................................................................................ 160 |
| 3.3. Uncertainties and limitations about favourable effects...........................................                 | 163                                                                                              |
| 3.4. Unfavourable effects.........................................................................................     | 164                                                                                              |
| 3.5. Uncertainties and limitations about unfavourable effects                                                          | ....................................... 166                                                      |
| 3.6. Effects Table.................................................................................................... | 167                                                                                              |
| 3.7. Benefit-risk assessment and discussion...............................................................             | 170                                                                                              |
| 3.7.1. Importance of favourable and unfavourable effects............................................                   | 170                                                                                              |
| 3.7.2. Balance of benefits and risks...........................................................................        | 172                                                                                              |
| 3.7.3. Additional considerations on the benefit-risk balance .........................................                 | 172                                                                                              |
| 3.8. Conclusions ..................................................................................................... | 176                                                                                              |
| 4. Recommendations...............................................................................176                   |                                                                                                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

aPPT

activated partial thromboplastin time

A5V

p.Ala5Val

ABL

Pooled group from Study 101 Part A and B and Study 102

ADA

Antidrug antibody

ADR

Adverse drug reaction

(S)AE

(Serious) Adverse event

AESI

Adverse events of special interest

ALT

Alanine transaminase

ALS

Amyotrophic lateral sclerosis

ALSAQ-5

ALS Assessment Questionnaire

ALSFRS-R

ALS Functional Rating Scale-Revised

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

ASO

Antisense oligonucleotide

AST

Aspartate transaminase

AUC(0-24/48/last)

Area under the concentration time curve (from time 0 to 24/48 hours / to the last measured concentration)

BSA

Body surface area

BUN

Blood urea nitrogen

CC

Correlation coefficients

CDF

Cumulative Distribution Function

CDP

Clinical development program

CHL

Chinese Hamster Lung

CI

Confidence interval

CIR

Copy-increment-from-reference

CL

Clearance

CL

Pooled group from Study 101 Part C and Study 102

CL1

Early start tofersen treatment group (pooled group from Study 101 Part C tofersen and study 102)

CL2

Placebo-delayed start tofersen treatment group (pooled group from Study Part C placebo and Study 102)

CMA

Conditional marketing authorisation

CMAP

Compound muscle action potential

Cmax

Maximum observed concentration

CNS

Central nervous system

CR

Copy-reference

CSA

Country-specific amendment

CSF

Cerebrospinal fluid

CTCAE

Common Terminology Criteria for Adverse Events

CYP450

Cytochrome P450

<div style=\"page-break-after: always\"></div>

| DART     | Developmental and reproductive toxicity    |
|----------|--------------------------------------------|
| DDI      | Drug-drug interaction                      |
| DNA      | Deoxyribonucleic acid                      |
| EAP      | Expanded access program                    |
| EC 50    | half maximal effective concentration       |
| ECG      | electrocardiogram                          |
| ED 50    | Half-maximal effective dose                |
| EFD      | Embryo-foetal development                  |
| ELISA    | Enzyme-linked immunosorbent assay          |
| EMA      | European Medicines Agency                  |
| EOS      | End of study                               |
| EQ-5D-5L | EuroQol 5 Dimension, 5 Level Questionnaire |
| ERA      | Environmental risk assessment              |
| ES       | Early start                                |
| fALS     | familial ALS                               |
| FDA      | United States Food and Drug Administration |
| FEFD     | Fertility and embryo-foetal development    |
| FPS      | Faster progressing group                   |
| FSS      | Fatigue Severity Scale                     |
| GD       | Gestation day                              |
| GGT      | Gamma-glutamyl transferase                 |
| HCP      | Health care professional                   |
| HED      | Human equivalent dose                      |
| hERG     | human ether-à-go-go related gene           |
| HHD      | Hand held dynamometry                      |
| HR       | Hazard ratio                               |
| K A      | Absorption rate                            |
| IC 50    | Half-maximal inhibitory concentration      |
| ICV      | Intracerebroventricular                    |
| IDMC     | Independent Data Monitoring Committee      |
| IIV      | Inter-individual variability               |
| IT       | intrathecal                                |
| J2R      | Jump to reference                          |
| JRT      | Joint rank test                            |
| K        | Elimination rate                           |
| LD       | Lactation day                              |
| LFT      | Liver function test                        |
| LS       | least squares                              |
| LTE      | Long-term extension                        |
| MAD      | Multiple ascending dose                    |
| MAR      | Missing at random                          |

MAUEC

Marketing Authorisation under Exceptional Circumstances

M(C)ID

Minimally (clinically) important difference

MI

multiple imputation

(m)ITT

(modified) intent-to-treat

MRI

Magnetic Resonance Imaging

mRNA

messenger ribonucleic acid

N/A

Not applicable

NCA

Non-compartmental analysis

NE

Not estimable

NfH

Neurofilament heavy chain

NfL

Neurofilament light chain

NHP

Nonhuman primate

NOAEL

No observed adverse effect level

non-mITT

Non-modified intent-to-treat

NR

Not reported

OLE

Open-label extension

PBT

Persistence bioaccumulation toxicity

PD

Pharmacodynamic(s)

PK

Pharmacokinetic(s)

pNfH

Phosphorylated neurofilament heavy chain

popPK

Population PK

PRO

Patient-reported outcome

PT

Preferred term

PV

permanent ventilation

SAD

single-ascending dose

sALS

sporadic ALS

SAP

Statistical analysis plan

SC

Subcutaneous

SD

Standard deviation

SE

Standard error

SMQ

Standardized Medical Dictionary for Regulatory Activities Query

SOB

Specific Obligation

SOC

System organ class

SOD1

Superoxide dismutase-1

SOD1-ALS

ALS associated with a mutation in the SOD1 gene

SPS

Slow progressing group

Study 101 Part A

Study 233AS101 Part A SAD

Study 101 Part B

Study 233AS101 Part B MAD

Study 101 Part C

Study 233AS101 Part C Phase 3

Study 102

Study 233AS102 LTE

SVC

Slow vital capacity

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| t 1/2         | Elimination half-life             |
|---------------|-----------------------------------|
| TEAE          | Treatment-emergent adverse event  |
| t max         | Time of maximal concentration     |
| TK            | Toxicokinetic                     |
| V central V 2 | Central volume of distribution    |
| V peripheral  | Peripheral volume of distribution |
| ULN           | Upper Limit of Normal             |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Biogen  Netherlands  B.V.  submitted  on  31  October  2022  an  application  for  marketing authorisation to the European Medicines Agency (EMA) for Qalsody, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 November 2019.

Qalsody  was  designated  as  an  orphan  medicinal  product  EU/3/16/1732  on  29  August  2016  in  the following condition: treatment of amyotrophic lateral sclerosis.

The  applicant  applied  for  the  following  indication:  the  treatment  of  adults  with  amyotrophic  lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Qalsody as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website:

https://www.ema.europa.eu/en/medicines/human/EPAR/Qalsody

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0337/2018 on the granting of a product-specific waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. Marketing authorisation under exceptional circumstances

The applicant requested consideration of its application for a marketing authorisation under exceptional circumstances in accordance with Article 14(8) of the above-mentioned Regulation.

## 1.5.2. New active Substance status

The applicant requested the active substance tofersen contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Protocol assistance

The applicant received the following protocol assistance on the development relevant for the indication subject to the present application:

| Date          | Reference                    | SAWP co-ordinators                             |
|---------------|------------------------------|------------------------------------------------|
| 26 April 2019 | EMEA/H/SA/4090/1/2019/PA/III | Dr. Marion Haberkamp Dr. Armando Magrelli      |
| 25 June 2020  | EMEA/H/SA/4090/2/2020/PA/I   | Dr. Marion Haberkamp Dr. Finbarr Patrick Leacy |

The protocol assistance pertained to the following quality, non-clinical, and clinical aspects.

- Sufficiency of the manufacturing process, analytical and facility for registration of the ready-to-fill drug substance; whether the drug substance process development and validation programs have demonstrated  the  ability  to  consistently  deliver  ready-to-fill  drug  substance;  the  proposed adjustments  to  presentation  of  the  data  reflecting  the  facility,  process  and  control  strategy  for tofersen manufacture in a modified CTD content structure.
- Adequacy of the proposed non-clinical data package for MAA.
- The design of the planned pivotal study and, in particular, the population, primary and secondary endpoints, dose selection, study duration, sample size and statistical analysis; the proposed clinical data package for MAA.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Martina Weise

Co-Rapporteur:  Alexandre Moreau

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                                                              | 31 October 2022   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                                                | 01 December 2022  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                                                            | 20 February 2023  |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                                                         | 06 March 2023     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                                                            | 03 March 2023     |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                 | 30 March 2023     |
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:                                                 |                   |
| - A GCP inspection at two clinical sites, one in Germany, one in France and the sponsor in the USA were conducted between 20 Feb and 31 Mar 2023. The outcome of the inspection carried out was issued on 05 June 2023. | 05 June 2023      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                     | 13 July 2023      |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                                                         | 21 August 2023    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                                | 31 August 2023    |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                                                 | 14 September 2023 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                                         | 09 October 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                                                | 25 October 2023   |
| SAG/Expert group (were convened to address questions raised by the CHMP on The CHMP considered the views of the SAG/Expert group as presented in the minutes of this meeting.                                           | 30 October 2023   |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                                                 | 09 November 2023  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                                         | 14 December 2024  |

<div style=\"page-break-after: always\"></div>

| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                                                                                                               | 10 January 2024   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Qalsody on                                                                                                | 22 February 2024  |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                                                                                                                           | 22 February 2024  |
| The European Commission returned the Opinion to the Agency, requesting to further substantiate the recommendation to grant a marketing authorisation under exceptional circumstances for Qalsody                                                                                       | 22 March 2024     |
| The CHMP, in the light of the available scientific data and scientific argumentations, considered that the conditions for authorisation under exceptional circumstances are fulfilled and adopted a revised positive Opinion recommending the granting of the marketing authorisation. | 19 April 2024     |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Amyotrophic lateral sclerosis  (ALS),  first  described by  Charcot  in  19 th   century,  (also  known  as  \"Lou Gehrig's disease\") is a rare, progressive, and ultimately fatal neurodegenerative disease that causes loss of  upper  and  lower  motor  neurons  and  their  axons  within  the  cortex,  brainstem,  spinal  cord,  and peripheral nervous system. The loss of motor neurons leads to progressive loss of muscle mass, strength, and function in bulbar, respiratory, and limb muscles, typically leading to paralysis and ultimately death from respiratory failure within approximately 3 years of symptom onset (with medians from different studies ranging from 1.6 to 5.2 years). Long survivors (defined as &gt;8 years from diagnosis) have also been reported recently in a cohort in Scotland (Leighton et al 2022). Disease progression for individual mutations is variable, with survival ranging from less than a year to over 20 years (Bali 2017; Cudkowicz 1997).

ALS may present in any anatomical region and spread throughout the body with variable speeds and patterns in different patients. ALS is a disease with limited treatment options.

Functional decline and death are inevitable unless tracheostomy and mechanical ventilation are elected to support life, although these interventions do not stop or slow the decline in physical independence.

SOD1-ALS  is  a  primarily  autosomal-dominant  disorder  representing  approximately  2%  of  the  ALS population. In these patients, mutations in SOD1 gene lead to accumulation of a toxic form of SOD1 protein. The natural history of SOD1-ALS is highly variable with a mean onset of 49.7 ± 12.3 years and mean disease duration of 4.6 (1.4 for A4V and 6.6 for non-A4V) years.

The target indication is: Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

<div style=\"page-break-after: always\"></div>

## 2.1.2. Epidemiology and risk factors

ALS is a rare disease. The global prevalence of ALS is estimated to be approximately 4.42 per 100,000.

ALS has  historically  been  classified  as  familial  (fALS;  5%  to  10%  of  ALS  cases)  or  sporadic  (sALS; approximately 90% to 95% of ALS cases) based on the presence or absence of a known family history. However, both fALS (approximately 70%) and sALS (approximately 10%) can be caused by genetic mutations. This is thought to be attributable, at least in part, to certain limitations, including the lack of a standardized definition of what constitutes a family history, challenges with obtaining a complete and accurate  family  history,  and  multiple  reasons  why  a  family  history  of  ALS  could  be  missed  during diagnosis (e.g., small family size or reduced penetrance).

In approximately 2% of people living with ALS, the disease is attributed to mutation(s) in the gene encoding the enzyme SOD1. Applying the pooled ALS incidence and prevalence rate estimates for Europe to  an  additional  15  European countries, the estimated numbers are 314 incident and 844 prevalent SOD1-ALS cases across 37 European countries. Based on these estimates, the prevalence and incidence rates of SOD1-ALS in Europe can be calculated as 0.12 and 0.04, respectively.

## 2.1.3. Aetiology and pathogenesis

The aetiology of ALS is unknown. A number of potential mechanisms have been proposed including abnormal RNA processing, disorders of protein quality control, excitotoxicity, cytoskeletal derangements, mitochondrial  dysfunction,  viral  infections,  apoptosis,  growth  factor  abnormalities,  inflammatory responses, and others.

The  disease  is  attributed  to  mutation(s)  in  the  gene  encoding  the  enzyme  SOD1.  Over  200  SOD1 mutations associated with ALS have been identified to date, with varying degrees of evidence about pathogenicity. All SOD1 variants associated with ALS (&gt; 200 identified to date) are assumed to cause SOD1 gain of function; i.e., they lead to an accumulation of mutant SOD1 protein that is believed to underlie  the  pathogenicity  of  SOD1  ALS.  These  mutations  primarily  follow  an  autosomal-dominant inheritance pattern, though the p.Asp91Ala (D91A; D90A) mutation most prevalent in the Scandinavian population also displays recessive inheritance. The SOD1 gene encodes an abundant dimeric enzyme, copper/zinc  superoxide  dismutase  (Cu/Zn  SOD  or  SOD1),  which  catalyses  the  transmutation  of superoxide (O2-) into oxygen (O2) and hydrogen peroxide (H2O2).

ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear, leading to retrograde axonal loss and gliosis in the corticospinal tract. This gliosis results in the bilateral white matter changes sometimes seen in the brain magnetic resonance imaging (MRI) of patients with ALS. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large, myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping.

## 2.1.4. Clinical presentation, diagnosis and prognosis

The loss of motor neurons results in the primary clinical symptoms and signs of ALS. These may produce impairment affecting limb, bulbar, axial, and respiratory function.

The clinical hallmark of ALS is the combination of upper and lower motor neuron signs and symptoms. The upper motor neuron findings of weakness with slowness, hyperreflexia, and spasticity result from degeneration of frontal lobe motor neurons located in the motor strip (Brodmann area 4) and their axons traversing the corona radiata, internal capsule, cerebral peduncles, pontine base, medullary pyramids, and the lateral corticospinal tracts of the spinal cord. The lower motor neuron findings of weakness,

<div style=\"page-break-after: always\"></div>

atrophy or amyotrophy, and fasciculations are a direct consequence of degeneration of lower motor neurons in the brainstem and spinal cord producing muscle denervation.

The natural history of SOD1-ALS is highly variable and generally poorly characterized due to the rarity of the disease and limited data availability. The rapidity of disease progression also varies substantially across SOD1 mutation types.

## 2.1.5. Management

There is a high unmet medical need for effective therapies that preserve function and prolong life for people living with ALS. Functional decline and death are inevitable unless tracheostomy and mechanical ventilation are elected to support life, although these interventions do not stop or slow the decline in physical independence. Symptomatic management includes treatment options for pain, cramps, excess saliva, spasticity, fatigue, pseudobulbar affect, anxiety, and insomnia; therapy (physical, occupational, and speech); and ventilation assistance.

Riluzole, the most widely approved ALS treatment, received its first global approval for treatment of ALS in  1995  (US)  based  on  2  studies  that  demonstrated  that  the  time  to  tracheostomy  or  death  was approximately 2 months longer in participants receiving riluzole than in those receiving placebo.

Edaravone received its first approval for the treatment of ALS in 2015 in Japan based on a single study in Japanese patients with ALS of Grade 1 or 2 in the Japan ALS Severity Classification. In Europe, a MA application was filed (EMEA/H/C/004938) and later withdrawn in 2019. Edaravone (Radicava) is not approved  in  the  EU.  Edaravone  is  available  through  a  compassionate  use  programme  in  some  EU countries.

Sodium phenylbutyrate/ursodoxicoltaurine (AMX0035 also called taurusodiol; tradename Albrioza and Relyvrio) was recently approved in Canada and the US for the treatment of ALS. In EU, a MA application was filed (EMEA/H/C/005901) but received a final negative opinion on 12 October 2023.

## 2.2. About the product

Tofersen is a 20-base residue (20-mer) ASO that contains 15 phosphorothioate diester and 4 phosphate diester linkages.

Tofersen is complementary to a portion of the 3′ untranslated region of the messenger ribonucleic acid (mRNA) for human SOD1, binding by Watson-Crick base pairing (hybridisation). This hybridisation of tofersen to the cognate mRNA results in RNase-H-mediated degradation of the mRNA for SOD1, which reduces the amount of SOD1 protein synthesis and accumulation.

The recommended dose is 100 mg of tofersen per treatment.

Tofersen treatment should be initiated with 3 loading doses administered at 14-day intervals.

A maintenance dose should be administered once every 28 days thereafter.

Qalsody is administered as an intrathecal bolus injection using a lumbar puncture needle over 1 to 3 minutes.

## 2.3. Type of Application and aspects on development

The applicant requested consideration of its application for a Marketing Authorisation under exceptional circumstances in accordance with Article 14(8) of the above-mentioned Regulation based on inability to

<div style=\"page-break-after: always\"></div>

provide comprehensive efficacy and safety data due to rarity of the indication. The SOD1-ALS is an ultrarare condition. The applicant estimates that there are less than 1000 prevalent cases in the EU. It is pointed out that additional  placebo-controlled  studies  in  symptomatic  SOD1  ALS  are  not  considered operationally feasible. Thus, the applicant considers that it will not be possible to provide comprehensive data on the efficacy and safety under normal conditions of use.

## 2.4. Quality aspects

The  finished  product  is  presented  as  solution  for  intrathecal  injection  containing  100  mg/15  mL  of tofersen as active substance. Each ml contains 6.7 mg of tofersen.

Other ingredients are sodium dihydrogen phosphate dihydrate, disodium phosphate, sodium chloride, potassium  chloride,  calcium  chloride  dihydrate,  magnesium  chloride  hexahydrate,  and  water  for injection.

The  product  is  available  in  a  20  ml  Type  I  glass  vial  closed  with  a  chlorobutyl  rubber  stopper  and aluminium overseal with a flip-off plastic button.

## 2.4.1. Active Substance

## 2.4.1.1. General Information

Tofersen is a 20-base residue (20-mer) 5-10-5 MOE gapmer mixed backbone oligonucleotide. Of the nineteen internucleotide linkages, fifteen are 3'-O to 5'-O phosphorothioate diesters, and four are 3'-O to 5'-O phosphate diesters. Ten of the twenty sugar residues are 2'-deoxy-D-ribose and the remainder are  2'-O-(2-methoxyethyl)-D-ribose  (MOE).  The  residues  are  arranged  so  that  there  are  five  MOE nucleosides at the 5' and 3'-ends of the molecule flanking a gap of ten 2'- deoxynucleosides.

The chemical name of tofersen is 2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O → 5'-O)-2'-O-(2methoxyethyl)-adenylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)guanylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O → 5'-O)-2'-deoxy-P-thiothymidylyl-(3'-O → 5'-O)2'-deoxy-P-thioadenylyl-(3'-O → 5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O → 5'-O)-2'-deoxy-P-thioadenylyl-(3'O → 5'-O)-2'-deoxy-P-thiothymidylyl-(3'-O → 5'-O)-2'-deoxy-P-thiothymidylyl-(3'-O → 5'-O)-2'-deoxy-P-thiothymidylyl(3'-O → 5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O → 5'-O)-2'-deoxy-P-thiothymidylyl-(3'-O → 5'-O)-2'-deoxy-Pthioadenylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-Pthioadenylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-guanylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-5-methyl-Pthiocytidylyl-(3'-O → 5'-O)-2'-O-(2-methoxyethyl)-5-methyluridine corresponding to the molecular formula C230H317N72O123P19S15 (free acid).

The tofersen sequence can be written in shorthand as follows:

5′ - Me CsAoGsGoAsTsAs Me CsAsTsTsTs Me CsTsAs Me CoAsGo Me Cs Me U3′

The underlined residues are MOE nucleosides. The locations of phosphorothioate and phosphate diester linkages are designated by s and o, respectively.

It has a relative molecular mass of 7127.86 g/mol and the following structure (Figure 1):

<div style=\"page-break-after: always\"></div>

Figure 1: active substance structure

<!-- image -->

The chemical structure of tofersen was elucidated by a combination of ion-pair high performance liquid chromatography, 1H-/13C-/31P-NMR, TOF-MS, LC-TOF-MS, MS/MS, Tm ,CD and UV spectroscopy. NMR results were consistent with the expectations for the active substance structure. Also, accurate mass, sequence analysis and melting temperature indicate the correct primary structure.

Tofersen exhibits stereoisomerism due to the presence of 15 chiral centres. Tofersen is a mixture of 2 15 (i.e. 32,768) diastereoisomers. From the characterisation data, diastereomer distribution calculations were performed.

The solid-state properties of the active substance are not considered relevant, as the tofersen active substance is formulated as a liquid consisting of tofersen in solution with sodium phosphate monobasic dihydrate, sodium phosphate dibasic anhydrous, and sodium chloride.

## 2.4.1.2. Manufacture, process controls and characterisation

The active substance is manufactured by one manufacturing site.

Tofersen is  a  synthetic  oligonucleotide  that  is  manufactured  in  a  7-step  process,  using  well  defined starting materials with acceptable specifications.

Solid phase synthesis is performed on an oligonucleotide synthesizer. Synthesis is followed by cleavage of  the  oligonucleotide  from  the  solid  support  and  removal  of  the  amide  protecting  groups  from  the nucleobases.  Purification  steps  follow.  Ultimately  the  active  substance  is,  after  filtration  through  a sterilisation  grade  filter,  dispensed  and  stored  in  bags,  protected  from  light.  The  narrative  process description  covers  applied  reagents,  process  conditions,  tabular  overviews  on  critical  controlled parameters as well as critical in-process controls/tests including limits and is sufficiently detailed.

The proposed in process controls and the acceptable ranges for the operation of critical steps in the tofersen  active  substance  manufacturing  process  have  been  provided.  These  controls  have  been established to ensure that the process produces acceptable product quality.

The starting materials for the manufacture of tofersen are defined. The choice of starting materials is well justified according to the principles outlined in ICH Q11. The applicant confirms that upon change or addition of starting material suppliers a variation will be submitted.

Detailed information on critical (result in impurities that cannot be removed during purifications steps) and non-critical (have no negative impact on drug substance purity) impurities in the phosphoramidites

<div style=\"page-break-after: always\"></div>

is  provided. Structure, origin, prevalence and resulting drug substance impurities are described. The starting material specifications are defined. The starting materials specifications are sufficiently justified. Summaries of historical batch data are provided and well within the currently proposed specifications.

It is confirmed that no materials of biological origin are used in the commercial manufacturing process.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development  program.  Changes  introduced  have  been  presented  in  sufficient  detail  and  have  been justified.

The  process  development  history,  namely  changes  in  process  and  the  respective  rationales,  is  well described. Batch data is provided from before and after the different changes to show comparability sufficiently. The overall control strategy is described The applicant indicates that a risk-based approach based on ICH Q8 and ICH Q9 was applied throughout the product development lifecycle. In a product risk  assessment,  based  on  a  tofersen  quality  target  product  profile,  active  substance,  and  finished product CQAs and non-CQAs were identified. The classifications and justifications are acceptable.

Manufacturing development studies were performed to assess the impact of process performance on the product  quality  attributes.  These  were  confirmed  in  process  validation.  Sufficient  details  have  been provided  on  Process  Risk  Assessment  to  comprehend  the  respective  results.  Extensive  process characterisation studies have been performed to optimise the commercial process. The proposed overall control strategy could be acceptable.

Finally, it should be pointed out that the active substance is a solution. The addition of the formulation electrolyte excipients (KCl, CaCl2, MgCl2) and final dilution to target concentration were relocated from the active substance to the finished product process. Elimination of the lyophilisation step is considered justified. The overall strategy regarding the liquid drug substance is acceptable.

The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

Impurities are classified into organic impurities, inorganic impurities and residual solvents. Inorganic impurities,  residual  solvents,  small  molecule  impurities,  impurities  with  genotoxic  potential  and nitrosamines are discussed.

The organic impurities are sub-classified into process-related impurities, impurities derived from starting materials and reagents as well as potential degradation products. The grouping strategy for the organic impurities is based on their structures and formation mechanisms and well justified by toxicological qualification of the impurity groups. This is acceptable for a synthetic oligonucleotide with a complex impurity profile. A good general understanding of possible organic impurities is demonstrated. Impurity characterisation  was  performed.  It  is  justified  that  the  test  method  is  suitable  and  sufficient  for characterisation of all impurities and degradation products in the active substance. The active substance in solution is packaged in sterile, single use, flexible bioprocess bags with a LDPE contact layer. The bags are sealed with polycarbonate aseptic connectors. An acceptable specification for the primary container closure is provided. The applicant indicates compliance with the European Pharmacopoeia and foodstuff legislation (European Union Directive 2011/10/EC Regarding Plastic Materials and Articles Intended to Come into Contact with Food). Extractable studies were performed with model solvents on the inner bag material. An adequate evaluation of the safety risks of measured extractables concluded that levels of identified extractables are all below accepted toxicity limits.

<div style=\"page-break-after: always\"></div>

## 2.4.1.3. Specification,  analytical  procedures,  reference  standards,  batch  analysis,  and container closure

The active substance specification includes tests for appearance (visual), pH (Ph. Eur.), concentration (LC-UV-MS), identity (LC-UV-MS, LC-UV, Failure Sequence Analysis), purity and impurities (LC-UV-MS), bacterial endotoxins (Ph. Eur.) and bioburden (Ph. Eur.).

The proposed specification is acceptable and appropriate limits have been set in line with guidelines, batch data from development, clinical and stability batches.

Impurities are grouped according to their structures and formation mechanisms. The concept of grouping as proposed in the specification is acceptable. All relevant active substance attributes are covered and omission of residual solvents and elemental impurities testing is justified. Process-related impurities are adequately controlled.

The selected set of impurities is acceptable. The specification limits for the specified impurities in the active substance are established based on historical release and stability data in addition to toxicological qualification data. Identification and qualification thresholds are acceptable. A risk assessment indicated that  levels  of  elemental  impurities  are  below  the  control  threshold.  Omission  of  routine  testing  for elemental impurities is therefore acceptable. A nitrosamine risk assessment was performed, and the report included in Module 1. It was concluded that there is no risk of presence of nitrosamine impurities in  the  drug substance. No confirmatory testing was performed. The conclusions are reasonable. The analytical methods used have been adequately described and non-compendial methods appropriately validated  in  accordance  with  the  ICH  guidelines.  Satisfactory  information  regarding  the  reference standards used for release testing has been presented.

Batch analysis data (13 batches) of the active substance are provided comprising release data for nine non-clinical toxicology/clinical/stability batches/process development batches as well as for four process validation/commercial/stability batches is included in the dossier. Purity/impurity data for five clinical or pilot batches is provided additionally. The proposed commercial specifications or historic specifications are met for all attributes in all batches.

## 2.4.1.4. Stability

Stability studies were conducted in accordance with ICH Q1A (R2) and data for four primary process validation batches produced by the commercial process are provided. Data were collected at the longterm condition of 5±3  °C/Ambient  RH  for  24 months  and  at the accelerated condition of 25 °C ± 2 °C/60±5% RH for 6 months for all batches. Long-term stability studies are ongoing. The active substance  is  stored  in  sterile  bags  with  PE  product  contact  layer  representative  for  the  commercial container closure system during stability studies. Stability protocols covering 60 months at long-term and 6 months at accelerated conditions comprising appearance, pH, purity, impurities and concentration by LC-UC-MS are provided.

Most attributes did not change during 24 months at long-term or 6 months at accelerated conditions. All results  remain  within  specifications.  Statistical  analyses  indicate  that  specifications  will  be  met throughout the proposed retest period. No details are provided on methodology and results of said statistical analysis. This is acceptable since no retest period extrapolation is performed.

The stability data for all batches and both storage conditions show variability over time. Since the values do not present any trend and are well below proposed specifications limits, this is acceptable.

Forced degradation studies have been performed for the following stress types: visible light, ultraviolet light,  acid,  alkaline,  oxidative,  heat.  Representative  chromatograms  including  peak  assignment  are

<div style=\"page-break-after: always\"></div>

provided. Two main degradation products were detected under the most relevant stress condition of heat.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period of 24 months when stored at 5±3  °C/Ambient  RH  in  the  proposed  container.  The  post-approval  stability  protocol  and  stability commitment are acceptable.

## 2.4.2. Finished Medicinal Product

## 2 . 4 . 2 . 1 . Description of the product and Pharmaceutical Development

The  finished  product  is  an  aqueous  solution  for  intrathecal  injection.  It  is  presented  as  clear  and colourless to slightly yellow solution with a pH of 6.7 to 7.7. The finished product is supplied in a Type I glass vial closed with a rubber stopper and seal with a flip-off cap. Each vial of finished product contains a single dose of 100 mg tofersen at a concentration of 6.7 mg/mL in a formulation at pH 7.2.

The quantitative composition, function, and quality standard of each component in the finished product are provided. There is sufficient fill to ensure a 15.0 mL deliverable volume. There are no overages in the drug product formulation.

Tofersen finished product was designed as a sterile solution for intrathecal injection in a single-dose glass vial with a rubber stopper. A comprehensive QTPP has been established. The formulation and the manufacturing process were developed based on the CQAs required for this type of finished product.

The active substance is in a buffered aqueous solution. The properties of the active substance that may affect the finished product manufacturing process are concentration of ASO, concentration of sodium phosphate/sodium chloride and pH.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

For intrathecally applied finished product, the composition corresponding to endogenous cerebrospinal fluid with physiological pH and osmolality is critical. Tofersen was found to be physically and chemically stable in the artificial cerebrospinal fluid (aCSF). Different tofersen concentrations, freeze-thaw stability and  robustness  to  differences  in  excipients  concentrations  and  pH  were  investigated.  No  significant impact on purity and impurities was found.

For clinical supply the product was initially provided as a concentrate in aCSF together with a second vial containing aCSF diluent ('Two-vial presentation') for dose selection. The selected dose for pivotal studies was  100  mg,  provided  as  a  ready-to-use  (RTU)  solution  for  injection.  The  excipients  are  the  same between the two-vial and the RTU presentations. The commercial formulation is the same as the 100 mg RTU formulation used in the pivotal clinical studies. The finished product does not contain overages. However, an overfill is necessary to extract the nominal volume of 15 mL from the vials. The limits are acceptable, as per USP &lt;1151&gt;.

The manufacturing process is a common process for aqueous sterile finished product that cannot be subjected to terminal sterilisation. It consists of electrolyte solution and aCSF dilution buffer preparation, finished product bulk compounding, bioburden reduction filtration, in-line sterile filtration, aseptic vial filling, stoppering and capping followed by visual inspection.

<div style=\"page-break-after: always\"></div>

The  applicant  claims  that  steam  sterilisation  of  the  finished  product  is  not  feasible.  Although  the degradation  of  the  active  substance  is  not  considered  significant,  this  is  acceptable  due  to  the incompatibility of the aCSF for terminal sterilisation demonstrated with an autoclave cycle of F0=8 min. Due to the concentration of salts, precipitation occurs in the solution (turbidity).

The development of the manufacturing process is described. A list of process steps with their respective process controls and criticality classification is provided, which is considered adequate. Comparability of the  commercial  manufacturing  process  to  the  previous  processes  used  for  clinical  supply  was demonstrated based on release and stability data.

The applicant provided conclusions of risk assessments concerning the contribution of the product and manufacturing  components  to  the  levels  of  endotoxins  in  the  finished  product,  extractables  and leachables from process wetted surfaces, and elemental impurities in the finished product. With respect to  extractables  and  leachables  from  process  contact  surfaces  no  risks  to  patient  safety  have  been identified.

The commercial primary container closure system (CCS) for the finished consists of type 1 clear glass vials closed with chlorobutyl rubber stoppers with cross-linked silicone oil coating.

Sufficient information has been provided for the CCS in terms of protection, security and compatibility. For the quality requirements of the type I glass and the chlorobutyl rubber of the packaging components reference is made to the relevant compendial monographs. Additional tests carried out by the applicant cover supplier certificate check, catalog number check, appearance, and dimensions.

Container closure integrity testing results demonstrate that the primary container closure components prevent microbial ingress under the foreseen storage conditions. Leachable data showed no leachables above  the  Analytical  Evaluation  Threshold  (0.1  µg/mL)  derived  from  the  Threshold  of  Toxicological Concern (ICH M7: ≤ 1.5 µ g/day). The chemical compatibility of the CCS with the finished product has been demonstrated in stability studies.

The compatibility of the finished product with a polypropylene syringe for withdrawing the solution from the vials, a stainless steel/polypropylene spinal needle, and a polypropylene IV extension set was tested. This in-use test supports the instructions provided in the SmPC section 4.2 Posology and method of administration : 'Once drawn into the syringe, the solution should be administered immediately (within 4 hours since removal from refrigeration) at room temperature; otherwise, it must be discarded.'

## 2.4.2.2. Manufacture of the product and process controls

The  finished  product  is  manufactured  by  one  manufacturing  site.  Biogen  Netherlands  B.V.,  Prins Mauritslaan 13, 1171 LP Badhoevedorp, The Netherlands is responsible for batch release in the EU/EEA. The finished product manufacturing process covers a batch size range and comprises four steps plus a pre-processing preparation of electrolyte solution and aCSF dilution buffer. The manufacturing process starts  with  compounding  of bulk drug product including bioburden reduction filtration in-line sterilefiltration, aseptic vial filling, stoppering and capping , and visual inspection . The process is considered to be a non-standard manufacturing process.

The applicant defines a reprocessing step. This reprocessing step was part of the PPQ and is considered acceptable.

Critical process steps and the corresponding critical process parameters (CPPs) and their action limits were presented. Appropriate in-process controls for the various process steps were also presented.

Major steps of the manufacturing process have been validated by a number of studies. In terms of IPCs and the release testing results, all acceptance criteria for the PPQ batches were met. In addition, media

<div style=\"page-break-after: always\"></div>

fill runs demonstrated that the filling conditions are validated. The bracketing approach is accepted given the straightforward manufacturing process. Validation studies were performed on the membrane used for sterile filtration.

It has been demonstrated that the manufacturing process is capable of producing the finished product of  intended  quality  in  a  reproducible  manner.  The  in-process  controls  are  adequate  for  this  type  of manufacturing process and pharmaceutical form.

## 2.4.2.3. Product specification, analytical procedures, batch analysis

The finished product specification includes tests for appearance (visual), pH (Ph. Eur.), osmolality (Ph. Eur.), assay (LC-UV), extractable volume (Ph. Eur.), identity (LC-UV, melting temperature), purity (LCUV), degradation products (LC-UV), particulate matter (Ph. Eur.), bacterial endotoxins (Ph. Eur.), sterility (Ph. Eur.), container closure integrity testing (High Voltage Leak Detection).

The proposed specification is acceptable and appropriate limits have been set in line with guidelines, batch data of clinical batches, stability data, manufacturing capability and variability and analytical test method capability.

Based on release and stability data, the applicant proposes specification limits for % label claim and to review the assay limit through annual review when more DP lots are produced. This is acceptable. The analytical methods used have been adequately described and appropriately validated in accordance with the  ICH  guidelines.  Satisfactory  information  regarding  the  reference  standards  used  for  release  and stability testing has been presented. They are the same as those used for active substance testing.

The risk assessment and confirmatory testing of four finished product batches confirm that elemental impurities  are  consistently  below  the  PDE  from  ICH  guideline  Q3D  (R2)  on  elemental  impurities. Therefore, routine controls are not required.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed  (included  in  Module  1)  considering  all  suspected  and  actual  root  causes  in  line  with  the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article  5(3)  of  Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004 - Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on  the  information  provided  it  is  accepted  that  no  risk  was  identified  of  the  possible  presence  of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

Release  results  for  development  batches  manufactured  by  earlier  process(es)  and  for  batches manufactured by the proposed commercial process are provided. Based on the batch results it can be concluded that the manufacturing process is under control and results in consistent and uniform drug product.

## 2.4.2.4. Stability of the product

Stability studies in accordance with ICH Guideline Q1A for the four PPQ batches were conducted. In addition,  stability  studies  for  supportive  finished  product  (7  batches)  manufactured  during  process development  and  for  clinical  use  are  presented.  Samples  have  been  stored  at  the  long-term  (5  ± 3°C/Ambient RH), accelerated (25 ± 2°C/60 ± 5%RH) and stressed storage conditions (40 ± 2°C/75 ± 5%RH). The stability study protocols are provided.

<div style=\"page-break-after: always\"></div>

The analytical methods for stability testing of batches and the clinical/process development  batches are the  same  as  those  used  for  release  testing.  Finished  product  was  stored  in  containers  that  are representative of the commercial containers.

For the PPQ batches) long-term stability data are available for 24 months, for the clinical/development batches for up to 48 months. Stability results at accelerated conditions are presented for 12 months and at  stress  conditions  for  6  months.  Under  long-term  storage  conditions,  no  significant  changes  were observed in any of the attributes. Under accelerated conditions, impurities increase slightly, under stress conditions they are more pronounced after 6 months.

Photostability studies demonstrated that the drug product needs to be kept in the secondary packaging as the finished product is sensitive to light exposure. However, further studies demonstrated that the finished product can be held for 36 hours at room temperature and ambient light following removal from the secondary packaging.

An additional study showed that the finished product in its secondary packaging can be held at room temperature not exceeding 30 °C for up to 2 weeks within the drug product shelf-life.

Thermal cycling studies confirmed that short-term temperature excursions during supply chain handling have no negative impact on drug product quality.

Based on available stability data, the proposed shelf life and storage conditions stated in the SmPC (section 6.3 and 6.4) are acceptable:

## Shelf life: 30 months

The vial of QALSODY in its original carton can be stored for up to 14 days at room temperature (not to exceed 30°C).

Unopened  vials  of  QALSODY  can  be  removed  from  and  returned  to  the  refrigerator,  if  necessary. Unopened vials can be removed from the original carton for not more than 6 hours per day at room temperature for a maximum of 6 days.

## Storage conditions:

Store in a refrigerator (2°C - 8°C).

## Do not freeze.

Store in original package in order to protect from light. '

A sufficient post-approval stability protocol and commitment has been included.

## 2.4.2.5. Post approval change management protocol(s)

Not applicable.

## 2.4.2.6. Adventitious agents

No materials of animal or human origin are used in the manufacture of the active substance or finished product.

## 2.4.3. Discussion on chemical and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  consistency  and

<div style=\"page-break-after: always\"></div>

uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.4. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.5. Recommendation(s) for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The non-clinical program with tofersen was conducted using in vitro and in vivo studies to support chronic intrathecal (IT) administration for the treatment of ALS associated with a mutation in the SOD1 gene. The non-clinical testing strategy for tofersen followed a development pathway typical of a pharmaceutical product and was consistent with existing regulatory guidance (ICH M3(R2)). The objectives of the nonclinical program were to evaluate the pharmacology, pharmacokinetics (PK), and safety of tofersen as follows:

- Pharmacology studies to evaluate the effect of SOD1 lowering and efficacy in vitro and in both transgenic mouse and rat models as well as non-human primates (nonhuman primate NHPs, Cynomolgus monkeys),
- PK studies to evaluate the half-life of tofersen in central nervous system (CNS) tissue to aid in estimating  IT  dosing  frequency  in  patients  and  correlate  antisense  oligonucleotide  (ASO) cerebrospinal fluid (CSF) concentrations with tissue concentrations in animal pharmacology and toxicology  models.  Furthermore,  the  PK  profile  of  tofersen  was  characterized  in  plasma  of animals.  Additional  studies  were  conducted  to  characterize  the  potential  for  drug-drug interactions (DDI), including protein binding, metabolite identification, inhibition, or induction of CYP450 enzymes, and inhibition and binding to absorptive and efflux transporters,
- GLP  non-clinical  safety  pharmacology  and  toxicology  studies  to  support  the  chronic  use  of tofersen for the treatment of patients with ALS.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

Tofersen is complementary to a portion of the 3' UTR of the mRNA for human SOD1. The binding of tofersen to the cognate mRNA results in RNase-H1-mediated degradation of the mRNA for SOD1, and thus reduces the amount of SOD1 protein. RNase H1 is a ubiquitously expressed nuclease that recognizes a DNA-RNA heteroduplex and cleaves the RNA strand of the duplex. Since tofersen binds to a site in the 3' UTR of human SOD1 mRNA, it is expected to reduce expression of both wild type and mutant variants of SOD1.

<div style=\"page-break-after: always\"></div>

Primary PD of tofersen was studied in vitro and in vivo . A series of informatics searches were completed to assess the potential cross-reactivity in non-human species and polymorphisms in the target-binding site of the SOD1 gene in the general human population and specifically in ALS mutation databases were examined. The analyses support presence of the tofersen binding site in the target patient population. In addition, no relevant polymorphisms were identified in the SOD1 gene of ALS patients. Furthermore, a single base-pair mismatch to the Cynomolgus monkey gene suggests it may be active in NHPs, thereby enabling assessment of possible on-target effects, while wild-type animals of all other species appear not to be suitable due to at least four or more mismatches in the target sequence.

The in  vitro potency  of  tofersen  was  established  in  two  human  cell  lines  (SH-SY-5Y  and  A431)  and monkey hepatocytes. Tofersen suppressed SOD1 mRNA in a concentration-dependent manner in all cell lines (half-maximal inhibitory concentration (IC50): 1.1 μ M, 0.65 μ M and 0.98 µM in SH-SY5Y, A431 cells and monkey hepatocytes, respectively).

In vivo activity of tofersen was investigated in SOD1-G93A mice and rats and in monkeys. An overview of performed studies and relevant findings are displayed in Table 1.

Table 1: Overview of in vivo PD studies performed with tofersen .

| Study Number   | Study Type                                                                                         | Test System                                                                                                                   | Results / ED 50 / EC 50                                                                                                                                                                                                                                                                                                                                               |
|----------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EXP-15- AA2184 | Dose-response evaluation of tofersen in human SOD1-G93A mice                                       | SOD1-G93A mice (6-8 weeks old), 10, 30, 100, 300, or 700 μ g tofersen ICV single dose, sample collection at 2 weeks post dose | SOD1 mRNA reduction, ED 50 : Lumbar cord: 64 µg Cervical cord: 44 µg Cortex: 144 µg SOD1 mRNA reduction per µg tofersen/g tissue, EC 50 : Lumbar cord: 0.87 µg/g                                                                                                                                                                                                      |
| ASO-13         | Survival study to assess effect of time of tofersen injection on survival of human SOD1- G93A mice | SOD1-G93A mice, 300 µg tofersen or control ASO ICV at 30, 50, 80, or 110 days of age, single dose                             | Cortex: 7.9 µg/g Median disease onset at dosing at 30, 50, 80, or 110 days of age: Control ASO: 147.5, 151, 145, and 155 days, respectively Tofersen: 168, 169, 176.5, and 188 days, respectively. Median survival at 30, 50, 80, or 110 days of age: Control ASO: 170, 162, 164, and 167 days, respectively Tofersen: 193.5, 182, 186.5, and 201 days, respectively. |
| ASO-14         | Effect on survival and motor performance of 2 different doses of tofersen in human SOD1-G93 mice   | SOD1-G93A mice, 100 µg, 300 µg tofersen or 300 µg control ASO ICV at 50 and 94 days of age                                    | Disease onset: Control ASO = 20 weeks; tofersen 100 μ g = 25.3 weeks; tofersen 300 μ g = 26.1 weeks Median survival: control ASO = 24 weeks; tofersen 100 μ g = 28.3; tofersen 300 μ g = 29.3 weeks Rotarod performance: Tofersen 100 μ g and 300 μ g: comparable improvements on motor performance. Tofersen- treated animals stayed on the rotarod                  |

<div style=\"page-break-after: always\"></div>

|                |                                                                                                              |                                                                                                                                                                   | significantly longer relative to control ASO treated mice.                                                                                                                                                                                                                                                                       |
|----------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ASO-15         | Electrophysiological and histological study on the effect of tofersen in human SOD1-G93A mice                | SOD1-G93A mice, 300 µg tofersen or control ASO ICV single dose at 35 days of age, sample collection at weeks 15 and 17 post dose                                  | Tofersen significantly protected the neuromuscular structure and function and reversed effects comparable to wild-type mice.                                                                                                                                                                                                     |
| ASO-27         | Histological study on the effect of tofersen in human SOD1-G93 mice                                          | SOD1-G93A mice, 100 µg tofersen or control ASO ICV at 50 and 94 days of age, sample collection at 16- and 24-weeks post dose                                      | Tofersen significantly protected denervation- dependent fiber-type switching in the anterior tibialis muscle. Moreover, tofersen significantly decreased the amount of microglial activation in the spinal cord, suggesting protective activity against inflammation in the CNS.                                                 |
| ASO-28         | Analysis of dose- response efficacy of tofersen in human SOD1-G93A mice                                      | SOD1-G93A mice, 10 µg, 30 µg, 100 µg tofersen or 100 µg control ASO ICV at day 35 of age, sample collection at days 56 (serum) and 70 (serum/tissues).            | Native SOD1 protein levels: Significant reduction in cortex and spinal cord at ≥ 10 µg Misfolded SOD1 protein levels: Significant reduction in cortex at ≥ 10 µg and spinal cord at 100 µg only Tibialis anterior muscle function: Significant effect at ≥ 30 µg pNfH serum levels: Significant reduction at ≥ 30 µg at 8 and 10 |
| EXP-15- AA2185 | Dose-response evaluation of tofersen in human SOD1-G93A rats                                                 | SOD1-G93A rats, 10, 30, 100, 300, 1000, or 3000 μ g tofersen, IT single dose, sample collection at 2 weeks post dose                                              | SOD1 mRNA reduction, ED 50 : Lumbar cord: 48 µg Cervical cord: 93 µg Cortex: 534 µg SOD1 mRNA reduction per µg tofersen/g tissue, EC 50 : Lumbar cord: 1.4 µg/g                                                                                                                                                                  |
| EXP-15- AA2186 | Time course of in vivo efficacy (RNA and protein levels) of tofersen in human SOD1-G93A rats                 | SOD1-G93A rats, 1000, 3000 µg IT twice, ICV 1000 µg single dose, tissue collection at 2, 4 and 8 weeks post dose                                                  | Cortex: 2.3 µg/g Tofersen lowered both SOD1 mRNA (> 50%) and protein in lumbar cord, cervical cord and cortex. Furthermore, these tissue changes are reflected as changes in SOD1 protein in CSF (> 50% at weeks 4 and 8).                                                                                                       |
| 666853- AS01   | Dose-response evaluation of tofersen in Cynomolgus monkeys as part of a 13 weeks repeat- dose toxicity study | Cynomolgus monkeys, 4, 12, 35 mg IT by lumbar bolus injection biweekly for the first month (Days 1, 14, and 28), then monthly thereafter (Days 56 and 84). Sample | SOD1 mRNA reduction per µg tofersen/g tissue, EC 50 : Brain tissues (combined): 20.7 µg/g                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| 13-weeks with a 13-week recovery phase   | collection 1 week after last dose   |
|------------------------------------------|-------------------------------------|

In order to establish in vivo potency, C57BL6 mice expressing the human SOD1 locus, including the 3' UTR to which tofersen is targeted, were used as main animal model (Gurney, 1994). This transgenic mouse model was chosen because the binding site of tofersen is not conserved in wild-type mouse or rats.

Tofersen  showed  suppression  of  SOD1  mRNA  in  SOD1-G93A  mice,  with  a  half-maximal  effective concentration (EC50) of 0.87 μ g/g in the lumbar spinal cord and 7.9 μ g/g in the cerebral cortex. Based on the EC50 of 0.87 µg/g in the target tissue spinal cord, a target exposure for patients of ~ 1 µg/g tissue was predicted and this exposure is anticipated to be reached in patients. Autopsy samples of three participants showed tofersen tissue concentrations of &gt; 200 μ g/g in the target spinal cord regions.

Dosing of SOD1-G93A mice with tofersen administered by intracerebroventricular (ICV) injection in the range of 30 µg - 300 µg also significantly delayed disease onset (reduction in body weight) and survival for  all  treatment  ages,  improved  motor  performance,  prevented  myofiber  atrophy  as  measured  by myofiber diameter in the tibialis anterior and improved fiber type composition of the soleus muscle loss of muscle function. In addition, tofersen reduced levels of neuroinflammation markers in the spinal cord of SOD1-G93A mice and treatment dose-dependently lowered serum levels of phosphoneurofilament heavy chain (pNfH).

The mice were 35 days old at the start of therapy, which corresponds to a human age of about 3.8 years (assuming 1 human year corresponds to 9 mouse days). Afterwards, they were examined for another 35 days, corresponding to 3.8 human years (Day 70, Week 10). First effects on pNfH were seen after 8 weeks  (measurements  before  that  were  not  possible),  which  corresponds  to  2.3  human  years  of treatment (Das 35 to Day 56 = 21 days = 2.3 human years).

The animals were treated with a single dose of ICV injection, first effects appeared at 30 µg/mouse. The half-maximal effective dose (ED50) for the reduction of SOD1 mRNA is in the range of 64 µg/mouse in the  lumbar  cord,  which  corresponds  to  0.87  µg/g  tissue  lumbar  cord.  In  humans  &gt;  200  µg/g  were measured in the spinal cord in 3 volunteers. Assuming that a mouse weighs approx. 20 g, the dose would be 30 µg x 50 = 1.5 mg/kg, i.e. 105 mg for a 70 kg adult, which is almost exactly the human dose.

In the same experiment, the muscle function (tibialis anterior) was also measured, and the effect also occurred after 8 weeks from 30 µg, i.e. parallel to pNfH. Although this was not investigated beforehand either, it may have started earlier.

Figure 2: Dose-dependent effect of tofersen on compound muscle action potential (CMAP) recordings in SOD1-G93A mice

<div style=\"page-break-after: always\"></div>

<!-- image -->

Tofersen 30 and 100 μ g bolus doses, but not 10 μ g, significantly improved compound muscle action potential (CMAP) readings at 8 and 10 weeks of age as compared with the control group (p&lt;0.0001). Both the 30 and 100 μ g dose levels provided a significant improvement as compared with the 10 μ g dose at both 8 (p&lt;0.05) and 10 (p&lt;0.0005) weeks of age; no significant difference was found between 30 and 100 μ g doses at either 8 or 10 weeks of age. The statistical analysis was performed by 2-way analysis of variance (ANOVA) (n=10-12).

It is also interesting that an inflammatory marker (IBA-1) was reduced from 24 weeks. Dose 100 µg at day 50 (5.5 human years) and 100 µg at day 94 (10 human years). From age 24 weeks (18.4 human years, i.e., over 10 years of treatment), the marker was reduced. This is already clearly behind the pNfH effect, which was already changed after a 30-µg dose on Day 56 = 21 days treatment duration = 2.3 human years.

Figure 3: Effect of 2 doses of tofersen on inflammatory markers in the spinal cord of SOD1-G93A mice

<!-- image -->

GFAP and IBA-1 staining was quantified in the spinal cord of tofersen- or control ASO-treated SOD1G93A animals and WT animals 10, 16, and 24 weeks of age. While GFAP was not significantly reduced in  tofersen-treated  SOD1-G93A  animals  relative  to  control  treated  animals  (p&gt;0.05),  IBA-1  was significantly reduced at 24 weeks of age (p=0.002; 2-way ANOVA). Ten-week group received one dose of tofersen; 16- and 24-week groups received two doses.

In the same study, muscle composition (reduction in slow myosin-positive fibres) was also investigated. The effect was seen from an age of 16 weeks (12.3 human years, corresponding approximately to 10 years of treatment), but not before.

<div style=\"page-break-after: always\"></div>

Figure 4: Effect of 2 doses of tofersen on fiber-type composition of the tibialis anterior muscle in SOD1G93A mice

<!-- image -->

Tibialis anterior muscle from SOD1 animals treated with tofersen had a significantly lower percentage of slow myosin-positive fibers, at 16 weeks of age. Treatment with tofersen significantly decreased the number of slow myosin-positive fibers in the tibialis anterior muscle, both at 16 weeks of age (p=0.005) and 24 weeks of age (p&lt;0.0001), as compared to muscle of the SOD1, inactive ASO group (2-way ANOVA). Ten-week group received one dose of tofersen; 16- and 24-week groups received two doses.

The biological plausibility as observed by non-clinical data and supported by the effect on the biomarkers suggest a strong mechanistic rationale for the tofersen effect.

Furthermore, non-clinical data in a SOD1 mouse model support this specific pathway: administration of SOD1-lowering  ASO  reduced  accumulation  of  the  levels  of  SOD1  protein  reduced  levels  of neurofilaments = reduced neuronal death  reversed compound muscle action potential loss (after some time lag)  increased survival.

This has been shown in G93A mice in Figure 5 .

Figure 5: SOD1-lowering ASO reduces phosphorylated neurofilament heavy chain (pNfH) and prolongs motor performance and survival of SOD1G93A mutant mice

<!-- image -->

<div style=\"page-break-after: always\"></div>

In line with previously performed experiments in mice, the dose-response relationship between tofersen and SOD1 mRNA in rat CNS following IT administration was investigated. The main reason for utilizing the rat in this study was that its larger size facilitates CSF collection. Similar to the mouse, the rat model expresses the full-length human SOD1 gene with G93A mutation, including the 3' UTR which harbours the tofersen binding site, at high levels (Howland, 2002). Tofersen reduced SOD1 mRNA with an EC50 of 1.4 μ g/g in the lumbar spinal cord and 2.3 μ g/g in the cervical spinal cord comparable to the mouse EC50 value for the lumbar spinal cord. Both IT and ICV administration of tofersen suppressed SOD1 mRNA and protein in the rat CNS for at least eight weeks following a single administration, consistent with the long half-life of the ASO. SOD1 protein in the CSF was also lowered up to 8 weeks in the SOD1-G93A rat.

In NHPs, SOD1 mRNA was reduced in all brain regions in a dose-dependent manner especially in ALSrelevant regions such as spinal cord and motor cortex while a ~50% reduction in pons and cerebellum was only achieved at the 35 mg high dose. An EC50 of 20.7 µ/g tissue was obtained (all brain regions combined). This is a about 10-fold lower potency as compared to transgenic mice or rats expressing human SOD1-G93A. The applicant discussed that this might be in part due to the one base pair mismatch of monkey SOD1 as compared to human SOD1. On the other hand, a very good and comparable knock down of SOD1 mRNA was achieved with tofersen in monkey hepatocyte cell cultures (IC50: 0.98 µM monkey  hepatocytes  vs.  IC50:  1.1  µM  human  SH-SY5Y  cells  and  IC50:  0.65  µM  human  A431  cells, respectively). This implicates that the base pair mismatch apparently has no major impact on SOD1 mRNA knock down in monkey cells. One possible explanation could be the formation of neutralizing antidrug  antibodies  (ADAs)  which  reduce  exposure  towards  tofersen.  In  fact,  the  PK  analysis  might indicate that there was a tendency towards reduced exposure (area under the concentration time curve (AUC) and maximum observed concentration (Cmax)) and a higher clearance at day 84 as compared to day 1, albeit this appears not to be significant as standard deviations of AUC and Cmax values were high (refer to Repeat-dose toxicology for details). An ADA analysis has not been performed and thus a firm conclusion on potency differences of tofersen in monkeys and mice/rats expressing humans SOD1 cannot be drawn.

## 2.5.2.2. Secondary pharmacodynamic studies

There was small but significant increase in IP-10 in response to tofersen treatment (6.9 pg/ml relative to 1.8 pg/ml in untreated cells at 8 µM tofersen) and also other SOD-1 ASOs. The applicant discusses that the degree of change is not expected to translate to a biological effect and is in contrast to the IP10 induction yielded by treatment with the positive control ASO (513.4 pg/ml). In addition, there was no observed increase in IL-8 in response to any of SOD-1 ASOs tested. It is agreed that the increase is only minor and at tofersen concentrations (8 µM = 57 µg/mL) that are unlikely to be reached in patients (plasma mean Cmax ~1.4 µg/mL at 100 mg tofersen). Therefore, no tofersen effects on TLR9 and related cytokine production are anticipated in patients.

In total 27 potential off-targets were identified by in silico analyses using a transcriptome database. Tofersen was shown to be highly specific for SOD1 mRNA and over 100-fold more potent for the ontarget SOD1m RNA than for any of the assessed off-target mRNAs. Overall, no unspecific off-target activities of tofersen are anticipated to occur in patients.

## 2.5.2.3. Safety pharmacology programme

Safety pharmacology was assessed in an in vitro the human Ether-à-go-go-Related Gene (hERG) assay, a single dose toxicity study including assessment of respiratory function and functional observational battery, and during 13-Week and 9-Month Cynomolgus monkey repeat-dose toxicity studies. Tofersen

<div style=\"page-break-after: always\"></div>

did not inhibit hERG current up to 34 µM which &gt; 100-fold the plasma concentration reached in patients. In addition, the were no tofersen related cardiovascular effects observed in Cynomolgus monkeys up to the highest dose tested. In the single dose rat study, transient acute tactile hypersensitivity was noted in animals receiving 3 mg. In addition, decreases in arousal, gait, mobility, respiration, and sensorimotor observations were also noted in the 3 mg group corresponding to a human equivalent dose (HED) of 1500 mg. In general, no relevant tofersen-related effects were observed in Cynomolgus monkeys. There were transient neurological signs in single high dose animals with no correlates in clinical and anatomic pathology and were not considered adverse or relevant.

## 2.5.2.4. Pharmacodynamic drug interactions

No pharmacodynamics (PD) DDI are expected for tofersen; therefore, the lack of respective studies is justified.

## 2.5.3. Pharmacokinetics

The PK profile of tofersen was characterized in CSF, plasma, and tissues from Cynomolgus monkeys following repeat IT administration (bi-weekly for first month, then monthly) for up to 9 months and in plasma and tissues from mice following single and repeat (bi-weekly for 26 weeks) subcutaneous (SC) administration. Additional studies were conducted to characterize the potential for DDI, including protein binding, metabolite identification, inhibition or induction of CYP450 enzymes, and inhibition or binding to absorptive and efflux transporters.

Considering the nature of tofersen as a second generation, chimeric, mixed backbone ASO and the well know experience with this compound class, the extent of PK studies is regarded as sufficient.

IT is the intended route of administration in humans, and therefore the non-clinical PK studies after IT administration in Cynomolgus monkeys are most relevant for the intended clinical use. Studies after SC administration should be regarded as supportive.

## Methods of analysis

The main bioanalytical method, a hybridisation-based ELISA method used for quantification of tofersen in monkey CSF, plasma, and tissues; in the mouse plasma; and rabbit plasma, has been adequately and successfully validated.

## Absorption

Following  IT  injection  to  Cynomolgus  monkeys  tofersen  concentrations  in  the  CSF  declined  in  a multiphasic manner, with a rapid distribution phase (which dominated the clearance from the CSF), followed by a slower and longer elimination phase. The rapid distribution phase is due to the rapid and broad distribution  from  the  CSF  to  the  CNS  tissues  with  additional  clearance  due  to  transfer  to  the systemic circulation. The estimated CSF elimination half-life (t½) was 20 to 45 days, which was similar to the t½ in the CNS tissues (31 to 40 days), suggesting equilibrium between CSF and CNS tissues. The mean tofersen predose CSF concentrations generally appeared to increase during the initial bi-monthly administration likely due to accumulation in the CNS tissues and remained at the same level or increased only slightly at higher doses following monthly administration, suggesting that steady state level has been achieved.

Plasma PK demonstrated a dose-dependent peak (Cmax) and total exposure (area under the concentration time curve from time 0 to 48 hours (AUC0-48h)) to tofersen. Plasma exposure increased in a greater than dose-proportional manner with a median time of maximal concentration (tmax) between 1 and 4 hours. Plasma concentrations exhibited multiphasic disposition showing a rapid decline during the first 48 hours

<div style=\"page-break-after: always\"></div>

post-dose (distribution phase) with a rapid distribution phase followed by a much slower elimination (post-distribution) phase. The post-distribution plasma t½ values in the 12 mg/kg dose-group at day 28 and at the 35 mg/kg dose group at day 84 were 22.4 and 50.6 days, respectively. Plasma exposures after repeated administration were generally similar to day 1, with only a slight trend to lower exposure after repeated exposure.

When comparing the corresponding mean post-distribution CSF and plasma concentrations, the mean post-distribution CSF values were generally higher than the corresponding plasma values.

The  plasma  PK  in  mice  following  SC-administration  of  tofersen  was  generally  similar.  Tofersen  was absorbed rapidly into the systemic circulation with a tmax of 0.5-1 hour. After achieving Cmax, the plasma concentrations rapidly declined over the next 24 to 48 hours following administration, which along with the  multiphasic  concentration-time  profile  suggests  rapid  and  extensive  distribution  of  the  drug  to tissues. Following repeat SC injection of tofersen once every 2 weeks for 26 weeks a slight increase in exposure (accumulation) to tofersen was observed based on area under the concentration time curve from time 0 to 24 hours (AUC0-24h).

Review  of  the  tofersen  plasma  concentrations  and  resulting  toxicokinetic  (TK)  parameters  revealed similar systemic exposure between sexes in Cynomolgus monkey and mice.

## Distribution

The dose-dependent tissue distribution of tofersen was seen in all the species studied (i.e., monkey, mouse,  and  rat)  with  no  clear  or  consistent  evidence  of  a  sex  difference  in  distribution  to  tissues. Following SC administration in mice, tofersen was rapidly and extensively distributed from plasma to the liver and kidney, with no distribution in the brain.

Following IT administration in monkeys, tofersen is broadly distributed to the CNS tissues, with the CNS tissue concentrations at least 90-fold higher than the CSF concentrations. The highest concentrations were observed in the lumbar spinal cord consistent with the route of administration. Relatively high concentrations  were  observed  in  the  liver  and  kidney,  indicating  a  significant  proportion  of  the administered dose was distributed from the CSF to the systemic circulation. Tofersen appeared to be cleared very slowly from the CNS tissues. The estimated t½ values for tofersen in the CNS tissues ranged from 30.8 to 39.9 days. The estimated t½ values for the kidney cortex and liver tissues were 22.5 and 19.8 days, respectively, in the 12 mg/kg dose group and 18.4 and 15.3 days, respectively, in the 35 mg/kg dose group.

Similar to monkeys, tofersen is broadly distributed to the CNS tissues in rats following IT administration.

The investigation of distribution into peripheral organs and tissues was limited to the liver and kidney. There  is  experience  with  other  oligonucleotides  that  the  liver  and  kidney  are  the  major  organs  of distributions  after  systemic  administration  (Geary,  2003;  Yu,  2007).  Furthermore,  no  further  target organs for toxicity have been identified in repeat-dose toxicity studies. Therefore, the lack of extensive tissue distribution studies is acceptable for tofersen as an ASO compound.

In vitro protein binding studies in mice, monkeys and humans showed that tofersen is highly bound to plasma proteins (≥ 95% bound) at the clinically relevant or higher plasma concentrations (0.1 to 30 μ g/mL).

Distribution in the blood cells has not been evaluated for tofersen.

Distribution  studies  in  lactating  mice  on  postnatal  day  21  following  SC  administration  showed  that tofersen appeared in the liver of the F0 mice and is excreted into mouse milk. However, no measurable level was detected in mouse pup liver and brain.

<div style=\"page-break-after: always\"></div>

## Metabolism

The metabolism of tofersen was investigated in Cynomolgus monkey liver and kidney cortex, after IT lumbar bolus injection (10 mg)  of tofersen. All observed metabolites were chain-shortened oligonucleotides with a relative amount of &lt;6% and &lt; 2% of the total peak area in liver and kidney cortex, respectively. Intact tofersen was the most abundant species and accounted for 80 and 75% of the total drug-related peak area in the liver tissue samples, respectively, and 92% of the total drugrelated peak area in kidney cortex tissue. Tofersen was also the most abundant species in mice liver and kidney following SC administration. The metabolites of tofersen observed in the kidney and liver of monkeys, suggest that tofersen is metabolized slowly and predominantly via exonuclease (3′ -and 5′) -mediated hydrolysis. The results of the metabolism studies are consistent with the previous experience with similar classes of ASOs (e.g., 2′ -MOE modified ASOs) (Geary, 2003; Yu, 2007). No cross-species comparative metabolism studies, including human, have been performed with tofersen. However, it is expected that the same fate of metabolism also occurs in humans.

## Excretion

Non-clinical evaluation of the urinary excretion of tofersen has not been performed but is expected to be minimal as for other 5-10-5 MOE gapmer ASOs following SC drug administration (Geary, 2003). The metabolism of similar classes of ASOs in tissues has been reported to be slow, followed by urinary excretion of the metabolites together with the parent drug as a minor component (Geary, 2003). A similar disposition is expected for tofersen. Given the experience with ASOs, the lack of urinary excretion studies for tofersen is acceptable.

## Pharmacokinetic drug interactions

In vitro studies PK DDI studies indicate that tofersen is neither an inducer of CYP450-mediated oxidative metabolism nor a substrate or inhibitor for absorptive or efflux transporters. Therefore, the likelihood of PK DDI interactions is considered low.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

The single dose study in the rat was conducted to assess the effects of local delivery using the clinical route of administration (IT lumbar) in a rodent species.

Decreases in arousal, gait, mobility, respiration, and sensorimotor observations were noted 3 hours post dose  in  the  3  mg  (1500  mg  HED)  group.  No  clinical  observations  were  noted  on  subsequent  days, suggesting a transient effect. The no-observed-adverse-effect-level (NOAEL) was determined to be 1 mg.

No ASO specifically targeting rat and mouse SOD1 was used in toxicology studies, due to the lack of sequence homology of tofersen in rodents.

## 2.5.4.2. Repeat dose toxicity

In a 26-week repeated dose study in CD-1 mice with a SC administration, tofersen was well tolerated. The NOAEL was determined to be the highest dose of 150 mg/kg based on the absence of any adverse findings.

In the 13-week monkey toxicology study, there was transient reduced movement in 2 female monkeys in the highest dose group (35 mg). Therefore, the NOAEL is considered to be at 12 mg/kg.

<div style=\"page-break-after: always\"></div>

In the 9-month study, tofersen-related and relevant neurological findings and CSF inflammation were observed in animals administered 35 mg. As a diazepam treatment was considered required for the female administered 35 mg, the neurological findings were considered adverse.

Dose levels of 4 and 12 mg tofersen were well tolerated over a period of 9 months of repeated dosing. In conclusion, the NOAEL upon repeated IT dosing over 9 months is considered 12 mg tofersen.

The neuronal vacuoles - macrovesicular and microvesicular - were not associated with morphological evidence of necrosis.

The microscopic findings in repeat-dose studies in the monkey could be consistent with oligonucleotide uptake  and/or  cellular  activation  and  cytokine  production  due  to  pro-inflammatory  effects.  The consequences  of  such  uptake  and  of  the  potential  pro-inflammatory  effects  were  discussed  by  the applicant, to support the reduced risk of long-term adverse effects.

However, the lack of functional or clinical consequence in relation to microscopic findings such as these, and the long-term consequences of the persistence of tofersen in neurons in the brain is not known.

The calculated safety margin for IT doses in monkeys to IT doses in humans is based on the different CSF volumes in the two species (approximately 10-fold greater absolute CSF volume in humans 2 years or older).

The NOAEL from the 9-month NHP toxicology study was determined to be 12 mg, which converts to a HED of 120 mg (based on the monkey-to-human CSF volume scaling) thus providing safety margins of 1.2-fold, based on CSF volumetric scaling (10x), relative to the human dose of 100 mg.

The development of anti-tofersen antibodies was not investigated in the chronic toxicity studies in rat, mice and monkeys. But ADAs against tofersen were investigated in patients with post-baseline plasma samples for ADAs. Overall, 58.4% of the patients developed treatment-emergent ADAs, but it is difficult to draw conclusions regarding the effects of ADAs on efficacy.

## 2.5.4.3. Genotoxicity

In vitro , tofersen was negative for an increase in reverse mutations in Ames tests in bacteria and for chromosomal aberrations, polyploidy and endoreduplication in a mammalian chromosome aberration assay in Chinese Hamster Lung (CHL) cells, respectively.

Tofersen did also not increase the formation of micronuclei in polychromatic erythrocytes of mouse bone marrow in  vivo .  A  sufficiently  high  safety  margin  can  be  assumed  based  on  toxicokinetic  data  from repeat-dose toxicity studies in mice. Thus, tofersen exerts no genotoxic potential.

## 2.5.4.4. Carcinogenicity

As already observed for other phosphorothioate oligonucleotides tofersen did not exert any genotoxic potential in vitro and in vivo .  Its  sequence does not contain the prerequisite of ≥10 non -interrupted purine  or  pyrimidine  nucleotide  stretches  and  therefore  bares  only  a  negligible  potential  for  triplex formation with genomic DNA.

In NHP, the only PD active species, tofersen did not show any pre-neoplastic or neoplastic lesions and neither  immunosuppressive  effects  nor  an  endocrine  dysfunction  were  observed  in  chronic  toxicity studies.

<div style=\"page-break-after: always\"></div>

In agreement with the CHMP (EMA/CHMP/SAWP/229464/2019) carcinogenicity studies with tofersen are regarded dispensable with respect to the life-threatening nature of ALS, the negative genotoxic potential and the absence of (pre)neoplastic changes, cell proliferation, and immune or endocrine dysfunction in chronic toxicity studies in mice and NHP's.

The carcinogenic potential of tofersen is considered to be low.

## 2.5.4.5. Reproductive and developmental toxicity

The reproductive and developmental toxicity of tofersen was investigated in a combined study on fertility and embryo-foetal development in mice, a study on embryo-foetal development in rabbits, and on prepostnatal development in mice. Toxicokinetic data on exposure as well as tofersen tissue concentrations were obtained within some of these studies. In all studies, tofersen was administered via SC injection once every other day to ensure maximum exposure of adult tissues (and especially reproductive organs) and fetuses to tofersen.

In the pivotal combined study on fertility and embryo-foetal development in mice, tofersen was not found to have any adverse effects on either male or female fertility at any dose (3, 10, or 30 mg/kg). However, in  male  mice,  evaluation  revealed  that  tofersen-related  histopathologic  findings  in  testes  and epidid ymides were detected at ≥ 10 mg/kg. Similar microscopic findings are known class effect of ASOs. Findings  such  as  tofersen-related  vacuolated  macrophages/cytoplasmic  vacuolation/macrovesicular vacuolation were also found in other organs (please refer to repeat-dose toxicity). The evaluation also revealed that the prostate in the 30 mg/kg dose group had a significant increase in absolute and ratio of organ weight to body weight. The NOAEL for male reproductive and general toxicity of tofersen was 10 mg/kg.

In female mice, no tofersen-related adverse effects were noted. There were no tofersen-related effects on any fetal external, visceral, or skeletal malformations or variations. The maternal general toxicity and reproductive/developmental NOAEL for tofersen was 30 mg/kg, the highest dose tested (&gt; 50 times the human exposure [AUC] following 100 mg tofersen).

In  the  study  on  embryo-foetal  development  in  rabbits,  tofersen  did  not  result  in  any  mortality.  No tofersen-related  adverse  clinical  signs  or  tofersen-related  findings  were  present  in  maternal  rabbits. There were no tofersen-related effects on embryo-foetal survival or foetal body weights and no tofersenrelated fetal external, visceral, or skeletal malformations or variations. The maternal and developmental NOAEL for tofersen was 30 mg/kg, the highest dose tested (more than 40-times the human exposure following 100 mg/month tofersen).

In a pre-postnatal development study in mice, tofersen administration did not produce tofersen-related mortality in F0 generation females or F1 generations pups at any dose (3, 10 or 30 mg/kg). There were no tofersen-related effects on either the F0 females or the F1 generations (males and females). The NOAEL for both the F0 and F1 generations was 30 mg/kg, the highest dose tested. Plasma exposures (area under the concentration time curve from time 0 to the last measured concentration (AUC0-last)) collected in pregnant mice in the pivotal fertility and embryo-fetal development (FEFD) Study indicate that a dose of 30 mg/kg in mice is &gt;50 times the human exposure [AUC] following 100 mg of tofersen.

Placental transfer of tofersen was not investigated. Overall, maternal exposure does not appear to lead to any toxicologically relevant exposure in the developing foetus, indicating that tofersen may not cross the placenta, or may do so only to a very limited extent.

Tofersen was detected in the milk samples of F0 maternal mice from all tofersen-dosed animals following dose administration on LD 13. No clear dose-dependent increase in tofersen concentration in milk was observed. However, tofersen was also detected in three out of the six control samples analysed. Why tofersen  was  detected  in  the  control  samples,  however,  could  not  finally  be  clarified.  Given  these

<div style=\"page-break-after: always\"></div>

limitations, these findings should only be considered as qualitative detection of tofersen in mice milk samples.

F0 generation mice administered tofersen had measurable levels of tofersen in the liver on lactation day (LD) 21; however, tofersen was not detected in liver and brain tissue from the F1 generation pups (on postnatal day 21), indicating that it may be degraded in the gastrointestinal tract of nursing F1 pups.

As tofersen is not pharmacologically active in mice and rabbits, the results of the developmental and reproductive toxicity (DART) studies would primarily reflect only the evaluation of the toxicity of its chemical structure. While the available data on DART indicate that the backbone of the ASO does not result in toxicity, adverse events related to SOD1 down-regulation are currently unknown and therefore are reflected in sections 4.6 and 5.3 of the SmPC.

## 2.5.4.6. Toxicokinetic data

Drug concentration data for CSF (monkey only), plasma (monkey and mouse only), and evaluated tissues (monkey, mouse, and rat) were assessed to characterize the PK properties of tofersen. Following bolus IT administration in monkeys, tofersen concentrations in CSF declined in a multiphasic manner, with a rapid distribution, followed by a slower and longer elimination phase. Following SC administration in mice, tofersen was rapidly absorbed into the systemic circulation, then similar to monkeys, declined over the next 48 hours due to extensive distribution to systemic tissues. Distribution of tofersen was dose dependent in all species studied, with broad distribution to CNS tissues following IT administration.

TK plasma exposure was determined following administration of tofersen once every other day by SC injection at 3, 10, and 30 mg/kg in pregnant mice and pregnant rabbits in the reproductive toxicity program. Toxicokinetic parameters were evaluated in female mice on gestation day (GDs) 6 and 14 and in female rabbits on GDs 7 and 19.

In pregnant mice, toxicokinetic evaluation indicated that evidence of systemic exposure to tofersen was observed in all tofersen treated pregnant mice following SC injection on GDs 6 and 14. High variability in the plasma concentration values was observed between animals at all dose levels on GDs 6 and 14 with concentrations quantifiable up to 24 hours post-dose. The tmax values were observed at 1- or 2hours post-dose on GDs 6 and 14 and apparent t1/2 was observed at 5.91 hours at 10 mg/kg on GD 14. In  general,  tofersen  plasma  exposure  based  on  Cmax  and  AUC0-last  increased  in  a  dose-proportional manner over the dose range evaluated and this increase in exposure was in general dose levels, except between 10 and 30 mg/kg on GD 6 where the increase was greater than approximately dose proportional (&gt;2-fold) for AUC0-last. A slight accumulation (AUC) of tofersen was observed at 3 and 10 mg/kg/dose on GD 14 relative to GD 6.

In  the  TK  evaluations  in  pregnant  rabbits,  the  tmax  was  mostly  observed  at  1  and  2  hours  after  SC injection of tofersen on DGs 7 and 19. Systemic exposure to tofersen (as assessed by mean Cmax and AU0-last) increased with increasing in dose levels on DGs 7 and 19. The observed increase in both Cmax and AUC0-last was approximately dose proportional over the whole dose range tested except between 3 and 10 mg/kg/dose on DG 7 where the exposure increased in a less than proportional manner for Cmax. The mean t1/2 ranged between 2.44 and 2.90 hours on DGs 7 and 19. Repeated subcutaneous injections of tofersen at 3, 10 and 30 mg/kg/dose once every other day on DGs 7 through 19 did not revealed accumulation as assessed by mean AUC0-last.

## 2.5.4.7. Local Tolerance

Local  tolerance  was  assessed  in  repeat-dose  toxicity  studies.  Inflammation  and  haemorrhage  were observed at the injection site in mice but resolved after recovery. In NHPs, IT administration of tofersen

<div style=\"page-break-after: always\"></div>

caused mononuclear inflammatory cell infiltrates in the meninges at the injection site of the lumbar spinal cord in males and females at ≥ 4 mg, possibly as a local pro -inflammatory effect caused by RNAse H-based  ASOs.  Remnants  of  such  inflammatory  infiltrates  were  still  detectable  after  13  weeks  of recovery, although at a lower magnitude.

## 2.5.4.8. Other toxicity studies

## Impurities

Independent of the mixture and impurity composition, the toxicity profiles of the 3- and 9-month toxicity and impurity studies were comparable with no supplementary signs of toxicity and similar TK profiles of the parent drug at nearly the same dose level. Margins at NOAEL were 1 - 3.5 times to the corresponding human dose of 100 mg with regard to the HED concept monkey-to-human CSF volume scaling (human CSF 10 x &gt; NHP CSF) for IT administration.

Therefore, on the basis of the impurity profile of all mixtures and batches tested the qualified level for an individual impurity was the maximum percentage used.

## Phototoxicity

Tofersen absorbed light peaking at approximately 260 nm that exhibits a spectral pattern that is typical for nucleic acids and consistent with the known absorbance spectrum of oligonucleotides.

In general, oligonucleotides are exempted from ICH S10 requirements (EMA/CHMP/ICH/752211/2012).

Tofersen did not induce ophthalmological or cutaneous alterations in repeat-dose toxicity studies.

The  phototoxic  potential  for  tofersen  is  considered  to  be  low  and  therefore,  no  studies  concerning phototoxicity testing were conducted or are deemed necessary.

## 2.5.5. Ecotoxicity/environmental risk assessment

The  applicant  submitted  an  environmental  risk  assessment  (ERA)  Phase  I  for  the  active  substance tofersen.

Based  on  prevalence  data  taken  from  the  orphan  designation  for  tofersen  (EU/3/16/1732)  for  the treatment of ALS and the treatment regime, the Fpen has been refined and used for calculation of a refined PECsurfacewaterresulting in a value of 0.0005 µg/l. As the PECsurfacewater does not exceed the action limit of 0.01 µg/l it is concluded that a Phase II testing is not triggered. The provided calculation is acceptable, and the risk assessment stopped in Phase I of the procedure.

For screening on persistence, bioaccumulation, toxicity (PBT) a study on log Kow according to OECD 107 has been provided. As the resulting log Kow values of -1.11 (pH 5), -1.83 (pH 7) and -1.90 (pH 9) does not exceed the trigger value no further screening for persistence, bioaccumulation and toxicity is deemed necessary.

<div style=\"page-break-after: always\"></div>

Table 2 : Summary of ERA main study results

| Substance: tofersen                                                 | Substance: tofersen                     | Substance: tofersen                     | Substance: tofersen                     |
|---------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| CAS-number (if available): 2088232-70-4                             | CAS-number (if available): 2088232-70-4 | CAS-number (if available): 2088232-70-4 | CAS-number (if available): 2088232-70-4 |
| PBT screening                                                       |                                         | Result                                  | Conclusion                              |
| Bioaccumulation potential- log K ow                                 | study is missing                        | -1.11 (pH 5) -1.83 (pH 7) -1.90 (pH 9)  | Potential PBT (N)                       |
| Phase I                                                             | Phase I                                 | Phase I                                 | Phase I                                 |
| Calculation                                                         | Value                                   | Unit                                    | Conclusion                              |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.0005                                  | µ g/L                                   | > 0.01 threshold (N)                    |
| Other concerns (e.g. chemical class)                                |                                         |                                         | (N)                                     |

The PEC surface water value is below the action limit of 0.01 µg/L and tofersen is not PBT substance as log Kow does not exceed 4.5.

## 2.5.6. Discussion on non-clinical aspects

The non-clinical pharmacology programme evaluated the selectivity and efficacy of tofersen using in vitro and in vivo studies. In vitro , tofersen showed suppression of SOD1 mRNA in two human cell lines and Cynomolgus primary hepatocytes to a similar extent.

In vivo pharmacological activity of tofersen was demonstrated in transgenic mouse and rat models, each expressing human SOD1 with a G93A mutation, and in Cynomolgus monkeys. The non-clinical findings provide a mechanistic rational for the effect of tofersen and support a delay in the treatment effect of tofersen.

Bioinformatic analysis was performed to identify potential off target transcripts based on the primary sequence of tofersen. The in silico predicted off-targets were either not expressed in the CNS, did not show evidence of reduction by tofersen in vitro , or had a much lower sensitivity to tofersen compared to on-target SOD1 mRNA inhibition (&gt;100 fold by IC50 values) in human cells.

Safety  pharmacology  assessments  for  potential  CNS,  respiratory,  and  cardiovascular  effects  were assessed in a single dose rat study and in 13-week and 9-month toxicity studies in Cynomolgus monkeys (NHPs). In rats, decreases in arousal, gait, mobility, respiration, and sensorimotor observations were seen in the 3 mg dose group corresponding to a HED of 1500 mg. In NHPs, there were no relevant tofersen-related effects on any of the safety pharmacology endpoints evaluated. In addition, tofersen demonstrated no relevant potential for cardiac hERG channel inhibition.

PK  studies  with  tofersen  were  performed  in  CSF,  plasma,  and  tissues  from  Cynomolgus  monkeys following IT administration, the intended route of administration in humans. In addition, supportive PK studies were conducted in mice following SC administration. Tofersen showed a PK profile typical for ASOs.

Following  IT  injection  to  cynomolgus  monkeys  tofersen  concentrations  in  the  CSF  declined  in  a multiphasic  manner,  with  a  rapid  distribution  phase  from  CSF  to  CNS  tissues  followed  by  a  longer elimination phase into the systemic circulation, where also biphasic decline was observed. The t1/2s of tofersen were 20 to 45 days in CSF, 31 to 40 days in CNS tissues and up to 50.6 days in plasma.

Following IT administration in monkeys, tofersen is broadly distributed to the CNS tissues, with the CNS tissue  concentrations  at  least  90-fold  higher  than  the  CSF  concentrations  and  relatively  high concentrations in the liver and kidney. Following SC administration in mice no distribution in the brain was observed. Tofersen is highly bound to plasma proteins (≥ 95% bound) in mice, monkeys ,  and human.

<div style=\"page-break-after: always\"></div>

Tofersen is metabolized slowly and predominantly via exonuclease (3′ -and 5′) -mediated hydrolysis to chain-shortened oligonucleotides but intact tofersen was the most abundant species in liver and kidney.

Non-clinical evaluation of the urinary excretion of tofersen has not been performed but is expected to be minimal as for other 5-10-5 MOE gapmer ASOs.

Tofersen is neither an inducer of CYP450-mediated oxidative metabolism nor a substrate or inhibitor for absorptive or efflux transporters and the likelihood of PK DDI is considered low.

Considering the nature of tofersen as a second generation, chimeric, mixed backbone ASO and the well known experience  with  this  compound  class,  the  extent  of  PK  studies  with  tofersen  is  regarded  as sufficient.

Overall, the toxicology programme revealed that tofersen was well tolerated. The microscopic findings in repeat-dose studies in the monkey could be consistent with oligonucleotide uptake and/or cellular activation and cytokine production due to pro-inflammatory effects. The consequences of such uptake and of the potential pro-inflammatory effects were discussed by the applicant, to support the reduced risk of long-term adverse effects. However, the lack of functional or clinical consequence in relation to microscopic findings such as these, and the long-term consequences of the persistence of tofersen in neurons in the brain is not known. The development of anti-tofersen antibodies was not investigated in the chronic toxicity studies in rat, mice and monkeys. But ADAs against tofersen were investigated in patients  with  post-baseline  plasma  samples  for  ADAs.  Overall,  58.4%  of  the  patients  developed treatment-emergent ADAs, but it is difficult to draw conclusions regarding the effects of ADAs on efficacy.

Tofersen  was  not  genotoxic,  and  no  carcinogenicity  studies  have  been  performed  due  to  the  lifethreatening nature of ALS, the negative genotoxic potential, and the absence of (pre)neoplastic changes, cell proliferation, and immune or endocrine dysfunction in chronic toxicity studies in NHPs .

The potential DART of tofersen was investigated in mice and rabbits. These  studies do not indicate harmful effects with respect to reproductive toxicity at therapeutic doses. Considering that tofersen is not  pharmacologically  active  in  mice  and  rabbits,  these  studies  do  not  provide  data  regarding  the pharmacological activity of tofersen in terms of its potential effects on reproduction or development. This limits the predictive value of these studies in terms of human safety. In this regard, the applicant points out, that an appropriate rodent surrogate ASO for SOD1 was not identified. It is important to note that the use of surrogates in non-clinical safety studies is challenging in that they may sometimes produce a different pattern of toxicity unrelated to target pharmacology. Findings from studies in SOD1 KO-mice have  shown  that  loss  of  SOD1  has  harmful  effects  on  fertility,  pregnancy  and  development.  The interpretation of the clinical relevance of these toxic effects in SOD1 KO-mice could be difficult.

The applicant highlighted that the effects of SOD1 KO in humans by the SOD1 ASO is not 100% and is more reminiscent of SOD1 heterozygous mice. A literature review of the available data on the effects of SOD1  down-regulation  indicates  that  the  potential  effects  of  ASO  (tofersen)  on  reproduction  and development are likely to be low; however, they are currently unknown. The lack of pharmacologically relevant studies with regard to pregnancy and fertility is now also adequately reflected in sections 4.6 and 5.3 of the SmPC.

Tofersen PEC surfacewater value is below the action limit of 0.01 µ g/L. and is not a PBT substance as log Kow does not exceed 4.5.

<div style=\"page-break-after: always\"></div>

## Assessment of paediatric data on non-clinical aspects

A product specific PIP waiver was granted (EMEA-002403-PIP01-18). It is widely accepted that SOD1ALS only occurs in the adult population. The European Medicines Agency has waived the obligation to submit the results of studies with tofersen in all subsets of the paediatric population in ALS. It is endorsed that no juvenile toxicity studies have been performed.

## 2.5.7. Conclusion on the non-clinical aspects

Overall, the  primary pharmacodynamic studies provided adequate evidence that tofersen shows good efficacy in vitro and in relevant animal models. No relevant off target effects are anticipated based on secondary PD studies. Safety pharmacology studies did not reveal safety signals for patients.

From the PK point of view, the monkey was the most relevant species for non-clinical efficacy and safety studies.

Overall, the toxicology programme revealed that tofersen was well tolerated.

The wording of sections 4.6 and 5.3 of the SmPC in relation to the lack of pharmacologically relevant DART studies has now been revised to adequately reflect this aspect.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The tofersen clinical development program (CDP) consists of two completed and two ongoing clinical studies:  Study  233AS101  Parts A,  B,  and  C  (complete)  and  open-label  extension  Study 233AS102 (ongoing) in participants with SOD1-ALS and Study 233HV101 (complete) in healthy volunteers and Study 233AS303 or ATLAS (ongoing) in presymptomatic SOD1 mutation carriers. No efficacy data from Study 233AS303 have been included in this application because the study remains blinded.

Separate to the CDP, there is an ongoing Expanded Access Program (EAP) (section 2.6.5.7.1).

The applicant has also in place an ongoing evidence generation plan (section 2.6.5.7.1). Continual longterm data generation in this rare, highly heterogeneous disease is important and could probably help further contextualize the longer-term benefit/risk of tofersen and better understand its long-term impact on disease progression and survival.

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 3: Listing of clinical studies

| Study Identifier [Countries]                                                                                                                                        | Study Design                                                                                                    | Test Products, Dose Regimen, Route of Administration                                                                                                                                                                                                                                                                                                                                                 | Primary Objectives                                                                                 | Number of Partici- pants Enrolled                                                                  | Duration of Treatment                                                                              | Study Status                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation)                                                                  | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation)              | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation)                                                                                                                                                                                                                                                                                                   | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation) | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation) | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation) | Studies in Participants with SOD1 ALS (weakness attributable to ALS and a confirmed SOD1 mutation) |
| 233AS101                                                                                                                                                            | Part A Phase 1/2 randomized, double-blind, placebo- controlled SAD study in participants with                   | Placebo vs. tofersen 10, 20, 40, 60 mg Intrathecal bolus injection                                                                                                                                                                                                                                                                                                                                   | Safety, tolerability, and PK.                                                                      | Tofersen: 15 Placebo: 5                                                                            | Single dose                                                                                        | Complete                                                                                           |
| CSR 233AS101 Parts A and B CSR 233AS101 Part C [Australia, Belgium,                                                                                                 | ALS a Part B Phase 1/2 randomized, double-blind, placebo- controlled MAD study in participants                  | Placebo vs. tofersen 20, 40, 60, 100 mg Intrathecal bolus injection                                                                                                                                                                                                                                                                                                                                  | Safety, tolerability, and PK.                                                                      | Tofersen: 38 Placebo: 12                                                                           | 12 weeks                                                                                           | Complete                                                                                           |
| Canada, Denmark, France, Germany, Italy, Japan, Republic of Korea, Poland, United Kingdom, United States]                                                           | with SOD-1 ALS Part C Phase 3 randomized, double-blind, placebo- controlled study in participants with SOD1-ALS | Placebo vs. tofersen 100 mg Intrathecal bolus injection Dosage regimen: 3 loading doses administered 2 weeks apart followed by maintenance doses every 4 weeks thereafter Treatment duration: 24 weeks (8 doses)                                                                                                                                                                                     | Efficacy Primary endpoint: Change from baseline to Week 28 in the ALSFRS- R total score            | Tofersen: 72 Placebo: 36                                                                           | 24 weeks                                                                                           | Complete                                                                                           |
| 233AS102 CSR 233AS102 Interim 1 CSR 233AS102 Interim 2 [Belgium, Canada, Denmark, France Germany, Israel, Italy, Japan, New Zealand, United Kingdom, United States] | Phase 3 open- label extension for participants who completed Study 233AS101                                     | Tofersen 100 mg b Intrathecal bolus injection Dosage regimen: 3 loading doses administered 2 weeks apart* followed by maintenance doses every 4 weeks thereafter. *Participants who received tofersen in Study 101 Part C receive 2 loading doses of tofersen 100 mg on Days 1 and 29, and placebo on Day 15 to maintain the study blind. Treatment duration: At least 152 weeks and up to 360 weeks | Long-term safety and tolerability Primary endpoint: Incidence of AEs and SAEs                      | Tofersen: 139 Participants with SOD1- ALS who completed Study 101                                  | Up to 360 weeks                                                                                    | Ongoing                                                                                            |

<div style=\"page-break-after: always\"></div>

| Study Identifier [Countries]                                                                                                                                  | Study Design                                                                                                                                            | Test Products, Dose Regimen, Route of Administration                                                       | Primary Objectives                                                                 | Number of Partici- pants Enrolled              | Duration of Treatment                          | Study Status                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Study in Healthy Volunteers                                                                                                                                   | Study in Healthy Volunteers                                                                                                                             | Study in Healthy Volunteers                                                                                | Study in Healthy Volunteers                                                        | Study in Healthy Volunteers                    | Study in Healthy Volunteers                    | Study in Healthy Volunteers                    |
| 233HV101 CSR 233HV101 [United States]                                                                                                                         | Phase 1 open- label study of a single-dose of radiolabelled tofersen (99mTc-MAG3- BIIB067) coadministered with unlabeled tofersen in healthy volunteers | Tofersen 40 mg and 100 mg containing up to 111 to 148 MBq 99mTc-MAG3- tofersen Intrathecal bolus injection | Evaluate CNS distribution of radiolabelled tofersen given with unlabelled tofersen | 8 c                                            | Single dose                                    | Completed                                      |
| Study in Pre-symptomatic SOD1Mutation Carriers                                                                                                                | Study in Pre-symptomatic SOD1Mutation Carriers                                                                                                          | Study in Pre-symptomatic SOD1Mutation Carriers                                                             | Study in Pre-symptomatic SOD1Mutation Carriers                                     | Study in Pre-symptomatic SOD1Mutation Carriers | Study in Pre-symptomatic SOD1Mutation Carriers | Study in Pre-symptomatic SOD1Mutation Carriers |
| 233AS303 (ATLAS) [Australia, Belgium, Brazil, Canada, France, Germany, Italy, Japan, Republic of Korea, Poland, Spain, Sweden, United Kingdom, United States] | Phase 3 randomized, placebo- controlled study with a longitudinal natural history run-in and open-label extension                                       | Placebo vs. tofersen 100 mg Intrathecal bolus injection                                                    | Efficacy                                                                           | 150 (planned)                                  | 2 years                                        | Ongoing d                                      |

MAD = multiple ascending dose; MBq = megabecquerel; PD = pharmacodynamics; PK = pharmacokinetics; SAD = single ascending dose

a A total of 6 participants in Study 233AS101 Part A did not have a SOD1 mutation, since this was not required prior to Protocol Version 2.0. None of these 6 participants enrolled in Study 233AS102; 2 only received placebo while 4 received a single dose of tofersen.

b A blinded loading dose period was incorporated in Study 233AS102 for participants who enrolled after completing Part C of Study 233AS101; blinded placebo or tofersen was administered at Day 15 for those who received tofersen or placebo in Study 233AS101 Part C respectively

c 5 of the 8 participants were enrolled at a site that was ultimately discontinued due to Good Clinical Practice noncompliance; data from these participants were reported but not analysed.

d Study 233AS303 will enrol n=150 participants in the observational run-in period (Part A) of the study, of which ~34 participants (~28 in Part B/C and ~6 in Part D) will enter the interventional study period. No data were available from Study 233AS303 as of the data cutoff for this application.

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Analytical Methods

In total, 12 different bioanalytical assay were reported. The PK of tofersen was analysed in plasma, serum, CSF, and CNS tissue via hybridisation enzyme-linked immunosorbent assay (ELISA). SOD1 PD was analysed in CSF (sandwich immunoassay and Liquid chromatography-mass spectrometry) and CNS tissue (sandwich immunoassay). The biomarkers pNfH and neurofilament light chain (NfL) were both

<div style=\"page-break-after: always\"></div>

each  analysed  in  CSF  (immunoassay  and  single-molecule  immunoassay,  respectively)  and  plasma (immunoassay, single-molecule immunoassay, and sandwich immunoassay), and immunogenicity (antitofersen antibodies) were analysed in plasma (immunoassay). The lower limit of quantification in CSF and plasma were 1 ng/mL.

## Pharmacokinetic data analysis

The PK of single and multiple doses of IT administered tofersen was characterised in plasma and CFS. CSF and Plasma PK were analysed using non-compartmental analysis (NCA) in studies 233AS101 and 233AS102. In addition, PK data from studies 233AS101 and 233AS102 were analysed using population PK (popPK) modelling and simulation techniques using the nonlinear-mixed effects modelling approach with NONMEM software.

## Evaluation and Qualification of Models

Standard  model  evaluation  and  validation  methods  such  as  goodness-of  fit  plots,  visual  predictive checks, and precision of parameter estimates were used.

## Statistical methods

For NCA PK results AUC0-24h, Cmax and tmax results were presented with standard descriptive statistics.

## Absorption

IT injection of tofersen into the CSF allows the drug to be administered in close proximity to the site of action within the CNS. Following IT bolus administration, tofersen was rapidly transferred from CSF into the CNS tissue and systemic circulation, with a median tmax of 2 to 6 hours in plasma.

In CSF steady state after multiple dosing was achieved immediately after the loading dose period (3 doses administered every 2 weeks). The maximum CSF trough concentration occurred at the third dose, which was the last dose of the loading dose period. There was little to no accumulation with monthly dosing after the loading dose period; the accumulation ratio appears to be less than 2-fold. This CSF accumulation indicates that the effective t1/2 of tofersen in CSF is approximately 1 month. Trough tofersen CSF concentrations stabilized at steady state and remained generally unchanged for the remainder of the administration period.

In plasma dose-dependent mean plasma Cmax was observed within a few hours after dosing, indicating that the drug was rapidly transferred from the site of administration (CSF) into systemic circulation. Mean plasma drug concentrations typically declined rapidly after reaching Cmax, mainly due to extensive distribution from plasma to systemic tissues. After single dose plasma concentrations were below limit of quantification at Day 8 (168 hours post dose) as well as later timepoints, precluding estimation of the terminal  plasma  t1/2.  After  multiple  dose  administration  the  AUC  and  Cmax  values  were  generally consistent between the first and last doses.

The trough plasma concentration versus time profiles appear to stabilize in the 2 months after the loading dose period (until Day 85), after which a slow drift toward higher trough concentrations over time is observed. The reason for this drift is not understood at this time.

## Distribution

Tofersen is distributed extensively in CNS tissues with highest concentrations present close to the site of  administration  (spinal  cord  tissues),  as  confirmed  by  the  analysis  of  autopsy  tissues  from  three tofersen-treated patients in Study 233AS102. After reaching the peak level, plasma concentrations of tofersen declined rapidly, likely due to extensive distribution to systemic tissues.

<div style=\"page-break-after: always\"></div>

## Elimination

Plasma elimination t1/2 could not be estimated, as plasma concentrations of treated participants were below the limit of quantification at 8 days (168 hours postdose) and after. The observed descending portions  of  the  curves  probably  represent  redistribution  phases.  The  effective  t1/2  of  tofersen  in cerebrospinal fluid was approximately 1 month.

The  route  of  excretion  was  not  specifically  investigated  in  humans.  The  expected  primary  route  of elimination  is  likely  via  urinary  excretion  of  nucleotides  after  tofersen  is  metabolized  slowly  by exonuclease-mediated hydrolysis.

The metabolism of tofersen has been evaluated in CD-1 mice and in cynomolgus monkey. The results in liver and kidney samples are consistent with the previous experience with similar classes of ASOs (e.g., 2'-MOE  modified  ASOs).  In  addition  to  the  parent  compound,  putative  oligonucleotide  metabolites, consistent with nuclease-mediated metabolism, were evident in the kidney and liver samples. Based on the previous experience with similar classes of ASOs, major circulating or unexpected metabolites for tofersen would not be expected in humans.

## Dose proportionality and time dependencies

In  CSF  tofersen  exposures  (troughs)  increased  with  dose  level;  the  increase  was  less  than  dose proportional from 20 to 100 mg. The tofersen CSF concentration in participants receiving tofersen 10 mg was below the limit of quantitation at all sampling timepoints. Concentrations were highest in the 100 mg group, lowest in the 20 mg group, and similar in the 40 and 60 mg groups. Concentrations of the 100 mg dose were approximately 2 to 3 times higher than those observed for the 20 mg dose.

In plasma significant tofersen plasma PK variability was observed, and formal PK linearity analysis was not performed due to the small sample size; however, in plasma it seems that exposure tend to increase more than dose-proportional from 20 mg single dose and multiple dose onwards.

## Population PK modelling

PK data from studies 233AS101 and 233AS102 were analysed using popPK modelling and simulation techniques. Two different models for plasma and CSF PK were developed. The plasma PK data were best described  by  a  two-compartment  model  with  depot  compartment  and  first  order  elimination.  The absorption  rate  from  CSF  to  plasma  (KA)  of  the  final  covariate  model  was  0.142  L/hr,  the  plasma clearance (CL) was 9.04 L/hr and central volume of distribution (V2 or Vcentral) was 58.2 L. The interindividual variability (IIV) were moderate to high on CL (IIV = 69.6 %CV), KA (IIV = 49.8 %CV), Vcentral (IIV = 129 %CV), Vperipheral (IIV = 131 %CV) and inter-compartmental clearance (IIV = 66.8 %CV). The following covariates were identified: ADA on CL (positive response of ADA antibodies decreased the plasma clearance of tofersen), body surface area (BSA) baseline level on CL, and sex on Vcentral. Relative standard errors were below 25 %.

The  CSF  PK  data  was  best  described  by  a  one-compartment  model.  The  elimination  rate  (K)  was 0.000876 /h (IIV = 84.1 %CV) and volume of distribution V was 8730 L (IIV = 105 %CV) a proportional residual unexplained variability at 79% was estimated. The CSF PK model was used to describe the PKPD relationship with SOD1 CSF and NfL plasma measures. Simulations for different doses higher than the proposed 100 mg IT dose were carried out (please refer to section Pharmacodynamics). Admittedly, the CSF PK model has limitations due to the data on which it is based on. However, it is regarded difficult to get more/better conclusions from the data by refining the model.

<div style=\"page-break-after: always\"></div>

Using pharmacometric software, VPCs stratified by nominal dose level for the plasma PK model were generated, which were not identified in the popPK report provided by the applicant (see the Figure 6 below;  x-axis  is  limited  to  the  first  day  only  and  shows  only  data  following  the  first  dose  in  each individual). The model appears to give an overall acceptable description of the plasma PK data during the first 24 hours, however, observations during the absorption phase are slightly over-predicted.

Upon further scrutiny of the raw data for plasma PK, it was found that ~50% of the observations have the concentration set to the value 1.0 ng/mL (same as the lower limit of quantification) and these values were included in the final PopPK model, treating them as a continuous variable. Handling of the data using M3 was submitted on request. The run with M3 method shows an extremely high condition number and high RSE on all THETAs, suggesting that the model is highly unstable and not able to show much advantage compared to the original based model in fitting the data.

Figure 6:  Visual predictive check (VPC) of plasma drug concentrations versus time since first dose for the tofersen population pharmacokinetic model.

<!-- image -->

Time since first dose (h)

Data are presented on a semi-log scale. Observed data (open circles) are presented as median (red solid line), 5th and 95th percentiles (red  dashed  lines).  The  predictions  are  based  on  500  simulated  datasets.  For  simulations,  the  95%  confidence  intervals  of  the corresponding median, 5th and 95th percentiles are shown as shaded areas. The lower limit of quantification (1 ng/mL) are shown as a horizontal grey line. Only observations following each subjects' first dose are included.

## Special populations

Impaired renal function

The PK of tofersen has not be investigated in a dedicated renal impairment study.

Impaired hepatic function

The PK of tofersen has not be investigated in a dedicated hepatic impairment study.

Gender

Overall, 49 and 48 % of the PK population from studies 233AS101 and 233AS102, respectively, were male and 51 and 52 % female.

<div style=\"page-break-after: always\"></div>

Based on popPK modelling, sex was identified as statistically significant covariate (factor -0.579) on Vcentral for tofersen in plasma, leading to a lower Vcentral for female patients of about -57.9 %. Thus, Vcentral in females for tofersen in plasma is expected to be about 24 L compared to males who are expected to have a Vcentral of about 52 L.

## Body weight

Baseline body weight was not a significant covariate for the PK parameters such plasma volume, and CL. However, BSA, an alternative measure of body size, was identified as a covariate of CL of tofersen.

## Race

Among the PK study population in study 233AS101 and 233AS102, the majority was white (n=111 [63 %] and n=83 [59 %]). Overall, 51 (29 %) and 44 (31 %) participants were of unknown race, 10 (6 %) and 9 (6 %) Asian, and each 4 (2 % and 3%, respectively) where of 'Other' races.

Race was not identified as a statistically significant covariate affecting the PK of tofersen. Observed PK difference across different races are likely attributed to differences in BSA. No dose adjustments based on race are proposed by the applicant.

## Body weight and Body surface area

Among the study population, body weight ranged from 42.5 to 146.5 kg (mean=78.7 kg) and 42.5 to 146.5 kg (mean=83 kg) in study 233AS101 and 233AS102, respectively. BSA ranged from 1.37 to 2.71 m 2  (mean=1.92 m 2 ) and 1.38 to 2.71 m 2  (mean=1.95 m 2 ), respectively.

Based on popPK modelling BSA was identified as statistically significant covariate (factor 1.26) on CL for tofersen  in  plasma,  leading  to  a  varying  CL  between  -35  to  +52  %  (i.e.  CL=5.8  L/h  and  13.7  L/h, respectively for BSA values of min=1.37 and max=2.71) compared to the typical value of 9.05 L/h (BSA=1.94).

## Elderly

Among the study population, age ranged from 21 to 78 years (mean=49 years) and 23 to 75 years (mean=49 years) in study 233AS101 and 233AS102, respectively. Age was not identified as significant covariate in any of the PK analyses seems not to have an impact on the plasma PK of tofersen.

Study 233AS101 Part B: Participant were ages from 21 to 66 years (mean = 51.3 years), with the placebo group having a slightly higher mean participant age (58.4 years) than the active treatment groups (45.0 to 55.3 years). In total, three participants (15 %) were aged ≥ 65 years.

Study 233AS101 Part B: Participant were aged from 26 to 75 years (mean=48.5 years), with the 40 mg treatment group having a slightly higher mean participant age (58 years) than the other groups (41.5 to 49.2 years). In total, five participants were aged ≥ 65 years.

Study 233AS101 Part C: The age ranged from 23 to 78 years (mean=49.2 years), with an overall higher mean participant age in the placebo group (51.2 years) compared with the tofersen group (48.1 years), this difference was driven by a difference in the 'enriched' subgroup, where the mean age was higher in the placebo group (54.0 years) compared with the tofersen group (47.3 years). In total, 14 participants (13 %) were aged ≥ 65 years.

Study 233AS102: n=13 age 18 - 35 years, n = 57 age 35 - &lt; 50 years, n = 52 age 50 - &lt; 65 years, n = 17 ≥ 65 years (overall n=139)

Based on popPK modelling age was not identified as a covariate affecting PK.  No dose adjustment based on age is proposed by the applicant.

<div style=\"page-break-after: always\"></div>

## Children

Tofersen is not planned to be used in paediatrics below the age of 18 years. The PK of tofersen has not been studied in paediatrics. In 2018, a waiver was granted for paediatrics from birth to less than 18 years of age (EMEA-002403-PIP01-18 and EMA/670855/2018).

## Immunogenicity

Among  the  PK  study  populations,  33  (19  %)  and  22  (16  %)  patients  were  ADA  positive  in  study 233AS101 and 233AS102, respectively.

Based on a preliminary popPK analysis, ADA were identified as statistically significant factor influencing the clearance of tofersen in plasma, leading to a lower tofersen clearance of about 5.16 L/h in ADA positive patients compared to ADA negative patients.

The popPK model was updated using data from the July 2021 data cut for Study 233AS102 and refined resulting in a model with time varying ADA effect on CL. ADA positive patients are expected to have a 32.2% reduced clearance of tofersen (compared to 42,9% in the previous model) leading to higher Ctrough concentrations for ADA positive patients (9.33 ng/mL vs 3.64 ng/mL). The applicant provided no mechanistic interpretation of this phenomenon. The applicant plans to further evaluate the impact of ADAs on efficacy, on the incidence of serious neurological events and other areas of interest, which may arise, in the ongoing clinical studies, which is endorsed. However, the impact of ADAs on efficacy should also be continued to be evaluated in the ongoing studies. (see also discussion on Clinical Safety)

## Pharmacokinetic interaction studies

In vitro studies with cryopreserved human primary hepatocytes indicate that tofersen is not an inducer or inhibitor of CYP450-mediated oxidative metabolism and, therefore, should not compete with other drugs for this metabolic pathway.

Tofersen  is  not  an in  vitro substrate  of  BCRP  and  MDR1  efflux  or  MATE1,  MATE2-K,  OAT1,  OAT3, OATP1B1, OATP1B3, OCT1, or OCT2 SLC transporters. Tofersen is also not an in vitro inhibitor of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 SLC, BCRP, BSEP, and MDR1 transporters. Therefore, the likelihood of DDI due to competition or inhibition of these transporters is very low.

Tofersen is highly bound to human plasma proteins (≥ 95% bound) at clinically relevant or higher plasma concentrations (0.1 and 30 μ g/mL). Protein binding in plasma for this class of ASOs is relatively weak, and the binding sites for this type of hydrophilic drug differs from the binding sites of low molecular weight  hydrophobic  drugs.  Therefore,  the  likelihood  of  DDI  due  to  competition  with  plasma  protein binding is very low.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Tofersen is complementary to a portion of the 3' untranslated region of the mRNA for human SOD1, binding by Watson-Crick base pairing (hybridisation). This hybridisation of tofersen to the cognate mRNA results in the ribonuclease H-mediated degradation of the mRNA for SOD1, which reduces the amount of  SOD1 protein synthesis and accumulation. The  binding site is independent from all known SOD1 mutations.

<div style=\"page-break-after: always\"></div>

## Primary and Secondary pharmacology

## Primary pharmacology

CSF SOD1 protein acts as an indirect biomarker of target engagement. A target therapeutic threshold for total CSF SOD1 reduction has not been established. Reductions of at least 20% was targeted as confirmation of target engagement, a threshold beyond the assay and biologic variabilities.

Tofersen administration led to rapid and sustained reductions in total CSF SOD1. A total reduction of SCF SOD1 protein of 35% was observed after 28 weeks of 100 mg tofersen treatment, compared to 2% in the  placebo  group  (difference  in  geometric  mean  ratios  for  tofersen  to  placebo:  34%;  nominal p&lt;0.0001). Reductions were apparent by approximately Week 8 and sustained for over 104 weeks of follow-up. However, physiological based PK modelling based on nonclinical data in NHPs suggests that the SOD1 lowering effect of tofersen is unevenly distributed in the CNS with reductions of SOD1 levels of greater than 99% in the spinal cord and of approximately 25% to 30% in the cortex.

In ALS, a lowering of neurofilament levels is generally thought to represent a slowing of axonal injury and neurodegeneration and thus provides evidence of treatment effect. Plasma NfL was evaluated as a key secondary biomarker endpoint in both Studies 101 Part C and 102 and as an exploratory endpoint in Study 101 Parts A and B.

Tofersen administration led to robust and sustained reductions in neurofilament over time. Plasma NfL levels  were  reduced  by  55%  (geometric  mean  ratio  to  baseline)  in  tofersen-treated  participants, compared to a 12% increase in placebo-treated participants from baseline to Week 28 (difference in geometric mean ratios for tofersen to placebo: 60%; post-hoc nominal p&lt;0.0001). Neurofilament levels declined through approximately Week 16 and were sustained over 104 weeks of follow-up.

## Secondary pharmacology

The immunogenic response for tofersen in plasma was evaluated in 166 tofersen-treated participants in Studies 101 and 102 with post-baseline plasma samples for ADAs. Overall, including the 15 July 2022 interim data cutoff from Study 102 for participants receiving any tofersen dose, 5 (3.0%) of participants were  ADA  positive  prior  to  their  first  dose  of  tofersen.  Ninety-seven  (58.4%)  tofersen-treated participants developed treatment emergent ADAs, of which 14 were transient and 83 were persistent.

The occurrence of ADA is not expected to produce notable effects on CSF PK since large molecules such as ADAs have limited penetration through the blood brain barrier into the CSF compartment. The impact of ADA was evaluated, but not identified as significant covariate for either the SOD1 protein or NfL PKPD models. Given this, no true impact on clinical function is expected.

A quantitative evaluation of the relationship between tofersen concentration and QTc was performed with results suggesting the absence of a concentration dependent QTcF prolongation. Covariates tested were age, weight, race, sex, baseline QTcF, treatment arm, time of QT collection, administration of concomitant drugs. None of the evaluated covariate relationships were statistically significant (P&gt;0.01). In the final analysis, the mean ∆∆QTcF increased with increasing tofersen concentration with a slope of a pproximately zero. Therefore, the mean and upper limit of the confidence region was below a ∆∆QTcF of 10 ms for the 5 th  to 95th percentiles of the observed tofersen concentration range.

## Relationship between concentration and effect

In  popPK  modelling the  development of a combined model for plasma and CSF was  not successful, therefore two separate models were developed. The PK of tofersen in plasma was described using a twocompartment model with depot and first order elimination. Three significant covariates were identified in plasma PK model development ADA on CL, baseline BSA on CL and sex on V2=Vcentral. Unexpectedly, positive ADA status was associated with 42.9% reduced clearance, a finding that should be interpreted

<div style=\"page-break-after: always\"></div>

with caution. The PK of tofersen in CSF was characterised using a simple one compartment bolus model, no significant covariates were found. The sparse data available (no PK data from phase 3, modelling based  on  n=166,  only  trough  concentrations)  showed  high  IIV.  Both,  the  plasma,  and  the  CSF compartments were downstream of the CNS, where the site of application and action of tofersen was. Therefore, the findings of the population PK modelling were difficult to interpret. It is agreed that the results of the CSF PK model were only useful to provide an approximation of exposure for the population PKPD models.

Two population PKPD models were developed. For both PD markers indirect response models were used with a maximum effect function. For SOD1 PKPD modelling, 3743 SOD1 protein observations, from 176 patients were used. For NFL PKPD modelling, a total of 2297 observations from 176 participants were included in the final modelling dataset.

The SOD1 pharmacodynamics were described using an indirect response model, where tofersen exposure in CSF was modelled to have an inhibiting effect on the SOD1 entering in the CSF. No covariate effects were found, especially for race this is not regarded as a meaningful result because of the high percentage of patients with white or unknown race. The SOD1 model was used to simulate for dosing of 100 mg, 150 mg, and 200 mg to show that the increase of effect is low using higher dosage than 100 mg. However, the IIV was high, sample size was small (n=176), and data sampling was sparse. Provided results for PKPD modelling suggest a median reduction in CSF SOD1 by about 23 %.

The NfL pharmacodynamics were described as well with an indirect response model used for simulations of dosing for 100 mg, 150 mg, and 200 mg tofersen. No significant covariate effects were found. Also, in  CSF-NFL  model  development  there  were  difficulties  regarding  convergence  of  the  model,  high variability and sparsity of data. Provided results for PKPD modelling suggest a median reduction in plasma NFL of 39 %.

## 2.6.3. Discussion on clinical pharmacology

Overall, the clinical pharmacology of tofersen has been well characterized.

The provided popPK and PK/PD have a low impact and are considered sufficient to provide information on tofersen PK in humans in the SmPC.

Nevertheless, it should be emphasized that the absence of 1) a joint population PK model (handling both CSF  and  plasma  PK  samples)  and  2)  an  exposure-response  (safety)  analysis,  hampers  any  dosing recommendation (if it exists).

The SmPC is updated with detailed on different PK parameters and exposures as known of today.

## 2.6.4. Conclusions on clinical pharmacology

In general, the PK of tofersen seem to be sufficiently investigated in CSF and plasma given the sparsity of the available data. The proposed dose is 100 mg IT across patients and no dose adjustments are proposed for different patient populations.

## 2.6.5. Clinical efficacy

Due to the various analyses from the applicant - two interim analyses with data cut-off 16 January 2022 (week 52) and 28 February 2023 (week 104) - and the Raw Data Pilot project analyses, the structure and sections of Clinical Efficacy as submitted by the applicant have been modified to facilitate the reading flow

<div style=\"page-break-after: always\"></div>

The dossier submitted contains only the very minimum number of studies. It is agreed that patients with SOD1 mutation in ALS represent an ultra-orphan disease since they belong to approximately 2% of ALS patients (approximately 1000 prevalent cases in the European Union).

As already pointed out the duration of the pivotal trial Study 101 Part C was short and the population was enriched,  and  these  had  consequences  in  clearly  establishing  efficacy  of  tofersen  in  SOD1-ALS patients.

It is considered that the most appropriate way to summarise the data submitted with this dossier is to present the results for the pivotal phase 3 Study 101 Part C followed by the integrated/combined results of studies 101 Part C and long term extension (LTE) 102 (with the results of two interim analyses with data cutoff after 52 weeks on 16 January 2022 and after 104 weeks 28 on February 2023).

There are three interim analyses relevant for efficacy with data cutoff on:

16 July 2021- 1st Interim analysis

16 January 2022 - 2nd Interim analysis

28 February 2023 - 3rd Interim analysis (CHMP requested)

## 2.6.5.1. Dose response study(ies)

Dose  levels  evaluated  in  clinical  trials  were  informed  by  nonclinical  toxicology  studies,  iterative translational predictions, and clinical trial experience.

Study 101 was a randomized, double-blind, placebo-controlled study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered to participants with SOD1-ALS. Initially designed as a Phase 1 single ascending dose (SAD) (Part A) and multiple ascending dose (MAD) (Part B) study.

Study 101 Part A (SAD) was a randomized, double-blind, placebo-controlled evaluation of 4 dose levels of tofersen (10, 20, 40, and 60 mg) administered to participants with SOD1-ALS. In total, 15 participants received a single dose of tofersen, and 5 participants received placebo. Participants were followed for approximately  8  weeks  in  the  study  and  were  eligible  to  be  screened  for  Part  B  (MAD)  thereafter. Participants who did not meet eligibility criteria for Part B were offered the opportunity to enrol in the ongoing open-label study, Study 102 LTE.

Study 101 Part B (MAD) was a randomized, double-blind, placebo-controlled evaluation of 4 dose levels of tofersen (20, 40, 60, and 100 mg) administered for approximately 12 weeks (3 loading doses on Days 1, 15, and 29 plus 2 maintenance doses on Days 57 and 85) in participants with SOD1-ALS. In total, 50 participants were randomized to receive tofersen (n = 38) or placebo (n = 12) and were followed for approximately 24 weeks before having the opportunity to enrol in Study 102.

Study 101 Part B was originally designed to test 3 dose levels of tofersen (20, 40, and 60 mg). PK data from the 39-week NHP toxicology study indicated that higher exposure to tofersen would effectively reduce CSF SOD1 levels. A fourth dose level of tofersen (100 mg) was added by amendment.

In total, 50 participants were enrolled in the MAD portion of Study 101 (Part B), of whom 12 received placebo and 10 received tofersen 100 mg. Consistent with the proportion of participants that met the fast  progressor  criteria  defined  in  the  statistical  analysis  plan  (SAP),  baseline  disease  progression characteristics  were  most  balanced  in  the  tofersen  100  mg  and  placebo  groups  thus,  enabling comparison.

<div style=\"page-break-after: always\"></div>

IT administration of tofersen 100 mg in Study 101 Part B led to the highest tofersen exposures, the greatest  reduction  in  total  CSF  SOD1  protein,  and  an  apparent  slowing  of  decline  across  several exploratory clinical outcome measures compared with lower doses. Physiological based PK modelling based on nonclinical data in NHPs suggests that tofersen 100 mg achieves exposures in CNS that are likely to reduce SOD1 levels by greater than 99% in the spinal cord and by approximately 25% to 30% in the cortex.

The PK of tofersen is summarized as follows. Maximum CSF concentrations of tofersen are achieved rapidly after IT administration. Steady-state concentrations in CSF were achieved immediately after the 4-week loading dose period. Minimal accumulation of tofersen in CSF was observed after the loading dose period. The effective t1/2 of tofersen in CSF was approximately 1 month. Although CNS tissue t1/2 cannot be measured in humans, the terminal t1/2 was measured in the CNS tissue of cynomolgus monkeys and found to be 31 to 40 days. This suggests that the CSF and CNS tissue concentrations likely reached equilibrium during the post-distribution period. Because the site of action of tofersen is within the CNS, these findings support the proposed frequency of dosing and route of administration.

Tofersen is  rapidly  transferred  from  CSF  into  the  systemic  circulation,  with  a  median  time  to  reach maximum observed concentration of 2 to 6 hours. After reaching the peak levels, plasma concentrations of tofersen declined rapidly, likely due to extensive distribution to systemic tissues.

Recognizing  that  SOD1-ALS  is  thought  to  be  a  predominantly  lower  motor  neuron  disease  and  a substantially higher dose level would be required to achieve a meaningfully differentiated SOD1 reduction in the cortex, the 100 mg dose level was selected for evaluation in the Phase 3 study (101 Part C). Specifically, tofersen 100 mg was administered as 3 loading doses at 14-day intervals on Days 1, 15, and 29, followed by maintenance doses every 28 days thereafter.

Based on the results described in the application, the proposed commercial dosage regimen is identical to the regimen investigated in Study 101 Part C (CSR 233AS101 Part C), i.e., 3 loading doses of tofersen 100 mg once every 2 weeks, followed by maintenance doses once every 4 weeks administered via IT bolus injection.

In CSF there was a less than proportional increase of tofersen exposures with increasing doses from 20 to 100 mg. The tofersen CSF concentration in participants receiving tofersen 10 mg was below the limit of quantitation at all sampling timepoints. Concentrations were highest in the 100 mg group, lowest in the 20 mg group, and similar in the 40 and 60 mg groups. Concentrations of the 100 mg dose were approximately 2 to 3 times higher than those observed for the 20 mg dose. However, tofersen plasma PK showed significant variability and formal PK linearity analysis was not performed due to the small sample size. However, there seemed to be a roughly dose-proportional increase in Cmax and AUC values over the evaluated dose range. The plasma PK parameter values were generally consistent between the first and last doses.

## 2.6.5.2. Main study(ies)

The applicant has completed study 233AS101, consisting of phase 1/2 parts A and B and phase 3 part C. Part C of study 101 is intended to support the efficacy and safety of tofersen together with the openlabel extension (OLE) or LTE study 233AS102 (further referred to as study 102).

In  the  following  sections,  each  study's  methods  and  results  are  presented  separately.  The  pivotal controlled  study,  study  101  Part  C  will  be  presented  first  and  then  the  open-label  Study  102  LTE afterwards. The analyses across studies 101 and 102 will be also summarised.

<div style=\"page-break-after: always\"></div>

## 2.6.5.2.1. Study 101 Part C (up to week 28)

## Methods

Study 101 Part C was a Phase 3, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of tofersen 100 mg versus placebo over 6 months. Initially designed to enrol 60 participants and subsequently amended to enrol 99 participants following regulatory feedback, a total of 108 participants with weakness attributable to ALS and a confirmed SOD1 mutation were randomized 2:1 to receive tofersen or placebo for approximately 24 weeks (3 loading doses followed by 5 maintenance doses).

## · Study Participants

A total of 108 participants were randomized (tofersen 100 mg, n = 72; placebo = 36), of whom 60 participants met prognostic enrichment criteria for faster disease progression and were included in the modified intent-to-treat (mITT) population (tofersen 100 mg = 39; placebo = 21). The prespecified primary analysis population, or mITT population, comprised the subset (n = 60) of participants who met the prognostic enrichment criteria for rapid disease progression based on their SOD1 mutation type and prerandomisation Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) slope (also referred to as the enriched or faster progressing/faster progressor subgroup - Table 4). All other participants (n = 48) were classified as the non-mITT population (also referred to as the other or slower progressing/slower progressor subgroup). As such, only descriptive analyses were performed, except for total CSF SOD1, which was formally tested as the primary endpoint in the non-mITT population.

Table 4:  Protocol-defined disease progression subgroups

|                                                      | Faster-Progressing Subgroup ('enriched'; mITT)                                                                                                                                                                                | Slower-Progressing Subgroup ('other'; non-mITT)   |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| Mutation type and prerandomisation ALSFRS-R slope OR | Protocol-defined SOD1 mutation historically associated with shorter survival a and ≥ 0.2 points/month prerandomisation slope Another SOD1 mutation and ≥ 0.9 points/month prerandomisation slope Another 0.9 prerandomisation | SOD1 mutation and < points/month slope            |
| ≥ 65% predicted                                      | ≥ 50% predicted                                                                                                                                                                                                               | SVC cutoff                                        |

a p.Ala5Val, p.Ala5Thr, p.Leu39Val, p.Gly42Ser, p.His44Arg, p.Leu85Val, p.Gly94Ala, p.Leu107Val, and p.Val149Gly

Study 101 Part C enrolled adults with weakness attributable to ALS and a confirmed SOD1 mutation.

SOD1 mutation must have been confirmed by the central reader based on the sample obtained during the  Screening  Visit;  participants  with  an  SOD1  mutation  interpreted  by  the  central  reader  to  be pathogenic or likely pathogenic were eligible.

Concomitant riluzole and/or edaravone use was permitted for participants who were on a stable dose for at  least  30  or  60  days  prior  to  study  baseline,  respectively.  In  the  overall  intent-to-treat  (ITT), approximately 62% of participants were receiving riluzole and 8% were receiving edaravone at baseline.

Study 101 was a Phase 1/2/3 study evaluating the efficacy, safety, tolerability, PK, and PD of tofersen administered to adult participants with ALS and confirmed SOD1 mutation. The applicant has chosen to modify  the  ITT  population  based  on  the  prerandomisation  ALSFRS-R  slope.  It  is  not  considered appropriate  to  create  ITT  subgroups  in  a  population  which  is  already  a  proportion  of  ALS  patients.

<div style=\"page-break-after: always\"></div>

However, due to the heterogeneity of the SOD1 ALS population it can be justified, as long as it is prespecified.

## · Treatments

Tofersen (BIIB067) was supplied as a liquid in vials containing 6.7 mg/mL of BIIB067. Artificial CSF was used as placebo. A total of 8 lots of tofersen and placebo were used.

A total of 100 mg of tofersen or placebo was administered 8 times (3 loading doses once every 2 weeks and 5 maintenance doses once every 4 weeks) by IT administration. A total volume of 15 mL tofersen or placebo was administered over a 1- to 3-minute bolus injection.

Study duration was approximately 32 to 36 weeks:

- 4-week screening period
- 24-week treatment period
- 4- to 8-week follow-up period as follows:
- o Participants  who  enrolled  (uninterrupted)  in  the  long-term  extension  (LTE)  study (233AS102), the Week 28 Visit served as the end of study (EOS) Visit.
- o Participants with delayed enrolment in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).

▪ If enrolment in the LTE occurred ≤ 28 days from the planned Week 28 Visit, the Week 32 Visit (EOS) assessments were conducted at the time of enrolment in the LTE.

▪ If enrolment in the LTE occurred &gt; 28 days from the planned Week 28 Visit, the Week 32 Visit (EOS) assessments were conducted as planned (4 weeks from the planned Week 28 Visit).

- o Participants who did not enrol in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).

The treatment regimen of tofersen has been selected using PK modelling data and the data from study Parts A and B. The use of placebo as a comparator is appropriate as no product has been approved for the treatment of SOD1-ALS.

## Storage

Tofersen and placebo were to be stored at 2°C to 8°C and protected from light.

## Missed doses

No description of handling of missed doses was described in the protocol of Study 101 Part C.

## · Objectives

The primary objective was to evaluate the clinical efficacy of tofersen administered to adult participants with ALS and a confirmed SOD1 mutation.

## · Outcomes/endpoints

The primary endpoint was change from baseline to Week 28 in ALSFRS-R total score.

Key secondary endpoints in order of hierarchical testing

- Change (i.e., ratio) from baseline in total SOD1 protein concentration in CSF
- Change (i.e., ratio) from baseline in neurofilament light chain (NfL) concentration in plasma
- Change from baseline to Day 197(Week 28) in percentage predicted slow vital capacity (SVC)
- Change from baseline to Day 197 in hand-held dynamometry (HHD) megascore

<div style=\"page-break-after: always\"></div>

- Time to death or permanent ventilation (PB) ( defined as ≥ 22 hours of mechanical ventilation [invasive or noninvasive] per day for ≥ 21 consecutive days )
- Time to death

Analytically, the following endpoints were measured for efficacy:

- ALSFRS-R
- SVC
- HHD megascore
- Participant diary/eDiary to record ventilation use
- Time to death
- Motor unit number index
- Quality  of  life  as  measured  by  the  following:  Amyotrophic  Lateral  Sclerosis  Assessment Questionnaire (ALSAQ-5), Fatigue Severity Scale (FSS), European Quality of Life Five Dimension Five Level Questionnaire (EQ-5D-5L), Work Productivity and Activity Impairment (WPAI), Zarit Burden Interview (ZBI), 36-Item Short Form Health Survey (SF-36), Patient Global Impression of Change, Clinician Global Impression of Change, Patient Global Impression of Status (PGIS), and Clinician Global Impression of Status.

Pharmacodynamics:

- total SOD1 protein in CSF

## Biomarkers*:

- Misfolded or mutant SOD1
- NfL [blood (serum) and CSF]
- pNfH [blood (plasma, serum) and/or CSF]
- Urinary p75 extracellular domain (p75ECD)

*  The  following  biomarker  data  were  not  available  at  the  time  of  writing  of  the  CSR  due  to  assay availability: urinary p75ECD and misfolded or mutant SOD1. Both NfL and pNfH were measured in CSF and plasma, not in serum.

Pharmacokinetics:

- Tofersen concentrations in the plasma and CSF were determined using validated assays.

The functional scales as well as the patient reported outcomes (PRO) selected for the conduct of the study are considered appropriate. The choice of the time-point for the end of study measurements, week 28, is considered too short to show any potential efficacy of tofersen. This issue has been extensively discussed during the scientific advice procedures.

## · Sample size

For Study 101 Part C, the sample size was selected primarily based on the JRT combining the Week 28 change from baseline in ALSFRS-R total score and mortality in the mITT population.

Interim data from Study 101 Part B in the fast-progressor group as well as the observed ALSFRS-R decline in a similar fast-progressor SOD1-ALS population receiving placebo from a historical data set (Benatar 2018) are the basis of the assumed treatment effect and variability according to the applicant.

Participants from both datasets were matched with the prognostic enrichment criteria for rapid disease progression  specified  in  Protocol  233AS101  Version  8.  Based  on  these  2  datasets  to  determine  the expected  ALSFRS-R  decline  and  limited  survival  data  in  fast-progressors  from  the  literature  on participants with a SOD1 A5V mutation, the sample size calculation assumed a 24.7-point decline in the placebo group and a 4.8-point decline in the tofersen group over 28 weeks, a pooled SD of 3.166, and expected survival of 82% in the placebo group and 90% in the tofersen 100 mg group. The assumptions for  overall  survival  were  taken  from  overall  survival  data  in  fast-progressors  from  the  literature  on individuals with a SOD1 A5V mutation. With 60 participants in the mITT population and a two-sided significance level of 0.05, the JRT would provide 84% power. Because events of death were factored into

<div style=\"page-break-after: always\"></div>

the analysis, no sample size overage was planned for missing values. For the population outside the mITT population, the primary focus was on the PD endpoint, total CSF SOD1 protein concentration, as this population was anticipated to have a slower decline in clinical function than the mITT population. A sample size of 26 participants in the tofersen-treated group and 13 participants in the placebo group for the population outside of the mITT would provide 97% power to detect a 25% reduction in total CSF SOD1 protein from baseline in the tofersen-treated group, with an assumed SD of 0.216 (natural log scale), compared with the placebo group. A 25% reduction in the CSF SOD1 protein concentration was estimated to exceed both the SOD1 assay variability and the longitudinal biovariability of CSF SOD1 as measured in humans.

Therefore, Part C was planned to randomize a total of approximately 99 participants, with participants receiving tofersen and placebo in a 2:1 ratio. The COVID-19 mitigation plan lowered the risk of missed doses and assessments and was in place to avoid the need for a sample size increase.

However, rather than the anticipated 24.7-point decline on the ALSFRS-R, the placebo arm declined by 8.1 points over the 6-month period, suggesting that the relatively short trial duration limited the amount of time to overcome disease heterogeneity in the population.

## · Randomisation and Blinding (masking)

Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active: placebo) ratio for 28  weeks  (197  days)  at  32  sites  globally.  Randomisation  was  stratified  by  3  factors:  1)  whether  a participant met prognostic enrichment criteria for rapid disease progression; 2) whether a participant used edaravone at baseline; and 3) whether a participant used riluzole at baseline.

With respect to blinding (masking) in  Study 101, treatment assignments were blinded to applicant, vendors, participants, caregivers, and study site personnel involved in the assessment of efficacy and safety. To preserve this blind, Study 102 was designed with a blinded loading dose period in which those who previously received tofersen in Study 101 received a dose of placebo at Day 15, and vice versa.

Unblinded  safety  data  for  Studies  101  Part  C  and  102  were  reviewed  on  a  quarterly  basis  by  the independent data safety monitoring committee (IDMC). An independent biostatistician and statistical programmer prepared the unblinded outputs and sent these via a secure method to the IDMC.

Though elevations in CSF white blood cells have been observed in both placebo and tofersen-treated participants, these elevations have been observed at a greater frequency and to a greater magnitude with tofersen treatment. In an abundance of caution, access to participant-level CSF related laboratory data was restricted from blinded applicant team members in the clinical database. Measures implemented are detailed in the Unblinding Plan. Designated ALSFRS-R raters were not involved in any other aspect of the study and remained blinded to results of all other study assessments.

These  measures  were  implemented  for  both  Studies  101  Part  C  and  102,  and  they  continue  to  be maintained for the ongoing Study 102.

Following the study completion and database lock of Study 101 Part C, a small team at applicant´s side was unblinded to treatment assignments to prepare this application, while an independent blinded team continued  to  work  on  the  ongoing  study  management  activities  for  Study  102.  This  study  team overseeing  Study  102  remains  blinded  to  treatment  assignments,  as  do  all  vendors,  participants, caregivers, investigators, and study site personnel. The unblinded team were not involved in the study management and collection of data for the ongoing Study 102 following the initial interim lock based on the 16 July 2021 data cut. On conducting a second interim analysis, the unblinded team had no access to the data collected between the 16 July 2021 data cut and the 16 January 2022 data cut until after the second interim lock occurred, at which time they were given access to all data up to this data cut. The unblinded team were responsible for the modified SAP which was finalized prior to the interim lock based

<div style=\"page-break-after: always\"></div>

on the data cut of 16 January 2022. All these measures continue to be maintained. Post-withdrawal vital status data for participants who withdrew from Studies 101 Part C or 102 were collected retrospectively in a blinded manner by the blinded study team, while the unblinded team have no access to these data.

## · Statistical methods

## Estimand (target of estimation)

The estimand of the primary analysis was defined as follows:

- Population: all participants in the mITT population.
- Variable: change from baseline to Day 197 in the ALSFRS-R total score.
- Intercurrent events: relevant intercurrent events (death and withdrawals) were handled using a  composite  strategy  in  which  participants  who  had  these  intercurrent  events  were  ranked against  each  other  and  against  participants  without  any  intercurrent  event  using  the  JRT methodology based on MI datasets. Participants were ranked using their Day 197 value (or imputed Day 197 value for withdrawals).
- Summary statistics: difference between treatment groups in least squares (LS) means of Day 197  change  from  baseline  with  corresponding  standard  errors  (SEs)  and  95%  confidence intervals (CIs) taken from the ANCOVA for change from baseline to Day 197, based on the MI dataset.

The definition of the estimand is not compliant with ICH E9(R1) and is overall inconsistent. The estimand describes the target of estimation (scientific question of interest) in alignment with the objective of the study. Statistical methods need to be aligned to the estimand definition but are not part of the estimand definition.

The intercurrent events 'death' and 'withdrawal' are claimed to be handled by a composite strategy. However, according to the description of the applied JRT+MI method only deaths were actually handled in alignment with a composite strategy (by assigning worst ranks according to survival time), while imputing missing values for withdrawals under a missing at random (MAR) assumption is not aligned to a composite strategy but to the hypothetical strategy 'if the patient had not withdrawn'.

The  ANCOVA+MI  for  estimation  of  the  population  level  summary  measure  is  also  aligned  to  a hypothetical strategy not only for withdrawal but also for death and is therefore not consistent with the description of the strategies for the intercurrent events.

However,  for  treatment  withdrawals,  the  treatment  policy  strategy  (i.e.  the  effect  irrespectively  of withdrawal) is usually of regulatory interest as withdrawal from treatment may be related to effects of the treatment. For the intercurrent event death, a composite strategy is appropriate. However, in case of ALSFRS-R as the variable of interest, the value '0' can also be considered as the true value as death can be considered as complete loss of function.

## Statistical methods

The SAP describes in detail the planned statistical methods for data collected in Part C.

## Analysis populations:

ITT  population:  all  subjects  in  Part  C  who  were  randomized  and  received  at  least  1  dose  of  study treatment.

Modified  ITT  Population:  all  subjects  who  meet  the  prognostic  enrichment  criteria  for  rapid  disease progression in Part C who were randomized and received at least 1 dose of study treatment.

<div style=\"page-break-after: always\"></div>

Non mITT Population: the subset of subjects in the overall ITT population who were not included in the mITT population, i.e. all other eligible subjects.

For each of the primary efficacy and secondary efficacy endpoints, the key analysis used for formal testing was in the mITT population and was classified as the 'primary analysis' for that efficacy endpoint. Analyses in the non-mITT population and overall ITT population of each of the primary and secondary endpoints were also conducted and were classified as secondary analyses, with the exception of total SOD1 protein in CSF, which was the primary endpoint for the non-mITT population.

The primary efficacy endpoint in Study 101 Part C was change from baseline to Week 28 in ALSFRS-R total  score  in  the  mITT  population.  The  primary  efficacy  analysis  was  a  Joint  Rank  Test  (JRT)  in conjunction with multiple imputation (MI) to handle withdrawals for reasons other than death. MI was used to impute all missing data before determining the rank score, including data after withdrawal from the study except after death. The MI model for the mITT population included treatment, riluzole or edaravone use, baseline score, and postbaseline scores. Subjects who died were given lower ranks than subjects who completed the study or withdrew from study for other reasons than death, with the lowest ranks  being  given  to  the  subjects  who  died  in  the  shortest  time  after  first  dose.  For  subjects  who completed study or discontinued for other reasons than death, progressively higher ranks were given to subjects with a higher change from baseline at Day 197 (i.e. smaller decline at Day 197). For each of the imputed datasets, the ranked scores were analysed using an ANCOVA model with treatment included as a fixed effect and adjusted for the following covariates: baseline disease duration since symptom onset, baseline ALSFRS-R total score, and use of riluzole or edaravone. The model was then used to obtain  the  p-value  based  on  Rubin's  rule  from  PROC  MIANALYZE  for  the  joint  rank.  The  treatment comparison was based on a two-sided alpha level of 0.05.

As summary statistics for the treatment effect, the difference between treatment groups in LS means of Day 197 change from baseline with corresponding SEs and 95% CIs taken from the ANCOVA+MI for change  from  baseline  ALSFRS-R  total  score  to  Day  197,  replacing  missing  values  after  withdrawal, intermittent missing data and after death based on the MI model described above. The ANCOVA model included treatment group as a fixed effect and covariates baseline ALSFRS-R total score, baseline disease duration since symptom onset, and use of riluzole or edaravone. The corresponding nominal p-value was also presented for the ANCOVA+MI.

Change from baseline to Week 28 (Day 197) in percent predicted SVC for the mITT population was analysed as for the primary efficacy endpoint.

Changes from baseline to Week 28 (Day 197) i.e., ratios to baseline in each of total CSF SOD1 protein, plasma NfL and HHD megascore were analysed for the mITT population using ANCOVA with MI. Total CSF  SOD1  protein  was  also  analysed  similarly  in  the  non-mITT  population.  Data  for  PD/biomarker endpoints were log transformed for the ANCOVA analysis with MI.

Ventilation assistance-free survival and overall survival, respectively, were analysed as time to event endpoints. Kaplan-Meier estimates of the cumulative probability of event occurrence over time were determined. Treatment comparison was based on a log-rank test stratified by treatment and riluzole or edaravone use. A Cox regression model adjusted for baseline disease duration since symptom onset, and riluzole  or  edaravone  use  was  used  to  obtain  the  hazard  ratio  and  95%  CIs  for  each  of  these endpoints.

If  the  primary  endpoint  was  statistically  significant  at  the  two-sided  alpha  of  0.05,  the  analyses  of secondary endpoints were based on a sequential testing procedure in the order of the rank of secondary endpoints as listed in the endpoint section.

<div style=\"page-break-after: always\"></div>

Among several sensitivity analyses to assess the robustness of the primary efficacy analysis, given the potential utility of neurofilament as a biomarker of ALS disease activity, baseline plasma NfL was included as an additional covariate in ANCOVA model for both ranked scores and change from baseline to Day 197 in ALSFRS-R total score.

## Post-hoc analyses

An ANCOVA analysis was performed for the overall ITT population; it included treatment as a fixed effect and was adjusted for the following covariates: baseline plasma NfL (in original scale), riluzole/edaravone use, and the corresponding baseline value for the endpoint. Disease duration since symptom onset was replaced by baseline plasma NfL because this is a better predictor of disease progression. In addition, for SVC, baseline plasma NfL replaced both duration since symptom onset and baseline ALSFRS-R score, which had originally been specified as prognostic factors for disease progression.

The following analyses were specified for the ISE but also provided for Study 101, Part  C: Disease progression  subgroup  analyses  (mITT/nonmITT and &lt; median, ≥ median baseline NfL) and ITT population analyses include post hoc analyses adjusting for both disease duration and baseline plasma NfL,  analyses  adjusting  for  ALSFRS-R  prerandomisation  slope,  analyses  adjusting  for  ALSFRS-R prerandomisation slope and baseline plasma NfL.

## Results

## · Participant flow

<div style=\"page-break-after: always\"></div>

Figure 7: Participants flow and disposition of screened participants for study 101 Part C

<!-- image -->

Reasons for discontinuation may include adverse event, consent withdrawn, non-compliance with study protocol, disease progression and others. The specific reasons per arm are removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

## · Recruitment

Date of first treatment: 27 March 2019 - End of Study Date: 16 July 2021

Approximately 99 participants were planned to be randomized. A total of 108 participants were randomized  and  dosed,  with  72  participants  receiving  tofersen  and  36  participants  receiving placebo. A total of 97 participants completed the study. One participant discontinued treatment arm due to pulmonary embolism but continued in the study.

## · Conduct of the study

The original protocol, dated 24 September 2015, was amended 8 times (the current protocol is Version 8), with an additional 24 country-specific amendments (CSAs). Part C was added to Study 233AS101 as part of Version 5 (20 Dec 2018); this amendment and all subsequent amendments are described in the table below. Protocol amendments Version 2 through Version 4 are described in the separate Part A/B case study report because they predated the addition of Part C to the study.

<div style=\"page-break-after: always\"></div>

Overall,  in  the  ITT  population,  88.9%  of  participants  (96/108  participants)  had  a  major  protocol deviation.  The  most  common  deviations  were  in  the  categories  of  efficacy  criteria  (63.0%,  68/108 participants),  study  procedures  criteria  (32.4%,  35/108)  and  laboratory  assessments  (30.6,  33/108 participants). Major protocol deviations due to COVID-19 were reported in 33.3% of participants (36/108 participants).  The  most  frequently  reported  reason  for  major  COVID-19-related  protocol  deviations included movement restrictions related to COVID-19 pandemic (11.1%), other COVID-19-related reason (11.1%), and sites closed or access restricted due to the COVID-19 pandemic (9.3%)

Multiple  procedures  were  implemented  across  studies  to  ensure  data  integrity.  Study  personnel underwent  standardized  training  on  the  protocol  and  study  assessments  prior  to  the  enrolment  of participants  at  their  institution.  To  preserve  the  integrity  of  data,  site  staff,  study  participants,  and vendors remain blinded to individual treatment assignments from Study 101 Part C.

There were some major amendments to the protocol with the most important one being the change of the analyses focusing on the NfL levels and not the pre-randomisation slope. This change took place just before the interim database lock 2 for Study 102 in February 2022. Thus, it cannot be considered as 'Prespecified' in terms of the initial protocol and prior to the final database lock and unblinding. It was post-hoc for Study 101 Part C and although it was specified at a later time-point and before the analysis of study 102, changes were made in knowledge of results from the ongoing study because study 102 as an extension study is not independent from Study 101 Part C.

Major protocol deviations were observed but these were similar between the 'enriched' subgroup and the other. A slightly higher percentage of the overall protocol deviations were recorded in the tofersen group  (91.7%)  compared  to  the  placebo  group  (88.3%)  in  the  ITT  population.  However,  for  the deviations categorised under 'efficacy criteria' the percentages among groups were similar 62.5 % for tofersen and 63.9% for placebo. Since differences were not observed, an impact of the deviations on the outcome of this double-blind randomised study is not expected.

## · Baseline data

## Applicant's analyses and presentation

Most participants were White (63.9%), followed by Asian (8.3%). A large proportion of participants did not report their race and ethnicity (25.9%) due to confidentiality regulations. The percentage of males and females was similar across treatment groups and populations, with more males enrolled overall (males, 57.4% and females, 42.6%). Participant ages ranged from 23 to 78 years with a higher mean participant age in the placebo group in the 'enriched' subgroup (54.0 years) compared with the tofersen group  (47.3  years).  Other  demographic  characteristics  were  generally  balanced  between  treatment groups and populations.

Baseline demographic and most disease characteristics (Table 5) were balanced across treatment arms for use of riluzole and/or edaravone and characteristics related to the stage of disease, including time from onset, total ALSFRS-R score, and SVC. Higher levels of NfL were observed in the tofersen group suggesting potentially faster disease progression compared to the placebo group.

The population enrolled in this study was representative of the broad SOD1-ALS population. Forty-two unique SOD1 mutations centrally confirmed as pathogenic or likely pathogenic were enrolled. The most commonly  identified  SOD1  mutation  types  were  p.Ile114Thr  (n=  20/108;  18.5%),  p.Ala5Val  (n  = 17/108; 15.7%) and p.Gly94Cys (n = 6/108; 5.6%), and p.His47Arg (n = 5/108; 4.6%). It is noted that A4V/A5V (p.Ala5Val) mutation carriers are considered the most prevalent fast progressing mutation type enrolled which is consistently associated with a median survival (based on Kaplan Meier) at or below 1.2 years.

<div style=\"page-break-after: always\"></div>

Table 5: Baseline disease characteristics

|                                                                                               | mITT (n=60)                   | mITT (n=60)                   | non-mITT (n=48)                  | non-mITT (n=48)                 | ITT (n=108)                     | ITT (n=108)                     |
|-----------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                                               | placebo (n=21)                | tofersen 100 mg (n=39)        | placebo (n=15)                   | tofersen 100 mg (n=33)          | placebo (n=36)                  | tofersen 100 mg (n=72)          |
| Mutation1 type n (%) p.Ile114Thr p.Ala5Val p.Gly94Cys p.His47Arg                              | 6 ( 29 ) 6 (29) 1 (5) 0       | 5 ( 13 ) 11 (28) 1 (3) 0      | 4 (27) 0 1 (7) 4 (27)            | 5 (15) 0 3 (9) 1 (3)            | 10 ( 28 ) 6 ( 17 ) 2 (6) 4 (11) | 10 ( 14 ) 11 ( 15 ) 4 (6) 1 (4) |
| Site of onset n (%) Bulbar Lower limbs Upper limbs Respiratory Multiple sites                 | 2 (10) 14 (67) 5 (24) N N     | 3 (8) 19 (49) 14 (36) N N     | N 12 (80) 2 (13) 0 0             | N 27 (82) 6 (18) 0 0            | 3 (8) 26 (72) 7 (19) N N        | 3 (4) 46 (64) 20 (28) N N       |
| Time from symptom onset (months) median (min, max) ALSFRS-R pre- randomisation slope : median | 8.3 (2.4, 21.3) -1.51 (-4.91, | 8.3 (1.7, 18.5) -1.34 (-8.30, | 39.6 (11.8, 103.2) -0.17 (-0.84, | 35.5 (3.9, 145.7) -0.30 (-0.77, | 14.6 (2.4, 103.2) -0.89 (-4.91, | 11.4 (1.7, 145.7) -0.75 (-8.30, |
| (min, max) ALSFRS-R baseline total score:                                                     | -0.42) 35.4 (5.66)            | -0.39) 36.0 (6.40)            | -0.02) 39.9 (5.09)               | 0.00) 38.1 (5.13)               | -0.02) 37.3 (5.81)              | 0.00) 36.9 (5.91)               |
| mean (SD) Range: min, max                                                                     | 24, 45                        | 15, 44                        | 32, 47                           | 26, 48                          |                                 |                                 |
| ALSFRS-R run-in slope (Screening to Day 15) raw mean (SD)                                     | -1.3 (3.91)                   | -1.8 (2.47)                   | 0.1 (1.87)                       | -0.1 (1.34)                     | 24, 47 -0.7 (3.25)              | 15, 48 -1.0 (2.19)              |
| % predicted SVC at baseline:                                                                  | 83.7 (17.87)                  | 80.3 (14.22)                  | 87.1 (14.82)                     | 84.2 (19.02)                    | 85.13 (16.53)                   | 82.1 (16.59)                    |
| mean (SD) Range: min, max                                                                     | 57.4,                         | 46.7,                         | 54.8, 114.4                      | 134.7                           | 54.8, 120.4                     | 46.7, 134.7                     |
|                                                                                               | 120.4                         | 114.8                         |                                  | 55.4,                           |                                 |                                 |
| Plasma NfL at baseline (pg/mL) mean (SD)                                                      | 127.3 (94.4)                  | 146.2                         | 37 (29.5)                        | 47.6 (41.8)                     | 89.7 (86.5)                     | 100.4                           |
|                                                                                               |                               | (82.6)                        |                                  |                                 |                                 | (82.8)                          |
|                                                                                               |                               |                               |                                  |                                 |                                 | 66.6                            |
| Geometric mean Range: min, max                                                                | 92.7 9, 370                   | 121.8 12, 329                 |                                  | 33.2 5, 211                     | 56.6 8, 370                     | 5, 329                          |
|                                                                                               |                               |                               | 28.4 8, 99                       |                                 |                                 |                                 |

1 Most common mutations, i.e., n &gt; 4

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

In the ITT population mean values for ALSFRS-R baseline total score and % predicted SVC at baseline were slightly worse in the tofersen group with 36.9 and 82.1% respectively, compared to the placebo group with values of 37.3, and 85.13% and, respectively. The geometric mean baseline plasma NfL for the prespecified mITT population was approximately 29 pg/mL (23%) higher in the tofersen group (122

<div style=\"page-break-after: always\"></div>

± 83 [standard deviation, SD] pg/mL) than in the placebo group (93 ± 94 [SD] pg/mL). Baseline NfL levels, which have been shown to correlate with disease progression, were approximately 15% to 25% higher in the tofersen group (100.4 pg/ml) than in the placebo group (89.7 pg/ml) in the whole ITT population. Consistently, the rate of decline on ALSFRS-R from screening to Day 15 (approximate 42day period) was greater in the tofersen group compared to the placebo group. Together with the duration of symptom onset (median 14.6 months for placebo vs median 11.4 months for tofersen group) this may indicate  more  stable  disease  in  patients  in  the  placebo  group.  According  to  the  applicant,  these imbalances are apparent in the ITT population as well as the protocol-defined subgroups. Subgrouping the population by baseline plasma NfL levels (rather than mutation type and pre-randomisation ALSFRSR slope decline) appeared to correct these imbalances between the tofersen and placebo groups.

To account for the significant disease heterogeneity in SOD1-ALS and the relatively short study duration of Study 101 Part C, the applicant had implemented protocol-defined prognostic enrichment criteria for the mITT population.

However,  consistent  with  the  literature  (Thompson  2022),  baseline  neurofilament  levels  were  more strongly  correlated  with  longitudinal  change  in  ALSFRS-R  (Spearman  correlation  coefficient:  -0.59; p = 0.0003) than was prerandomisation ALSFRS-R slope decline (Spearman correlation coefficient: 0.46; p = 0.0071) in the placebo participants in Study 101 Part C (Figure 8).

Figure 8: Baseline plasma NfL outperformed prerandomisation ALSFRS-R decline as a predictor of 6month change in ALSFRS-R in Study 101 Part C placebo participants

<!-- image -->

## Baseline characteristics (SOD1 CSF protein levels)

The mean concentration of total SOD1 protein in the CSF was balanced between placebo and tofersen groups at baseline in the mITT population (117.2 ng/mL and 118.1 ng/mL, respectively), and slightly lower in the tofersen group than in the placebo group for the non-mITT population (120.4 ng/mL versus 135.8 ng/mL) and ITT population (118.7 ng/mL versus 125.5 ng/mL).

## Raw Data Pilot Project analyses and presentation

The Figure below shows the distribution of NfL concentration (pg/ml) at baseline in the two treatment groups.  X-axis  indicates  NfL  concentration  in  pg/ml  and  y-axis  indicates  proportion  of  subjects,  i.e. counts of subjects with a NfL assessment in the indicated group divided by the number of subjects in the treatment groups at baseline (see below at Figure 9 the 1 st  and the 2 nd  evaluation phase of the Raw Data Pilot project).

<div style=\"page-break-after: always\"></div>

Figure 9: Distribution of neurofilament light chain concentration (pg/ml) at baseline

<!-- image -->

With respect to mutation types, all participants had a centrally confirmed pathogenic or likely pathogenic SOD1 mutation, as adjudicated by the central laboratory, with 42 unique SOD1 mutations. The most commonly identified SOD1 mutation types (&gt; 10% of participants) were p.Ile114Thr (n=20/108; 18.5%) and p.Ala5Val (n=17/108; 15.7%). It would have been worthwhile to further explore the results with patients with certain variants or mutation types such as A4V/A5V (p.Ala5Val), but its small number in the study (17 out of 108) would not allow any meaningful conclusions. In addition, it appears that in most cases there are only 1 or 2 patients per variant, which is not helpful for subgroup analysis.

It is noted that the natural history of SOD1-ALS is highly variable with a mean onset of 49.7 ± 12.3 years and mean disease duration of 4.6 (1.4 for A4V and 6.6 for non-A4V) years. Disease progression for individual mutations is variable, with survival ranging from less than a year to over 20 years (Bali 2017; Cudkowicz 1997).

It should be also noted that recently a study with a cohort of long survivors in Scotland was published (Leighton et al 2022). Recent analysis of a historical cohort of 428 Scottish people with motor neuron disease indicated a median survival of 3.5 years from onset of symptoms and 2 years from diagnosis. However, the upper range of survival was 25.8 years from diagnosis. Fifty-eight long survivors with MND were  identified  in  Scotland.  Median  survival  from  diagnosis  was  15.5  years.  Long  survivors  were significantly  younger  at  onset  and  diagnosis  than  incident  patients  and  had  a  significantly  longer diagnostic delay. 42% had the motor neuron disease subtype of primary lateral sclerosis. Whole genome sequencing was performed in 46 individuals: 14 (30.4%) had a potentially pathogenic variant. Four carried the known SOD1 p.(Ile114Thr) variant (Leighton et al 2022). From these 4 survivors, 2 had a mean survival from onset in months (years): 199 (16.6), one 232 (19.3) and one 263 months (21.9). The authors suggested that for example the absence of a C9orf72 pathogenic expansion and presence of the SOD1 p.(Ile114Thr) mutation or other rare mutation might indicate better outcome.

## · Numbers analysed

## Applicant's analyses and presentation

A total of 97 participants completed the study. Treatment discontinuations and study withdrawals were similar  in  the  tofersen  group  compared  to  the  placebo  group;  treatment  discontinuations  and  study withdrawals  were  more  common  in  the  'enriched'  subgroup.  The  most  common  reason  for

<div style=\"page-break-after: always\"></div>

discontinuation of study treatment was disease progression (n = 5, 4.6%), all of which occurred in the 'enriched' subgroup, followed by adverse events (AEs) (n = 3, 2.8%). One participant (in the 'enriched' subgroup) died 114 days after being randomized to tofersen 100 mg. The cause of death was reported as congestive cardiac failure, and the Investigator assessed the event to be unrelated to tofersen.

Table 6: Study 101 Part C participant disposition

|                                 | Faster-Progressing Subgroups; mITT   | Faster-Progressing Subgroups; mITT   | Slower- Progressing Subgroups; Non- mITT   | Slower- Progressing Subgroups; Non- mITT   | ITT      | ITT      |
|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------------------|--------------------------------------------|----------|----------|
|                                 | placebo                              | tofersen                             | placebo                                    | tofersen                                   | placebo  | tofersen |
| Dosed n (%)                     | 21 (100)                             | 39 (100)                             | 15 (100)                                   | 33 (100)                                   | 36 (100) | 72 (100) |
| Died n (%)                      | 0                                    | 1 (3)                                | 0                                          | 0                                          | 0        | 1 (1)    |
| Completed study treatment n (%) | 19 (91)                              | 33 (85)                              | 14 (93)                                    | 30 (91)                                    | 33 (92)  | 63 (88)  |
| Withdrew from study n (%)       | 2 (10)                               | 6 (15)                               | 1 (7)                                      | 2 (6)                                      | 3 (8)    | 8 (11)   |
| - AE                            | 0                                    | 1 (3)                                | 0                                          | 1 (3)                                      | 0        | 2 (3)    |
| - Consent withdrawn             | 0                                    | 1 (3)                                | 1 (7)                                      | 1 (3)                                      | 1 (3)    | 2 (3)    |
| - Death                         | 0                                    | 1 (3)                                | 0                                          | 0                                          | 0        | 1 (1)    |
| - Disease progression           | 2 (10)                               | 3 (8)                                | 0                                          | 0                                          | 2 (6)    | 3 (4)    |

## · Raw Data Pilot Project analyses and presentation

Table 7: Reasons for study discontinuation in 101 Part C. Disregarding discontinuation in 101 Part C if the subject entered OLE.

|                                |                       | Treatment group        | Treatment group   |
|--------------------------------|-----------------------|------------------------|-------------------|
| Visit                          | Reason                | Tofersen 100 mg (n=72) | Placebo (n=36)    |
| DAY57 PART C                   | PROGRESSIVE DISEASE   | 1                      | .                 |
| DAY113 PART C                  | ADVERSE EVENT         | 1                      | .                 |
|                                | PROGRESSIVE DISEASE   | 1                      | 1                 |
|                                | DEATH                 | 1                      | .                 |
| DAY141 PART C                  | PROGRESSIVE DISEASE   | .                      | 1                 |
| DAY169 PART C                  | WITHDRAWAL BY SUBJECT | 1                      | .                 |
| END OF STUDY/DAY197 PART C     | PROGRESSIVE DISEASE   | 1                      | .                 |
|                                | WITHDRAWAL BY SUBJECT | 1                      | 1                 |
| SAFETY FOLLOW-UP DAY225 PART C | ADVERSE EVENT         | 1                      | .                 |

Eight patients in the tofersen group and 3 in the placebo discontinued study 101 Part C. However, due to the 2:1 randomisation, approximately the same percentage of patients completed the study treatment with  92%  and  88%  for  placebo  and  tofersen,  respectively.  One  death  in  the  tofersen  group  was considered unrelated to tofersen treatment. Analysis of the discontinuations did not reveal any particular issues of concern. Notably, although patients were  intended to be followed after treatment discontinuation, all but one patient who discontinued treatment withdrew from the study.

## · Outcomes and estimation

<div style=\"page-break-after: always\"></div>

## ALSFRS-R

Change in ALSFRS-R total score over 28 weeks was assessed in the mITT population as the primary endpoint using JRT in conjunction with MI for withdrawals other than death (Table 8). In this subgroup, a non-statistically significant difference of 1.2 favoring tofersen was observed in ALSFRS-R change from baseline at Week 28 (95% CI, -3.2 to 5.5; p = 0.97 via JRT+MI). The results from the ANCOVA + MI sensitivity  analysis  support  the  results  from  the  JRT  +  MI  (nominal  p  =  0.60).  In  the  non-mITT population, formal statistical testing was not performed as clear separation between treatment arms was not expected in the non-mITT population at 6 months. There were no deaths in this population, negating the  need  for  a  JRT.  In  this  population,  the  treatment  difference  favoured  tofersen  (adjusted  mean difference [95% CI]: 1.4 [-1.1, 3.9]; nominal p = 0.27 ANCOVA+MI).

Based on the postulation that NfL has a prognostic value, which is not fully established yet, the applicant performed several analyses. Post hoc analyses performed in the overall ITT population, adjusting for baseline NfL as a covariate rather than disease duration and including it also as part of the imputation model, show a 2.1-point treatment difference in favor of tofersen (~34% slowing of decline for tofersen relative to placebo) with greater statistical differentiation (95% CI: -0.33, 4.54; JRT+MI nominal p = 0.5015;  ANCOVA+MI  nominal  p  =  0.0904),  but  still  non-significant.  For  performing  the  subgroup analysis, the applicant has chosen the median baseline value of 75.6 pg/ml NfL. During the Raw Data Pilot Project, the mean NfL concentration at baseline in the ITT population was found to be 100.39 pg/ml and  89.65  pg/ml  in  the  tofersen  group  and  the  placebo  tofersen  group,  respectively,  indicating  an imbalance, which did not favour the tofersen group.

In the fasterprogressing NfL subgroup (baseline plasma NfL ≥ median), a 3.9 -point treatment difference (95% CI: -1.0 to 8.86; p = 0.1184 via ANCOVA + MI analysis) also did not show statistically significant results in ALSFRS-R change from baseline at Week 28. A favoring trend for tofersen was observed. In the slower-progressing NfL subgroup (baseline plasma NfL &lt; median), a modest trend favoring tofersen was observed in change from baseline at Week 28 (treatment difference of 0.6 points; [95% CI: -1.33, 2.58]).

Due to various reasons, such as drug interruptions and inability to attend clinic visits, some participants missed doses of study treatment; two or more consecutive missed doses may have a potential impact on efficacy. Post hoc sensitivity analyses performed in the ITT population show the influence of i) missing at least 2 consecutive doses and ii) outliers resulting from missing at least 2 consecutive missed doses in a small study.

In the view of the applicant, both analyses showed greater treatment differences in favor of tofersen compared  to  the  planned  analysis:  2.2  [95%  CI:  -0.23,  4.54]  and  2.4  [95%  CI:  0.15,  4.66], demonstrating the influence one or two outliers, due to consecutive missed dosing, can have in a small sample size. The post hoc alternative joint rank methodology is presented initially for the mITT population adjusting for baseline disease duration since symptom onset as in the original primary efficacy analysis. The nominal p-value from the alternative JRT is 0.61, which is more consistent with the result from the ANCOVA+MI analysis. When further accounting for the prognostic value of baseline NfL, by replacing baseline disease duration since symptom onset with baseline plasma NfL as a covariate in the model for the mITT population, the p-value becomes smaller in line with other analyses conducted when adjusting for baseline plasma NfL (nominal p = 0.27). The alternative joint rank analysis for the ITT population when adjusting for baseline plasma NfL also gives a more consistent p-value (nominal p-value = 0.06) with the corresponding ANCOVA+MI analysis.

According to the applicant, plasma NfL at baseline turns out to be a better prognostic factor and thus, it has replaced both baseline ALSFRS-R score and disease duration in the ANCOVA models to account for disease progression. Original scale of NfL instead of the logarithm of the NfL value was used due to its better interpretability as a predictor.

<div style=\"page-break-after: always\"></div>

Table 8: Summary of key analyses for ALSFRS-R total score at week 28

|                              |                                                                                                                                                                                                                         | Study 101 Part C   | Study 101 Part C                                               |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------|
|                              |                                                                                                                                                                                                                         | Placebo            | Tofersen                                                       |
| Faster- progressing subgroup | mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) p-value (Joint rank+MI) Nominal p-value (ANCOVA+MI) Post hoc (alternative Joint Rank + MI): Nominal p-value adjusting for disease duration Nominal p-value | 21 -8.14           | 39 -6.98 1.2 (-3.2, 5.5) 0.9689 0.5998 0.6098                  |
| Faster- progressing subgroup | adjusting for baseline plasma NfL ≥median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI                                                            | 16 -11.3           | 0.2716 38 -7.3 3.9 (-1.0, 8.9) 0.1184                          |
|                              | non-mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (ANCOVA+MI) <median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI | 15 -2.73 20 -1.8   | 33 -1.33 1.4 (-1.1, 3.9) 0.2726 34 -1.2 0.6 (-1.3, 2.6) 0.5281 |
|                              | Prespecified analyses with disease duration as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Post hoc nominal p-value (joint rank + MI)                                                           | 36 -5.8            | 72 -4.5 1.4 (-1.3, 4.1) 0.9130 0.3218                          |
|                              | Post hoc nominal p-value ANCOVA + MI Post hoc analyses with baseline plasma NfL as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (joint rank + MI)                                | 36                 | 72 -4.1 2.1 (-0.3, 4.5)                                        |
|                              | Nominal p-value (ANCOVA + MI) Post hoc (alternative Joint Rank + MI): Nominal p-value adjusting for baseline plasma NfL Post hoc analyses accounting for ≥2 consecutive doses and inclusion of baseline plasma NfL      | -6.2               | 0.5015 0.0904 0.0595                                           |
|                              | missed N Adjusted mean Tof - plac: Adj. mean difference (95% CI) Nominal p-value (Joint-rank + MI) Nominal p-value (ANCOVA + MI) Post hoc analyses excluding outliers and inclusion of baseline plasma NfL              | 36 -6.1            | 72 -4.0 2.2 (-0.23, 4.54) 0.5656 0.0769                        |
|                              | N Adjusted mean Tof - plac: Adj. mean difference (95% CI) Nominal p-value (Joint-rank + MI) Nominal p-value (ANCOVA + MI)                                                                                               | 36 -6.2            | 71 -3.8 2.4 (0.15, 4.66) 0.4359 0.0369                         |

NOTE 1: Lower scores depict a worsening in function. Data are presented at Week 28. Analyses for subgroups defined by median plasma NfL and run-in slope are based on the ITT population. All p-values for the ITT population are post hoc.

NOTE 2: MI was used for missing data. Prespecified model included treatment, use of riluzole or edaravone, relevant baseline score and postbaseline values. Separate models for mITT and non-mITT were used and combined for ITT analyses. In the post hoc analyses adjusting for baseline plasma NfL, this was also included in the MI model.

NOTE 3: Adjusted means, treatment differences and corresponding 95% CIs and nominal p-values for prespecified analyses were obtained from the ANCOVA model for change from baseline in conjunction with MI. Joint-rank p values were obtained from the ANCOVA model for ranked scores where deaths were ranked the lowest, in conjunction with MI for handling missing data due to withdrawals other than death. The original joint rank method is based on the ANCOVA for ranked score for the change from baseline and includes

<div style=\"page-break-after: always\"></div>

original scale values for continuous covariates; the alternative joint rank method is based on the ANCOVA for change of ranked score pre- and post-treatment and includes ranked covariates for continuous variables. The ANCOVA models included treatment as a fixed effect and adjusted for the following covariates: baseline disease duration since symptom onset, relevant baseline score, and use of riluzole or edaravone. For analyses adjusting for baseline plasma NfL, this is included in the model instead of baseline disease duration.

Figure 10: 233AS101 Part C: Forest plot of ALSFRS-R total score change from baseline to week 28

<!-- image -->

| Population/Subgroup                        | Covariateadjustmentforbaselinedisease status   | Include NfL in MI model>   | Study 101 Part C SAP prespecified   | No. of subjects (a)   | LSM Diff              | 95% CI                | ANCOVA+MI p-value (a)   | JRT+MI p-value (b)    | Posthoc Alternative JRT+MI p-value (c)   |
|--------------------------------------------|------------------------------------------------|----------------------------|-------------------------------------|-----------------------|-----------------------|-----------------------|-------------------------|-----------------------|------------------------------------------|
| ITT                                        | Base. plasma NIL                               | Y                          |                                     | p= 36; t 72           | 2.1                   | (-0.33, 4.54)         | 0.0904                  | 0.5015                |                                          |
|                                            | Disease duration                               | N/A                        | Y                                   | p= 36: t= 72          | 1.4                   | (-1.34, 4.09)         | 0.3218*                 | 0.9130*               | 0.2605                                   |
|                                            | ALSFRS-R pre-rand slp.                         | V/N                        |                                     | p= 36; t= 72          | 1.3                   | (-1.53, 4.19)         | 0.3634                  | 0.9632                | 0.3678                                   |
|                                            | ALSFRS-R pre-rand. slp + Base. plasma NfLY     |                            |                                     | p= 36; t= 72          | 2.1                   | (-0.39, 4.51)         | 0.0997                  | 0.5588                | 0.0751                                   |
|                                            | Disease duration + Base. plasma NfL            | Y                          |                                     | p= 36; t= 72          | 2.0                   | (-0.42, 4.44)         | 0.1052                  | 0.5781                | 900                                      |
|                                            | Unadj. for base. disease status                | N/A                        |                                     | p=36; t= 72           | 1.5                   | (-1.43, 4.33)         | 0.3239                  | 0.8743                | 0.3448                                   |
| mITT                                       | Base. plasma NfL                               | Y                          |                                     | p= 21; t= 39          | 2.2                   | (-1.82, 6.16)         | 0.2858                  | 0.5842                | 0.2122                                   |
|                                            | Base. plasma NfL                               | N                          |                                     | p= 21; t= 39          | 2.0                   | (-2.22, 6.21)         | 0.3532                  | 0.6810                | 0.2716                                   |
|                                            | Disease duration                               | N/A                        | 人                                   | p- 21; t= 39          | 1.2                   | (-3.19, 5.53)         | 0.5998                  | 0.9689                | 0.6098                                   |
|                                            | Disease duration + Base. plasma NfL            | Y                          |                                     | p= 21; t=39           | 2.0                   | (-1.96, 5.99)         | 0.3211                  | 0.6217                | 0.2115                                   |
|                                            | Disease duration + Base. plasma NfL            | N                          | Y                                   | p= 21; t= 39          | 1.8                   | (-2.37, 5.96)         | 0.3987                  | 0.7310                | 0.2649                                   |
| non mITT                                   | Base. plasma NfL                               | Y                          |                                     | p= 15; t= 33          | 1.6                   | (-0.66, 3.93)         | 0.1615                  |                       |                                          |
|                                            | Base. plasma NfL                               | N                          |                                     | p= 15; t= 33          | 1.6                   | (-0.71, 3.95)         | 0.1733                  |                       |                                          |
|                                            | Disease duration                               | N/A                        | Y                                   | p= 15; t= 33          | 1.4                   | (-1.10, 3.90)         | 0.2726                  |                       |                                          |
|                                            | Disease duration + Base. plasma NfL            | Y                          |                                     | p= 15; t= 33          | 1.7                   | (-0.59, 3.96)         | 0.1471                  |                       |                                          |
|                                            | Disease duration + Base. plasma NfL            | N                          | Y                                   | p= 15; t= 33          | 1.7                   | (-0.64, 3.97)         | 0.1570                  |                       |                                          |
| ITT: >=Median (75.60 pg/mL)Base.plasma NfL |                                                | Y                          |                                     | p- 16; t 38           | 4.2                   | (-0.33, 8.80)         | 0.0688                  |                       |                                          |
|                                            | Disease duration                               | N/A                        | Y                                   | p=16; t= 38           | 3.9                   | (-1.00, 8.86)         | 0.1184*                 |                       |                                          |
|                                            | Disease duration + Base. plasma NfL            | Y                          |                                     | p=16;t= 38            | 4.3                   | (-0.35, 8.89)         | 0.0698                  |                       |                                          |
| ITT: < Median (75.60 pg/mL)                | Base. plasma NL                                | Y                          |                                     | =10z=d                | 0.8                   | (-1.22, 2.89)         | 0.4250                  |                       |                                          |
|                                            | Disease duration                               | V/N                        | Y                                   | p= 20; t= 34          | 0.6                   | (-1.33, 2.58)         | 0.5281*                 |                       |                                          |
|                                            | Disease duration + Base. plasma NfL            | Y                          |                                     | p=20; t=34            | 0.7                   | (-1.36, 2.70)         | 0.5180                  |                       |                                          |
|                                            |                                                |                            |                                     |                       | Favors tofersen100 mg | Favors tofersen100 mg | Favors tofersen100 mg   | Favors tofersen100 mg | Favors tofersen100 mg                    |

-10

10

LSmeantreatmentdifference(95%CI)

NOTE 1: SAP V2.0 is the integrated efficacy SAP that was finalized prior to the final database lock for 233AS101 and interim lock for 233AS102 based on 16 July 2021 data cut; prespecified analyses were primarily based on disease progression subgroups and adjusted for disease duration since symptom onset. SAP V3.0 was an amendment to the integrated efficacy SAP following the initial data readout and incorporated plasma NfL as a covariate with the focus on the ITT population. SAP V3.0 was finalized prior the interim lock for 233AS102 based on 16 January 2022 data cut.

NOTE 2: For ITT population, multiple imputation including the specified covariate(s), use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include the specified covariate(s), baseline ALSFRS-R, and use of riluzole or edaravone.

NOTE 3: For the analyses including disease duration since symptom onset in mITT and non mITT population, multiple imputation including use of riluzole or edaravone and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include covariates for baseline disease duration since symptom onset, baseline ALSFRS-R and use of riluzole or edaravone.  For the other analyses in mITT and non mITT population, multiple imputation including baseline plasma NfL, use  of  riluzole  or  edaravone  and  the  relevant  baseline  and  postbaseline  values  for  the  endpoint  is  used  for  missing  data.  The corresponding ANCOVA models include covariates for the specified covariate(s), baseline plasma NfL, baseline ALSFRS-R and use of riluzole or edaravone.

* No statistical testing was prespecified in SAP Version 2; all p-values are post hoc for SAP V2 analyses.

(a) From the listed ANCOVA analysis based on change from baseline.

(b) From the ANCOVA on ranked scores; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.

(c) From the ANCOVA on change of ranked scores pre- and post-treatment; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.

Abbreviations: ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; ANCOVA = analysis of covariance; MI = multiple imputation; LS = least square; P+DS = placebo + delayed-start tofersen 100 mg; ES = Early-start tofersen 100 mg.

From the Forest plot above it can be observed that various analyses ALSFRS-R total score change from baseline  to  week  28  show  a  favouring  trend  for  tofersen,  without,  however,  reaching  statistical significance.

The most important issue is the outcome of the various analyses with the ALSFRS-R scale. The results in primary analysis of the functional scale ALSFRS-R were not statistically significant in the pre-specified mITT population. Hence, the study has failed the pre-specified conditions. For the general ALS population functional decline averages about 1 point per month in untreated patients, however the decline might not be linear. The difference of 2.1 points of ALSFRS-R total score change from baseline to week 28 in the ITT population using post hoc analysis with baseline plasma NfL as a covariate between tofersen and placebo  is  small,  and  the  clinical  relevance  cannot  be  determined.  This,  as  acknowledged  by  the applicant, can be due to study design (e.g., enrichment strategy and study duration) as well as inherent heterogeneity in SOD1-ALS.

<div style=\"page-break-after: always\"></div>

McElhiney et al in 2014 reported that while the ALSFRS-R is widely used in clinical trials, its relationship to clinically meaningful changes is elusive and may require a longer time-frame than the 6 months period utilized in their study. During their six-month study, ALSFRS-R total scores declined on average 5.7 points (SD=4.7). This is close to the mean 0.8-point drop/month expected, which for six months would be a 4.8-point decline (McElhiney et al 2014).

In a more recent publication, the mean decline per month was -2.03 points per month on the normed ROADS score (SD = 2.44) and -0.76 points per month on the ALSFRS -R total sum score (SD = 1.09) (Fournier et al 2022). On the ALSFRS-R, the mean decline in sumscore was -0.64 points (SD = 2.17) for patients who rated themselves as better or unchanged, -3.88 points (SD 3.98) for patients who rated themselves as a little worse, and -7.21 points (SD = 6.08) for participants who rated themselves as  much  worse.  Based  on  the  difference  between  mean  change  in  score  for  participants  who  rated themselves as a little worse compared to unchanged/better, the Minimal important difference (MID) was set to 5.81 (3.98%) for ROADS (based on the normed score, total possible points = 146) and MID to 3.24 (6.75%) for ALSFRS-R (based on 48 possible points). The authors concluded that changes that are on average less than 5.81 points (3.98%) on the normed ROADS score or less than 3.24 points (6.75%) on the ALSFRS-R sum-score over an average period of 6.41 months may not be clinically meaningful according to a patient-defined approach (Fournier et al 2022).

## SVC

The treatment difference favoured the tofersen group compared to the placebo group for both the mITT population (treatment difference of 7.9 in percent predicted SVC change from baseline at Week 28 [95% CI: -3.5, 19.3]; nominal p = 0.323 [JRT+MI]) and the non-mITT population (treatment differences of 4.6 [95% CI: -1.2, 10.5]).

In the fasterprogressing NfL subgroup (baseline plasma NfL ≥ median), a treatment difference of 9.91 percent predicted SVC change from baseline at Week 28 favoring tofersen was observed (95% CI: -2.27, 22.09).  In  the  slower-progressing  NfL  subgroup  (baseline  plasma  NfL  &lt;  median),  a  6.05  percent predicted treatment difference favoring tofersen was observed in percent predicted SVC change from baseline at Week 28 (95% CI: -0.58, 12.68).

Post hoc analyses performed in the overall ITT population, adjusting for baseline NfL as a covariate rather than disease duration and baseline ALSFRS-R score, show an 8.5 percent-predicted treatment difference at Week 28 in favor of tofersen (~54% slowing of decline for tofersen relative to placebo; [95% CI: 1.8, 15.2]; JRT+MI nominal p = 0.0689; ANCOVA+MI nominal p = 0.0128).

It is noted that as in the case of ALSFRS-R total score change from baseline to week 28, no statistically significant difference was observed on the analysis of SVC in the primary analysis mITT population. The post  hoc analysis  via  JRT+MI  was  also  statistically  non-significant.  Furthermore,  only  a  very  small difference (&lt;8.5%) in the percent predicted SVC was observed when a post hoc analyses with baseline plasma NfL as a covariate was performed in the ITT population.

<div style=\"page-break-after: always\"></div>

Table 9: Summary of key analyses for percent predicted SVC at week 28

|                              |                                                                                                                                                                                                    | Study 101 Part C   | Study 101 Part C                         |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------|
|                              |                                                                                                                                                                                                    | Placebo            | Tofersen                                 |
| Faster- progressing subgroup | mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (Joint rank+MI) Nominal p-value (ANCOVA+MI)                                                                           | 21 -22.2           | 39 -14.31 7.9 (-3.5, 19.3) 0.3233 0.1755 |
| Faster- progressing subgroup | ≥ median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI                                                                        | 16 -26.1           | 38 -16.2 9.9 (-2.3, 22.1) 0.1108         |
| Slower- progressing subgroup | non-mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (ANCOVA+MI)                                                                                                       | 15 -4.9            | 33 -0.3 4.6 (-1.2, 10.5) 0.1210          |
| Slower- progressing subgroup | < median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI                                                                        | 20 -5.6            | 34 0.4 6.1 (-0.6, 12.7) 0.0736           |
| ITT population               | Prespecified analyses with disease duration as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Post hoc nominal p-value (joint rank + MI) Post hoc nominal p-value ANCOVA + MI | 36 -14.8           | 72 -7.9 6.9 (-0.1, 13.8) 0.1517 0.0522   |
| ITT population               | Post hoc analyses with baseline plasma NfL as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (joint rank + MI) Nominal p-value (ANCOVA + MI)                  | 36 -15.8           | 72 -7.3 8.5 (1.8, 15.2) 0.0689 0.0128    |

NOTE 1: Lower values depict a worsening in function. Data are presented at Week 28. Analyses for subgroups defined by median plasma NfL and run-in slope are based on the ITT population. All p-values for the ITT population are post hoc.

NOTE 2: MI was used for missing data. For prespecified analysis, separate imputation models for mITT and non-mITT were used and combined for the ITT analysis. The model included treatment, use of riluzole or edaravone, baseline ALSFRS-R score, relevant baseline score and postbaseline values. For post hoc ITT analyses adjusted for baseline plasma NfL, the multiple imputation model was based on all participants in the ITT population and included treatment, baseline plasma NfL, use of riluzole or edaravone, relevant baseline score and postbaseline values.

NOTE 3: Adjusted means, treatment differences and corresponding 95% CIs and nominal p-values were obtained from the ANCOVA model for change from baseline in conjunction with MI. Joint-rank p-values were obtained from the ANCOVA model for ranked scores where deaths are ranked the lowest, in conjunction with MI for handling missing data due to withdrawals other than death. The ANCOVA models for prespecified analyses included treatment as a fixed effect and adjusted for the following covariates: baseline disease duration since symptom onset, baseline ALSFRS-R score, relevant baseline score, and use of riluzole or edaravone. The ITT analysis adjusted for baseline plasma NfL used the same model except baseline disease duration since symptom onset and baseline ALSFRS-R score were replaced by baseline plasma NfL.

<div style=\"page-break-after: always\"></div>

## HHD Megascore

Modest  trends  suggesting  slowing  of  decline  in  muscle  strength  were  observed  with  tofersen administration in the mITT and non-mITT populations: differences of 0.02 (95% CI: -0.21, 0.26) and 0.09 (95% CI: -0.08, 0.26) favoring tofersen were observed, respectively. These trends were most apparent in lower limb muscles as compared with upper limb muscles.

In the fasterprogressing NfL subgroup (baseline plasma NfL ≥ median), a difference of 0.13 (95% CI: -0.10, 0.37) favoring tofersen was observed in HHD megascore change from baseline at Week 28. In the slower-progressing NfL subgroup (baseline plasma NfL &lt; median), a difference of 0.09 favoring tofersen was observed in change from baseline at Week 28.

Post hoc analyses performed in the overall ITT population, adjusting for baseline NfL as a covariate rather than disease duration, show a difference of 0.10 treatment difference in HHD megascore at Week 28 in favor of tofersen (~31% slowing of decline for tofersen relative to placebo; [95% CI: -0.04, 0.23]; ANCOVA+MI  nominal  p  =  0.1547).  The  treatment  difference  in  the  ITT  population  for  HHD  lower extremities was 0.22 in favor of tofersen (95% CI: 0.04, 0.40) with a nominally statistically significant difference (p = 0.0169).

As in the case of ALSFRS-R total score and SVC, no statistically significant difference was observed on the analysis of HDD in the primary analysis mITT population. The post hoc analysis via ANCOVA+MI was also statistically non-significant. Furthermore, a very small difference (&lt;0.10) in HDD was also observed when a post hoc analyses with baseline plasma NfL as a covariate was performed in the ITT population.

Table 10: Summary of key analyses for HHD megascore at week 28

|                              |                                                                                                                                                         | Study 101 Part C   | Study 101 Part C                   |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------|
|                              |                                                                                                                                                         | Placebo            | Tofersen                           |
| Faster- progressing subgroup | mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (ANCOVA+MI)                                                                | 21 -0.37           | 39 -0.34 0.02 (-0.21, 0.26) 0.8390 |
| Faster- progressing subgroup | ≥ median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI                             | 16 -0.49           | 38 -0.36 0.13 (-0.10, 0.37) 0.2690 |
| Slower- progressing subgroup | non-mITT N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value (ANCOVA+MI)                                                            | 15 -0.18           | 33 -0.09 0.09 (-0.08, 0.26) 0.2832 |
| Slower- progressing subgroup | < median (75.6 pg/mL) baseline plasma NfL N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA+MI                             | 20 -0.17           | 34 -0.09 0.09 (-0.10, 0.27) 0.3508 |
| ITT population               | Prespecified analyses with disease duration as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Post hoc nominal p-value ANCOVA + MI | 36 -0.29           | 72 -0.23 0.06 (-0.09, 0.21) 0.4416 |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                               | Study 101 Part C   | Study 101 Part C                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------|
|                                                                                                                                               | Placebo            | Tofersen                           |
| Post hoc analyses with baseline plasma NfL as a covariate N Adjusted mean Tof-plac: Adj. mean difference (95% CI) Nominal p-value ANCOVA + MI | 36 -0.32           | 72 -0.23 0.10 (-0.04, 0.23) 0.1547 |

NOTE 1: Lower scores depict a worsening in function. Data are presented at Week 28. Analyses for subgroups defined by median plasma NfL and run-in slope are based on the ITT population. All p-values for the ITT population are post hoc.

NOTE 2: MI was used for missing data. For prespecified analysis, separate imputation models for mITT and non-mITT were used and combined for the ITT analysis. The model included treatment, use of riluzole or edaravone, baseline ALSFRS-R score, relevant baseline score and postbaseline values. For post hoc ITT analyses adjusted for baseline plasma NfL, the multiple imputation model was based on all participants in the ITT population and included treatment, baseline plasma NfL, use of riluzole or edaravone, relevant baseline score and postbaseline values.

NOTE 3: Adjusted means, treatment differences and corresponding 95% CIs and nominal p-values were obtained from the ANCOVA model for change from baseline, in conjunction with MI, including treatment as a fixed effect and adjusting for the following covariates: baseline disease duration since symptom onset, relevant baseline score, and use of riluzole or edaravone. The ITT analysis adjusted for baseline plasma NfL used the same model except baseline disease duration since symptom onset was replaced by baseline plasma NfL.

## Weight

Weight was collected as part of the safety battery in Study 101 Part C. Weight loss has been found to be a strong independent predictor of survival in ALS. Over time, the average weight increased in the tofersen group (mean change from baseline at Week 28 [±SD]: 0.5 kg [±4.4]) and decreased in the placebo group (mean change from baseline at Week 28 [±SD]: -1.6 kg [±5.4]).

It  can  be  agreed  that  body  weight  is  an  important  factor  strongly  associated  with  survival  in  ALS. However,  the  mean  changes  from  baseline  to  week  28  are  too  small  to  allow  any  meaningful comparisons. Notably, weight was not an efficacy endpoint according to protocol.

## Survival in Study 101 Part C (week 28)

## · Applicant's Analysis

The applicant recognizing the progressive and fatal nature of SOD1-ALS, time to death or PV and time to death assessed as key secondary endpoints in Study 101 Part C. PV was defined as ≥ 22 hours of mechanical ventilation (invasive or noninvasive) per day for ≥ 21 consecutive days. The threshold for PV of ≥ 21 consecutive days was extended beyond that used in previous studies (e.g., ≥ 7 to 10 days) in  an  effort  to  differentiate  between  PV  and  potential  acute  reversible  illnesses  (e.g.,  pneumonia) necessitating temporary ventilatory support. The definition is based solely on duration of use and does not distinguish between invasive and noninvasive ventilation. Recognizing that standards of care for tracheostomy vary globally, placement of a tracheostomy tube was not considered an event unless the threshold for ventilatory support was met.

Time to death or permanent ventilation was determined in a blinded fashion by a central, independent endpoint adjudication committee through review of data.

The applicant admitted that while survival is considered the gold standard for demonstrating efficacy, it necessitates studies of adequate size and duration. When designing the study, it was recognized that the short study duration (6-month duration of Study 101 Part C) and inter- and intra-SOD1 mutation heterogeneity in disease duration would make the detection of an effect on survival challenging.

Median time to death or PV and median time to death were not estimable in Study 101 Part C due to the limited number of events observed (CSR 233AS101 Part C).

<div style=\"page-break-after: always\"></div>

The applicant has provided an explanation for their choice of ≥ 21 consecutive days of ≥ 22 hours of mechanical ventilation. This number (of ≥ 21 consecutive days) is considered conservative and additional analyses were performed with the Raw Data Pilot Project (please see below).

In the mITT population, a similar proportion of participants in the placebo (2 participants [9.5%] with events of PV ) and tofersen (4 participants [10.3%] - 1 death due to congestive heart failure and 3 events  of  PV)  groups  experienced  events  of  death  or  PV.  The  percentage  of  patients  in  the  mITT population (and consequently in the ITT population) with an event of death or PV was similar in the placebo (9.5%) and tofersen (10.3%) groups. The numbers are too small to be considered as important survival data.

No events of death or PV occurred in the non-mITT population.

Table 11: Summary of time to death or permanent ventilation - mITT Population 233AS101 Part C: Secondary endpoint analysis: Summary of time to death or permanent ventilation - mITT population

|                                                                    | Placebo (N=21)   | Tofersen (N=39)   |
|--------------------------------------------------------------------|------------------|-------------------|
| Number of subjects with an event of death or permanent ventilation | 2 (9.5)          | 4 (10.3)          |
| Death                                                              | 0                | 1 (2.6)           |
| Permanent ventilation                                              | 2 (9.5)          | 3 (7.7)           |
| Number of days with ventilation use for at least 22 hours per day  |                  |                   |
| n                                                                  | 2                | 3                 |
| Mean (SD)                                                          | 15.0 (18.38)     | 20.0 (18.52)      |
| Median                                                             | 15.0             | 21.0              |
| Q1,Q3                                                              | 2.0, 28.0        | 1.0, 38.0         |
| Min, Max                                                           | 2, 28            | 1, 38             |

## Patient-Reported Outcome Measures Study 101 Part C

The results of the PRO were not statistically significant but have shown a trend in favour of tofersen.

## ALSAQ-5

Analysis of the ALSAQ-5 total scores indicated less worsening from baseline to Week 28 in the tofersen group for both mITT and non-mITT populations: -5.6-point treatment difference (95% CI: -15.55, 4.37) and -1.6-point treatment difference (95% CI: -9.55, 6.29), respectively.

In  the post  hoc ITT  population  analysis  where  baseline  NfL  was  adjusted,  a  -5.7-point  treatment difference favoring tofersen was observed in ALSAQ-5 total score change from baseline at Week 28 (95% CI: -11.83, 0.40; nominal p = 0.0668).

## FSS

In the mITT population, a trend favoring tofersen was observed in FSS change from baseline at Week 28, suggesting less fatigue (-4.91-point treatment difference [95% CI: -11.23, 1.42]). This trend was not evident in the non-mITT population (2.84-point treatment difference [95% CI: -4.72, 10.40])

In  the  post  hoc  ITT  population  analysis  where  baseline  NfL  was  adjusted,  a  -2.4-point  treatment difference favoring tofersen was observed in FSS total score change from baseline at Week 28 (95% CI: -7.45, 2.55; nominal p = 0.3365).

## EQ-5D-5L

In the mITT population, a smaller mean change from baseline to Week 28 in the EQ-5D-5L utility score in the tofersen group (-0.16) was observed compared with placebo group (-0.35), with a 0.20-point

<div style=\"page-break-after: always\"></div>

treatment difference in change from baseline at Week 28 (95% CI: 0.062, 0.332; nominal p = 0.0043). This trend was not evident in the non-mITT population as both treatment groups remained stable. In the post hoc ITT population analysis where baseline NfL was adjusted, tofersen administration was also associated with less decline as assessed by EQ-5D-5L utility score and VAS score change from baseline at Week 28.

## · Ancillary analyses (Study 101 Part C (week 28 and week 52)

For  the  ITT  population  of  study  101  Part  C,  analyses  were  performed  with  the  prespecified  disease progression  subgroups  mITT  (N=60)  (also  referred  to  as  the  enriched  or  faster  progressing/faster progressor subgroup) vs. non-mITT (n = 48) (also referred to as the other or slower progressing/slower progressor subgroup) as well as subgroups above and below the median NfL.

## Applicant's analyses

The applicant has performed several analyses (secondary, sensitivity and supplementary) of the ALSFRSR total score, as it was presented above for the ALSFRS-R section.

## Raw Data Pilot Project Analyses

Under the Raw Data Pilot Project, the following analyses were performed. Comparisons between allocated treatment groups in 101 Part C, at week 28 and week 52, i.e. extending into 102 OLE, using referencebased imputations on missing values after intercurrent events, are shown in the two tables below.

The following reference-based imputation rules have been applied:

- Jump-to-reference (J2R): Missing values in the early start tofersen treatment group following an intercurrent event will be imputed using the distribution of the delayed start tofersen treatment group (i.e. the reference), except deaths in which case missing values will be imputed as zero for both treatment groups.
- Copy-reference (CR): Subject with missing values following intercurrent events will have entire series imputed based on reference group, except deaths in which case missing values will be imputed as zero for both treatment groups.
- Copy-increments-from-reference  (CIR):  Missing  values  in  the  early  start  tofersen  treatment group following a intercurrent event will be imputed following a parallel track to the reference group, except deaths in which case missing values will be imputed as zero for both treatment groups.

The following events are regarded as intercurrent events with impact on the imputation applied. The list includes all causes for missing values following a monotone pattern, i.e. any missing values after last recording. Patterns consisting of intermittent missing values are imputed as occurring at random (MAR), and thus imputed based on a distribution based on allocated treatment group.

List of intercurrent events:

- Treatment discontinuation
- PV assistance
- Death
- Loss to follow-up (which is not an intercurrent event in itself but assumed to be preceded by an intercurrent event such as treatment discontinuation)

In case of more than one intercurrent for a subject, any missing values following the first will be imputed. The rule for imputation in case of deaths overrules the rule of any preceding intercurrent event. During the planning of the trial treatment interruptions of more than 2 consecutive doses were also regarded as an intercurrent event. However, all subjects experienced treatment interruption of four consecutive doses, or more, and thus this was excluded from the list.

<div style=\"page-break-after: always\"></div>

Table 12: ALSFRS-R change from baseline sensitivity analyses: imputation with CIR, CR &amp; J2R and analyses with applicants MMRM model at week 28 (time=197) and week 52 (time=365) (raw data pilot project)

| Impu tation   | Time point   | Statistics   | Treatment                     |   Estim ate |    SE |   Lower 95% CL |   Uppe r 95% CL | DF   | Prob < t   |
|---------------|--------------|--------------|-------------------------------|-------------|-------|----------------|-----------------|------|------------|
| CIR           | 197          | Difference   | (NA)                          |       -1    | 1.679 |          -4.36 |            2.35 | 60.3 | 0.5522     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -6.1  | 1.412 |          -8.92 |           -3.28 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -5.1  | 0.953 |          -7    |           -3.19 | .    | .          |
|               | 365          | Difference   | (NA)                          |       -1.59 | 2.449 |          -6.48 |            3.31 | 60.0 | 0.5199     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -8.98 | 2.073 |         -13.13 |           -4.84 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -7.4  | 1.412 |         -10.22 |           -4.57 | .    | .          |
| CR            | 197          | Difference   | (NA)                          |       -0.98 | 1.681 |          -4.34 |            2.39 | 60.5 | 0.5634     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -6.1  | 1.412 |          -8.93 |           -3.28 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -5.13 | 0.953 |          -7.03 |           -3.22 | .    | .          |
|               | 365          | Difference   | (NA)                          |       -1.53 | 2.455 |          -6.45 |            3.38 | 60.0 | 0.5342     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -8.99 | 2.072 |         -13.14 |           -4.85 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -7.46 | 1.408 |         -10.27 |           -4.64 | .    | .          |
| J2R           | 197          | Difference   | (NA)                          |       -0.97 | 1.684 |          -4.33 |            2.4  | 60.7 | 0.5686     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -6.11 | 1.413 |          -8.93 |           -3.28 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -5.14 | 0.968 |          -7.08 |           -3.21 | .    | .          |
|               | 365          | Difference   | (NA)                          |       -1.43 | 2.465 |          -6.36 |            3.5  | 60.7 | 0.5636     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -9.01 | 2.076 |         -13.16 |           -4.86 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -7.58 | 1.464 |         -10.5  |           -4.65 | .    | .          |

ALSFRS-R: ALS Functional Rating Scale - Revised; CIR: copy increment in reference; CR: copy reference; ITT: intent-to-treat; J2R: jump to reference

It is noted that the calculations were performed using macros with SAS.

Table 13: ALSFRS-R change from baseline sensitivity analyses: imputations with CIR, CR &amp; J2R and analyses with applicants MMRM model + baseline NFL covariate at week 28 (time=197) and week 52 (time=365) (raw data pilot project)

| Impu tation   | Time point   | Statistics   | Treatment                     |   Estima te |    SE |   Lower 95% CL |   Uppe r 95% CL | DF   | Prob < t   |
|---------------|--------------|--------------|-------------------------------|-------------|-------|----------------|-----------------|------|------------|
| CIR           | 197          | Difference   | (NA)                          |       -1.7  | 1.549 |          -4.79 |            1.39 | 68.8 | 0.2749     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -6.57 | 1.194 |          -8.95 |           -4.19 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -4.87 | 1.012 |          -6.89 |           -2.85 | .    | .          |
|               | 365          | Difference   | (NA)                          |       -2.85 | 2.178 |          -7.2  |            1.5  | 68.0 | 0.1950     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -9.83 | 1.696 |         -13.21 |           -6.44 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   |       -6.98 | 1.44  |          -9.85 |           -4.1  | .    | .          |
| CR            | 197          | Difference   | (NA)                          |       -1.68 | 1.547 |          -4.76 |            1.41 | 69.0 | 0.2825     |
|               |              | LS Mean      | Delayed start tofersen 100 mg |       -6.58 | 1.194 |          -8.96 |           -4.19 | .    | .          |

<div style=\"page-break-after: always\"></div>

| Impu tation   | Time point   | Statistics   | Treatment                     | Estima te   |    SE |   Lower 95% CL |   Uppe r 95% CL | DF   | Prob < t   |
|---------------|--------------|--------------|-------------------------------|-------------|-------|----------------|-----------------|------|------------|
|               |              | LS Mean      | Early start tofersen 100 mg   | -4.90       | 1.01  |          -6.92 |           -2.88 | .    | .          |
|               | 365          | Difference   | (NA)                          | - 2.80      | 2.175 |          -7.14 |            1.54 | 68.4 | 0.2025     |
|               |              | LS Mean      | Delayed start tofersen 100 mg | -9.83       | 1.695 |         -13.22 |           -6.45 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   | -7.04       | 1.431 |          -9.89 |           -4.18 | .    | .          |
| J2R           | 197          | Difference   | (NA)                          | -1.68       | 1.555 |          -4.78 |            1.42 | 68.7 | 0.2837     |
|               |              | LS Mean      | Delayed start tofersen 100 mg | -6.58       | 1.194 |          -8.96 |           -4.19 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   | -4.90       | 1.024 |          -6.94 |           -2.85 | .    | .          |
|               | 365          | Difference   | (NA)                          | -2.73       | 2.203 |          -7.13 |            1.66 | 67.9 | 0.2192     |
|               |              | LS Mean      | Delayed start tofersen 100 mg | -9.85       | 1.697 |         -13.23 |           -6.46 | .    | .          |
|               |              | LS Mean      | Early start tofersen 100 mg   | -7.11       | 1.492 |         -10.09 |           -4.14 | .    | .          |

ALSFRS-R: ALS Functional Rating Scale - Revised; CIR: copy increment in reference; CR: copy reference; ITT: intent-to-treat; J2R: jump to reference

The replication from the applicant of these analyses showed discrepancies to the above results that were not of a magnitude to impact the overall interpretation of the results. In additional analyses, the applicant added  interaction  terms  between baseline  plasma  NfL  and  riluzole/  edaravone  use  by  visit in  the imputation  models  (in  addition  to ALSFRS-R  total  score  at  each  visit,  baseline  plasma  NfL,  and riluzole/edaravone use) ,  which  were  used  for  generating  the  results  presented  and  reported  by  the applicant (Table 14).

Table 14: Reference-based imputation on missing data after intercurrent event - ALSFRS-R total score change from baseline at week 28 and week 52 - ITT population

| Macro       | Timepoint   | Imputation   | Estimated Difference (95% Confidence Interval)   |   p-value |
|-------------|-------------|--------------|--------------------------------------------------|-----------|
| Five Macros | Week 28     | MAR          | 2.0 (-0.54, 4.58)                                |    0.1222 |
| Five Macros | Week 28     | J2R          | 1.7 (-0.96, 4.38)                                |    0.2089 |
| Five Macros | Week 28     | CR           | 1.8 (-0.89, 4.40)                                |    0.1943 |
| Five Macros | Week 28     | CIR          | 1.8 (-0.85, 4.42)                                |    0.1847 |
| Five Macros | Week 52     | MAR          | 3.7 (0.32, 7.03)                                 |    0.0319 |
| Five Macros | Week 52     | J2R          | 3.0 (-0.59, 6.60)                                |    0.1012 |
| Five Macros | Week 52     | CR           | 3.1 (-0.38, 6.61)                                |    0.0806 |
| Five Macros | Week 52     | CIR          | 3.2 (-0.26, 6.71)                                |    0.0699 |
| RMConjPlus  | Week 28     | MAR          | 2.1 (-0.44, 4.66)                                |    0.1087 |
| RMConjPlus  | Week 28     | J2R          | 1.9 (-0.71, 4.49)                                |    0.1566 |
| RMConjPlus  | Week 28     | CR           | 1.9 (-0.63, 4.52)                                |    0.1419 |
| RMConjPlus  | Week 28     | CIR          | 2.0 (-0.61, 4.53)                                |    0.1378 |
| RMConjPlus  | Week 52     | MAR          | 3.7 (0.42, 6.97)                                 |    0.0294 |
| RMConjPlus  | Week 52     | J2R          | 3.1 (-0.35, 6.47)                                |    0.0815 |
| RMConjPlus  | Week 52     | CR           | 3.3 (-0.01, 6.61)                                |    0.0533 |

<div style=\"page-break-after: always\"></div>

| Macro   | Timepoint   | Imputation   | Estimated Difference (95% Confidence Interval)   |   p-value |
|---------|-------------|--------------|--------------------------------------------------|-----------|
|         |             | CIR          | 3.3 (0.00, 6.62)                                 |    0.0531 |

ALSFRS-R: ALS Functional Rating Scale - Revised; CIR: copy increment in reference; CR: copy reference; ITT: intent-to-treat; J2R: jump to reference; MAR: missing at random.

## 2.6.5.2.2. Study 102 LTE (on-going)

## Overview of Methods, Participants and Treatment

This study is an ongoing multicentre, OLE study to assess the long-term safety, tolerability, PK, and effect on disease progression of tofersen/BIIB067 administered to previously treated adults with ALS caused by SOD1 mutation.

Prespecified interim cuts of the ongoing Study 102 data were conducted on 16 July 2021, 16 January 2022 and the latest one was 28 February 2023 for the efficacy. An additional data cut for safety was performed on 15 July 2022.

Tofersen is administered by IT injection to participants with SOD1-ALS who completed Part A, B, or C of Study 233AS101. Of the 159 eligible participants who completed Study 101, a total of 139 participants enrolled from Study 101 Parts A, B, and C: 44 participants enrolled from Study 101 Parts A and B and 95 participants enrolled from Part C.

Participants in Study 233AS101 Parts A + B must have had a washout ≥ 16 weeks between the last dose of study treatment received in Study 233AS101 and the first dose of tofersen received in the current Study 233AS102. Participants in Part C did not require a washout period.

Participants initially received 3 loading doses of tofersen 20 mg (Group 1), 40 mg (Group 2), or 60 mg (Group 3) approximately 2 weeks apart, and 10 maintenance doses, approximately monthly, by IT injection.

It is noted that CSF NfL data were available for the first time during the January 2022 interim analysis. These data were presented to Week 24 in both subgroups and the ITT population due to sparse data beyond that time-point.

## Limitations of study 102 LTE

There are some limitations in the analyses of Study 102 alone and some trends may appear to differ slightly from the overall trends observed in the integrated analyses of Study 101 Part C and Study 102 comparing early-start with placebo/delayed-start participants. These are due to various reasons outlined below.

The baseline mean values in Study 102 are not equivalent to the Week 28 observed mean values in Study 101 Part C or the integrated analysis due to the following reasons:

- A subset of participants enrolled from Study 101 Part C into Study 102 (95 of 108 participants), so  the  baseline  mean  values  for  Study  102  are  not  the  same  as  the  Week  28  mean  values observed in Study 101 Part C.
- Some participants were not able to attend a clinic visit at Week 28 in Study 101 Part C and have missing  assessments  for  SVC  and  HHD  but  may  have  enrolled  later  into  Study  102;  these participants do not have observed data for the Week 28 assessment in Study 101 Part C but have baseline values for Study 102
- If baseline value was not available for Study 102, the screening value was used.

<div style=\"page-break-after: always\"></div>

Other factors contributing to these differences include the level of missing assessments, particularly for SVC, and the adjustment for baseline NfL in integrated analyses, which is not feasible to account for in Study 102 analyses.

## Summary of results of study 102 LTE

As of the 16 January 2022 interim data cut, in participants who received placebo in Study 233AS101 Part C and initiated tofersen 100 mg in Study 233AS102, initiation of treatment with tofersen 100 mg produced a robust biological effect, as measured by reduction of total CSF SOD1 protein, plasma and CSF NfL, and plasma and CSF pNfH, even when started 6 months later in disease. According to the applicant, clinical data from participants from Study 233AS101 Part C demonstrated that participants who had previously received tofersen 100 mg in Study 233AS101 Part C started Study 233AS102 with better clinical function (as measured by baseline ALSFRS-R total score, percent predicted SVC, and HHD megascore values) than did participants who had previously received placebo. During 24 weeks of openlabel treatment with tofersen, participants had modest declines (as measured by ALSFRS-R total score and percent predicted SVC) or maintenance (as measured by HHD megascore) of clinical function, with changes of similar magnitude over time regardless of previous treatment group.

Participants who were originally enrolled in Study 233AS101 Parts A and B are a unique population of participants who received either placebo or tofersen (in doses ranging from 20 to 100 mg) in Study 233AS101, then had a ≥ 16 -week washout of study medication before initiating tofersen at varying dose levels  in  Study  233AS102.  In  those  participants  that  ultimately  received  tofersen  100  mg  in  Study 233AS102, reductions in  CSF  SOD1 protein levels, plasma pNfH,  and  CSF pNfH were observed and sustained over 196 weeks. According to the applicant, tofersen treatment also resulted in a sustained clinical effect, with participants experiencing small declines in respiratory function (measured by percent predicted SVC) and maintenance of strength and clinical function (as measured by HHD megascore and ALSFRSR total scores) over 196 weeks of open-label treatment in Study 233AS102.

The data from the study 102 LTE alone are from an open-label design and as such, they do not have the convincing value of controlled data. However, the pooling of data from study 101 Part C and 102 is worth discussing due to the long-term treatment of SOD1-ALS patients.

## 2.6.5.3. Biomarkers

## 2.6.5.3.1. Biomarkers results only for Study 101 Part C (week 28)

## Total CSF SOD1 Protein - Change from Study 101 Part C Baseline to Week 28 (Day 197)

In the mITT population, a reduction in total CSF SOD1 protein was observed at Week 28 in the tofersen group compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 38% and nominal p &lt;0.0001).

In the non-mITT population, a reduction in total CSF SOD1 protein was also observed at Week 28 in the tofersen  group  compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 26% and nominal p = 0.0007).

In the ITT population, a reduction in total CSF SOD1 protein was also observed at Week 28 in the tofersen group compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 34% and post-hoc nominal p &lt; 0.0001).

Tofersen  is  designed  to  bind  and  degrade  SOD1  mRNA  to  reduce  SOD1  protein  synthesis  and accumulation via RNase-H-dependent degradation of SOD1 mRNA. All SOD1 variants associated with ALS  &gt;  200  identified  to  date  are  assumed  to  cause  SOD1  gain  of  function,  i.e.,  they  lead  to  an

<div style=\"page-break-after: always\"></div>

accumulation  of  mutant  SOD1  protein  that  is  believed  to  underlie  the  pathogenicity  of  SOD1  ALS. According to the applicant, although a target therapeutic threshold for total CSF SOD1 reduction has not been established, reductions of at least 20%, a threshold beyond the assay and biologic variabilities, was aimed as confirmation of target engagement.

Figure 11: Line Plot of Total CSF SOD1 Protein Adjusted Geometric Mean Ratio to Baseline Values (95% CI) by Visit from ANCOVA Analysis Using MI by Baseline Plasma NfL Level (Median) - ITT Population 233AS101  Part  C:  Secondary  endpoint  subgroup  analysis:  Line  plot  of  total  CSF  SOD1  protein  LS geometric mean ratio to baseline values (95% CI) by visit from ANCOVA analysis using MI by baseline plasma NfL level (median) - ITT population

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug. If day 1 value is missing, the non-missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value. NOTE 2: Values below limit of quantitation (BLQ) are set to half of lower limit of quantitation (LLOQ, 15.6 ng/mL) in calculations. Multiple imputation is used for missing data. NOTE  3:  The  analysis  is  based  on  ANCOVA  model  with  natural  log  transformed  data.  The  model  includes  covariates  for  the corresponding baseline value i.e. log value, baseline disease duration since symptom onset, and use of riluzole or edaravone. The analysis is based on the combined MI datasets from the mITT and non mITT populations. NOTE 4: The table at the bottom presents the number of subjects with observed non-missing data at each visit. Abbreviations:  CSF  =  cerebrospinal  fluid;  SOD1  =  superoxide  dismutase  1;  ANCOVA  =  analysis  of  covariance;  MI  =  multiple imputation; LS = least square.

## Plasma NfL - Change from Study 101 Part C Baseline to Week 28 (Day 197)

Despite  lower  levels  at  Baseline  in  the  non-mITT  population,  a  reduction  in  plasma  NfL  levels  from baseline to Week 28 were observed in both populations, with a 67% reduction (difference in geometric mean ratios for tofersen to placebo) and nominal p &lt; 0.0001 in the mITT population and a 48% reduction (difference in geometric mean ratios for tofersen to placebo) and nominal p &lt; 0.0001 in the non-mITT population. A statistically significant decrease of NfL levels has been observed with tofersen in both mITT and non-mITT populations.

In the ITT population, a reduction in plasma NFL levels was also observed at Week 28 in the tofersen group compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 60% and post hoc nominal p &lt; 0.0001).

It should be noted however, that neural injury biomarkers of the neurofilament heavy and light chain are the most promising biomarkers in neurodegeneration and have been used in several studies up to now. NfL is released from neurons following axonal injury and can be regarded as a measure of ongoing neurodegeneration. However, NfL and NfH are considered as non-specific, since they are related to the neuronal  damage  in  a  variety  of  neurodegenerative  conditions  including  ALS,  Alzheimer's  disease,

<div style=\"page-break-after: always\"></div>

Multiple Sclerosis and Huntington's disease. Thompson et al published in 2022 their work with Chitinase1 and NFL and their analysis offers support for the routine inclusion of plasma NfL in future therapeutic trials in ALS. As already mentioned, its prognostic and predictive value is not fully established yet. It should also be noted that there is enough precedence indicating that good results in biomarkers do not always translate into favourable results in clinical endpoints.

Figure 12: Line Plot of Plasma NfL Adjusted Geometric Mean Ratio to Baseline Values (95% CI) by Visit from ANCOVA Analysis Using MI by Baseline Plasma NfL Level (Median) - ITT Population  233AS101 Part C: Secondary endpoint subgroup analysis: Line plot of plasma NfL LS geometric mean ratio to baseline values (95% CI) by visit from ANCOVA analysis using MI by baseline plasma NfL level (median) - ITT population

2.6.5.3.2. Biomarkers from Study 101 Part C and Study 102 Week 52 (Day 365) and week 104

<!-- image -->

## Total CSF SOD1 - Study 101 Part C and Study 102 (weeks 52 and 104)

According to the applicant, given the underlying pathophysiology of SOD1-ALS and tofersen's mechanism of action, total CSF SOD1 protein was assessed as an indirect measure of target engagement. In Study 101 Part C, reductions in total CSF SOD1 became apparent by approximately Week 8, consistent with the time required to reach steady state of tofersen and the estimated half-life of SOD1 protein (each approximately 1 month). At Week 28 in the ITT population, a reduction in total CSF SOD1 protein of 35% (geometric mean ratio to baseline) in the tofersen group and a decrease of 2% in the placebo group were observed (difference in geometric mean ratios for tofersen to placebo: 34%; nominal p &lt; 0.0001).

In the integrated analysis of Study 101 and Study 102, reductions in total CSF SOD1 in the early-start tofersen group were sustained for 52 weeks of follow-up; similar reductions were observed with later initiation of tofersen in the placebo/delayed-start tofersen group.

<div style=\"page-break-after: always\"></div>

Figure 13: 233AS101 and 233AS102: Line Plot of Total CSF SOD1 Adjusted Geometric Mean Ratio to Study 101 Part C Baseline (95% CI) by Visit to Week 52 from ANCOVA Analysis Using MI - ITT Population 233AS101 and 233AS102 ISE: Line plot of total CSF SOD1 protein LS geometric mean ratio to baseline values (95% CI) by time point from ANCOVA analysis using MI - ITT population

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug. If day 1 value is missing, the non missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value.

NOTE 2: Lower limit of quantitation (LLOQ) is 15.6 ng/mL.

NOTE 3: Multiple imputation including treatment group, use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data.

NOTE  4:  The  analysis  is  based  on  ANCOVA  model  with  natural  log  transformed  data.  The  model  includes  covariates  for  the corresponding baseline value i.e. log value, and use of riluzole or edaravone. Abbreviations:  CSF  =  cerebrospinal  fluid;  SOD1  =  superoxide  dismutase  1;  ANCOVA  =  analysis  of  covariance;  MI  =  multiple imputation; LS = least square.

In the ITT population, the geometric mean ration to baseline was 0.67 for the early start tofersen group (N=72) and 0.79 for the Placebo → delayed-start tofersen (N=36), indicating reductions of 30% and 20%, respectively. For the pooled ABL population a similar geometric mean ratio to baseline of 0.76 was observed.

Results from the reduction of SOD1 causative protein by tofersen have been collected up to 2 years (week  104).  Evaluation  of  the  total  CSF  SOD1  protein  is  thought  an  indirect  measure  of  target engagement. As mentioned above SOD1 is considered as directly related to the pathogenicity of ALS. Reductions of SOD1 protein level up to 50% have been reported in the literature (Berdynski et al 2022). It has been also reported in the literature that gene silencing strategies targeting SOD1 may represent effective approaches for familial and sporadic ALS-related neurodegeneration (Abati et al 2020).

<div style=\"page-break-after: always\"></div>

Figure 14: 233AS101 and 233AS102 ISE: Line plot of total CSF SOD1 protein LS geometric mean ratio to  baseline  values  (95% CI) by time point (up to week 104) from ANCOVA analysis using MI - ITT population

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug. If day 1 value is missing, the non-missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value. NOTE 2:  Lower limit  of  quantitation  (LLOQ)  is  15.6  ng/mL.  Values  below  limit  of  quantitation  (BLQ)  are  set  to  half  of  LLOQ  in calculations. NOTE 3: Multiple imputation including treatment group, use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data. NOTE  4:  The  analysis  is  based  on  ANCOVA  model  with  natural  log  transformed  data.  The  model  includes  covariates  for  the corresponding baseline value i.e. log value, and use of riluzole or edaravone. Abbreviations:  CSF  =  cerebrospinal  fluid;  SOD1  =  superoxide  dismutase  1;  ANCOVA  =  analysis  of  covariance;  MI  =  multiple imputation; LS = least square.

It is observed that the reduction of SOD1 in the case of the early start tofersen treatment group achieves a noticeable decrease at week 12 and reaches the lowest point at week 28, after which it remains at decreased levels until week 104. In the case of the delayed start tofersen treatment group the levels until week 28 remain high and close to the baseline levels. After week 28 (when tofersen treatment started in this group) there is a decrease until week 40 and then SOD1 levels for this delayed start group remain at approximately the same low levels as the early-start group.

## 2.6.5.3.3. Neurofilament - Study 101 Part C and Study 102 (week 52)

Neurofilaments  are  intermediate  filaments  that  are  uniquely  expressed  in  neurons  and  are  a  major constituent of the cytoskeletal scaffold of the CNS and PNS neurons. Neurofilaments are heteropolymers composed of the light, middle, and heavy chains, plus α internexin in the CNS and peripherin in the peripheral nervous system.

Elevated neurofilament levels have been described in a variety of neurological conditions characterized by neuroaxonal damage, including neurodegenerative diseases and diseases with other pathophysiological processes. Despite the non-specificity, neurofilament levels in ALS are among the highest across neurodegenerative diseases, with levels 7- to 10-fold higher than in neurologically healthy controls.

Longitudinal increases in neurofilament levels were observed before emergence of clinically manifest ALS. Serum NfL levels were elevated 6 to 12 months prior to onset of signs or symptoms of ALS in SOD1 A5V mutation carriers.

<div style=\"page-break-after: always\"></div>

According to the applicant, levels of neurofilament have been found to correlate with the rate of disease progression, as measured by the rate of decline on ALSFRS-R from symptom onset to the time of the neurofilament  measurement.  In  other  neurological  diseases  including  spinal  muscular  atrophy  and relapsing  multiple  sclerosis,  neurofilament  levels  have  been  reduced  in  response  to  treatments associated with disease-modifying effects.

In  Study  101  Part  C  and  Study  102  (up  to  week  52),  tofersen-driven  sustained  reductions  in neurofilament emerged by week 12 following tofersen administration and preceded the clinical effects seen. At Week 28 of Study 101 Part C, plasma NfL was reduced by 55% (geometric mean ratio to baseline)  in  the  tofersen-treated  participants,  compared  to  a  12%  increase  in  placebo-treated participants (difference in geometric mean ratios for tofersen to placebo: 60%; post hoc nominal p &lt; 0.0001) in the ITT population.

Figure 15: 233AS101 Part C and 233AS102 ISE: Line Plot of Plasma NfL, CSF NfL, Plasma pNfH, CSF pNfH LS Geometric Mean Ratio to Baseline Values (95% CI) Over 52 Weeks From 233AS101 Baseline: ANCOVA Analysis Using MI - ITT Population

Plasma NfL

Plasma pNfH

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug. If day 1 value is missing, the non-missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value.

- NOTE 2: Values below limit of quantitation (BLQ) are set to half of LLOQ in calculations.
- NOTE 3: Multiple imputation including treatment group, use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data.  An extreme value of 477 pg/mL in plasma NfL is set to missing and is imputed with multiple imputation in the ANCOVA analysis.
- NOTE  4:  The  analysis  is  based  on  ANCOVA  model  with  natural  log  transformed  data.  The  model  includes  covariates  for  the corresponding baseline value i.e. log value, and use of riluzole or edaravone.

Abbreviations: CSF = Cerebral spinal fluid; NfL = Neurofilament light chain; pNfH = Phosphorylated neurofilament heavy chain

In  the  case  of  early  start  tofersen  treatment  group,  a  significant  reduction  of  NfL  has  been  noted, reaching a maximum at around week 12 and from then onwards remaining at the same low levels. Although NfL is not yet a validated surrogate endpoint, its role is increasingly acknowledged, and the findings are supportive that it is a reliable biomarker in ALS (see Discussion of Clinical Efficacy).

## 2.6.5.4. Summary of main efficacy results

The  following  modified  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 15: Summary of efficacy for Study 233AS101 Part C (VALOR) (week 28)

| Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide   | Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                              | Protocol number: 233AS101 Part C EudraCT number: 2015-004098-33 ClinicalTrials.gov identifier (NCT number): NCT02623699                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Protocol number: 233AS101 Part C EudraCT number: 2015-004098-33 ClinicalTrials.gov identifier (NCT number): NCT02623699                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Protocol number: 233AS101 Part C EudraCT number: 2015-004098-33 ClinicalTrials.gov identifier (NCT number): NCT02623699                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                        | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered by intrathecal bolus injection to adult participants with ALS associated with mutations in the SOD1 gene. Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active:placebo) ratio for 28 weeks (197 days) at 32 sites globally. Randomisation was stratified by disease progression subgroups ('enriched' 'other') and riluzole/edaravone use. Participants who completed the study had the opportunity to be screened for an open-label long-term extension study, Study 233AS102. | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered by intrathecal bolus injection to adult participants with ALS associated with mutations in the SOD1 gene. Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active:placebo) ratio for 28 weeks (197 days) at 32 sites globally. Randomisation was stratified by disease progression subgroups ('enriched' 'other') and riluzole/edaravone use. Participants who completed the study had the opportunity to be screened for an open-label long-term extension study, Study 233AS102. | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered by intrathecal bolus injection to adult participants with ALS associated with mutations in the SOD1 gene. Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active:placebo) ratio for 28 weeks (197 days) at 32 sites globally. Randomisation was stratified by disease progression subgroups ('enriched' 'other') and riluzole/edaravone use. Participants who completed the study had the opportunity to be screened for an open-label long-term extension study, Study 233AS102. |
| Design                                                                                                                                                                                                        | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 32 to 36 weeks 4-weeks screening period 24-week treatment period 4-to 8-week follow-up period as follows: - Participants who enrolled (uninterrupted) in the LTE study (233AS102), the Week 28 Visit served as the EOS visit. - Participants with delayed enrolment in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).                                                                                                                                                                                                                                                                                                 | 32 to 36 weeks 4-weeks screening period 24-week treatment period 4-to 8-week follow-up period as follows: - Participants who enrolled (uninterrupted) in the LTE study (233AS102), the Week 28 Visit served as the EOS visit. - Participants with delayed enrolment in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                        | Duration of Run- in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | - Participants who did not enroll in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | - Participants who did not enroll in the LTE study, the Week 32 Visit served as the EOS Visit (either in person or by telephone contact).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                        | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Not applicable No extension in the Study 101 protocol; Study 102 is the extension study for participants who completed Study 101 and is ~3.5-7 years in duration depending on timing of enrollment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Not applicable No extension in the Study 101 protocol; Study 102 is the extension study for participants who completed Study 101 and is ~3.5-7 years in duration depending on timing of enrollment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                             | tofersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Treatment: 100 mg tofersen administered via intrathecal bolus injection over 1 to 3 minutes Duration: 3 loading doses once every 2 weeks (Day 1, 15, 29), followed by 5 maintenance doses once every 28 days (4 weeks). Number randomised: 72                                                                                                                                                                                                                                                                                                                                                                                                                               | Treatment: 100 mg tofersen administered via intrathecal bolus injection over 1 to 3 minutes Duration: 3 loading doses once every 2 weeks (Day 1, 15, 29), followed by 5 maintenance doses once every 28 days (4 weeks). Number randomised: 72                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                                             | placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Treatment: Placebo consisted of artificial CSF administered by intrathecal bolus over 1 to 3 minutes, following the same dosing regimen as tofersen. Duration: 3 loading doses once every 2 weeks (Day 1, 15, 29), followed by 5 maintenance doses once every 28 days (4 weeks).                                                                                                                                                                                                                                                                                                                                                                                            | Treatment: Placebo consisted of artificial CSF administered by intrathecal bolus over 1 to 3 minutes, following the same dosing regimen as tofersen. Duration: 3 loading doses once every 2 weeks (Day 1, 15, 29), followed by 5 maintenance doses once every 28 days (4 weeks).                                                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                     | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | ALSFRS-R Change from baseline in ALSFRS-R total score in the mITT population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|               | Secondary: Change from baseline to Week 28 in total SOD1 protein concentration in CSF   | Total CSF SOD1 protein   | Change from baseline in total SOD1 protein concentration in CSF in the mITT population. Expressed as a ratio (Week 28 to baseline) as it is analysed on logarithmic scale. Also formally tested in non mITT population.                                                                                                                                              |
|---------------|-----------------------------------------------------------------------------------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               | Secondary: Change from baseline to Week 28 in plasma NfL                                | Plasma NfL               | Change from baseline in NfL concentration in plasma in the mITT population. Expressed as a ratio (Week 28 to baseline as it is analysed on logarithmic scale                                                                                                                                                                                                         |
|               | Secondary: Change from baseline to Week 28 in percent predicted SVC                     | SVC                      | Measure of respiratory function. Change from baseline in percent predicted SVC in the mITT population, using maximum i.e. best effort in predicted SVC at the visit as assessed using a spirometer, which is adjusted by sex, age, and height. Percent predicted SVC is calculated as observed SVC divided by predicted SVC                                          |
|               | Secondary: Change from baseline to Week 28 in HHD megascore                             | HHD                      | Measure of muscle strength. Change from baseline in HHD megascore in the mITT population, which is the average of the normalized Z scores for muscle strength in 16 muscle groups in upper and lower extremities on both right and left sides of the body.                                                                                                           |
|               | Secondary: Time to death or PV                                                          | Time to death or PV      | Time to earliest of death or PV from first dose in Study 101 Part C in the mITT population based on independent adjudication, where PV is defined as ≥ 22 hours of mechanical ventilation [invasive or noninvasive] per day for ≥21 consecutive days. Participants who do not meet the endpoint definition are censored at the last contact date in Study 101 Part C |
| Database lock | 16 th August 2021                                                                       | 16 th August 2021        | 16 th August 2021                                                                                                                                                                                                                                                                                                                                                    |

## Results and Analysis

Analysis

Primary Endpoint Analysis description

Analysis population

and time

point description

Endpoint:

mITT population

Treatment group  placebo

N number

Tofersen

21

39

Change from baseline to Week 28 in ALSFRS-R

ITT population

(Post hoc

analyses adjusting

for baseline plasma NfL as a covariate)

Placebo tofersen

36

72

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability                     | Adjusted mean                                                             | -8.14                                                               | -6.98                                                               | -6.2                                                                                | -4.1                                                                                |
|---------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Effect estimate per comparison tofersen vs placebo                  | Adjusted mean difference 95% CI p-value 1.2 -3.2, 5.5 0.9689              | Adjusted mean difference 95% CI p-value 1.2 -3.2, 5.5 0.9689        | Adjusted mean difference 95% CI p-value 1.2 -3.2, 5.5 0.9689        | 2.1 -0.3, 4.5 0.5015 0.0904                                                         | 2.1 -0.3, 4.5 0.5015 0.0904                                                         |
| Analysis description                                                | Secondary endpoint analysis                                               | Secondary endpoint analysis                                         | Secondary endpoint analysis                                         | Secondary endpoint analysis                                                         | Secondary endpoint analysis                                                         |
| Analysis population and time point description                      |                                                                           | mITT                                                                | mITT                                                                | ITT population (Post hoc analyses adjusting for baseline plasma NfL as a covariate) | ITT population (Post hoc analyses adjusting for baseline plasma NfL as a covariate) |
|                                                                     | Treatment group                                                           | Placebo                                                             | tofersen                                                            | Placebo                                                                             | tofersen                                                                            |
|                                                                     | N Number                                                                  | 21                                                                  | 39                                                                  | 36                                                                                  | 72                                                                                  |
| Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein | Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein       | Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein | Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein | Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein                 | Endpoint: Change from baseline to Week 28 in total CSF SOD1 protein                 |
| Descriptive statistics and estimate variability                     | Adjusted GMR to baseline                                                  | 1.16                                                                | 0.71                                                                | 0.98                                                                                | 0.65                                                                                |
| Effect estimate per comparison tofersen vs placebo                  | Difference in GMR (tofersen: placebo) 95% CI Nominal p-value (ANCOVA +MI) | 0.62 0.49, 0.78 <0.0001                                             | 0.62 0.49, 0.78 <0.0001                                             | 0.66 0.57, 0.77 <0.0001                                                             | 0.66 0.57, 0.77 <0.0001                                                             |
| Endpoint: Change from baseline to Week 28 in Plasma NfL             | Endpoint: Change from baseline to Week 28 in Plasma NfL                   | Endpoint: Change from baseline to Week 28 in Plasma NfL             | Endpoint: Change from baseline to Week 28 in Plasma NfL             | Endpoint: Change from baseline to Week 28 in Plasma NfL                             | Endpoint: Change from baseline to Week 28 in Plasma NfL                             |
| Descriptive statistics and estimate variability                     | Adjusted GMR to baseline                                                  | 1.20                                                                | 0.40                                                                | 1.12                                                                                | 0.45                                                                                |
| Effect estimate per comparison tofersen vs placebo                  | Difference in GMR (tofersen: placebo) 95% CI Nominal p-value (ANCOVA +MI) | 0.33 0.25, 0.45 <0.0001                                             | 0.33 0.25, 0.45 <0.0001                                             | 0.40 0.33, 0.49 <0.0001                                                             | 0.40 0.33, 0.49 <0.0001                                                             |
| Endpoint: Change from baseline to Week 28 in SVC                    | Endpoint: Change from baseline to Week 28 in SVC                          | Endpoint: Change from baseline to Week 28 in SVC                    | Endpoint: Change from baseline to Week 28 in SVC                    | Endpoint: Change from baseline to Week 28 in SVC                                    | Endpoint: Change from baseline to Week 28 in SVC                                    |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability            | Adjusted mean                                                                               | -22.20                                                                        | -14.31                                                                        | -15.82                                                                        | -7.34                                                                         |
|------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Effect estimate per comparison tofersen vs placebo         | Adjusted mean difference 95% CI Nominal p-value (Joint rank+MI) Nominal p-value (ANCOVA+MI) | 7.9 -3.5, 19.3 0.3233 0.1755                                                  | 7.9 -3.5, 19.3 0.3233 0.1755                                                  | 8.5 1.8, 15.2 0.0689 0.0128                                                   | 8.5 1.8, 15.2 0.0689 0.0128                                                   |
| Endpoint: Change from baseline to Week 28 in HHD Megascore | Endpoint: Change from baseline to Week 28 in HHD Megascore                                  | Endpoint: Change from baseline to Week 28 in HHD Megascore                    | Endpoint: Change from baseline to Week 28 in HHD Megascore                    | Endpoint: Change from baseline to Week 28 in HHD Megascore                    | Endpoint: Change from baseline to Week 28 in HHD Megascore                    |
| Descriptive statistics and estimate variability            | Adjusted mean                                                                               | -0.37                                                                         | -0.34                                                                         | -0.32                                                                         | -0.23                                                                         |
| Effect estimate per comparison tofersen vs placebo         | Adjusted mean difference 95% CI Nominal p-value (ANCOVA+MI)                                 | 0.02 -0.21, 0.26 0.8390                                                       | 0.02 -0.21, 0.26 0.8390                                                       | 0.10 -0.04, 0.23 0.1547                                                       | 0.10 -0.04, 0.23 0.1547                                                       |
| Endpoint: Time to death or PV                              | Endpoint: Time to death or PV                                                               | Endpoint: Time to death or PV                                                 | Endpoint: Time to death or PV                                                 | Endpoint: Time to death or PV                                                 | Endpoint: Time to death or PV                                                 |
| Descriptive statistics and estimate variability            | Number of events/Total number subjects (%) Median                                           | 2/21 (9.5%) NE                                                                | 4/39 (10.3%) NE                                                               | 2/36 (5.6%) NE                                                                | 4/72 (5.6%) NE                                                                |
| Effect estimate per comparison tofersen vs placebo         | Not available as median time is not estimable due to limited number of events               | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events |
| Endpoint: Time to death                                    | Endpoint: Time to death                                                                     | Endpoint: Time to death                                                       | Endpoint: Time to death                                                       | Endpoint: Time to death                                                       | Endpoint: Time to death                                                       |
| Descriptive statistics and estimate variability            | Number of events/Total number subjects (%) Median                                           | N NE                                                                          | N NE                                                                          | N NE                                                                          | N NE                                                                          |
| Effect estimate per comparison tofersen vs placebo         | Not available as median time is not estimable due to limited number of events               | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events | Not available as median time is not estimable due to limited number of events |
| Analysis description                                       | Exploratory analysis                                                                        | Exploratory analysis                                                          | Exploratory analysis                                                          | Exploratory analysis                                                          | Exploratory analysis                                                          |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description                      | Analyses for exploratory endpoints including quality of life measures were prespecified in the mITT population for changes from baseline to Week 28. Following the readout, post hoc analyses were conducted for quality-of-life measures in disease progression subgroups based on baseline plasma NfL as well as analyses adjusting for baseline NfL as a covariate in the ITT population.   | Analyses for exploratory endpoints including quality of life measures were prespecified in the mITT population for changes from baseline to Week 28. Following the readout, post hoc analyses were conducted for quality-of-life measures in disease progression subgroups based on baseline plasma NfL as well as analyses adjusting for baseline NfL as a covariate in the ITT population.   | Analyses for exploratory endpoints including quality of life measures were prespecified in the mITT population for changes from baseline to Week 28. Following the readout, post hoc analyses were conducted for quality-of-life measures in disease progression subgroups based on baseline plasma NfL as well as analyses adjusting for baseline NfL as a covariate in the ITT population.   | Analyses for exploratory endpoints including quality of life measures were prespecified in the mITT population for changes from baseline to Week 28. Following the readout, post hoc analyses were conducted for quality-of-life measures in disease progression subgroups based on baseline plasma NfL as well as analyses adjusting for baseline NfL as a covariate in the ITT population.   | Analyses for exploratory endpoints including quality of life measures were prespecified in the mITT population for changes from baseline to Week 28. Following the readout, post hoc analyses were conducted for quality-of-life measures in disease progression subgroups based on baseline plasma NfL as well as analyses adjusting for baseline NfL as a covariate in the ITT population.   |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                | mITT                                                                                                                                                                                                                                                                                                                                                                                           | mITT                                                                                                                                                                                                                                                                                                                                                                                           | ITT population                                                                                                                                                                                                                                                                                                                                                                                 | ITT population                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                     | Treatment group                                                                                                                                                                                                                                                                                                                                                                                | placebo                                                                                                                                                                                                                                                                                                                                                                                        | tofersen                                                                                                                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                                                                                                        | tofersen                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                     | N number                                                                                                                                                                                                                                                                                                                                                                                       | 21                                                                                                                                                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                                                                                                                                             | 72                                                                                                                                                                                                                                                                                                                                                                                             |
| Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score    | Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in ALSAQ-5 total score                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                     | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                  | 15.6                                                                                                                                                                                                                                                                                                                                                                                           | 10.0                                                                                                                                                                                                                                                                                                                                                                                           | 12.6                                                                                                                                                                                                                                                                                                                                                                                           | 6.9                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison tofersen vs placebo                  | Adjusted mean difference 95% CI Nominal p-value (ANCOVA+MI)                                                                                                                                                                                                                                                                                                                                    | -5.6 (-15.6, 4.4) 0.2715                                                                                                                                                                                                                                                                                                                                                                       | -5.6 (-15.6, 4.4) 0.2715                                                                                                                                                                                                                                                                                                                                                                       | -5.7 (-11.8, 0.4) 0.0668                                                                                                                                                                                                                                                                                                                                                                       | -5.7 (-11.8, 0.4) 0.0668                                                                                                                                                                                                                                                                                                                                                                       |
| Endpoint: Change from baseline to Week 28 in FSS                    | Endpoint: Change from baseline to Week 28 in FSS                                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in FSS                                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in FSS                                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in FSS                                                                                                                                                                                                                                                                                                                                               | Endpoint: Change from baseline to Week 28 in FSS                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                     | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                  | 10.46                                                                                                                                                                                                                                                                                                                                                                                          | 5.56                                                                                                                                                                                                                                                                                                                                                                                           | 6.3                                                                                                                                                                                                                                                                                                                                                                                            | 3.9                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison tofersen vs placebo                  | Adjusted mean difference 95% CI Nominal p-value (ANCOVA+MI)                                                                                                                                                                                                                                                                                                                                    | -4.91 (-11.23, 1.42) 0.1283                                                                                                                                                                                                                                                                                                                                                                    | -4.91 (-11.23, 1.42) 0.1283                                                                                                                                                                                                                                                                                                                                                                    | -2.4 (-7.45, 2.55) 0.3365                                                                                                                                                                                                                                                                                                                                                                      | -2.4 (-7.45, 2.55) 0.3365                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score | Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score                                                                                                                                                                                                                                                                                                                            | Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score                                                                                                                                                                                                                                                                                                                            | Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score                                                                                                                                                                                                                                                                                                                            | Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score                                                                                                                                                                                                                                                                                                                            | Endpoint: Change from baseline to Week 28 in EQ-5D-5L Utility Score                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                     | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                  | -0.35                                                                                                                                                                                                                                                                                                                                                                                          | -0.16                                                                                                                                                                                                                                                                                                                                                                                          | -0.21                                                                                                                                                                                                                                                                                                                                                                                          | 0.08                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison tofersen vs placebo                  | Adjusted mean difference                                                                                                                                                                                                                                                                                                                                                                       | 0.20 (0.06, 0.33)                                                                                                                                                                                                                                                                                                                                                                              | 0.20 (0.06, 0.33)                                                                                                                                                                                                                                                                                                                                                                              | 0.14 (0.05, 0.23)                                                                                                                                                                                                                                                                                                                                                                              | 0.14 (0.05, 0.23)                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                | 0.0029                                                                                                                                                                                                                                                                                                                                                                                         | 0.0029                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

Table 16: Summary of integrated efficacy in Study 101 Part C and Study 102 (on-going)

| Title: Study 101 Part C: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation Study 102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral   | Title: Study 101 Part C: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation Study 102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral                                                                                                                         | Title: Study 101 Part C: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation Study 102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Protocol number: 233AS101 Part C EudraCT number: 2015-004098-33 ClinicalTrials.gov identifier (NCT number): NCT02623699                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Protocol number: 233AS101 Part C EudraCT number: 2015-004098-33 ClinicalTrials.gov identifier (NCT number): NCT02623699                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study 101 Part C is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered by intrathecal bolus injection to adult participants with ALS associated with mutations in the SOD1 gene.                                                                                                                                                                                                                                                                                               | Study 101 Part C is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to examine the efficacy, safety, tolerability, PK, and PD of tofersen administered by intrathecal bolus injection to adult participants with ALS associated with mutations in the SOD1 gene.                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active:placebo) ratio for 28 weeks (197 days) at 32 sites globally.                                                                                                                                                                                                                                                                                                                                                                                                                                         | Participants were randomized to receive tofersen 100 mg or placebo in a 2:1 (active:placebo) ratio for 28 weeks (197 days) at 32 sites globally.                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Participants who completed the study had the opportunity to be screened for an open-label long-term extension study, Study 233AS102.                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Participants who completed the study had the opportunity to be screened for an open-label long-term extension study, Study 233AS102.                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study 102 is an ongoing, multicenter, open-label, long-term extension study to assess the long-term safety, tolerability, PK, PD, and efficacy of tofersen administered by IT injection to participants with SOD1-ALS who completed Part C of Study 233AS101. Efficacy data from Study 233AS101 Part C and an interim data cut of Study 102 performed on 16 January 2022 are described herein. Crossover, or evaluation of 'early-start' tofersen vs 'delayed-start' tofersen was prospectively incorporated into the design of the tofersen CDP. treatment sequences for both arms were | Study 102 is an ongoing, multicenter, open-label, long-term extension study to assess the long-term safety, tolerability, PK, PD, and efficacy of tofersen administered by IT injection to participants with SOD1-ALS who completed Part C of Study 233AS101. Efficacy data from Study 233AS101 Part C and an interim data cut of Study 102 performed on 16 January 2022 are described herein. Crossover, or evaluation of 'early-start' tofersen vs 'delayed-start' tofersen was prospectively incorporated into the design of the tofersen CDP. treatment sequences for both arms were |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Up to 360 weeks 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Early Start tofersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Participants who started tofersen 100 mg in Study 101 Part C and had the opportunity to continue on tofersen 100 mg in Study 102                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Placebo/Delayed Start tofersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Participants who received placebo in Study 101 Part C and had the opportunity to start tofersen 100 mg in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Participant accountability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | St d 102 A total of 97 participants who completed Study 233AS101 Part C were eligible to enroll in Study 233AS102. Of these 95 participants enrolled in Study 102. The integrated efficacy analyses account for all 108 participants who were randomized in Study 101 Part C.                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| The same important endpoints as in the case of Study 101 Part C were used.           | The same important endpoints as in the case of Study 101 Part C were used.           | The same important endpoints as in the case of Study 101 Part C were used.           | The same important endpoints as in the case of Study 101 Part C were used.           |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Database lock                                                                        | Data cut for Study 102 taken 16 January 2022 database lock on 28 February 2022       | Data cut for Study 102 taken 16 January 2022 database lock on 28 February 2022       | Data cut for Study 102 taken 16 January 2022 database lock on 28 February 2022       |
| Results and Analysis                                                                 | Results and Analysis                                                                 | Results and Analysis                                                                 | Results and Analysis                                                                 |
| Analysis description                                                                 | Primary Analysis                                                                     | Primary Analysis                                                                     | Primary Analysis                                                                     |
|                                                                                      | ITT population (adjusting for baseline plasma NfL as a covariate)                    | ITT population (adjusting for baseline plasma NfL as a covariate)                    | ITT population (adjusting for baseline plasma NfL as a covariate)                    |
|                                                                                      | Treatment group                                                                      | Placebo/Delayed -start tofersen                                                      | Early-start tofersen                                                                 |
|                                                                                      | N number                                                                             | 72                                                                                   | 36                                                                                   |
| Endpoint: Change from baseline to Week 52 in ALSFRS-R                                | Endpoint: Change from baseline to Week 52 in ALSFRS-R                                | Endpoint: Change from baseline to Week 52 in ALSFRS-R                                | Endpoint: Change from baseline to Week 52 in ALSFRS-R                                |
| Descriptive statistics and estimate variability                                      | Adjusted mean                                                                        | -9.5                                                                                 | -6.0                                                                                 |
| Effect estimate per comparison                                                       | Adjusted mean difference                                                             | 3.5                                                                                  | 3.5                                                                                  |
| Early-start vs. placebo/Delayed-start                                                | 95%CI                                                                                | 0.4, 6.7                                                                             | 0.4, 6.7                                                                             |
| Endpoint: Change from baseline to Week 52 in total SOD1 protein concentration in CSF | Endpoint: Change from baseline to Week 52 in total SOD1 protein concentration in CSF | Endpoint: Change from baseline to Week 52 in total SOD1 protein concentration in CSF | Endpoint: Change from baseline to Week 52 in total SOD1 protein concentration in CSF |
| Descriptive statistics and estimate variability                                      | Adjusted GMR to baseline                                                             | 0.79                                                                                 | 0.67                                                                                 |
| Endpoint: Change from baseline to Week 52 in plasma NfL                              | Endpoint: Change from baseline to Week 52 in plasma NfL                              | Endpoint: Change from baseline to Week 52 in plasma NfL                              | Endpoint: Change from baseline to Week 52 in plasma NfL                              |
| Descriptive statistics and estimate variability                                      | Adjusted GMR to baseline                                                             | 0.59                                                                                 | 0.49                                                                                 |
| Endpoint: Change from baseline to Week 52 in percent predicted SVC                   | Endpoint: Change from baseline to Week 52 in percent predicted SVC                   | Endpoint: Change from baseline to Week 52 in percent predicted SVC                   | Endpoint: Change from baseline to Week 52 in percent predicted SVC                   |
| Descriptive statistics and estimate variability                                      | Adjusted mean                                                                        | -18.6                                                                                | -9.4                                                                                 |
| Effect estimate per comparison                                                       | Adjusted mean difference                                                             | 9.2                                                                                  | 9.2                                                                                  |
| Early-start vs. placebo/Delayed-start                                                | 95%CI                                                                                | 1.7, 16.6                                                                            | 1.7, 16.6                                                                            |
|                                                                                      | p-value (ANCOVA+MI)                                                                  | 0.0159                                                                               | 0.0159                                                                               |
| Endpoint: Change from baseline to Week 52 in HHD megascore                           | Endpoint: Change from baseline to Week 52 in HHD megascore                           | Endpoint: Change from baseline to Week 52 in HHD megascore                           | Endpoint: Change from baseline to Week 52 in HHD megascore                           |
| Descriptive statistics and estimate variability                                      | Adjusted mean                                                                        | -0.45                                                                                | -0.17                                                                                |
| Effect estimate per comparison                                                       | Adjusted mean difference                                                             | 0.28                                                                                 | 0.28                                                                                 |
| Early-start vs. placebo/Delayed-start                                                | 95%CI                                                                                | 0.047, 0.517                                                                         | 0.047, 0.517                                                                         |
|                                                                                      | p-value (ANCOVA+MI)                                                                  | 0.0186                                                                               | 0.0186                                                                               |

<div style=\"page-break-after: always\"></div>

| Endpoint: Time to death or PV                                        | Endpoint: Time to death or PV                                   | Endpoint: Time to death or PV   | Endpoint: Time to death or PV   |
|----------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------|---------------------------------|
| Descriptive statistics and estimate variability                      | Number of events/Total number subjects (%) Median               | 8/36 (22.2%) NE                 | 12/72 (16.7%) NE                |
| Effect estimate per comparison Early-start vs. placebo/Delayed-start | Hazard ratio 95%CI Cox regression p-value Log-rank test p-value | 0.36 0.137, 0.941 0.0373 0.0687 | 0.36 0.137, 0.941 0.0373 0.0687 |
| Endpoint: Time to death                                              | Endpoint: Time to death                                         | Endpoint: Time to death         | Endpoint: Time to death         |
| Descriptive statistics and estimate variability                      | Number of events/Total number subjects (%) Median               | 6/36 (16.7%) NE                 | 8/72 (11.1%) NE                 |
| Effect estimate per comparison Early-start vs. placebo/Delayed-start | Hazard ratio 95%CI Cox regression p-value Log-rank test p-value | 0.27 0.084, 0.890 0.0313 0.0879 | 0.27 0.084, 0.890 0.0313 0.0879 |

*This Table was provided by the applicant and should be read in conjunction with the additional analyses and the discussion of the results in section 3.3.4.6.  Analysis performed across trials (pooled analyses and meta-analysis).

## 2.6.5.5. Clinical studies in special populations

The following information (Table 17) has been retrieved from the Clinical Study 233AS101 Report and the Clinical Study 233AS102 Report Interim 2

Table 17: Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older number number)   | subjects /total   | Age 85+ (Older number number)   | subjects /total   |
|-----------------------|---------------------------------------------------|-----------------------------------|-------------------|---------------------------------|-------------------|
| Controlled Trials     | 14 (9 tofersen, 5 placebo)                        |                                   |                   |                                 |                   |
| Non Controlled trials | 6                                                 | 2                                 |                   |                                 |                   |

However, a subgroup analysis based on age groups, especially those above 65 years of age would not be considered useful in ALS and with the available data on tofersen.

<div style=\"page-break-after: always\"></div>

## 2.6.5.6. Analysis performed across trials (pooled analyses and meta-analysis)

Data from the randomized controlled period of Study 101 were integrated with the Study 102 LTE to inform the longer-term benefit/risk of tofersen. The primary focus of the integration was the longitudinal experience of the Study 101 Part C participants across Studies 101 Part C and 102 (pooled group CL) who were grouped as follows:

- Early-start participants who started tofersen 100 mg in Study 101 Part C and had the opportunity to continue on tofersen 100 mg in Study 102 (CL1).
- Placebo/delayed-start  participants  who  received  placebo  in  Study  101  Part  C  and  had  the opportunity to start tofersen 100 mg in Study 102 (CL2).

## Participants

Ninety-five of 108 participants (87%) randomized in Study 101 Part C went on to receive tofersen in Study 102. At the time of the 16 January 2022 interim data cut, 71% (67/95) of these participants remained ongoing in Study 102 (Figure below). An accounting of participant disposition is below in Table below.

The following graph (Figure 16) is showing the participants flow of study 101 (Parts A, B and C) and 102.

Figure 16: Flow of participants through Study 233AS101 and Study 233AS102

Participants enrolled:

N=20 in Part A

N=50 in Part B (including 2 from Part A)

N=108 in Part C

Participants eligible for Study 233AS102:

N=19 from Part A

N=45 from Part B

N=97 from Part C

Participants enrolled inStudy 233AS102:

N=8 from Part A

N=36from Part B

N=95fromPart C

<!-- image -->

Seventy patients in total were receiving tofersen 100mg before entering the study 102 LTE. From these, 21 patients from study 101 Part C belonged to the mITT and were characterised as Faster Progressing and 28 patients were in the non-mITT population and were characterised as slower progressing. Seven

<div style=\"page-break-after: always\"></div>

patients in study 101 Part B and in study 102 received tofersen 100mg.  From the parts A and B, 35 patients enrolled in study 102 at tofersen less than 100mg and 9 patients from Part B enrolled in the study 102 at tofersen 100mg (in total 44 patients).

## 2.6.5.6.1. Pooling of Efficacy Data - 2 nd  Interim report (data cutoff 16 January 2022) with results up to week 52

The  integrated  summary  has  combined  efficacy  data  across  clinical  studies  of  tofersen.  Two  pooled groups  of  study  subjects  considered  in  SAP  Integrated  Summary  of  Efficacy,  Version  No.:  3.0)  are summarized in the following Table 18.

Table 18: Definitions of the pooled groups in this integrated summary of efficacy

| Pooled Group 1   | Studies Included                | Period                                        | Description                                                                                                                            |
|------------------|---------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| CL               | 233AS101 Part C and 233AS102    | Randomized placebo- controlled and long- term | Data of all Part C subjects in 233AS101 and the data in 233AS102 of 233AS101 Part C subjects who rolled over into the LTE              |
| ABL              | 233AS101 Part A, B and 233AS102 | Randomized placebo- controlled and long- term | Data of all 233AS101 Part A/B subjects in 233AS101 and the data in 233AS102 of 233AS101 Part A/B subjects who rolled over into the LTE |

1 CL: 233AS101 Part C and LTE; ABL: 233AS101 Part A, B and LTE.

The primary time points of interest for the integration of mITT population are 12 weeks (Day 85), 28 weeks (Day 197), 40 weeks (Day 281), and 52 weeks (Day 365) from 233AS101 Part C baseline. These will also be the primary time points of interest when presenting the integration of overall ITT population of pooled group CL. For by-visit summaries of observed data, all visits with data available up to 52 weeks (Day 365) from 233AS101 Part C baseline will be used.

The primary time points of interest for the integration of non-mITT population are 12 weeks (Day 85), 28 weeks (Day 197), 40 weeks (Day 281), 52 weeks (Day 365), 64 weeks (Day 449), 76 weeks (Day 533), 88 weeks (Day 617), and 104 weeks (Day 729) from 233AS101 Part C baseline. For by-visit summaries of observed data, all visits with data available up to 104 weeks (Day 729) from 233AS101 Part C baseline will be used.

No formal testing was performed. The reported p-values are for exploratory purpose only.

MI was used to impute data up to and including Week 52 for continuous endpoints; ANCOVA+MI analyses were conducted. The model for MI included all participants in the ITT population including treatment, baseline plasma NfL in the original scale, riluzole or edaravone use, the corresponding baseline value and post-baseline values. The ANCOVA analysis used these MI datasets and included treatment as a fixed  effect,  and  adjusted  for  covariates:  baseline  plasma  NfL,  riluzole  or  edaravone  use  and  the corresponding baseline value. ANCOVA analyses were performed at approximately 3-month time-points. Nominal p-values were presented for the treatment difference at Week 52. Log-transformed data were used for PD and biomarker endpoints. Nominal p-values were presented for the treatment difference at Week 52. In the subgroup analyses, data are presented to Week 104 for the non-mITT population.

Time to death or permanent ventilation and time to death analyses were performed using a KaplanMeier. Treatment comparison was based on a log rank test stratified by treatment and median baseline

<div style=\"page-break-after: always\"></div>

plasma NfL. A Cox regression model adjusted for baseline plasma NfL, and riluzole or edaravone use was used to obtain the hazard ratio and 95% confidence intervals for each of these endpoints.

Table  19:  Participant  disposition  of  integrated  analysis  of  studies  101  Part  C  and  102  for  the  ITT population

|                                                                                                                                                | ISE Based on Jul 2021 Data Cut       | ISE Based on Jul 2021 Data Cut                   | ISE Based on Jan 2022 Data Cut (week 52)   | ISE Based on Jan 2022 Data Cut (week 52)        |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------|--------------------------------------------|-------------------------------------------------|
| Participants                                                                                                                                   | Early-start Tofersen 100 mg (n = 72) | Placebo/delayed - start Tofersen 100 mg (n = 36) | Early-start Tofersen 100 mg (n = 72)       | Placebo/delayed- start Tofersen 100 mg (n = 36) |
| Dosed in Study 101 Part C n (%)                                                                                                                | 72 (100)                             | 36 (100)                                         | 72 (100)                                   | 36 (100)                                        |
| Dosed in Study 102 n (%)                                                                                                                       | 63 (88)                              | 32 (89)                                          | 63 (88)                                    | 32 (89)                                         |
| Completed Study 101 Part C but not enrolled in Study 102 n (%)                                                                                 | 1 (1)                                | 1 (3)                                            | 1 (1)                                      | 1 (3)                                           |
| Ongoing in Study 102 n (%)                                                                                                                     | 54 (75)                              | 22 (61)                                          | 49 (68)                                    | 18 (50)                                         |
| Died while on trial n (%)                                                                                                                      | 7 (10)                               | 4 (11)                                           | 8 (11)                                     | 6 (17)                                          |
| Withdrew from trial n (%) - AE - Consent withdrawn - Death - Disease progression Post-withdrawal vital status collected Total deaths including | 17 (24) 2 (3) 3 (4) 7 (10)           | 13 (36) 0 3 (8) 4 (11) 6 (17)                    | 22 (31) 2 (3) 4 (6) 8 (11) 8 (11) 5 (7)    | 17 (47) 0 4 (11) 6 (17) 7 (19)                  |
|                                                                                                                                                | 5 (7)                                |                                                  |                                            |                                                 |
| not                                                                                                                                            | N/A                                  | N/A                                              |                                            | 3 (8)                                           |
| post- withdrawal death a                                                                                                                       | N/A                                  | N/A                                              | 12 (17)                                    | 11 (31)                                         |

a Post withdrawal vital status was collected retrospectively for participants who withdrew from Study 101 Part C or Study 102 or who completed Study 101 Part C and did not enrol in Study 102.

The population which is more in the focus in study 102 LTE are patients who participated in study 101 Part C i.e. CL population, since it is the population for which double blind data are available and there was not a wash out period as in the case of ABL patients.

## ALSFRS-R Total Score

According  to  the  applicant,  analyses  for  Study  101  Part  C  performed  in  the  overall  ITT  population, adjusting for baseline plasma NfL as a covariate rather than disease duration in both the analysis model and  imputation  model,  show  a  greater  treatment  difference  in  favor  of  tofersen  compared  to  the prespecified primary analysis.

Table 20: Change in ALSFRS-R total score from study 101 Part C baseline up to week 52 - ITT population

| Endpoint (Post hoc analyses with baseline plasma NfL as a covariate)                                                                              | Study 101 Part C Tofersen (n=72) vs. placebo (n=36) -Change from baseline to Week 28   | Studies 101 Part C and 102 (ISE SAP V3.0) Early-start tofersen (n=72) vs. placebo/delayed-start tofersen (n=36)- Change from baseline to Week 52   |
|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Change from Baseline on ALSFRS-R Total Score Adjusted means: Tof, Placebo Tofersen-placebo: adjusted mean difference (95% CI) p-value (ANCOVA+MI) | -4.1, -6.2 2.1 (-0.33, 4.54) 0.0904                                                    | -6.0, -9.5 3.5 (0.4, 6.7) 0.0272                                                                                                                   |

NOTE 1: Lower scores depict a worsening in function. Post hoc analyses are presented for Study 101 Part C; analysis for Studies 101 Part C and 102 is based on January 2022 data cut and was prespecified in ISE SAP Version 3.0. All p-values are nominal.

NOTE 2: The multiple imputation model is based on all participants in the ITT population and includes baseline plasma NfL, treatment, use of riluzole or edaravone, relevant baseline score, and post-baseline values.

NOTE 3: Adjusted means, treatment difference and corresponding 95% CIs and nominal p-values are obtained from the ANCOVA model for change from baseline in conjunction with MI. Joint rank p-values are obtained from the ANCOVA model for ranked scores

<div style=\"page-break-after: always\"></div>

where deaths are ranked the lowest in conjunction with MI for handling missing data due to withdrawals other than death. The original joint  rank  method is  based on the ANCOVA for ranked score for the change from baseline and includes original scale values for continuous covariates; the alternative joint rank method is based on the ANCOVA for change of ranked score pre- and post-treatment and includes ranked covariates for continuous variables. The ANCOVA models include treatment as a fixed effect and adjust for the following covariates: baseline plasma NfL, relevant baseline score, and use of riluzole or edaravone.

Figure 17: 233AS101 and 233AS102 ISE: Line Plot of ALSFRS-R total score adjusted mean change from baseline values ± SE by timepoint from ANCOVA analysis using MI for pooled group CL - ITT population (week 52)

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug and presented as Day 1. If day 1 value is missing, the non-missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value.

NOTE 2: Multiple imputation including treatment group, use of riluzole or edaravone, baseline plasma NfL, and the relevant baseline and postbaseline values for the endpoint is used for missing data.

NOTE 3: For non-Japanese subjects, the Global ALSFRS-R is used. For Japanese subjects, the Japanese (Ohashi) ALSFRS-R is used except for Q5a and Q11 where the Japanese translated Global ALSFRS-R is used. A positive change indicates an improvement.

NOTE 4: LS means are obtained from the ANCOVA model with treatment included as a fixed effect and adjusted for the following covariates: baseline plasma NfL, baseline ALSFRS-R total score, and use of riluzole or edaravone.

Abbreviations: ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; NfL = neurofilament light chain; ANCOVA = analysis of covariance; MI = multiple imputation; LS = least square.

Figure 18: 233AS101 and 233AS102 ISE: Forest plot of ALSFRS-R total score change from baseline to week 52

<!-- image -->

LS mean treatment difference (95% CI)

NOTE 1: SAP V2.0 is the integrated efficacy SAP that was finalized prior to the final database lock for 233AS101 and interim lock for 233AS102 based on 16 July 2021 data cut; prespecified analyses were primarily based on disease progression subgroups and adjusted for disease duration since symptom onset. SAP V3.0 was an amendment to the integrated efficacy SAP following the initial data readout

<div style=\"page-break-after: always\"></div>

and incorporated plasma NfL as a covariate with the focus on the ITT population. SAP V3.0 was finalized prior the interim lock for 233AS102 based on 16 January 2022 data cut.

NOTE 2: For ITT population, multiple imputation including the specified covariate(s), use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include the specified covariate(s), baseline ALSFRS-R, and use of riluzole or edaravone.

NOTE 3: For the analyses including disease duration since symptom onset in mITT and non-mITT population, multiple imputation including use of riluzole or edaravone and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include covariates for baseline disease duration since symptom onset, baseline ALSFRS-R and use of riluzole or edaravone.  For the other analyses in mITT and non-mITT population, multiple imputation including baseline plasma NfL, use  of  riluzole  or  edaravone  and  the  relevant  baseline  and  postbaseline  values  for  the  endpoint  is  used  for  missing  data.  The corresponding ANCOVA models include covariates for the specified covariate(s), baseline plasma NfL, baseline ALSFRS-R and use of riluzole or edaravone.

* No statistical testing was prespecified in SAP Version 2; all p-values are post hoc for SAP V2 analyses.

(a) From the listed ANCOVA analysis based on change from baseline.

(b) From the ANCOVA on ranked scores; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.

(c) From the ANCOVA on change of ranked scores pre- and post-treatment; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.

Abbreviations: ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; ANCOVA = analysis of covariance; MI = multiple imputation; LS = least square; P+DS = placebo + delayed-start tofersen 100 mg; ES = Early-start tofersen 100 mg.

The analysis (data cutoff 16 January 2022) of the pooled double-blind data from study Part C and the open-label data from study 102 LTE up to week 52, have shown a difference between the early and the placebo/delayed  start  tofersen  treatment  group.  However,  these  results  from  exploratory  analyses cannot be considered a robust demonstration of efficacy. A clear and statistically significant difference may have been shown if the duration of the study with a placebo control was 52 weeks. Nevertheless, the Forest plot with all the analyses of ALSFRS-R is showing in all subgroups a trend in favour of tofersen.

The comparison of delayed start of tofersen with early start of tofersen is not an ideal basis to support deciding on B/R of tofersen but it still provides the only randomised comparison of longer-term tofersen treatment vs a control. As for the 28-week analysis, from a regulatory point of view, the treatment effect irrespectively of treatment discontinuation and considering the value 0 as the true value after death is of primary relevance. However, although reference-based imputation analyses were also conducted for the  52-week analysis time point, the interpretation of these analyses is not  straightforward,  as  the reference group is also actively treated in contrast to patients who discontinued treatment. Nevertheless, the analysis is at least more conservative than the analysis based on a missing at random assumption when targeting the treatment effect of primary regulatory relevance.

## SVC

Analyses for Study 101 Part C performed in the overall ITT population, adjusting for baseline NfL as a covariate  rather  than  disease  duration  and  baseline  ALSFRS-R  score,  show  a  nominally  statistically significant 8.5 percent-predicted treatment difference at Week 28 in favor of tofersen (approximately 54% slowing of decline for tofersen relative to placebo).

Over the longer term in the ITT population, participants in the placebo/delayed-start arm experienced a nominally statistically significant greater decline from baseline to Week 52 on percent-predicted SVC than  the  early-start  participants  (9.2  percent-predicted  treatment  difference;  95%  CI:  1.7,  16.6;). Notably in the placebo/delayed-start group, declines appeared to stabilize after Week 40, approximately 12 weeks after initiation of tofersen and the time point at which maximum biological activity would be expected.

According to the applicant, the 8.5 and 9.2 percent-predicted differences observed between treatment groups at 28 and 52 weeks, respectively, are highly clinically relevant.

As in the case of ALSFRS-R the combined double blind and open label data have shown a difference between the early and the placebo/delayed start tofersen treatment group in the percent predicted SVC, albeit small.

<div style=\"page-break-after: always\"></div>

## HDD Megascore

Change in HHD megascore over 28 weeks was assessed in the mITT population as a key secondary endpoint in Study 101 Part C. In this subgroup, a  modest difference of 0.02 favoring tofersen was observed (95% CI: -0.21 to 0.26); ANCOVA+MI nominal p = 0.8390.

Though not clearly discernible until Week 52, the stabilisation and, in some cases, improvement in muscle strength associated with tofersen treatment are completely inconsistent with the natural history of ALS.

Similarly, to SVC the combined double blind and open label data have shown a very small difference between the early and the placebo/delayed start tofersen treatment group in HDD.

## Survival (data cutoff 16 January 2022; week 52)

Survival and other time to event endpoints with data cut-off 16 January 2022 were provided but are not described and discussed here because more mature data with data cut-off 28 February 2023 at week 104 are available (see below).

- Raw Data Pilot Project Analysis 1 st  Evaluation phase (data cutoff 16 January 2022; week 52)

The following contains Table results of the survival analyses outlined in the SAP. Survival analyses are performed with the endpoint used by the applicant, death, or PV assistance. The analyses are similar to the analyses performed by the applicant but with four model adjustments, as represented by the last four rows in the table below. The first row is similar to the analysis by the applicant and is included as a reference.

In the second row, the survival analysis is restricted to an observation period of 52 weeks from baseline and adjusted for baseline NfL concentration, riluzole or edaravone use, and PV assistance defined as 21 consecutive days of ventilation. In the third and fourth rows, results of sensitivity analyses are shown with  PV  assistance  definitions  of  '7  consecutive  days  of  ventilation'  and  '10  consecutive  days  of ventilation' (always keeping steady the covariate of ≥ 22 hours of mechanical ventilation invasive or noninvasive), respectively. These analyses are adjusted for baseline NfL concentration and riluzole and edaravone use. Lastly, in the fifth row, results are shown without adjustment for NfL concentration but with adjustment for riluzole and edaravone use and a PV assistance definition of 21 consecutive days of ventilation.

Table 21: (the Raw Data Pilot Project): Results from survival analyses of time to death or permanent ventilation PV up to week 52 (16 January 2022 data cutoff).

| Description                              | Hazard ratio (95% CI)   |   Wald test |   Log- rank test | Events of total in early tofersen group   | Percentage, early tofersen group   | Events of total in delayed tofersen group   | Percentage, delayed tofersen group   |
|------------------------------------------|-------------------------|-------------|------------------|-------------------------------------------|------------------------------------|---------------------------------------------|--------------------------------------|
| Unrestricted analysis (as the Applicant) | 0.36 (0.137, 0.941)     |      0.0373 |           0.0687 | 12/72                                     | 16.7%                              | 8/36                                        | 22.2%                                |
| Restriction to 52 weeks                  | 0.87 (0.213, 3.582)     |      0.8508 |           0.8856 | 7/72                                      | 9.7%                               | 3/36                                        | 8.3%                                 |
| 7 days                                   | 0.38 (0.151, 0.938)     |      0.0359 |           0.044  | 12/72                                     | 16.7%                              | 9/36                                        | 25.0%                                |
| 10 days                                  | 0.36 (0.142, 0.892)     |      0.0275 |           0.0402 | 12/72                                     | 16.7%                              | 9/36                                        | 25.0%                                |
| No adjustment for NfL                    | 0.61 (0.248, 1.506)     |      0.2849 |           0.2773 | 12/72                                     | 16.7%                              | 8/36                                        | 22.2%                                |

<div style=\"page-break-after: always\"></div>

HR=hazard ratio, CI=confidence interval.

The limit of 21 consecutive days of ≥ 22 hours of permanent mechanical ventilation was considered conservative, taking into consideration publicly available information on clinical trials conducted in the field of ALS. Additional analyses with 7 and 10 consecutive days of ≥ 22 hours of permanent ventilation were performed with the Raw Data Pilot Project. However, due to the limited number of events there was no difference in the results whether 7, 10 or 21 consecutive days of ventilation were chosen. The percentage of events (time to death or permanent ventilation) in the early tofersen treatment group was 16.7% compared to the percentage of 22.2% events in the placebo/delayed tofersen treatment. Hazard ratio (HR) was in the region of 0.36-0.38.

These results could have been more convincing, provided that they had derived entirely from controlled data and that the functional endpoints would be significantly in favour of tofersen.

The results from a Cox model adjusting for baseline NfL and riluzole/edaravone use, and a log-rank test stratifying for median baseline NfL are presented. The adjustment for baseline NfL (continuous scale) was not included in V2 of the SAP but only in V3 when results of part C were already known. The number of events was overall small such that single events may have a relevant influence on the results, raising concerns on the robustness of the analysis.

For the analysis of time to death or permanent ventilation, the HR was 0.36 (95% CI: (0.13, 0.94). However, the interpretation of the clinical relevance of a HR is not directly possible as it is a relative effect. Its size is unexpectedly large considering the crude event probability and the Kaplan Meier-curves, as the HR often corresponds approximately to the relative risk. The discrepancy may be explained by the adjustment, differential drop-out and/or the time-dependency of the effect but a careful analysis of the cause is needed for a better understanding of the analysis and the reliability of the conclusions from this analysis.

The Kaplan-Meier curve shows separation of the survival curves only after 52 weeks. Consequently, the Cox regression model restricted to a maximal follow-up of 52 weeks shows a HR 0.87, 95% CI (0.21, 3.58). Thus, the treatment effect in terms of HR is mainly driven by the time period when the number of patients at risk was small (and constantly decreasing). Censoring appears to be differential between the treatment groups with e.g. a larger proportion of patients in the delayed start group being censored between week 52 and 78; informative censoring cannot be excluded. This increases the concerns on robustness.  Adjustment for NfL has a major influence on the estimate of the HR from the Cox model.

Considering the small number of events such that single patients may have a relevant influence on the results, no firm conclusions can be drawn with respect to beneficial effects on survival.

## Participant-Reported Quality of Life

According to the applicant the effects observed across exploratory participant-reported QoL measures, including ALSAQ-5, FSS, and EQ-5D, further substantiate the effects observed on the objective clinical outcome measures.

It  appears  that  all  PROS  are  showing  continuous  improvement  from  through  week  28  to  week  52. However, as already mentioned, these pooled blinded and uncontrolled data could have been considered supportive, in case the primary analysis had shown efficacy.

<div style=\"page-break-after: always\"></div>

## 2.6.5.6.2. Pooling of efficacy data - 3 rd  Interim analysis (data cutoff 28 February 2023): Patients with long time exposure up to week 104

## Study populations

The analysis results presented below, pertains to data collected during 233AS101 Part A, B and C, and the open label extension 233AS102, referred to as respective 101 Part C and 102 OLE.

The study populations reflected in the 28 February 2023 data cut were as follows:

- Pooled group CL as the full ITT population (N = 108), including:
- o Early-start  participants  who  started  tofersen  100  mg  in  Study  101  Part  C  and  had  the opportunity to continue on tofersen 100 mg in Study 102 (N = 72)
- o Placebo/delayed-start participants who received placebo in Study 101 Part C and had the opportunity to start tofersen 100 mg in Study 102 (N = 36)
- Part A and Part B participants who received at least 1 dose of tofersen 100 mg (either in Part B or Study 102 [N = 43] for survival analyses or in Study 102 [N = 40 overall or N = 31 for long-term tofersen exposure] for clinical function and strength,

Ninety-five of 108 participants (88%) randomized in Study 101 Part C went on to receive tofersen 100 mg in Study 102. At the time of the 28 February 2023 interim data cut, 16 participants (44.4%) in the placebo/delayed-start group and 44 participants (61.1%) in the early-start group remained ongoing in Study 102.

Figure 19: Flow of participants from Study 101 Part C to Study 102 week 104

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 22: 233AS101 and 233AS102 ISE: subject accountability for pooled group CL by Week 104 - ITT population (data cutoff 28 February 2023)

|                                              | placebo+delayed-starttofersen100mgEarly-starttofersen100mg (N=36)   | (N=72)     |
|----------------------------------------------|---------------------------------------------------------------------|------------|
| Number(%)of subjects                         | 36 (100)                                                            | 72 (100)   |
| Dosedin233AS101                              | 36 (100)                                                            | 72 (100)   |
| Dosedin233AS102                              | 32 (89)                                                             | 63 (88)    |
| Completed233AS101but notenrolledin233AS102   | 1( 2.8)                                                             | 1 ( 1.4)   |
| Ongoingin233AS102atinterim                   | 16 ( 44.4)                                                          | 44 ( 61.1) |
| Length offollow-upsince 233AS101baseline (a) |                                                                     |            |
| >=28weeks                                    | 33 (91.7)                                                           | 65 (90.3)  |
| >=52 weeks                                   | 28 (77.8)                                                           | 59 (81.9)  |
| >=76weeks                                    | 21(58.3)                                                            | 54 (75.0)  |
| >=100weeks                                   | 20 ( 55.6)                                                          | 51 (70.8)  |
| >=124weeks                                   | 13 (36.1)                                                           | 44 ( 61.1) |
| >=148weeks                                   | 10 ( 27.8)                                                          | 37 ( 51.4) |

CLITT:233AS101PartCand233AS102(PartCsubjects)

(a) Counts under the length of follow-up since 233AS101 baseline are based on actual observed data of the subjects up to their last assessment in the study. Subjects who died, withdrew or did not roll over to the extension study 233AS102 before the given threshold will be excluded from the counts.

The discontinuations and the missing data play an important role in the interpretation of data. The applicant has provided subject accountability for CL-ITT population at weeks 104 and 148 and for ABL population at week 168:

Table 23:  233AS101 and 233AS102 ISE: subject accountability for pooled group CL by week 104 - ITT population

|                                             | CL ITT: 233AS101 Part C and 233AS102 (Part C subjects)   | CL ITT: 233AS101 Part C and 233AS102 (Part C subjects)   |
|---------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                             | placebo + delayed-start tofersen 100 mg (N=36)           | Early-start tofersen 100 mg (N=72)                       |
| Discontinued treatment prior to Week 104(a) | 18 ( 50.0)                                               | 22 ( 30.6)                                               |
| Adverse event                               | N                                                        | N                                                        |
| Lost to follow-up                           | 0                                                        | 0                                                        |
| Consent withdrawn                           | 4 ( 11.1)                                                | 3 ( 4.2)                                                 |
| Investigator decision                       | 0                                                        | 0                                                        |
| Death                                       | 5 ( 13.9)                                                | 8 ( 11.1)                                                |
| Non-compliance with study protocol          | 0                                                        | 0                                                        |
| Pregnancy                                   | 0                                                        | 0                                                        |
| Disease progression                         | 7 ( 19.4)                                                | 9 ( 12.5)                                                |
| Other                                       | N                                                        | N                                                        |
| Withdrew from study prior to Week 104       | 15 ( 41.7)                                               | 21 ( 29.2)                                               |
| Adverse event                               | N                                                        | N                                                        |
| Lost to follow-up                           | 0                                                        | 0                                                        |
| Consent withdrawn                           | 3 ( 8.3)                                                 | 3 ( 4.2)                                                 |
| Investigator decision                       | 0                                                        | 0                                                        |
| Death                                       | 5 ( 13.9)                                                | 8 ( 11.1)                                                |
| Non-compliance with study protocol          | 0                                                        | 0                                                        |
| Pregnancy                                   | 0                                                        | 0                                                        |
| Disease progression                         | 7 ( 19.4)                                                | 8 ( 11.1)                                                |
| Other                                       | 0                                                        | 0                                                        |

(a) Defined as subjects who did not complete the study treatment and received the last study drug administration prior to Week 104. N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

Forty-four of 68 participants (65%) from Study 101 Part A and B went on to receive tofersen in Study 102. At the time of the 28 February 2023 interim data cut, 28 of 68 participants (41.2%) remained ongoing in Study 102. A total of 43 participants (63.2%) received at least 1 dose of tofersen 100 mg in Study 101 Part B or Study 102, and 40 participants (58.8%) received at least 1 dose of tofersen 100 mg

<div style=\"page-break-after: always\"></div>

in Study 102, comprising the OLE tofersen 100 mg group. A total of 31 (45.6%) participants comprises the 'ABL long-term tofersen 100 mg population'.

Table 24: 233AS101 and 233AS102 ISE: subject accountability for pooled group CL by week 148 - ITT

population

|                                             | CL ITT: 233AS101 Part C and 233AS102 (Part C subjects)   | CL ITT: 233AS101 Part C and 233AS102 (Part C subjects)   |
|---------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                             | placebo + delayed- start tofersen 100 mg (N=36)          | Early-start tofersen 100 mg (N=72)                       |
| Discontinued treatment prior to Week 148(a) | 20 ( 55.6)                                               | 25 ( 34.7)                                               |
| Adverse event                               | N                                                        | N                                                        |
| Lost to follow-up                           | 0                                                        | 0                                                        |
| Consent withdrawn                           | 5 ( 13.9)                                                | 4 ( 5.6)                                                 |
| Investigator decision                       | 0                                                        | 0                                                        |
| Death                                       | 6 ( 16.7)                                                | 9 ( 12.5)                                                |
| Non-compliance with study protocol          | 0                                                        | 0                                                        |
| Pregnancy                                   | 0                                                        | 0                                                        |
| Disease progression                         | 7 ( 19.4)                                                | 9 ( 12.5)                                                |
| Other                                       | N                                                        | N                                                        |
| Withdrew from study prior to Week 148       | 19 ( 52.8)                                               | 24 ( 33.3)                                               |
| Adverse event                               | N                                                        | N                                                        |
| Lost to follow-up                           | 0                                                        | 0                                                        |
| Consent withdrawn                           | 4 ( 11.1)                                                | 4 ( 5.6)                                                 |
| Investigator decision                       | 0                                                        | 0                                                        |
| Death                                       | 7 ( 19.4)                                                | 9 ( 12.5)                                                |
| Non-compliance with study protocol          | 0                                                        | 0                                                        |
| Pregnancy                                   | 0                                                        | 0                                                        |
| Disease progression Other                   | 7 ( 19.4) N                                              | 9 ( 12.5) N                                              |

(a) Defined as subjects who did not complete the study treatment and received the last study drug administration prior to Week 148 N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

In the CL-ITT population the percentages of deaths in those who discontinued treatment or withdrew from the study was smaller in the early start (12.5% and 12.5%) compared to the placebo/delayed start tofersen group (16.7% and 19.4%, respectively) at Week 148.

Table 25: 233AS101 and 233AS102 ISE: Subject accountability for pooled group ABL by Week 168 - ITT population

|                                       | ABL overall ITT: 233AS101 Part A, B and 233AS102 (Part A and B subjects) All doses   |
|---------------------------------------|--------------------------------------------------------------------------------------|
| Discontinued treatment prior to Week  | 12 (17.6)                                                                            |
| 168(a)                                |                                                                                      |
| Adverse event                         | 1 (1.5)                                                                              |
| Lost to follow-up                     | 0                                                                                    |
| Consent withdrawn                     | 2 (2.9)                                                                              |
| Investigator decision                 | 0                                                                                    |
| Death                                 | 3 (4.4)                                                                              |
| Non-compliance with study protocol    | 0                                                                                    |
| Pregnancy                             | 0                                                                                    |
| Disease progression                   | 5 (7.4)                                                                              |
| Other                                 | 1 (1.5)                                                                              |
| Withdrew from study prior to Week 168 | 15 (2.1)                                                                             |
| Adverse event                         | 0                                                                                    |
| Lost to follow-up                     | 1 (1.5)                                                                              |
| Consent withdrawn                     | 4 (5.9)                                                                              |
| Investigator decision                 | 0                                                                                    |
| Death                                 | 5 (7.4)                                                                              |
| Non-compliance with study protocol    | 0                                                                                    |
| Pregnancy                             | 0                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | ABL overall ITT: 233AS101 Part A, B and 233AS102 (Part A and B subjects) All doses (N=68)   |
|---------------------|---------------------------------------------------------------------------------------------|
| Disease progression | 4 (5.9)                                                                                     |
| Other               | 1 (1.5)                                                                                     |

NOTE 1: Four subjects completed treatment during 233AS101 but did not complete the study. These subjects are included under withdrawals from the study. (a) Defined as subjects who did not complete the study treatment and received the last study drug administration prior to Week 168.

The table below shows that there is large heterogeneity even in the small percentage of ALS patients (~2%) who have the  SOD1 mutation  (approximately  1,000  prevalent  cases  in  the  European  Union currently living with SOD1-ALS). The second observation one can make is that not all the patients who are ongoing in the study have the 'good variants' or 'long survivor variants' (e.g. p.Ile114Thr), which could have been responsible for long term survival and minimal changes in their function and condition. Except for very selected variants little is known about variability in the disease course. Overall, there is no indication that distribution of variants is unequal between groups, which may have biased the results. A5V (p.Ala5Val) is one of the most well studied variants with a median disease duration of ~1.0 to 1.2 years. With 3 A5V carriers ongoing as of the data cutoff, the median duration from ALS symptom onset to death or censoring was 1.9 years (range: 0.9 to 4.8 years) in the early-start group and 1.3 years (range: 0.7 to 2.9) in the delayed-start group.

Table 26: Subject accountability of ITT population with data cutoff 28 February 2023 (&gt;=148 weeks follow-up)

| Variant     |   N | CL1= Early / CL2= Delayed start tofersen   | On going   | Censored reason Death, PV or Disease progression   | Other   |
|-------------|-----|--------------------------------------------|------------|----------------------------------------------------|---------|
| p.Ile114Thr |  20 | N                                          | N          | N                                                  | N       |
| p.Ala5Val   |  17 | N                                          | N          | N                                                  | N       |
| p.Gly94Cys  |   6 | N                                          | N          | N                                                  | N       |
| p.His47Arg  |   5 | N                                          | N          | N                                                  | N       |
| p.Leu145Phe |   4 | N                                          | N          | N                                                  | N       |
| p.Ala90Val  |   4 | N                                          | N          | N                                                  | N       |
| p.Gly38Arg  |   4 | N                                          | N          | N                                                  | N       |
| p.Glu101Gly |   3 | N                                          | N          | N                                                  | N       |
| p.Gly94Ser  |   3 | N                                          | N          | N                                                  | N       |
| p.Leu85Phe  |   3 | N                                          | N          | N                                                  | N       |
| p.Arg116Gly |   2 | N                                          | N          | N                                                  | N       |
| p.Asp91Ala  |   2 | N                                          | N          | N                                                  | N       |
| p.Leu39Val  |   2 | N                                          | N          | N                                                  | N       |
| p.Phe65Leu  |   2 | N                                          | N          | N                                                  | N       |
| p.Thr138Ile |   2 | N                                          | N          | N                                                  | N       |
| p.Val149Gly |   2 | N                                          | N          | N                                                  | N       |
| p.Ala141Gly |   1 | N                                          | N          | N                                                  | N       |
| p.Ile113Thr |   1 | N                                          | N          | N                                                  | N       |

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

## Biomarkers: SOD1 and NfL up to week 104 (data cutoff 28 February 2023)

Based  on  the  knowledge  gathered  up  to  now,  a  mutation  in  the  SOD1  gene  is  responsible  for  the accumulation  of  toxic  SOD1  protein,  which  consequently  drives  loss  of  motor  neurons,  leading  to progressive loss of muscle mass, strength, function, and ultimately death. SOD1-ALS is a progressive disease with fewer than 1,000 patients in EU (ultra-rare disease).

Tofersen reduces the production and accumulation of SOD1 causative protein, as it was demonstrated in Study 101 Part C (placebo-controlled data) and its open-label extension (OLE or LTE), Study 102.

<div style=\"page-break-after: always\"></div>

Figure 20 : 233AS101 and 233AS102 ISE: line plot of total CSF SOD1 protein LS geometric mean ratio to  baseline  values  (95% CI) by time point (up to week 104) from ANCOVA analysis using MI - ITT population

<!-- image -->

NOTE 1: Baseline is defined as day 1 value prior to the study drug. If day 1 value is missing, the non-missing value (including screening visit) closest to and prior to the first dose will be used as the baseline value.

NOTE 2:  Lower limit  of  quantitation  (LLOQ)  is  15.6  ng/mL.  Values  below  limit  of  quantitation  (BLQ)  are  set  to  half  of  LLOQ  in calculations.

NOTE 3: Multiple imputation including treatment group, use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data.

NOTE  4:  The  analysis  is  based  on  ANCOVA  model  with  natural  log  transformed  data.  The  model  includes  covariates  for  the corresponding baseline value i.e. log value, and use of riluzole or edaravone.

Abbreviations:  CSF  =  cerebrospinal  fluid;  SOD1  =  superoxide  dismutase  1;  ANCOVA  =  analysis  of  covariance;  MI  =  multiple imputation; LS = least square.

It is observed that the reduction of SOD1 in the case of the early start tofersen treatment group achieves a noticeable decrease at week 12 and reaches the lowest point at week 28, after which it remains at decreased levels until week 104. In the case of the delayed start tofersen treatment group the levels until week 28 remain high and close to the baseline levels. After week 28 there is a decrease until week 40 and then SOD1 levels for this delayed start group remain at approximately the same low levels as in the early-start group.

It can be expected that reduction of the causative protein should lead to a reduction in neuronal axonal injury and neurodegeneration, as observed by lowering of the NfL in plasma and CSF.  Despite that the prognostic and predictive value of NfL in ALS is not fully established yet, NfL is being used in most of the clinical trials in ALS and it is currently recognised as a reliable biomarker for neurodegeneration in ALS.

Reductions in plasma ( Figure 21 ) and CSF NfL (were sustained over time, with reductions from baseline of ~60% to 70% observed at Week 104.

<div style=\"page-break-after: always\"></div>

Figure 21: Plasma NfL adjusted geometric mean ratio to Study 101 Part C baseline (95% confidence interval [CI]) by visit to week 104 from ANCOVA using multiple imputation (MI) - ITT population

<!-- image -->

Levels of NfL reached their nadir by approximately 16 weeks after tofersen administration. The graphical pattern of the levels of NfL is quite similar to the graphical pattern of SOD1 with a time delay.

Table 27: Part of summary of secondary and exploratory endpoints at week 28

| Key Endpoints                                            | Analysis Population   | Placebo       | Tofersen      | Absolute Difference          |
|----------------------------------------------------------|-----------------------|---------------|---------------|------------------------------|
| CSF SOD1 Protein %change from baseline in geometric mean | FPS (mutation/slope)  | 16% increase  | 29% reduction | 45% (p < 0.00010 a ; ANCOVA) |
| CSF SOD1 Protein %change from baseline in geometric mean | SPS (mutation/slope)  | 19% reduction | 40% reduction | 21% (p = 0.0007 a ; ANCOVA)  |
| Plasma NfL %change from baseline in geometric mean       | FPS (mutation/slope)  | 20% increase  | 60% reduction | 80% (p < 0.0001 a ; ANCOVA)  |

<div style=\"page-break-after: always\"></div>

Figure 22: Timeline of neurofilament behaviour characterisation in ALS literature

<!-- image -->

According to the applicant, the relationship between the reduction in NfL and clinical function cannot be adequately assessed using correlation coefficients (CC) without adjustment  for baseline NfL, as this approach does not take into account variable natural disease progression across participants. Partial correlation coefficients adjusted for baseline NfL help demonstrate that as the neurofilament levels are reduced at Weeks 12 and 16, tofersen-treated participants begin to show stabilisation at Week 28 with either  no  change  or  a  smaller  decline  in  ALSFRS-R  functional  score  (Pearson's  partial  CC  =  -0.32; Spearman's partial CC = -0.22 for NfL reduction at Week 16 versus change in ALSFRS-R at Week 28). This  relationship  is  strengthened  when  looking  at  reductions  in  NfL  at  Week  28  versus  changes  in ALSFRS-R at Week 52 (Pearson's partial CC = -0.63 and Spearman's partial CC = -0.34 in the earlystart group) as participants are stabilizing and even seeing improvement in clinical function.

With tofersen treatment, NfL reductions are observable as early as 8 weeks and appear to be maximized by  approximately  16 weeks  after  tofersen  initiation.  These  reductions  in  NfL  preceded  discernible differences on ALSFRS-R and other clinical outcome measures, highlighting the time needed for a slowing of neurodegeneration to translate into detectable slowing of clinical decline (Figure 23).

<div style=\"page-break-after: always\"></div>

Figure 23: ALSFRS-R total score adjusted mean difference (tofersen-placebo) and plasma NfL adjusted mean ratio to baseline (tofersen-placebo) by visit up to week 28 in Study 101 Part C

<!-- image -->

<!-- image -->

ALSFRS-Rtotalscore PlasmaNfL

Source:AdaptedfromClinicalStudyReportofStudy101Part C

Note: For least squares mean calculation on ALSFRS-R total score, treatment is included as a fixed effect after adjusting for baseline disease duration since symptom onset, baseline ALSFRS-R total score, and use of riluzole or edaravone.

ForleastsquaresmeancalculationonNfL,treatmentisincludedasafixedeffectafteradjustingforbaselinediseasedurationsince symptomonset,logbaselineNfl,anduseof riluzoleoredaravone.

Abbreviations: ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; LS, least squares; NfL, neurofilament light chain

Source: United States Food and Drug administration, Summary Basis for Approval Integrated Review Document.

## ALSFRS-R and other endpoints

There  is  a  continued  separation  between  the  placebo/delayed-start  participants  and  the  early-start tofersen treatment group over the longer-term in the ITT population adjusted for baseline plasma NfL through Week 104 (initially observed in the second interim data cut 16 January 2022, week 52.

Table 28: Change in ALSFRS-R total score from Study 101 Part C baseline at weeks, 28, 40, 76 and week 104 - ITT population adjusted for baseline plasma nfl

| ALSFRS-R                                   | Tofersen (n=72) vs. placebo (n=36) Change from baseline to Week 28   | ISE Based on Jul 2021 Data Cut Early-start tofersen (n=72) vs. placebo → delayed start tofersen (n=36) Change from baseline to Week 40   | ISE Based on Jan 2022 Data Cut Early-start tofersen (n=72) vs. placebo → delayed start tofersen (n=36) Change from baseline to Week 52   | ISE Based on Feb 2023 Data Cut Early-Start Tofersen (n=72) vs. Placebo/ Delayed-Start Tofersen (n=36) Change from Baseline to Week 76   | ISE Based on Feb 2023 Data Cut Early-Start Tofersen (n=72) vs. Placebo/ Delayed-Start Tofersen (n=36) Change from Baseline to Week 104   |
|--------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Original Multiple Imputation               | Original Multiple Imputation                                         | Original Multiple Imputation                                                                                                             | Original Multiple Imputation                                                                                                             | Original Multiple Imputation                                                                                                            | Original Multiple Imputation                                                                                                             |
| Adjusted Means: Tof; Pcb                   | -4.1 ; -6.2                                                          | -5.8 ; -8.5                                                                                                                              | -6.0 ; -9.5                                                                                                                              | -7.6 ; -11.0                                                                                                                            | -9.5 ; -13.2                                                                                                                             |
| Tof-Pcb: Adjusted Mean Difference (95% CI) | 2.1 (-0.3, 4.5)                                                      | 2.6 (-0.4, 5.7)                                                                                                                          | 3.5 (0.4, 6.7)                                                                                                                           | 3.4 (-0.3, 7.1)                                                                                                                         | 3.7 (-0.7, 8.2)                                                                                                                          |
| p-Value (ANCOVA+MI)                        | 0.0904                                                               | N/A                                                                                                                                      | 0.0272                                                                                                                                   | 0.0686                                                                                                                                  | 0.1004                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| ALSFRS-R                                            | Tofersen (n=72) vs. placebo (n=36) Change from baseline to Week 28   | ISE Based on Jul 2021 Data Cut Early-start tofersen (n=72) vs. placebo → delayed start tofersen (n=36) Change from baseline to Week 40   | ISE Based on Jan 2022 Data Cut Early-start tofersen (n=72) vs. placebo → delayed start tofersen (n=36) Change from baseline to Week 52   | ISE Based on Feb 2023 Data Cut Early-Start Tofersen (n=72) vs. Placebo/ Delayed-Start Tofersen (n=36) Change from Baseline to Week 76   | ISE Based on Feb 2023 Data Cut Early-Start Tofersen (n=72) vs. Placebo/ Delayed-Start Tofersen (n=36) Change from Baseline to Week 104   |
|-----------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| p-Value (original JRT+MI)                           | 0.5015                                                               | N/A                                                                                                                                      | 0.2090                                                                                                                                   | 0.0860                                                                                                                                  | 0.0835                                                                                                                                   |
| p-Value (alter. JRT+MI)                             | 0.0595                                                               | N/A                                                                                                                                      | 0.0340                                                                                                                                   | 0.0375                                                                                                                                  | 0.0335                                                                                                                                   |
| Multiple Imputation and Imputation Zero After Death | Multiple Imputation and Imputation Zero After Death                  | Multiple Imputation and Imputation Zero After Death                                                                                      | Multiple Imputation and Imputation Zero After Death                                                                                      | Multiple Imputation and Imputation Zero After Death                                                                                     | Multiple Imputation and Imputation Zero After Death                                                                                      |
| Adjusted Means: Tof; Pcb                            |                                                                      |                                                                                                                                          |                                                                                                                                          | -9.0; -14.5                                                                                                                             | -10.6; -16.2                                                                                                                             |
| Tof-Pcb: Adjusted Mean Difference (95% CI)          |                                                                      |                                                                                                                                          |                                                                                                                                          | 5.6 (1.0,10.1)                                                                                                                          | 5.6 (0.6,10.5)                                                                                                                           |
| p-Value (ANCOVA+MI)                                 |                                                                      |                                                                                                                                          |                                                                                                                                          | p=0.0160                                                                                                                                | p=0.0280                                                                                                                                 |

The table above shows that the largest difference between early start and placebo/delayed start tofersen is observed at week 52 and then the difference between the two groups remains the same or very similar over a period of another year, which is consistent with a disease modifying effect.

The trends observed at Week 52 for Study 101 Part C, were consistently in favor of tofersen across different populations and disease progression subgroups (mITT vs. non-mITT and NfL-based), regardless of which covariates were adjusted for. This consistency favouring tofersen treatment was observed in the forest plot at week 104.

Figure 24 : Forest Plot of ALSFRS-R Total Score Change From Baseline to Week 104

No.of subjects (a)

<!-- image -->

| Population/Subgroup                    | Covariate adjustment for baseline disease status   | SAP Version   | P+DS=placebo+ delayed-start tofersen100 mg;ES=Early-start tofersen100mg   |      | LSM Diff           | I%S6           | ANCOVA+MI p-value (a)   | Posthoc JRT+MI p-value (b)   | Posthoc Altermative JRT+MI p-value (c)   | Posthoc Altermative JRT+MI p-value (c)   | Posthoc Altermative JRT+MI p-value (c)   | Posthoc Altermative JRT+MI p-value (c)   | Posthoc Altermative JRT+MI p-value (c)   | Posthoc Altermative JRT+MI p-value (c)   |
|----------------------------------------|----------------------------------------------------|---------------|---------------------------------------------------------------------------|------|--------------------|----------------|-------------------------|------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| ITT                                    | Base. plasma NfL                                   | SAPV3         | P+DS=36;ES=72                                                             |      | 3.7                | (-0.72, 8.17)  | 0.1004                  | 0.0835                       | 0.0335                                   | 0.0335                                   | 0.0335                                   | 0.0335                                   | 0.0335                                   | 0.0335                                   |
|                                        | Log Base. plasma NfL                               |               | P+DS=36;ES=72                                                             |      | 3.5                | (-1.01, 7.93)  | 0.1290                  | 0.1091                       | 0.0496                                   | 0.0496                                   | 0.0496                                   | 0.0496                                   | 0.0496                                   | 0.0496                                   |
|                                        | Disease duration                                   | SAPV2*        | P+DS=36;ES=72                                                             |      | 2.2                | (-2.65,7.03)   | 0.3745                  | 0.2829                       | 0.1796                                   | 0.1796                                   | 0.1796                                   | 0.1796                                   | 0.1796                                   | 0.1796                                   |
|                                        | ALSFRS-R pre-rand. slp.                            |               | P+DS=36;ES=72                                                             |      | 2.1                | (-2.92, 7.05)  | 0.4174                  | 0.3301                       | 0.2297                                   | 0.2297                                   | 0.2297                                   | 0.2297                                   | 0.2297                                   | 0.2297                                   |
|                                        | ALSFRS-R pre-rand. slp + Base. plasma NfL          |               | P+DS=36;ES=72                                                             |      | 3.5                | (-1.01, 7.93)  | 0.1297                  | 0.0979                       | 0.0357                                   | 0.0357                                   | 0.0357                                   | 0.0357                                   | 0.0357                                   | 0.0357                                   |
|                                        | Disease duration + Base. plasma NfL                |               | P+DS=36;ES=72                                                             |      | 3.4                | (-1.11, 7.85)  | 0.1402                  | 0.1006                       | 0.0374                                   | 0.0374                                   | 0.0374                                   | 0.0374                                   | 0.0374                                   | 0.0374                                   |
|                                        | Unadj.for base.disease status                      |               | P+DS=36;ES=72                                                             |      | 2.3                | (-2.93,7.59)   | 0.3852                  | 0.2737                       | 0.2243                                   | 0.2243                                   | 0.2243                                   | 0.2243                                   | 0.2243                                   | 0.2243                                   |
| mITT                                   | Base. plasma NfL                                   | SAPV3         | P+DS=21;ES=39                                                             |      | 3.4                | (-4.59, 11.33) | 0.4064                  | 0.6503                       | 0.4631                                   | 0.4631                                   | 0.4631                                   | 0.4631                                   | 0.4631                                   | 0.4631                                   |
|                                        | Log Base. plasma NfL                               |               | P+DS=21;ES=39                                                             |      | 3.8                | (-4.30, 11.88) | 0.3583                  | 0.5649                       | 0.5032                                   | 0.5032                                   | 0.5032                                   | 0.5032                                   | 0.5032                                   | 0.5032                                   |
|                                        | Disease duration                                   | SAPV2*        | P+DS=21;ES=39                                                             |      | 1.1                | (-6.94, 9.19)  | 0.7840                  | 0.9025                       | 0.8786                                   | 0.8786                                   | 0.8786                                   | 0.8786                                   | 0.8786                                   | 0.8786                                   |
|                                        | Disease duration + Base. plasma NfL                |               | P+DS=21;ES=39                                                             |      | 3.0                | (-4.87,10.93)  | 0.4516                  | 0.7351                       | 0.4140                                   | 0.4140                                   | 0.4140                                   | 0.4140                                   | 0.4140                                   | 0.4140                                   |
| nonmITT                                | Base. plasma NfL                                   | SAPV3         | P+DS=15; ES=33                                                            |      | 3.4                | (-1.36,8.12)   | 0.1626                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Log Base. plasma NfL                               |               | P+DS=15; ES=33                                                            |      | 3.0                | (-1.81, 7.74)  | 0.2240                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration                                   | SAPV2*        | P+DS=15;ES=33                                                             |      | 3.1                | (-1.82, 8.10)  | 0.2143                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration +Base.plasma NfL                  |               | P+DS=15;ES=33                                                             |      | 3.4                | (-1.34,8.19)   | 0.1591                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
| ITT:>=Median(75.60pg/mL)Base.plasmaNfL |                                                    | SAPV3         | P+DS=16;ES=38                                                             |      | 6.5                | (-1.44, 14.49) | 0.1083                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Log Base. plasma NfL                               |               | P+DS=16;ES=38                                                             |      | 6.0                | (-2.14, 14.17) | 0.1481                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration                                   | SAPV2*        | P+DS=16;ES=38                                                             |      | 5.5                | (-2.74,13.84)  | 0.1897                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration + Base. plasma NfL                |               | P+DS=16;ES=38                                                             |      | 6.1                | (-1.90, 14.15) | 0.1347                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
| ITT:<Median (75.60pg/mL)               | Base. plasma NfL                                   | SAPV3         | P+DS=20;ES=34                                                             |      | 1.6                | (-2.14, 5.29)  | 0.4054                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Log Base. plasma NfL                               |               | P+DS=20; ES=34                                                            |      | 1.2                | (-2.64, 5.09)  | 0.5338                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration                                   | SAPV2*        | P+DS=20;ES=34                                                             |      | 1.0                | (-3.00,5.08)   | 0.6134                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        | Disease duration + Base. plasma NfL                |               | P+DS=20;ES=34                                                             |      | 1.5                | (-2.52,5.42)   | 0.4732                  |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               | Favors placebo+ delayed-start                                             |      | Favors Early-start |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               |                                                                           |      | tofersen100mg      |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               | tofersen100mg                                                             |      |                    |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               | -15                                                                       |      |                    |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               |                                                                           | -5 0 |                    |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               |                                                                           |      | 15                 |                |                         |                              |                                          |                                          |                                          |                                          |                                          |                                          |
|                                        |                                                    |               |                                                                           | 5    | 10                 |                |                         |                              |                                          | -10                                      |                                          |                                          |                                          |                                          |

LS mean treatment difference (95% CI)

NOTE 1: SAP V2.0 is the integrated efficacy SAP that was finalized prior to the final database lock for 233AS101 and interim lock for 233AS102 based on 16 July 2021 data cut; prespecified analyses were primarily based on disease progression subgroups and adjusted for disease duration since symptom onset. SAP V3.0 was an amendment to the integrated efficacy SAP following the initial data readout and incorporated plasma NfL as a covariate with the focus on the ITT population. SAP V3.0 was finalized prior the interim lock for 233AS102 based on 16 January 2022 data cut.

<div style=\"page-break-after: always\"></div>

NOTE 2: For ITT population, multiple imputation including the specified covariate(s), use of riluzole or edaravone, and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include the specified covariate(s), baseline ALSFRS-R, and use of riluzole or edaravone.

NOTE 3: For the analyses including disease duration since symptom onset in mITT and non mITT population, multiple imputation including use of riluzole or edaravone and the relevant baseline and postbaseline values for the endpoint is used for missing data. The corresponding ANCOVA models include covariates for baseline disease duration since symptom onset, baseline ALSFRS-R and use of riluzole or edaravone.  For the other analyses in mITT and non mITT population, multiple imputation including baseline plasma NfL, use  of  riluzole  or  edaravone  and  the  relevant  baseline  and  postbaseline  values  for  the  endpoint  is  used  for  missing  data.  The corresponding ANCOVA models include covariates for the specified covariate(s), baseline plasma NfL, baseline ALSFRS-R and use of riluzole or edaravone.

* No statistical testing was prespecified in SAP Version 2; all p-values are post-hoc for SAP V2 analyses.
- (a) From the listed ANCOVA analysis based on change from baseline.
- (b) From the ANCOVA on ranked scores; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.
- (c) From the ANCOVA on change of ranked scores pre- and post- treatment; deaths are ranked the lowest; MI is used for handling missing data due to withdrawals other than death.

Abbreviations: ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; ANCOVA = analysis of covariance; MI = multiple imputation; LS = least square; P+DS = placebo + delayed-start tofersen 100 mg; ES = Early-start tofersen 100 mg.

In order to view the functional condition of the patients, crude plots were constructed using the actual observed mean values of ALSFRS-R total score (without adjustment) over time.

Measurements for ALSFRS-R at week 104 were recorded for 20 (55.6%) patients of the placebo/ delayed start  tofersen  treatment  and  for  50  (69.4%)  patients  from  the  early  start  tofersen  group.  It  was considered appropriate to look at the discontinuations from the study trying to understand better the potential stabilisation of patients.

Figure 25 : ALSFRS-R total score mean actual values by visit for pooled group CL (observed data) - ITT population

<!-- image -->

CL ITT: 233AS101 Part C and 233AS102

(At baseline CL1 N=72 and CL2 N=36, at week 104 CL1 N=50 and CL2 N=20)

<div style=\"page-break-after: always\"></div>

Visual observation of this 'crude' figure shows a greater decline in function of placebo treated patients until week 28 compared to tofersen treated patients. After week 28 a stabilisation of ALSFRS-R score in both groups is observed and this remains throughout week 104, but with a lower number of patients (see section of subject accountability below). It is also observed that the difference achieved at week 52 between the two groups remains the same over a long period of time, which is consistent with a disease modifying effect from tofersen treatment.

However, one could argue that this figure is based on complete cases, such that it is not clear whether the changes over time are real, or just due to selection, i.e. patients performing worst discontinuing study (most discontinuations were due to death or disease progression). For example, the increase in ALSFRS-R in the delayed start group between week 48 and week 76 is in parallel with a decrease of observed cases from 27 to 20. However, a patient selection to provide such a picture of stabilisation is not very likely in the view of the assessment team. The characteristics of the patients included do not suggest that there could be a subgroup of patients, who would be stable for 2 years (at least) without any tofersen intervention (see section of subject accountability below).

The ALSFRS-R total score over time (up to week 104), ANCOVA analysis using MI - ITT population (studies 101 part C and 102) is presented in the following figure. Data suggest that tofersen slows the decline in function. The difference between early and delayed tofersen start groups remains stable over time suggesting greater benefit with earlier treatment and a disease modifying effect. The limitation is the MAR assumption used for the analysis.

Figure 26: Line plot of ALSFRS-R total score LS mean change from baseline values +/- SE by time point from ANCOVA analysis using MI for pooled group CL - ITT population

<!-- image -->

The applicant presented an analysis of estimated proportion of participants with improvement in the efficacy endpoints. Results for ALSFRS-R are presented in Table 29. The findings do not show the actually observed  proportions  of  patients  with  improvements,  but  proportions  estimated  based  on  a  logistic regression model adjusting for covariates, which is considered a limitation as this usually means that the response is shown for a hypothetical population where e.g. continuous values such as NfL are set to their mean. Additionally, the model is based on strong assumptions such as proportional odds.

<div style=\"page-break-after: always\"></div>

Table 29: Estimated Proportion (%) of Participants With Improvement or Stabilisation/Improvement on Clinical Function, Strength, and QoL Measures From Baseline to Week 100/104 - ITT Population Adjusted for Baseline Plasma NfL

| Endpoint   |                                                              | Week 100/104                  |                     |
|------------|--------------------------------------------------------------|-------------------------------|---------------------|
|            |                                                              | Placebo/delayed- start (n=36) | Early- start (n=72) |
| ALSFRS-R   | Proportion of participants with improvement                  | 9.3                           | 16.0                |
|            | Proportion of participants with stabilisation or improvement | 16.6                          | 23.5                |

The applicant  repeated  the  requested  analysis,  whereby  responses  should  be  provided  as  observed (considering death and withdrawal as failure, and replacing other missing values based on MI). The proportions of responders are slightly larger but absolute differences in response proportions between treatment groups are comparable to the analysis based on logistic regression.

Table 30:  Proportion  (%)  of  participants  with  improvement  or  stabilisation/improvement  on  clinical function,  strength,  and  quality  of  life  measures  from  baseline  to  week  100/104  (without  logistic regression) - ITT population

| Endpoint               | Endpoint                                                     | Week 100/104                  | Week 100/104       |
|------------------------|--------------------------------------------------------------|-------------------------------|--------------------|
|                        |                                                              | Placebo/Delayed- Start (n=36) | Early-Start (n=72) |
| ALSFRS-R               | Proportion of participants with improvement                  | 11.6                          | 19.5               |
| ALSFRS-R               | Proportion of participants with stabilisation or improvement | 22.7                          | 29.3               |
| Percent- Predicted SVC | Proportion of participants with improvement                  | 10.5                          | 21.4               |
| Percent- Predicted SVC | Proportion of participants with stabilisation or improvement | 10.5                          | 21.4               |
| HHD Megascore          | Proportion of participants with improvement                  | 10.1                          | 25.8               |
| HHD Megascore          | Proportion of participants with stabilisation or improvement | 10.1                          | 25.8               |
| ALSAQ-5                | Proportion of participants with improvement                  | 16.1                          | 19.7               |
| ALSAQ-5                | Proportion of participants with stabilisation or improvement | 25.1                          | 33.6               |
| FSS                    | Proportion of participants with improvement                  | 25.1                          | 25.3               |
| FSS                    | Proportion of participants with stabilisation or improvement | 32.8                          | 33.6               |
| EQ-5D-5L               | Proportion of participants with improvement                  | 18.2                          | 27.7               |
| EQ-5D-5L               | Proportion of participants with stabilisation or improvement | 23.8                          | 34.6               |

Note 1: Participants with any increase compared with Study 101 baseline were classed as improvement responders, and participants with no change or with a decrease compared with Study 101 baseline were classed as non-responders. Deaths and withdrawals are classed as non-responders. All other missing data are accounted for using MI.

Note 2: For ALSFRS-R, SVC, and HHD, results are presented at Week 104. For ALSAQ-5, FSS, and EQ-5D-5L, results are presented at Week 100. The difference in assessment week is due to assessments being performed at different visits.

These data in the CL-ITT population appear to be consistent with observations for Study 101 Parts A and B in which disease progression has essentially been stabilized for a median of 4.7 years (range: 3.1 to

<div style=\"page-break-after: always\"></div>

5.8 years) of follow-up in the cohort of participants who received at least 1 dose of tofersen in Study 102 (n = 40). These participants experienced a mean change from Study 102 baseline to Week 168 (~3.2 years) of -2.3 points on ALSFRS-R, -2.4 on percent-predicted SVC, and -0.1 on HHD megascore.

Figure 27 : 233AS101 and 233AS102 ISE: ALSFRS-R total score mean actual values and change from baseline by time point for pooled group ABL (Study 101 Parts A and B and study 102)

<!-- image -->

N=40 at baseline and N=30 (~75%) at week 168

A mean change from Study 102 baseline to Week 168 of -2.3 points in ALSFRS-R over 39 months (~3.2 years)  could  be  considered  an  indication  of  stabilisation  of  the  disease,  despite  that  the  data  are uncontrolled. However, these results may derive from a very selected patient population, which may not be  at  all  representative  of  the  ALS-SOD1  population  and  are  uncontrolled.  These  data  should  be interpreted  with  extreme  caution.  The  applicant  discussed  whether  these  ABL  patients  had  specific characteristics that would allow them to remain stable in their ALS condition irrespective of tofersen treatment (see discussion of Clinical Efficacy).

Despite that these data should be interpreted carefully; they may contribute to the suggestion that a potential stabilisation in tofersen-treated participants is unlikely attributable to biological/measurement noise. This is even more evident in the case of placebo/delayed-start tofersen treatment group for which potential stabilisation was shown after the initiation of tofersen treatment.

In the absence of a long-term placebo-controlled study correlation analyses between change in NfL and change in ALSFRS-R at a later time point are of interest. Under the Raw Data Pilot project, the subject profiles  using  change  from  baseline  in  NfL  and  change  from  baseline  in  ALSFRS-R  showed  some correlations in some patients but not in others. The graphs were provided by the Data Analysis Centre in groups of 10 patients to avoid confusion with many lines in the same area. Two of these graphs with the  early  and  placebo/delayed  start  tofersen  treatment  groups  and  patients  having  the  rapidly progressing p.Ala5Val (A5V) variant, as examples, are presented below.

<div style=\"page-break-after: always\"></div>

Figure 28 : Change from Study 101 Part C baseline ALSFRS-R total score and log(NfL) profiles, gene variant Ala5Val, early start tofersen

<!-- image -->

Figure 29: Change from Study 101 Part C baseline ALSFRS-R total score and log(NfL) profiles, gene variant Ala5Val, placebo delayed start tofersen

<!-- image -->

A5V variant is among the best characterized SOD1 variants and consistently found to be associated with a median disease duration of approximately 1 to 1.2 years (Bali 2017; Opie-Martin 2022). In the above graphs  a  clear  difference  between  the  early  start  and  the  placebo/delayed  start  tofersen  is  visually obvious, also indicating a beneficial effect of early tofersen treatment.

<div style=\"page-break-after: always\"></div>

## Event-free survival

The applicant provided analyses for three different time to event endpoints: Time to death or PV, Time to death, Time to death or PV or withdrawal due to disease progression.

The applicant claims that all available data consistently indicate that tofersen, particularly when initiated early, has a clinically meaningful effect on event-free survival.

However, the overall number of events (deaths or PV) at latest data cut-off (28. February 2023) is small (see table below) such that the uncertainty of estimates derived from all analyses is high and no robust conclusions are possible.

Table 31: Additional time to event analyses

| Description                                                             | Hazard ratio (95% CI)   |   Wald test |   Log-rank test | Events of total in early group   | Percentage, early   | Events of total in delayed group   | Percentage, delayed   |
|-------------------------------------------------------------------------|-------------------------|-------------|-----------------|----------------------------------|---------------------|------------------------------------|-----------------------|
| Time to death or Permanent Ventilation (21 days)                        | 0.76 (0.332, 1.720)     |      0.5049 |          0.4843 | 16/72                            | 22.2%               | 9/36                               | 25.0%                 |
| Time to death                                                           | 0.66 (0.252, 1.705)     |      0.387  |          0.3486 | 11/72                            | 15.3%               | 7/36                               | 19.4%                 |
| Time to death or Permanent Ventilation (21 days) or Disease Progression | 0.73 (0.378, 1.422)     |      0.3586 |          0.3669 | 24/72                            | 33.3%               | 14/36                              | 38.9%                 |

Figure 30: 233AS101 and 233AS102 ISE: Kaplan-Meier plot of time to death or permanent ventilation for pooled group CL - ITT population

233AS101 and 233AS102 ISE: Kaplan-Meier plot of time to death or permanent ventilation for pooled group CL - ITT population

Page: 1 of 1

NOTE 1: Time to death or permanent ventilation is defined as the time from first dose to death or permanent ventilation (&gt;= 22 hours of mechanical ventilation [invasive or noninvasive] per day for &gt;= 21 consecutive days),whichever comes first.Subjects who do not meet the endpoint definition are censored at the subject'slast known alive date.Only events that were adjudicated by the Endpoint Adjudication Committee are included. NOTE 2: + indicates censored data.

<!-- image -->

<div style=\"page-break-after: always\"></div>

The crude event rates and Kaplan-Meier curves show only small numerical differences in favor of early start tofersen. The marginal HR's (i.e. unadjusted HR) from a Cox model without including covariates are consistent with these results, being numerically in favor of tofersen ranging from 0.66-0.76 but with wide 95% CIs.

The applicant's claim of a larger effect is based on a Cox model including baseline NfL as a covariate (see Table 32 below).

Table 32: Part of the summary of time-to-event analyses (Study 101 Part C + 102)

|                    | Time to death or PV   | Time to death     | Time to death, PV, or withdrawal due to disease progression   |
|--------------------|-----------------------|-------------------|---------------------------------------------------------------|
| ITT                |                       |                   |                                                               |
| HR (95% CI)        | 0.47 (0.20, 1.11)     | 0.36 (0.13, 1.02) | 0.50 (0.25, 0.99)                                             |
| Log-rank p-value a | 0.1685                | 0.1224            | 0.0866                                                        |
| Cox p-value        | 0.0842                | 0.0538            | 0.0475                                                        |

HR: hazard ratio.

a Based on log rank test stratified by median baseline plasma NfL.

The resulting conditional HR does not only adjust for imbalances but has a different interpretation than the marginal HR. Adjustment for NfL was included in the SAP for the pooled analysis after results from study 101 part C were known. Furthermore, the analysis is based on the proportional hazards assumption for  baseline  NfL  (i.e.  assuming  a  continuous  increase  in  hazard  with  increasing  baseline  NfL)  and proportional hazards over time. Both are strong assumptions, and it is questionable that the model is robust to deviations from these assumptions, also considering the small number of events such that single patients may have a relevant influence on the results.

To contextualize the survival in the trial participants with the expected natural history of SOD1 -ALS, the applicant provided additional analyses of 'disease duration' by estimating time from ALS symptom onset to death or censoring. In addition, a rank preserving structural failure time model to compare what is observed in the early-start tofersen participants with what would have been expected in the delayedstart group if they had they not switched to tofersen in Study 102. However, these analyses are based on strong and unverifiable assumptions such that the robustness of these analyses is highly questionable. Firm conclusions cannot rely on such hypothetical approaches.

Overall,  although  numerical  trends  in  favour  of  the  early  start  tofersen  group  were  observed,  no conclusions  can  be  currently  drawn  on  an  effect  of  tofersen  on  time  to  event-free  survival  because robustness  is  highly  questionable  due  to  small  event  numbers  and  immature  data  and  the  strong assumptions made for analysis.

Additional analyses were also performed under the Raw Data Pilot project for the composite event: change  from  baseline  ALSFRS  &lt;-10,  death  or  PV  assistance  and  a  comparison  was  made  between subjects allocated to tofersen versus in 101 Part C and observed into 102 OLE. This was performed with the data by the applicant. Two models comparing events up to week 124 (any events occurring later are censored) have been applied for the comparison, one with and one without baseline NfL included, and with a noteworthy difference to the outcome of the comparison.

<div style=\"page-break-after: always\"></div>

Table 33: Comparison between treatment on new composite event endpoint (week 124)

| Description                                                     | Hazard ratio (95% CI)   |   Wald test |   Log- rank test | Events of total in early group   | Percenta ge, early   | Events of total in delayed group   | Percentage , delayed   |
|-----------------------------------------------------------------|-------------------------|-------------|------------------|----------------------------------|----------------------|------------------------------------|------------------------|
| Time to change<-10 or death or PV                               | 0.70 (0.375, 1.309)     |      0.2646 |           0.2645 | 26/72                            | 36.1%                | 16/36                              | 44.4%                  |
| Time to change<-10 or death or PV, Adjustment for log (baseNfL) | 0.46 (0.241, 0.883)     |      0.0194 |           0.0463 | 26/72                            | 36.1%                | 16/36                              | 44.4%                  |

This Table and the graph below indicate a better outcome for the patients with early tofersen treatment, especially  when  NfL  is  taken  into  account.  However,  the  underlying  non-informative  censoring assumption is questionable, which is a limitation of this analysis as it may lead to an overestimation of the proportion of event-free patients in both groups.

Figure 31: Kaplan Meier curves for event: Time to change from baseline ALSFRS-R total deterioration greater than 10 (&lt; -10) points, Death or Permanent ventilation assistance, whichever comes first

<!-- image -->

## Cumulative distribution function analyses (week 52)

Under the Raw Data Pilot project some additional 'responder like' analyses were also conducted.

In these analyses, the cumulative distribution functions of the change from baseline in the ALSFRS-R total  score  were  generated  for  both  treatment  groups  indicating  the  probability  of  failure  (y  axis) projected  versus  change  from  baseline  as  cut-off  value  defining  failure,  taking  into  consideration

<div style=\"page-break-after: always\"></div>

treatment discontinuation due to death, progressive disease, AE and other subject withdrawal as failure expressed as a decrease from baseline of -40 being lower than any other change from baseline.

For those two subjects that did not enter extension study 102, changes were extrapolated from week 28 to week 52. For one subject with intermediate missing value at week 52 the change was interpolated between week 48 and week 56.

Interpretation is that the proportion of subjects with a change lower than (and equal to) that on the xaxis is given by the value on the y-axis. Lower change means larger decrease, hence, failure. 1 - this proportion would be the response rate. In the graph below which shows, e.g., a probability of failure for a cut-off of -10, a rate of about 35% and 47% for the failure rates corresponds to early start and placebo delayed start tofersen treatment group, respectively. Values at -40 relate to the proportion of subjects that discontinue the study (except those 2 subjects that did not enter the extension study, see above).

Figure 32: Cumulative distribution function of ALSFRS-R changes from baseline at week 52 indicating the probability of failure at week 52 by differing cut-off values.

<!-- image -->

The applicant has repeated a cumulative distribution function analyses and discussed the results.

In the following figure, very similar to the one generated during the Raw Data Pilot Project, for a cutoff of -12, the rates of worsening in ALSFRS-R are approximately 32% and 44% for the early-start tofersen group and the placebo/delayed-start tofersen group, respectively. These shows that participants in the placebo/delayed-start group tend to have a higher rate of worsening in ALSFRS-R at Week 52.

<div style=\"page-break-after: always\"></div>

Figure 33: Cumulative distribution function of ALSFRS-R changes from baseline at week 52 indicating the probability of failure at week 52 - ITT population

<!-- image -->

The most reliable analysis is at week 52 with missing data of approximately 20% and only half a year without placebo data. A 6-month delay in the treatment effect for a disease modifying agent would be reasonable.

There  are  certainly  various  caveats  with  such  analyses  e.g.  interpretation  of  missing  data  and unresolvable multiplicity issues (referring to post hoc analyses). The most reasonable cut-off (or range of cut-offs) should rather be defined independently of the graph, e.g. in terms of what can be expected as a change for this period and the intra-subject variability/fluctuation. P-value of the corresponding non-parametric test would be 0.6 (not adjusted by NfL baseline values), i.e. a significant difference between the Cumulative Distribution Function (CDFs) is not given even if this analysis had been prespecified and difference between CDFs (hence distributions) can still be due to chance. However, the results suggest (with support from pre-clinical and biomarker/PD data) that tofersen treatment may exert a disease modifying effect.

## 2.6.5.7. Supportive studies

The following data are considered supportive of the main study 101 Part C and the pooled analyses together with some of the study 102 LTE data (interim 2, data cut: January 2022).

## 2.6.5.7.1. Expanded Access Program

An  EAP  providing  access  to  tofersen  outside  the  context  of  a  formal  clinical  trial  or  marketing authorisation was implemented for rapidly progressing SOD1-ALS patients in July 2021. The applicant expanded eligibility to include all SOD1-ALS patients as of 17 October 2021.

Safety data from EAP participants available as of the 15 July 2022 safety data cut for this application. As the EAP is not a clinical trial, efficacy data are not routinely or consistently collected; therefore, no efficacy data from EAP are included in this application. However, a case of an EAP participant with a relatively  quickly  progressing  SOD1  mutation  was  also  presented.  This  individual  experienced  a

<div style=\"page-break-after: always\"></div>

maintenance of a stable score on ALSFRS-R over 1 year of treatment and improvements on the timed up and go and 10-meter walk test.

## 2.6.5.7.2. Continuous Evidence Generation Plan

The applicant evaluated various approaches to generate additional comprehensive clinical data, including whether  these  data  could  be  generated  by  a  randomised,  placebo-controlled  clinical  trial.  For  this, informed by the learnings from the tofersen clinical studies and the evolving ALS literature, the applicant modelled alternative trial designs to confirm the results seen to date with statistical significance.

Based on this assessment, the applicant does not believe that additional placebo-controlled studies are feasible.

The applicant plans to collect long-term efficacy and safety data via the ongoing Study 102 and Study 303 (ATLAS) as well as supplementary real-world evidence via existing disease registries.  An integrated analysis of Study 101 Part C and Study 102, when all participants have had the opportunity to have at least 3.5 years of follow-up since randomisation will be reached in Q3 2024. In addition, the evidence generation  plan  includes  variant-specific  survival  analyses  (incorporating  data  from  tofersen  clinical trials, natural history datasets/literature, and real-world evidence collected via disease registries).

## Study 101 Part C and Study 102

The open-label Study 102 LTE is currently scheduled to continue through Q3 2024 to enable up to 7 years of treatment and follow-up, with the longest follow-up from patients who enrolled into Study 102 from either Parts A or B of Study 101, and to provide important supportive long-term data on the effect of tofersen on the trajectory of the disease and overall survival. For those participants randomised in Study 101 Part C, the longest follow-up will be approximately 5 years.

## Study 233AS303 (ATLAS)

Study 233AS303 is an ongoing, phase 3, randomized, double-blind, placebo-controlled, 4-part study designed to evaluate whether tofersen, when initiated in pre-symptomatic carriers of a SOD1 mutation with biomarker evidence (increased plasma NfL) of disease activity, can halt or delay the emergence of clinically manifest ALS and/or slow the decline in function once symptoms are observed compared to the initiation of tofersen at the time of, or after, the emergence of clinically manifest ALS. The selection of the population and the design of Study 303 was informed by the presymptomatic familial ALS (pre-fALS) natural history study (NCT00317616). Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. Unaffected (healthy) people from familial ALS (fALS) pedigrees in which a known genetic mutation associated with ALS has been  identified  are  recruited.  For  this  study,  a  fALS  pedigree  is  one  with  two  biologically  related individuals who have or have had ALS and/or frontotemporal dementia (FTD). Individuals who may be at genetic risk for ALS and who belong to families with at least one affected family member who has tested positive for a known ALS genetic mutation may also be eligible to participate. Data from these individuals  in  the  pre-fALS  study  were  used  to  model  the  presymptomatic  changes  in  NfL  and  to determine the study's predefined NfL threshold for Part B. This model was then used to estimate the expected phenoconversion rate after reaching the predefined NfL threshold and hence inform the sample size and duration of Study 303.

Approximately  150  pre-symptomatic  at-risk  carriers  of  highly  or  completely  penetrant  and  rapidly progressive  SOD1  mutations  will  be  enrolled  in  the  natural  history  portion  of  the  study  (Part  A). Individuals  in  Part  A  who  experience  an  increase  in  plasma  NfL  that  reaches  the  protocol-defined threshold (≥ 44 pg/mL and ≥ 10 pg/mL increase from baseline) and remain clinically pre -symptomatic will have the opportunity to enrol in the interventional, placebo-controlled study period (Part B; n = 28).

<div style=\"page-break-after: always\"></div>

Participants in Part B who experience an emergence of clinically manifest ALS will be eligible to screen for  the  OLE  (Part C).  The  duration  of  participation  in  Part  B  and/or  Part C  will  be  up  to  2  years. Participants who experience an emergence of clinically manifest ALS prior to detection of elevation in NfL will be eligible to screen for an open-label interventional period for up to 2 years (Part D).

The population enrolled in Study 303 is different from that of Study 101 Part C but represents an earlier part of the same disease spectrum. ALS is understood to have a presymptomatic phase in which the underlying  disease  activity  in  case  of  known  mutations  may  be  detected  by  genetic  testing  and biomarkers prior to overt clinical signs or symptoms.

Figure 34: Design of Study 303 (ATLAS). Study treatment (tofersen or placebo) is administered via intrathecal injection. The dosing regimen consists of three loading doses administered at 14-day intervals followed by maintenance doses once every 28 days thereafter.

<!-- image -->

Upto2yearsinduration a  Measured using Siemens Healthineers NfL Assay,  b  Assuming other eligibility criteria are met,  c  Follow-up in Part A will end once 28 participants have been enrolled in Part B,  d  Part D was originally designed with a placebo-control but was transitioned to open-label following the sponsor's review of the results of the Phase 3 VALOR study. ALS amyotrophic lateral sclerosis, NfL neurofilament light chain

Source:  Benatar  et  al  (2022)  'Design  of  a  Randomized,  Placebo-Controlled,  Phase  3  Trial  of  Tofersen  Initiated  in  Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study'.

The Study 303 primary analysis is expected to be in 2028.

No efficacy data from Study 233AS303 have been included in this application because the study remains blinded. Blinded safety data as of the 15 July 2022 safety data cut show no new safety signal. Data from Study 233AS303 will help inform the optimal timing of tofersen initiation.

## Registry Collaboration

The collection and analysis of real-world data will play a vital role in expanding our knowledge of the natural history of SOD1-ALS and the effects of tofersen. The applicant is collaborating with 2 large, ongoing disease registry consortia/networks, the ALS/motor neuron disease NHC (primarily US-based) and the TRICALS Network (European sites), to fund prospective data collection efforts, including the collection of information related to the safety and effectiveness of tofersen.

- ALS/MND NHC Study is an established multidisciplinary clinic-based registry that prospectively and longitudinally captures important clinical information about the disease process from people living  with  ALS.  The  consortium consists of academic medical centres in the US (9 sites) and Europe (1 site in Italy).
- The applicant is collaborating with TRICALS investigators to develop the Precision ALS program to conduct a multinational, multi-centric, observational population-based study that will examine ALS natural history and outcomes, including those associated with existing or new disease-modifying treatments, prospectively in a real-world setting. As of September 2022, the applicant has an active 3-year contract to fund prospective data collection in Precision ALS.

<div style=\"page-break-after: always\"></div>

In order to determine whether Precision ALS and/or the ALS/MND Natural History Consortium would be fit-for-purpose for a registry-based study to be conducted as a commitment to the European Medicines Agency (EMA), the applicant, through consultants, has conducted a feasibility assessment and submitted the relevant report. In that report it is stated that Precision ALS is a research initiative, recently funded through public-private partnership, for the development of a patient data platform. It is also stated that TRICALS  will  leverage  the  Precision  ALS  and  the  TRICALS  centers  to  create  a  research  platform, consisting of a longitudinal data collection infrastructure based on electronic medical records as well as primary data collection for some variables. It was concluded that based on the infrastructure and the type of data collected (with the possibility to implement additional data collection), it appears that a PASS on the safety and effectiveness of tofersen would be feasible within either registry. The number of countries that will be effectively included in the PASS will depend on the schedule of tofersen launch in Europe since it may not be launched at the same time in all countries covered by TRICALS.

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant has completed study 233AS101, consisting of phase 1/2 parts A and B and phase 3 Part C. Study 101 Part C is considered the single pivotal double-blind placebo controlled study. Upon request, several analyses have been provided and are included in the report. The OLE study 102 provided data up to 168 weeks. Data from two interim analyses (2 nd  interim analysis data cutoff 16 January 2022 after 52 weeks and 3 rd  interim analysis data cutoff 28 February 2023 after 104 weeks) are relevant for this discussion on efficacy. The present MAA was included in the Raw Data Pilot project which generated several additional analyses.

The design of the pivotal study 101 Part C as a randomised, double-blind, placebo-controlled study is appropriate. Given the inherent heterogeneity of SOD1-ALS and the fact that the decline on the ALSFRSR in the placebo arm turned out to be three-fold lower than initially assumed (i.e., a decline by 8.1 points over the 6-month period rather than the anticipated 24.7 points; see also Section 2.6.5.2.1 of this AR), the 28-week duration of the study (selected based on the above-mentioned assumptions) was in view of the results generated apparently too short to overcome the disease heterogeneity in the population and show a convincing clinical treatment effect.

The patient population was focused on SOD1-ALS. However, there are over 200 variants in the SOD1 mutation making this small proportion of the general ALS population very heterogeneous. Forty-two unique SOD1 mutations centrally confirmed as pathogenic or likely pathogenic were enrolled. The most commonly  identified  SOD1  mutation  types  were  p.Ile114Thr  (n=  20/108;  18.5%),  p.Ala5Val  (n  = 17/108; 15.7%), p.Gly94Cys (n = 6/108; 5.6%), and p.His47Arg (n = 5/108; 4.6%).

The ALSFRS-R scale was chosen as primary endpoint and is considered appropriate. The selected 28week duration for the primary analysis is considered too short to show a clinical response for the reasons discussed in the previous paragraphs.

Protocol deviations in study 101 Part C were not considered to have affected the conclusions of the study. A GCP inspection concluded that the majority of the data reported for the 233AS101 Part C clinical trial are acceptable and the findings of the inspection do not have a substantial impact on the data of the clinical trial inspected.

The SAP versions describe in detail the planned statistical methods for data collected in the studies and subsequent post hoc analyses.

<div style=\"page-break-after: always\"></div>

The JRT of survival and function difference after 28 weeks in the mITT population was the pre-specified primary analysis. The JRT is an established analysis for ALS and was an appropriate choice for primary analysis but failed to show a statistically significant difference between tofersen and placebo.

As summary statistics for the treatment effect on ALSFRS-R changes, the difference between treatment groups in LS means of Day 197 was provided based on ANCOVA+MI. Additional sensitivity analyses and post  hoc analyses  including  alternative  covariates  than  in  the  pre-specified  ANCOVA  model  and imputation model were conducted, whereby the applicant particularly emphasizes the relevance of the analyses adjusting for baseline NfL due to an observed imbalance and the claimed importance of baseline plasma NfL as a prognostic factor. However, as stated in the EMA 'Guideline on adjustment for baseline covariates  in  clinical  trials',  a  baseline  imbalance  in  a  covariate  should  not  be  considered  as  an appropriate reason to include this baseline measure as a covariate in the primary analysis. Even if it is acknowledged that NfL may be a prognostic factor, control of the type 1 error is ensured only for the pre-specified primary analysis, which should also be the starting point for considerations on the size of the effect.

With respect to the untransformed baseline NfL values, which were included in the applicant's ANCOVAs as a covariate, the applicant's response provides some reassurance on the robustness of the statistical results in relation to the scale used for baseline NfL adjustment. Log-transformation of NfL had no major impact on the time to death or PV analysis.

Missing data were replaced under a MAR assumption, which can be considered to leading to an analysis aligned to targeting the hypothetical effect 'if all patients had completed treatment until the analysis time point and survived'. From a regulatory point of view, targeting the treatment effect irrespectively of treatment discontinuation is of primary relevance. For targeting this effect, assuming loss of potential benefit  from  treatment  appears  to  be  plausible  such  that  replacing  missing  data  after  treatment discontinuation using reference-based imputation appears appropriate. The appropriate strategy how to account  for  death  is  challenging  but  it  could  be  considered  as  complete  loss  of  function  such  that imputation of 0 may be meaningful. These alternative missing data strategies were explored within the raw data pilot and reproduced by the applicant.

Participants with SOD1-ALS who completed Part A, B, or C of Study 233AS101 were allowed to continue to the ongoing multicentre, open-label, extension study to further assess efficacy and safety in the longterm Study 102 LTE. Of the 159 eligible participants who completed Study 101, a total of 139 participants enrolled from Study 101 Parts A, B, and C: 44 participants enrolled from Study 101 Parts A and B and 95 participants enrolled from Part C.

The same functional scale and important endpoints as the ones used in study 101 Part C were used for evaluating the potentially long-term effect of tofersen in study 102 LTE.

A study in pre-symptomatic ALS patients is on-going. Study 233AS303 (ATLAS) is a Phase 3, randomized, double-blind, placebo-controlled, 4-part study designed to evaluate tofersen in presymptomatic carriers of a SOD1 mutation. No efficacy data from this study was submitted as part of the current application.

The applicant has also submitted a continuous evidence generation plan. (see below).

## Efficacy data and additional analyses

The population enrolled in this study was representative of the broad SOD1-ALS population. It is noted that A4V/A5V (p.Ala5Val) mutation carriers are considered the most prevalent fast progressing mutation type enrolled which is consistently associated with a median survival (based on Kaplan Meier) of or below 1.2 years. There were 17 (16%) of them included in the study.

It appears that the tofersen group in general was in a worse condition than the placebo group. Mean values  for  ALSFRS-R  baseline  total  score,  %  predicted  SVC  at  baseline  and  plasma  NfL  at  baseline

<div style=\"page-break-after: always\"></div>

(pg/mL) were slightly worse in the tofersen group  with 36.9, 82.1% and 100.4 pg/ml respectively, compared to the placebo group with values of 37.3, 85.13% and 89.7 pg/ml, respectively.

Study 101 Part C baseline plasma NfL levels in the ITT population were approximately 15% to 25% higher in the early-start tofersen group than in the placebo/delayed-start group at baseline. These higher plasma NfL levels in the early start group were not in favour of tofersen treatment.

In the pivotal study 101 Part C, no statistically significant difference in ALSFRS-R change from baseline to  Week  28  was  observed  in  the  primary  analysis  mITT  population  (difference:  1.2 points  favoring tofersen; 95% CI: -3.2 to 5.5; p = 0.97 via JRT + MI analysis). Hence, study 101 Part C has failed to provide  confirmatory  evidence  of  efficacy  necessary  to  support  a  full  marketing  authorisation. Consequently, all other analyses provided from study 101 Part C need to be considered exploratory. The applicant performed several analyses including a post hoc analysis of ALSFRS-R with baseline plasma NfL as a covariate and found a statistically non-significant difference of 2.1 (95% CI: -0.3 to 4.5; p = 0.0904 via JRT + MI analysis) between tofersen and placebo in the ALSFRS-R total score change from baseline to week 28 in the ITT population.

With a reference based imputation analysis of the results (via the Raw Data Pilot Project), a smaller treatment effect (as expressed in difference between tofersen and placebo in the change of ALSFRS-R total score from study 101 part C baseline to week 28) was observed (J2R, not adjusted for baseline NfL: -0.97; 95% CI (-4.3,2.4), J2R, adjusted for baseline NfL: -1.7, 95% CI (-4.8,1.4)).

With respect to the analyses using the Raw Data Pilot Project, from a regulatory point of view, targeting the treatment effect irrespectively of treatment discontinuation is of primary relevance. For targeting this effect, assuming loss of potential benefit from treatment after treatment discontinuation appears to be  more  plausible  than  a  MAR  assumption  such  that  replacing  missing  data  after  treatment discontinuation using reference-based imputation as in the analyses above appears appropriate. If the treatment were disease-modifying, it would appear plausible that some effect from active treatment is retained at least for some time after treatment discontinuation, which is more in alignment with CR or CIR. However, as the size of the possible retention is unclear, J2R providing a lower bound is also of relevance. As death could be considered as complete loss of function, 0 could be considered the true ALSFRS-R value after death. A smaller effect is observed when reference-based imputation analysis is implemented.

The applicant repeated the analysis. Minor differences between the analyses with the Raw Data Pilot project and the analyses by the applicant were observed but the differences are not critical and not considered to have a major impact for the conclusions of the clinical outcome.

In a prespecified analysis based on the baseline median NfL value of 75.6 pg/ml, numerically larger differences were observed between tofersen and placebo over 28 weeks in patients with baseline NfL values above the median [mean difference (95% CI 3.9, (-1.0;8.9)] compared to patients with baseline NfL values below median [0.6, (-1.3,4.2)].

Analyses of the secondary endpoints percent predicted SVC and HDD megascore showed small and not statistically significant differences between tofersen treatment and placebo at week 28 i.e. 8.5%, JR+MI p=0.0689 and 0.10 ANCOVA+MI p=0.1547, respectively. There was, however, a consistent numerical trend favouring tofersen.

With respect to survival, the percentage of patients in the mITT population (and consequently in the ITT population) the percentage for an event of death or PV was similar in the placebo (9.5%) and tofersen (10.3%) groups. However, the numbers from Study 101 Part C are too low to be considered meaningful (see also below).

<div style=\"page-break-after: always\"></div>

The results of the quality of life PROs were not statistically significant but also showed a trend in favour of tofersen.

In  conclusion,  although  there  was  a  trend  in  favour  of  tofersen  treatment,  efficacy  could  not  be demonstrated  in  a  confirmatory  way  in  the  pivotal  phase  3  study  101  Part  C  at  week  28.  The heterogeneity of the SOD1 population, the selection of suboptimal prognostic variables for enrichment purposes  (e.g.  pre-randomisation  ALSFRS-R  and  type  of  mutations  instead  of  baseline  plasma  NfL levels), and the short duration of the study are considered factors which contributed to no statistically significant difference being found on the primary endpoint in the pivotal trial.

In the study 102 LTE report, 2 nd  interim analysis (with data cutoff 16 January 2022 up to week 52), the applicant has summarised accurately the situation of the pivotal phase 3 study 101 Part C.

In Study 233AS101 Part C (Phase 3), administration of tofersen 100 mg for up to 28 weeks did not result in a statistically significant slowing of decline across measures of clinical function (ALSFRS-R), respiratory function (SVC), and muscle strength (HHD megascore) compared with placebo over 28 weeks. However, consistent trends favoring tofersen over placebo and suggesting a slowing of disease progression were observed in primary, secondary, and exploratory measures. Consistent with its intended mechanism of action, tofersen administration resulted in sustained reductions in total CSF SOD1 protein. Reductions in plasma NfL suggest tofersen is reducing axonal injury and motor neuron loss.

A mechanistic basis for the potential treatment effect of tofersen exists. There is a strong biological plausibility, that the lowering of toxic SOD1 exerts disease-modifying effects of tofersen, which can be pharmacodynamically measured by an appropriate neurodegeneration biomarker, i.e. NfL.

Exploratory analyses were prespecified in alternative disease progression subgroups defined according to baseline plasma NfL levels, whereby those with a baseline plasma NfL level greater than the median (75.6 pg/ml) comprised the faster-progressing subgroup (FPS [NfL-based]), and those with a baseline plasma NfL level  less  than  the  median  (&lt;75.6  pg/ml),  the  slower-progressing  subgroup  (SPS  [NfLbased]). The applicant, recognizing that adjustment for baseline NfL as a continuous covariate could provide even greater precision to the estimated treatment difference than categorical subgrouping based on the median, prespecified also sensitivity analyses incorporating baseline plasma NfL as a covariate in the ANCOVA model for the disease progression subgroups defined by mutation and ALSFRS-R slope (FPS [mutation/slope] and SPS [mutation/slope]). These NfL-based analyses were planned and prespecified in the SAP [Study 101 Part C SAP Version 2.0, 14 August 2021] prior to analysis of data from Study 101 Part C. After analysis of data from Study 101 Part C, the integrated efficacy analysis plan for Studies 101 and 102 was amended, prior to analysis for the 16 January 2022 data cutoff, to include covariate adjustment for baseline levels of NfL in the analyses of the full ITT population (SAP Version 3.0, 02 February 2022). This approach was also utilized for the analyses of the most recent data cut (28 February 2023  data  cut;  18 May 2023  database  lock),  which  was  conducted  in  accordance  with  the  SAP Version 4.0, 17 May 2023.

The pooled analysis at  week  52  (2 nd   interim  analysis  data  cutoff  16  January  2022,  ITT  population) , consisting of the double-blind data from study Part C and the open-label data from study 102 LTE, showed a nominally statistically significant difference between the early and the placebo/delayed start tofersen treatment group of 3.5 (ANCOVA+MI pnominal=0.0272) in ALSFRS-R total score when adjusting for baseline NfL. Additional analyses adjusting for alternative covariates and all subgroups show positive trends in favour of tofersen as well. The most important secondary endpoints 'percent predicted SVC' and  'HDD  megascore'  were  also  nominally  statistically  significant  albeit  the  differences  between treatment  groups  were  small,  i.e.,  9.2%  (ANCOVA+MI  pnominal=0.0159)  and  0.028  (ANCOVA+MI pnominal=0.0186),  respectively.  Two  quality  of  life  outcomes  (change  from  baseline  in  ALSAQ-5  and change from baseline in ED-5D-5L utility score) were nominally statistically significant and two (change from baseline on FSS and on EQ-5D-VAS) showed trends in favour of tofersen.

<div style=\"page-break-after: always\"></div>

The applicant has performed, upon request, an additional interim analysis for efficacy using as data cut 28 February 2023 (3 rd  interim analysis).

Ninety-five out of 108 participants (88%) randomized in Study 101 Part C went on to receive tofersen 100 mg in Study 102. In the early-start group (tofersen/tofersen), from baseline of study 101 Part C, 19 participants discontinued study due to death (n=10, 14%) or disease progression (n=7, 10%), while in  the  delayed-start  group,  16  participants  discontinued  study  due  to  death  (n=7,  19%)  or  disease progression  (n=5,  14%).  Rates  of  study  discontinuation  due  to  death  or  disease  progression  are numerically more in favour of the early-start group (24%) when compared to the delayed-start group (33%) at Week 104. At the time of the 28 February 2023 data cutoff (3 rd  interim analysis), 16 participants (44.4%)  in  the  placebo/delayed-start  group  and  44  participants  (61.1%)  in  the  early-start  group remained ongoing in OLE Study 102.

Sustained reductions were observed in CSF SOD1 with 39% in the placebo/delayed-start group and 37% in the early-start group at week 76 and 19% in the placebo/delayed-start group and 27% in the earlystart group at week 104. In the case of plasma NfL, robust reductions in the placebo/delayed-start group, in plasma NfL of 43% at Week 76 and 60% at Week 104 were observed. For the early-start group, reductions in plasma NfL were sustained, i.e. 55% at Week 76 and 66% at Week 104. NfL cannot be considered as a validated surrogate endpoint for predicting efficacy. However, consistent reductions in CSF SOD1 and plasma NfL, supported by nonclinical data are supporting the biological plausibility with target engagement and a strong mechanistic rationale for the effect of tofersen treatment.

The data suggest that these reductions in SOD1 protein and consequently NfL result in a delayed effect on  function  as  measured  by  ALSFRS-R  and  other  clinical  outcome  measures,  which  is  considered biologically plausible. The applicant states ' highlighting the time needed for a slowing of neurodegeneration to translate to detectable slowing of clinical decline '. A delayed clinical effect is also supported by nonclinical findings.

Long-term data from studies 101 and 102 up to Week 104 indicate numerical differences in favour of early-start  tofersen  treatment  on  different  assessments  (e.g.  ALSFRS-R  and  SVC)  across  several analyses of populations and covariates. With respect to the most important clinical endpoint on function, participants in Study 101 Part C and Study 102 lost 9.5 and 13.2 points (adjusted mean on ANCOVA+MI) over 24 months in the tofersen early-start and placebo/delayed-start tofersen group, respectively. It is estimated that people living with ALS decline by an average of ~1 point per month. The adjusted mean difference between groups was 3.7 (nominal ANCOVA+MI p=0.1004) and remained similar compared to week 52. The effects on respiratory strength seen at earlier timepoints were sustained at 104 weeks, with  a  9.7  percent-predicted  difference  in  SVC  in  favor  of  early-start  tofersen.  Tofersen  treatment continued to favor the early-start group with a 0.19-point difference in HHD megascore.

The analyses at week 104 using the new data cut-off (28 February 2023) show some attenuation of the differences between treatment groups (i.e. between early-start and delayed-start of tofersen) that were previously observed at week 52 but a clear difference still exists further supporting a greater benefit with  early  treatment  start.  The  data  provided  by  the  applicant  suggest  stabilisation  or  even  some improvement in participants  remaining  in  the  study  regarding  clinical  function,  respiratory  function, muscle  strength  and  quality  of  life  assessments  (ALSFRS-R,  SVC,  HHD,  ALSAQ-5,  EQ-5D-5L)  over 100/104 weeks, which would not be expected from the natural course of the disease. As highlighted by the applicant, there are some relevant limitations associated with comparisons with the natural history data (e.g. inter- and intra-mutation variability), and therefore, such comparisons should be interpreted with caution.

However, the differences observed between early start and placebo/delayed start tofersen treatment group at week 52 remain similar until week 104. This observed stabilisation would be supportive of a true disease modifying effect of tofersen.

<div style=\"page-break-after: always\"></div>

Performing a responder analysis without logistic regression at week 100 (for patient-reported outcomes (PRO))  or  week  104  (clinical  measures),  in  the  early-start  tofersen  group,  19.5%  of  participants experienced improvement on the ALSFRS-R, 21.4% improvement on SVC, and 25.8% improvement on HHD. In the case of placebo/delayed start tofersen group these improvements were 11.6% for ALSFRR, 10.5% for SVC and 10.1% for HHD. A logistic regression model was used in the original analysis to allow the adjustment of baseline NfL, due to its prognostic value. Both analyses with or without logistic regression indicate a slowing of decline and even an improvement in function, strength, and QoL for the early and placebo/delayed start tofersen treatment group with a clear difference between groups and are rather unexpected for the natural course of the disease. Early initiation of tofersen treatment appears to be more beneficial compared to a delayed start. Some response is also seen on the placebo/delayed start tofersen treatment.

The cumulative distribution function analyses do not contradict the observed trends in favour of tofersen. Participants in the placebo/delayed-start group tend to have a higher rate of worsening in ALSFRS-R at Week 52. As an example, for a cutoff of -12, the rates of worsening in ALSFRS-R are approximately 32% and 44% for the early-start tofersen group and the placebo/delayed-start tofersen group, respectively.

Although the decline in ALS is not always linear, it is estimated that people living with ALS decline by an average  of  ~1  point  per  month,  which  can  reflect  the  difference  between  being  able  to  walk  with assistance and being non-ambulatory.

Indications for stabilisation of the disease or even improvement have been observed in the case of rapidly progressing p.Ala5Val (A5V) SOD1 mutation carriers, which is also rather inconsistent with the usual progressive decline in these patients, who have a median survival of ~1 to 1.2 years.

Participants  from  Study  233AS101  Part  A  and  B  who  ultimately  received  tofersen  100  mg  in  Study 233AS102 appear to have achieved stabilisation in clinical function for over 3.5 years since the start of the  study  with  a  median  follow-up  time  of  4.7  years  (range:  3.1  to  5.8  years).  These  participants experienced a mean change from Study 102 baseline to Week 168 (approximately 39 months or 3.2 years)  of  -2.3 points  on  ALSFRS-R  total  score,  -2.4  on  percent-predicted  SVC,  and  -0.1  on  HHD megascore. As discussed by the applicant, Part A/B participants (ABL) should be interpreted with caution due to the significant  washout  periods,  variable dosing  history,  and  having  SOD1  mutation  variants known to  belong  to  the  slower/intermediately  progressing  nature  of  the  disease.  However,  even  in slower-progressing SOD1-ALS patients, the disease is associated with progressive declines in strength and function.

There were also several analyses for event-free survival. The HR for the time to death, PV, or withdrawal due to disease progression was 0.50 and the HR for time to death or PV was 0.47. The applicant claims that the longer-term data show that the risk of death or PV was reduced. However, although numerical trends in favour of the early start tofersen group were observed, no conclusions can be currently drawn on  an  effect  of  tofersen  on  time  to  event-free  survival.  The  reason  is  that  robustness  is  highly questionable due to small event numbers and immature data and the strong assumptions made for the analysis.

Under the Raw Data Pilot project, a new time to event analysis was conducted with event defined as change from baseline in ALSFRS-R total score greater than 10 points (&lt; -10), 21 days of PV assistance or death at any time point up to Week 124 (~17 months). Stable patients were those who did not present an event described above i.e. death, PV or deterioration of ALSFRS-R greater than 10 points (change of ALSFRS-R  total  score  &lt;-10).  The  HR  for  a  'survival'  event  was  0.70  and  upon  adjusting  for log(baselineNfL) HR was 0.46. Looking at the 'distribution' of variants across groups it can be agreed that  the  survival  benefit  in  the  early-start  participants,  relative  to  the  delayed-start  participants,  is unlikely to be attributed to enrollment of individuals with more slowly progressing disease.

<div style=\"page-break-after: always\"></div>

Looking at the totality of data submitted, the following can be noted. SOD1-ALS is an ultra-rare disease (with approximately 1000 prevalent cases in EU) with a high unmet medical need. The placebo-controlled study failed to provide confirmatory evidence of efficacy of tofersen, as the pre-specified primary analysis did not reach statistical significance at week 28, in the change from baseline on the ALSFRS-R between tofersen and placebo regardless of the analyses conducted. However, all endpoints showed a trend in favour of tofersen. Consistently, these trends in favour of tofersen were observed at week 52 and at week 104, irrespective of the type of analysis performed.

It can be expected that reduction of the causative toxic mutant protein SOD1 in SOD1- ALS should lead to a reduction in neuronal axonal injury and neurodegeneration, which would subsequently stabilize or delay  the  progression  of  the  disease.  Treatment  with  tofersen,  an  ASO  that  specifically  targets  the production of SOD1, led to a relevant and sustained lowering of both SOD1 and NfL in plasma and CSF. Neurofilament has not been established as a surrogate endpoint for efficacy (or a worldwide acceptable reasonably  likely  surrogate  endpoint)  but  is  increasingly  recognised  as  an  important  biomarker  in neurodegenerative diseases, including ALS and is being used in most of the clinical trials in ALS. A number of references are available supporting the relevance of reductions in neurofilaments after active treatment (Thompson et al 2022, Brousse et al 2023, Jiang et al 2022, Mead et al 2023, McCluskey et al 2023 and Sanchez-Tejerina et al 2023). Researchers are advocating the use of neurofilament as being prognostic for disease progression across ALS populations. In another trial conducted with interleukin2, FDA recommended that the prespecified analyses is adjusted for baseline neurofilament levels when analysing disease progression and survival. Recently, the EXPERTS-ALS program in the UK announced that NfL levels will be utilized to help screen potential drugs in ALS patients and select the best candidates to advance to larger Phase 3 trials [University of Sheffield 2023]. On the specific issue, the SAG-N experts considered by consensus that the level of NfL is a biomarker of axonal injury in ALS. The SAG-N experts also specified that NFL is not an ALS specific biomarker.

Although,  the  pivotal  study  101C  failed  its  primary  objective  at  week  28,  which  is  unsurprising considering  the  short  placebo-controlled  phase  of  only  6  months,  favourable  trends  in  the  clinical endpoints were observed and were consistent over 104 weeks. Various analyses of survival and 'survivalrelated' (or death-equivalent) events also suggest a benefit but cannot be considered robust, mainly due  to  the  low  number  of  events.  However,  the  long-term  data  illustrate  that  tofersen-treated participants are exceeding the expected survival time as derived from natural history data, with the majority of participants being alive and ongoing in the study. Based on the results from the PROs, the apparently increased survival is not at the expense of reduced quality of life and using machinery to just keep the patients alive.

Data suggest that clinical effects are delayed compared to effects on NfL, which is considered biologically plausible. Examples of delayed effects of patient-customized treatments with ASOs in neurodegenerative disorders have become known for milasen (Kim et al. NEJM 2019) and jacifusen (for the patient Anna Kaempfer  [preliminary  presentation  in  https://www.nature.com/articles/s41591-021-01615-z]).  The latter is an ASO directed against mutations in the FUS gene, which is another rare cause of genetic ALS (1% of  ALS).  The  case  was  presented  at  the  ALS  workshop  in  Bonn  18  August  2023  (https://alscharite.de/fus-als-medikament-jacifusen-experten-und-angehoerige-im-podcast-der-n-lorem- foundation/). The specific treatment in this patient showed a delayed clinical response in a 16 year old girl with FUS ALS recovering from full mechanical ventilation to being able to walk and climb stairs again. A phase 3 trial (NCT04768972) is currently ongoing.

These cases support the postulation that ASOs can reduce toxic protein aggregates and consequently slow or even halt the neurodegenerative process, provided that they are administered for a sufficiently long period of time. It should be noted that the biomarker and clinical findings are supported by data in relevant animal models.

<div style=\"page-break-after: always\"></div>

During the procedure, potential correlations between changes in NfL from baseline to week 16 (when the full effect on NfL had been achieved) and changes from baseline to week 28 (placebo-controlled phase) in ALSFRS-R were explored in the Raw Data Pilot Project. While only weak correlations were observed in the Raw Data Pilot Project, the correlations were stronger in the applicant's model with causal inference component. The applicant argued that adjustment for baseline NfL is necessary in the correlation analyses to take into account the variable natural disease progression across participants. The justification is considered plausible; however, uncertainty remains regarding the level of association between reductions in NfL and slowing of disease progression, and these results are considered to remain hypothesis-generating only. Correlation coefficients adjusted for baseline NfL showed modest inverse correlations between change in NfL levels at week 16 (when the full effect on NfL had been achieved) and change in ALSFRS-R functional score at week 28 (end of placebo-controlled study), which became stronger at week 52, which is according to the expectation when there is a delayed clinical effect following the reduction in neuronal loss.

Neither the size of the (partial) correlation coefficients nor their statistical significance provide added value  with  regard  to  the  evaluation  of  the  clinical  relevance  of  the  effects.  However,  the  partial correlations are in line with the hypothesis of a relationship between changes in NfL and clinical outcomes such that the previously apparent inconsistency between the correlation levels observed in the Raw Data Pilot  Project  and  the  statistical  results  of  the  applicant's  model  with  causal  inference  component  is resolved.

The majority of the SAG-N experts considered that NFL levels can be used for predicting a clinical effect in  patients  with  ALS,  at  least  on  a  cohort  level  (for  details  see  below  section  on  Additional  expert consultation).

Additional long-term clinical data were submitted during the procedure. An extended duration of followup from baseline to 3.4 years showed that the majority of patients remain alive on-study, since the number of death-equivalent events were limited. The range of follow-up from 2.2 to 3.9 years certainly exceeds the 2.3 years median survival for SOD1-ALS characterized in the literature. This finding further supports the efficacy of tofersen.

A case of an EAP participant with a relatively quickly progressing SOD1 mutation was also presented. This individual experienced a maintenance of a stable score on ALSFRS-R over 1 year of treatment and improvements on the timed up and go and 10-meter walk test.  Although this is an isolated case within the EAP, it suggests a benefit of tofersen treatment for the person concerned, especially as this person was characterised as progressing relatively quickly.

SOD1-ALS,  accounting  for  only  approximately  2%  of  all  ALS  cases,  is  a  serious,  progressive  and invariably fatal disease.  In the CHMP view, the totality of data illustrates the potential of tofersen to slow  disease  progression,  improve  strength,  function  and  QoL  and  finally  prolong  survival  in  these patients,  that  clearly  exceed  the  expected  natural  history  of  the  disease. The  targeted  MoA  and supportive non-clinical  results  further  strengthen  the  plausibility  and  likelihood  of  tofersen  being  an effective  treatment  for  SOD1-ALS.  However,  as  the  CHMP  considered  that  the  data  included  in  the application is not comprehensive as required for a full marketing authorisation, the CHMP has thoroughly discussed  the  applicable  requirements  for  either  a  conditional  marketing  authorisation  (CMA)  or  a Marketing Authorisation under Exceptional Circumstances (MAUEC) and whether the specific obligations (SOBs) proposed by the applicant can provide comprehensive data to confirm the positive benefit-risk balance of the medicinal product (see Additional efficacy data needed in the context of a MA under exceptional circumstances as well as Section 3.7.3 Additional considerations on the benefit-risk balance).

## Generation of additional/comprehensive data

See below under Additional efficacy data needed in the context of a MA under exceptional circumstances.

<div style=\"page-break-after: always\"></div>

## Additional expert consultation

A SAG-Neurology meeting enriched with ALS experts, was convened by the CHMP.

## 1.  Is NfL considered to be a biomarker reflecting neuronal injury in ALS?

The SAG-N experts considered by consensus that the level of NfL is a biomarker of axonal injury in ALS. The SAG-N experts specified that NFL is not an ALS specific biomarker.

## 2. Do you believe NfL can be used for predicting a clinically relevant effect in patients with ALS?

The majority of the SAG-N experts considered that NFL levels can be used for predicting a clinical effect in patients with ALS. In the view of some SAG-N experts, it is uncertain whether NFL can be used for predicting a clinically relevant effect in ALS because there is no clear definition on what constitutes a clinically relevant effect in ALS (e.g., a threshold of change in a clinical scale) besides a change in survival which is considered as clinically relevant by all SAG-N experts.

Further, all restricted SAG-N experts considered that NfL levels can be used for predicting a clinically relevant effect in ALS on a cohort level. The distinction between cohort level and individual level was made in the view of the wide range of NfL levels. Among the SAG-N restricted experts, divergent views were expressed about the value at individual level for which only a single restricted SAG-N expert was clearly in favour of its use. Further, some restricted SAG-N experts recognized that timelines -time since the NFL change to the occurrence of the clinical effect - are unclear. Finally, one SAG-N restricted expert indicated that the type of mutation could be relevant but even this expert agreed on the predictive value on a general basis.

## 3. Is the available evidence sufficient to conclude that the observed reduction in plasma NfL in Tofersen -treated patients can translate into a clinical benefit in patients with SOD1 -ALS?

Overall, the majority of the SAG-N experts agreed that there is evidence -although not a strong onesupporting that the observed reduction in plasma NfL in tofersen -treated patients can translate into a clinical benefit in patients with SOD1 -ALS. A minority of the SAG-N experts expressed that there is no evidence. The results from the VALOR RCT do not allow for concluding that a reduction in plasma NfL can translate into a clinical benefit. However, the biological plausibility, the consistency of all clinical outcomes with point-estimates in favour of the treatment, and results from the open label extension (OLE) phase are highlighted as reasons supporting the position that reduction in plasma NfL can translate into a clinical benefit. However, the SAG-N experts also noted that there is some uncertainty in the prediction mainly due to the rarity of the events, the high heterogeneity of the population, and the short duration of the trial.

## 4. Does the available clinical and non-clinical data support a treatment effect of tofersen in SOD1-ALS patients?

The SAG-N experts agreed by consensus that the evidence from the double-blinded phase in VALOR study  is  not  strong.  A  short  study  duration  was  highlighted  as  the  most  relevant  limitation  likely contributing to the absence of statistically significant effect on the primary endpoint. However, the SAGN experts highlighted not only the results on the changes in NFL and SOD1 but also the positive trends in secondary clinical outcomes including respiratory function -a relevant aspect in ALS-in favour of the tofersen arm in the VALOR trial and the results in the OLE phase strongly suggesting treatment effects. None  of  these  effects  were  statistically  significant  in  the  mITT  population  in  the  double-blinded randomized phase. All experts acknowledged that open label extension studies are as a general principle prone to bias.

<div style=\"page-break-after: always\"></div>

Further, the majority of the experienced restricted SAG-N experts highlighted their clinical experience with tofersen reporting stabilisation of the clinical course in individual patients in clinical practice, an outcome that these experts never saw before in their vast clinical practice over the last years.

The  patient  representative  acknowledged  the  limitations  of  the  study  results.  However,  the  patient representative highlighted the undisputed unmet medical need for ALS and the positive results not only in the trial but also in the clinical practice as shared by the restricted SAG-N experts.

## 5. Are the design and endpoints of the ATLAS study in presymptomatic SOD1 mutation carriers considered suitable to provide confirmatory evidence for efficacy of tofersen in patients with symptomatic SOD1-ALS?

Overall,  the  SAG-N  experts  are  not  convinced  that  ATLAS  study  in  presymptomatic  SOD1  mutation carriers could provide confirmatory evidence for efficacy of tofersen in patients with symptomatic SOD1ALS. The uncertainty is based on several limitations. First, it was considered that ATLAS will recruit presymptomatic SOD1 mutation carriers while VALOR study has been conducted in SOD1-ALS patients. However, one SAG-N restricted expert clarified that presymptomatic SOD1 mutation carriers will be randomized once they become (early) symptomatic. Second, the study population for the randomized clinical  trial  in  ATLAS  (n=28)  is  considered  too  small  in  the  view  of  the  heterogeneous  SOD1-ALS population. Third, it was noted that not all SOD1 mutations are considered in the study (only mutations associated with rapid progression are included), and it is unclear whether results of ATLAS could be extrapolable to all SOD1 mutations. In this regard, one SAG-N restricted expert provided a rationale on some exclusions: mutations that are not thought to be pathogenic were excluded, mutations that have not ≈ 100% penetrance were excluded, and mutations associated with a very low progressing course (some genotypes associate life expectancy beyond 10 years) were also excluded.

The SAG-N discussed the possibility of a new well-designed RCT with sufficient statistical power, which would require a longer follow-up than the VALOR trial and a larger sample size that the ATLAS trial. Overall, the SAG-N experts considered that conducting such a new randomized controlled trial is not feasible given the current situation. Feasibility is unlikely, because many ALS-experts are convinced that tofersen is effective in SOD1-ALS and are currently prescribing it within a compassionate use program. Furthermore, the rarity of the condition was acknowledged, and it was highlighted by one of the restricted SAG-N experts that the possibility of recruiting more patients is further limited because not all mutations leading to SOD1-ALS could be considered eligible (e.g. mutations that are not pathogenic should not be included in his views).

At  this  stage,  the  majority  of  the  SAG-N  experts  considered  that  is  very  unlikely  that  we  will  have comprehensive evidence in SOD1-ALS.

## Additional efficacy data needed in the context of a MA under exceptional circumstances

The initial application was for a 'full' marketing authorisation. The CHMP concluded the data are not comprehensive, even if they would finally be sufficient for approval.

The CHMP requested the applicant to discuss the plan for generation of additional post-authorisation data and whether such data will result in a comprehensive dossier.

The applicant has carefully considered alternative ways to generate additional data and whether these could  be  deemed  comprehensive  by  the  CHMP.  The  applicant  provided  justification  in  support  of  a MAUEC, including justification for the inability to provide comprehensive data under normal conditions of  use.  The  SAG-N  experts  also  remarked  that:  ' At  this  stage,  the  majority  of  the  SAG-N  experts considered that it is very unlikely that we will have comprehensive evidence in SOD1-ALS '. Based on the totality of the data to be generated through the proposed plan, the CHMP agreed on a MAUEC as being

<div style=\"page-break-after: always\"></div>

the appropriate type of marketing authorisation because of the rarity of the disease and the improbability that comprehensive data for a full marketing authorisation can be generated.

The applicant has pointed out that additional placebo-controlled studies in symptomatic SOD1 ALS are not considered operationally feasible. This is agreed, given the ultra-rarity of the disease and especially if tofersen would be approved. In particular, as the condition is SOD1-ALS, only a small subset of all ALS patients could be considered eligible for a new trial. Therefore, the epidemiology of the condition per se challenges the feasibility of conducting a new trial. Second, it is also agreed that the approval and the subsequent  commercialisation  of  tofersen  could  impact  the  ability  to  recruit  patients  in  a  placebocontrolled trial, because ALS is a fatal condition for which the existing therapeutic armamentarium is very limited. As pointed out by the SAG-N, many ALS-experts are convinced that tofersen is effective in SOD1-ALS and are currently prescribing it within a compassionate use program. Consequently, the CHMP agreed  that  conducting  additional  placebo-controlled  studies  in  symptomatic  SOD1-ALS  is  unlikely feasible.

In the frame of the discussion concerning the data that can be generated post-approval, the applicant proposed a continuous evidence generation plan based on the Study 303, ongoing Study 102 and an observational registry-based study.

Table  34  shows  the  agreed  SOBs.  Specific  milestones  have  also  been  proposed  by  the  applicant. Moreover, the applicant will submit yearly updates on any new information concerning the efficacy and safety of tofersen (fifth SOB). It is expected that the agreed SOBs will provide important additional data to further support the benefit-risk profile of tofersen and additional insight in SOD1-ALS.

Study 233AS303 which is an ongoing phase 3, randomized, double-blind, placebo-controlled, 4-part study  designed  to  evaluate  whether  tofersen,  when  initiated  in  presymptomatic  carriers  of  a  SOD1 mutation  with  biomarker  evidence  (increased  plasma  NfL)  of  disease  activity,  can  halt  or  delay  the emergence of clinically manifest ALS and/or slow the decline in function once symptoms are observed compared to the initiation of tofersen at the time of, or after, the emergence of clinically manifest ALS (see section 2.6.5.7.2). The CHMP highlighted several uncertainties with this study. First, the CHMP noted that the time from NfL elevation to emergence of clinically manifested ALS (CMALS) could be longer in non-A5V carriers. Thus, the applicant has amended the primary analysis timepoint from 12 to 24 months, which impacts the timing of data availability (expected Q4 2028). Another uncertainty is the need to evaluate potentially confounding factors for neurofilament elevations, e.g. other concomitant diseases that lead to NfL elevations such as prion diseases, frontotemporal dementia, vascular dementia, multiple systems atrophy, progressive supranuclear palsy and others (Gordon 2020, Yuan and Nixon 2021). NfL elevations are a nonspecific indicator of neurodegeneration, and investigators will be required to assess for alternative (unrelated to ALS) identifiable causes for an elevation when a participant's NfL level meets the protocol-defined criteria.  There is also the possibility that more frequent monitoring of NfL will lead to earlier detection of disease activity and therefore to an earlier diagnosis of symptomatic SOD1-ALS (compared to the pre-symptomatic familial ALS [Pre-fALS] study). According to the study design, subjects who become symptomatic before reaching the NfL threshold are assigned to part D where they will receive tofersen. Efficacy data from this uncontrolled open-label study arm D, although valuable, will not provide confirmatory evidence of efficacy. Additionally, Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS but who are at genetic risk for developing ALS (NCT00317616). The investigators aim to recruit unaffected (healthy) people from familial ALS (fALS) pedigrees in whom a known genetic mutation associated with ALS has been identified (see more details  above).  Of  note,  different  mutations  carry  different  prognoses  in  ALS.  The  most  frequently reported mutation associated with fALS in Europe is C9orf72 mutation and not mutations leading to SOD1-ALS. It is unclear if the assumption underlying the NfL trajectory model to inform the design of study 303 which are based on the Pre-fALS study is reliable. Furthermore, ATLAS is enrolling an enriched population of presymptomatic SOD1-ALS carriers (based on selected variants of SOD1 mutations thought

<div style=\"page-break-after: always\"></div>

to have high or complete penetrance and are associated with rapid disease progression), which casts doubts  on  the  extrapolability  of  the  results  towards  the  broad  SOD1-ALS  patient  population  with symptomatic  disease,  which  reflects  the  indication  to  be  authorised  (as  also  highlighted  by  SAG-N experts).  The  presymptomatic  population  to  be  studied  in  study  303  (apart  from  the  symptomatic patients in Parts C and D) is clearly different from the population in the indication. A demonstrated tofersen  treatment  benefit  in  this  presymptomatic  population  would  certainly  be  supportive  of  the approved indication, but this study is not expected to generate a comprehensive dossier as it would not generate confirmatory evidence of efficacy in the authorised indication. Finally, the sample size of 28 patients in the placebo-controlled part B is small such that a treatment effect can be shown only if it is large. This has been highlighted as the most relevant limitation by the SAG-N experts. The applicant discussed whether an enlargement of the sample size of the placebo-controlled part B of study 303 is possible in order to increase the likelihood of the study to provide confirmatory evidence of treatment effect under trial conditions. Various changes have been explored by the applicant, upon request from CHMP. According to the applicant, changes such as expanding eligibility to slower progressing variant carriers, increasing the study sample size, etc. are not expected to meaningfully improve the likelihood that data from Study 303 would be considered comprehensive, but would rather have a substantial impact on feasibility and study timelines.

The applicant's view is that the ability of Study 303 to provide comprehensive confirmatory data postauthorisation remains uncertain. This view is also shared by CHMP and the SAG-N experts. In addition, the  feasibility  of  completing  the  ATLAS  study  as  planned  once  tofersen  is  approved  has  also  been addressed. The applicant provided the latest update of the status of the on-going study 233AS303. Study 303 is well in progress with 68% of the planned presymptomatic at-risk carriers of SOD1 mutation already enrolled. Based on the current study design and enrollment rate in the interventional study period (Part B), data from Study 303 are anticipated in 2028. There is no plan for an interim analysis of Study 303.  The applicant is committed to completing study 303 and is confident for several reasons that approval in Europe will not impact the feasibility of completing the study.

The CHMP concluded that the data expected to be generated by this study cannot provide comprehensive evidence due to the limitations and uncertainties described above. However, the CHMP is of the opinion that this study could provide relevant information on whether treatment with tofersen should already be initiated  in  asymptomatic carriers of SOD1 mutations (part B). Therefore, the tofersen treatment in presymptomatic SOD1 mutation carriers could provide additional data supporting efficacy of tofersen. Further,  participants  in  study  303  who  become  symptomatic  before  reaching  the  NfL  thresholds  for enrolling part B (meaning they become SOD1-ALS patients) will remain in the study part D receiving tofersen. Therefore, efficacy data from these patients is considered valuable. Upon approval of tofersen, study 303 will be a SOB. Last patient out is expected in Q4 2027, and the final report of the study is scheduled for Q4 2028 (please see Table with Specific Obligations).

With regards to the extension Study 233AS102 , it is agreed that the study will provide meaningful data in further characterising the benefits and the risks, in particular with regards to long-term safety (primary aim). It is also agreed that the longer follow-up will allow to provide more information on survival. However, due to the limitations of the design (the study is not a placebo-controlled trial; all patients will be treated (open label)), this would not generate data that would allow to provide confirmatory evidence of the clinical benefits of the medicinal product. Therefore, the results of this study are not expected to lead to a comprehensive confirmatory dataset.

With regards to Study 233AS401 , collaborations with two large ongoing disease registries, including Precision-ALS in Europe (TRICALS), have already been initiated. From the applicant's experience, the successful management of high-quality and sustainable registry-based studies take time and can be resource intensive for the institutions. Given these known challenges, the applicant proposes to focus

<div style=\"page-break-after: always\"></div>

initial  efforts  on  the  current  collaborations  and  successful  implementation  of  the  Precision-ALS  data platform before expanding further.

The applicant has been under discussions with NHC to fund prospective data collection with the ALS/MND NHC consortium, which consists of academic medical centres in the US and Europe. ALS-NHC is active and data reports and data cuts will be received every 6 months for the assessment of data quality and completeness. TRICALS is the world's largest network of specialty ALS centres which, through a common data  model,  collects  and  combines  patient-level  data  from  47  centres  in  15  European  countries. Moreover,  the  applicant  informed  that  registry  contracts  are  in  place  with  TRICALS  and  ALS-NHC. Approximately 2000 incident ALS cases (all ALS types) per year will be recruited to this bespoke Patient Data  Platform,  supported  by  the  Precision  ALS  Program.  Once  established,  the  data  collection  will continue indefinitely as part of an ongoing TRICALS initiative and will be stored on a bespoke patient data platform designed by the Precision ALS Program. As this is a population-based study, existing prevalent  cases  will  also  be  included,  and  patients  will  be  recruited  during  routine  clinic  visits.  The applicant have already provided information for their indefinite collaboration with the two registries in their continuous evidence generation plan document.

However, study 233AS401 is an observational registry-based study, and as such, the ability of this study to  provide  comprehensive  data  is  limited  compared  to  a  well-designed  and  well-conducted  placebocontrolled trial due to the lack of randomisation and blinding. The outcomes in treated patients may need to be compared with the outcomes in untreated patients. In essence, a comparison with a natural history cohort requires that natural history is characterized with high certainty which is not the case in this heterogeneous  SOD-ALS  population.  Since  the  interpretation  of  the  causal  effects  depends  on  a comparison with natural history which is not well characterised, the potential to interpret the observed effects as causal effects is questionable. Therefore, CHMP concluded it is unlikely that the data generated from this study will provide a comprehensive dataset.

Table 34: Applicant's proposed List of specific obligations (SOBs) in the context of MA under exceptional circumstances

| Study Status                                                                                                                                                                                                                                                            | Summary of Objectives                                                                                                                                                                                                                                                    | Milestones       | Due Date           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------|
| 233AS102 An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation Ongoing | Primary Objective: • Evaluate the long-term safety and tolerability of BIIB067 in participants with SOD1-ALS. Secondary Objectives: • Evaluate the PK, PD, biomarker effects, and efficacy of BIIB067 administered to participants with ALS and confirmed SOD1 mutation. | Final report     | 30 September 2025  |
| 233AS303 A phase 3 randomized, placebo-controlled study in clinically presymptomatic adults with a confirmed SOD1 mutation Ongoing                                                                                                                                      | To investigate if initiation of tofersen in presymptomatic SOD1- ALS patients can delay or even prevent emergence of CMALS                                                                                                                                               | Last Patient Out | 31 December 2027 a |
| 233AS303 A phase 3 randomized, placebo-controlled study in clinically presymptomatic adults with a confirmed SOD1 mutation Ongoing                                                                                                                                      | To investigate if initiation of tofersen in presymptomatic SOD1- ALS patients can delay or even prevent emergence of CMALS                                                                                                                                               | Final report     | 31 December 2028   |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                    | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Milestones                  | Due Date                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------------|
| Integrated Analysis of Variant-Specific Survival Planned                                                                        | Descriptive analyses of disease duration (survival) by SOD1 variant-type in tofersen- treated (Studies 101/102; disease registries) vs. untreated patients (disease registries, natural history datasets/literature) Combined data from: • Study 101 (A, B, C) • Study 102 • Disease registries (ALS/MND-Natural History Consortium [NHC] and Precision- ALS) • Natural history datasets/literature                                                                                                                                                                                                                                                                                                                                                                                                         | Initial analysis and output | 30 June 2027 b                                                                      |
| 233AS401 An observational registry- based study to evaluate the long-term safety of tofersen in patients with SOD1- ALS Planned | Primary Objectives: • Describe demographic and clinical characteristics of SOD1 -ALS participants at baseline and stratified by tofersen treatment status. • Estimate the incidence of serious adverse events (SAEs) among all participants and stratified by tofersen treatment status, including serious neurologic events previously reported in clinical trial participants (e.g., myelitis, radiculitis, aseptic meningitis, increased intracranial pressure, and/or papilledema) Secondary Objectives: • Disease progression measured by the ALSFRS-R as rate of change over time in total scores • Occurrence of relevant clinical outcomes, including permanent ventilation and feeding tube placement as well as changes in pulmonary function measured by FVC and SVC • Variant specific survival | Protocol submission         | Within 6 months after the European Commission's decision on this application        |
| 233AS401 An observational registry- based study to evaluate the long-term safety of tofersen in patients with SOD1- ALS Planned |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Interim reports             | 12 months after the Agency's approval of the final protocol and annually thereafter |
| 233AS401 An observational registry- based study to evaluate the long-term safety of tofersen in patients with SOD1- ALS Planned | • Reports of new comorbid conditions, pregnancy and pregnancy outcome, and hospitalisations (including reason for hospitalisation) not reported as SAEs • Treatment discontinuation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Continued evaluation        | Annually (with annual reassessment)                                                 |
| Yearly updates on any new information concerning safety and efficacy of tofersen Planned                                        | In order to ensure adequate monitoring of safety and efficacy of tofersen in the treatment of patients with SOD1-ALS, the MAH shall provide yearly updates on any new information concerning the safety and efficacy of tofersen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Annual report               | Annually (with annual reassessment)                                                 |

a Dependent on enrollment timeline for Part B

b To be confirmed pending finalisation of registry collaboration agreements and consolidation of available natural history datasets

See also section 3.7.3 for details on the criteria of comprehensiveness.

## 2.6.7. Conclusions on the clinical efficacy

Tofersen, an ASO designed to bind to and degrade SOD1 mRNA, leads to reduction of the synthesis of toxic mutant SOD1 protein in patients with SOD1-ALS. The mechanism of action of tofersen is therefore targeted and well-defined.

Reducing  toxic  mutant  SOD1  in  SOD1-ALS  may  be  expected  to  reduce  neuronal  injury  and  death. Neurofilaments are an integral component of neurons and an accepted biomarker of neurodegeneration.

<div style=\"page-break-after: always\"></div>

Treatment  with  tofersen  was  shown  to  induce  relevant  and  persistent  reductions  in  SOD1  and subsequently in neurofilaments, suggesting target engagement and reduction in neuronal loss.

Despite its clear biological activity, tofersen did not significantly improve function in patients with SOD1ALS in the 28-week single pivotal trial in comparison to placebo. This may be explained by a lag-time between effects on biomarkers and clinical effects, which appears biologically plausible and is supported by anecdotal evidence from two other ASOs used in patients with neurodegenerative diseases, including another form of ALS. Indeed, longer-term results showed consistent favourable effects on functional, strength,  QoL  and  survival-related  endpoints  for  early  start  vs.  delayed  start  tofersen  treatment, irrespective of the analyses performed and over long periods of time, at least up to week 104. In addition, the reported survival times in treated patients clearly exceed those expected from natural history data.

The targeted MoA and supportive non-clinical results further strengthen the plausibility and likelihood of tofersen being an effective treatment for SOD1-ALS.

Although, efficacy of tofersen in SOD1 ALS has not been proven in a confirmatory sense all results are consistent with a reasonably likely disease-modifying treatment effect.

Since the data are not considered comprehensive, and in view that the applicant has provided convincing arguments of inability to provide comprehensive data under normal conditions of use, it was therefore concluded that the recommendation of a MAUEC is appropriate.

The CHMP considers the following measures (SOB) necessary to address the missing efficacy data in the context of a MA under exceptional circumstances:

- 233AS102 An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation.
- 233AS303 A phase 3 randomized, placebo-controlled study in clinically presymptomatic adults with a confirmed SOD1 mutation.
- Integrated  Analysis  of  Variant-Specific  Survival  Descriptive  analyses  of  disease  duration (survival) by SOD1 variant-type in tofersen-treated (Studies 101/102; disease registries) vs. untreated patients (disease registries, natural history datasets/literature).
- 233AS401 An observational registry-based study to evaluate the long-term safety of tofersen in patients with SOD1-ALS.
- Submission of yearly  updates on any new information concerning the safety and efficacy of tofersen

## 2.6.8. Clinical safety

Clinical safety data for this application are drawn from:

- 2 clinical studies conducted in participants with SOD1-ALS:

-  Study  101  (completed; randomised, placebo-controlled in all  three  study  parts,  i.e.  Part  A  [single ascending dose], Part B [multiple ascending dose], and Part C [constituting the pivotal study for this application]), and

- Study 102 (ongoing open-label extension for participants, who completed any part of study 101);
- a phase I study in healthy volunteers (233HV101), and
- an ongoing EAP.

<div style=\"page-break-after: always\"></div>

A third clinical study (Study 303), evaluating tofersen vs. placebo in pre-symptomatic SOD1 mutation carriers is ongoing and still blinded; therefore, no detailed safety data are available for this study.

The cut-off date for safety and immunogenicity data originally submitted with the application is 15 th  July 2022, updated safety data for the ongoing study 102 and the EAP as of the 28 th  Feb 2023 have been provided with the responses to the D120 LoQ.

The primary focus of the safety evaluation is set on the comparison of safety in the active treatment group of study 101 Part C, receiving 100 mg tofersen each (' Pool RC1 '), with the respective placebo group (' Pool RC2 '), as well on the pooled safety data of the total of subjects receiving at least one dose of tofersen 100 mg during either part of study 101 or 102 ( Pool ABCL1 ). Where relevant, reference is also made to the pooled population receiving at least one dose of tofersen (≤ 100 mg) during either pa rt of study 101 or 102 ( Pool ABCL2 ) and to all participants of study 101 Part C, who received tofersen 100 mg either during study 101 part C or during the extension study 102 ( Pool CL ).

## 2.6.8.1. Patient exposure

As of the 28 Feb 2023, 166 participants with ALS were exposed to any dose of tofersen for overall 408.82 participant-years (Pool ABCL2). Only four ALS subjects had no SOD1 mutations, all four were treated in the single-dose part A of study 101 only.

The median total exposure to any dose of tofersen was 131.7 weeks with a minimum exposure of 4 and a maximum exposure of 316 weeks (Pool ABCL2). A total of 147 participants from studies 101 and 102 with ALS were exposed to 100 mg of tofersen for 368.83 participant-years (Pool ABCL1). The median total duration of exposure to tofersen 100 mg for this pool was 148.4 weeks. In Pool ABCL1, the median number of doses received (via lumbar puncture procedures each) was 33, seven subjects received 5660 and one subject received 61 doses.

An EAP is ongoing. As of 28 Feb 2023, patients from at least 13 countries have enrolled in the EAP. As dose administration is not tracked in the EAP, the number of tofersen shipments is used to approximate tofersen exposure. It is estimated, that overall, 287 SOD1-ALS patients were exposed to tofersen in the EAP. 67 EAP participants may have received tofersen for a year or longer up to approx. two years.

All safety results from the EAP were presented based on the data available in the global safety database. A total of 169 AEs (113 non-serious and 56 serious) were reported in 88 cases. The most frequently reported (≥ 4 events) AEs at the event level were post lumbar puncture syndrome (10 ), back pain (7), pneumonia aspiration (6), and procedural pain, headache, amyotrophic lateral sclerosis, COVID-19, CSF protein increased, diarrhoea, and respiratory failure (4 events each). Overall, 47 events in 34 cases reported at least 1 AE assessed as related or possibly related to tofersen by the health care professional (HCP) . The most common (≥ 2 events) AEs related to tofersen were CSF cell count increased, intercepted product dispensing error, and post lumbar puncture syndrome (3 events each); and back pain, COVID19, CSF lymphocyte count increased, CSF white blood cell count increased, disease progression, gait disturbance, meningitis aseptic, myalgia, and myelitis (2 events each). All AEs reported from the EAP pertaining to CSF parameters (n=15) were assessed as tofersen related and nonserious. The following AEs were also assessed as tofersen related: One serious event each of radiculopathy and papilloedema and 1 nonserious event of lumbar radiculopathy (radiculitis).

A total of 15 cases from the EAP reported a fatal outcome. These included a fatal event (PT) of death with  minimal  information  reported  and  causality  not  assessed  by  the  health  care  professional;  the causality was therefore reported as related. None of the fatal events was assessed as related to tofersen by the HCP. The most common SOCs with fatal events (≥ 5 events) were Respiratory, thoracic, and mediastinal disorders, with PTs of respiratory failure (4 events), acute respiratory failure (2 events),

<div style=\"page-break-after: always\"></div>

respiratory distress (1 event), bronchial secretion retention (1 event), and hypoventilation (1 event), followed by the system organ class (SOC) of Infections and infestations, with PTs of pneumonia aspiration (3 events), sepsis (1 event), and parotitis (1 event, temporally related to a myobloc injection).

A total of 56 SAEs were reported in 39 cases from the EAP. The most frequently (≥3) S erious AEs (SAEs) reported by PT were pneumonia aspiration (5), respiratory failure (4).

Eleven SAEs in 8 cases were assessed by the HCP as related or possibly related to tofersen. These concerned  myelitis  (2  cases);  gait  disturbance,  speech  disorder,  and  posture  abnormal  (1  case); meningitis  aseptic  (1  case);  meningitis  aseptic  and  papilloedema  (1  case);  post  lumbar  puncture syndrome (1 case); radiculopathy (1 case); and intervertebral discitis (1 case). Relevant information on related SAEs is depicted below:

· Myelitis (one Case) presented with symptoms of headache and tingling in the legs after the first and second doses and left-sided numbness and leg weakness 2 days after the third dose. MRI of the spine demonstrated multiple areas of demyelination, and CSF pleocytosis was noted. Tofersen was temporarily discontinued, and as of the 28 Feb 2023 data cut, it is unknown if tofersen has been resumed and if the event has resolved.

· Myelitis (one Case) became symptomatic 2 days after the 6 th  tofersen dose and was accompanied by CSF protein increase and cervical and thoracical contrast enhancement and oedema in the MRI. Tofersen was permanently discontinued, and the event resolved with sequelae of reduced strength endurance performance and improved but persistent weakness.

· Radiculopathy (one Case) including CSF pleocytosis and protein increase and contrast enhancement of the roots of the cuada and subpial medullary cone without sign of myelitis in the MRI was diagnosed in a patient who reported subacute worsening of their motor function. As of 28 February 2023, the outcome of the event of radiculopathy and action taken with tofersen as a result of the event remained unknown.

· The three SAEs of meningitis aseptic and/or papilloedema in two patients (two Cases) were not resolved as of the 28 Feb 2023, tofersen administration was maintained in both patients.

· Intervertebral discitis was reported in 1 case and was assessed by the HCP as possibly treatment related.  The  patient  underwent  MRI  for  an  increase  in  chronic  lumbago  symptoms,  which  had  been present for 10 years. MRI results demonstrated findings in the subchondral spongy bone at L4 to L5 and L5  to  S1  levels,  partially  extending  to  the  interbody  discs.  The  event  resolved  completely  without antibiotic  therapy  or  other  intervention.  According  to  the  narrative,  tofersen  had  been  temporarily stopped as a result of this SAE and was later resumed.

· Gait disturbance, speech disorder, and posture abnormal were reported in 1 case. The HCP considered these events to be related to tofersen because they occurred within 24 hours of injection and there was no evidence of inflammation or other alternative cause for the symptoms. The patient had a confounding medical history of ALS with an additional cerebellar ataxia component since April 2018.

·  Hallucination  visual  and  hypokalaemia  were  reported  in  1  case.  As  causality  assessment  was  not provided by the HCP, the events were reported as related in the original submission. Updated data (as of 28 Feb 2023) revealed that the patient experienced further of such episodes (without hypokalaemia) with subsequent doses. All episodes resolved within 24 hours, apparently decreased in severity with subsequent administrations, improved with anxiolytics and were rather considered suggestive of anxious manifestations and assessed as probably unrelated to tofersen by the HPC. MRI and electroencephalogram were without abnormal findings.

AEs leading to discontinuation of tofersen treatment from the EAP were reported in 14 cases (21 AEs). Adverse events by PT that led to study treatment discontinuation reported in ≥ 2 cases were pneumonia aspiration,  amyotrophic  lateral  sclerosis,  acute  respiratory  failure,  and  disease  progression  (2  cases

<div style=\"page-break-after: always\"></div>

each).  Of  note,  1  serious  event  of  myelitis  and  1  nonserious  event  of  lumbar  radiculopathy  led  to discontinuation of tofersen. Action taken was unknown for 22 AEs and not applicable for 18 AEs.

AEs leading to interruption of tofersen from the EAP were reported in 9 cases and included influenza (1 case), intervertebral discitis (1 case), pneumonia aspiration (1 case), myelitis (1 case), femur fracture and fall  (1  case),  thrombocytopenia  (1  case);  intervertebral  disc  protrusion  and  gait  disturbance  (1 case); deep vein thrombosis (1 case); and pulmonary embolism (1 case). The event of thrombocytopenia was non-serious and assessed by the HPC as unrelated to tofersen but secondary to a helicobacter pylori infection.

## 2.6.8.2. Adverse events

An overview of adverse events reported during study 101 Part C, and Pool CL as well as the total tofersen population (Pools ABCL1, 2) is presented in Table 35.

Table 35: Overall summary of adverse events - safety population (cut-off: 28 Feb 2023)

|                                                  | RC: Study 101 Part C (Part C subjects) placebo-controlled period   | RC: Study 101 Part C (Part C subjects) placebo-controlled period   | CL: Study 101 Part C and Study 102 (Part C subjects) tofersen treated period   | ABCL: Overall Studies 101 and 102 (Parts A, B and C subjects) tofersen treated period   | ABCL: Overall Studies 101 and 102 (Parts A, B and C subjects) tofersen treated period   |
|--------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Number of subjects with treatment emergent event | Tofersen 100 mg, Pool RC1 (N=72) n (%)                             | Placebo Pool RC2 (N=36) n (%)                                      | Tofersen 100 mg (N=104) n (%)                                                  | Total tofersen 100 mg Pool ABCL1 (N=147) n (%)                                          | Total tofersen all doses Pool ABCL2 (N=166) n (%)                                       |
| Any event                                        | 69 ( 95.8)                                                         | 34 ( 94.4)                                                         | 103 ( 99.0)                                                                    | 146 ( 99.3)                                                                             | 164 ( 98.8)                                                                             |
| CTCAE grade (a,d)                                |                                                                    |                                                                    |                                                                                |                                                                                         |                                                                                         |
| Grade 1                                          | 25 ( 34.7)                                                         | 15 ( 41.7)                                                         | 12 ( 11.5)                                                                     | 17 ( 11.6)                                                                              | 25 ( 15.1)                                                                              |
| Grade 2                                          | 32 ( 44.4)                                                         | 15 ( 41.7)                                                         | 43 ( 41.3)                                                                     | 64 ( 43.5)                                                                              | 68 ( 41.0)                                                                              |
| Grade 3                                          | 10 ( 13.9)                                                         | 4 ( 11.1)                                                          | 25 (24.0)                                                                      | 36 ( 24.5)                                                                              | 39 ( 23.5)                                                                              |
| Grade 4                                          | N                                                                  | N                                                                  | 5 ( 4.8)                                                                       | 7 ( 4.8)                                                                                | 7 ( 4.2)                                                                                |
| Grade 5                                          | N                                                                  | N                                                                  | 18 ( 17.3)                                                                     | 22 ( 15.0)                                                                              | 25 ( 15.1)                                                                              |
| Related event (b)                                | 28 ( 38.9)                                                         | 2 ( 5.6)                                                           | 66 ( 63.5)                                                                     | 98 ( 66.7)                                                                              | 105 ( 63.3)                                                                             |
| Events related to lumbar puncture (c)            | 58 ( 80.6)                                                         | 29 ( 80.6)                                                         | 87 ( 83.7)                                                                     | 126 ( 85.7)                                                                             | 143 ( 86.1)                                                                             |
| Serious event                                    | 13 ( 18.1)                                                         | 5 ( 13.9)                                                          | 48 ( 46.2)                                                                     | 65 ( 44.2)                                                                              | 71 ( 42.8)                                                                              |

<div style=\"page-break-after: always\"></div>

| Related serious event               | N          | N         | 7 ( 6.7)   | 10 ( 6.8)   | 11 ( 6.6)    |
|-------------------------------------|------------|-----------|------------|-------------|--------------|
| Events leading to drug withdrawal   | N          | N         | 23 ( 22.1) | 30 ( 20.4)  | 3 31 ( 18.7) |
| Events leading to study withdrawal  | 3 (4.2)    | 0         | 22 ( 21.2) | 28 ( 19.0)  | 31 ( 18.7)   |
| Events leading to drug interruption | 3 (4.2)    | 0         | 22 ( 21.2) | 28 ( 19.0)  | 30 ( 18.1)   |
| Events leading to hospitalisation   | 13 ( 18.1) | 4 ( 11.1) | 41 ( 39.4) | 55 ( 37.4)  | 55 ( 33.1)   |
| Number of subjects who died         | 1 (1.4)    | 0         | 18 ( 17.3) | 22 ( 15.0)  | 25 ( 15.1)   |

NOTE 1: A subject can appear in more than one category.

(a) Each subject counted once at maximum CTCAE grade.

(b) Related as assessed by the investigator.

(c) Related to lumbar puncture as assessed by the investigator.

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

The most common treatment-emergent adverse events (TEAEs) by preferred term (PT) (occurring in ≥ 10% subjects in either study 101 Part C or the total tofersen 100 mg population) are presented in Table 36.

Table 36: Adverse events by preferred term occurring in 10% or more subjects in any pooled group data presented for Pool RC and ABCL1 - safety population (as of 15 Jul 2022)

|                                   | RC: 233AS101 Part C (Part Cparticipants) placebo-controlled period   | RC: 233AS101 Part C (Part Cparticipants) placebo-controlled period   | ABCL1: Overall 233AS101 and 233AS102 (Parts A, B and C participants) tofersen-treated period   |
|-----------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
|                                   | tofersen 100 mg (N=72) n (%)                                         | placebo (N=36) n (%)                                                 | Total tofersen 100 mg (N=147) n (%)                                                            |
| Number of subjects with any event | 69 (95.8)                                                            | 34 (94.4)                                                            | 145 (98.6)                                                                                     |
| PT                                |                                                                      |                                                                      |                                                                                                |
| Headache                          | 33 (45.8)                                                            | 16 (44.4)                                                            | 90 (61.2%)                                                                                     |
| Procedural pain                   | 41 (56.9)                                                            | 21 (58.3)                                                            | 84 (57.1)                                                                                      |
| Fall                              | 17 (23.6)                                                            | 15 (41.7)                                                            | 66 (44.9)                                                                                      |
| Back pain                         | 14 (19.4)                                                            | 2 (5.6)                                                              | 62 (42.2)                                                                                      |
| Pain in extremity                 | 19 (26.4)                                                            | 6 (16.7)                                                             | 58 (39.5)                                                                                      |
| Arthralgia                        | 10 (13.9)                                                            | 2 (5.6)                                                              | 47 (32.0)                                                                                      |
| Fatigue                           | 12 (16.7)                                                            | 2 (5.6)                                                              | 39 (26.5)                                                                                      |
| Post lumbar puncture syndrome     | 13 (18.1)                                                            | 11 (30.6)                                                            | 34 (23.1)                                                                                      |
| CSF protein increased             | 6 (8.3)                                                              | 1 (2.8)                                                              | 36 (24.5)                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                      | RC: 233AS101 Part C (Part Cparticipants) placebo-controlled period   | RC: 233AS101 Part C (Part Cparticipants) placebo-controlled period   | RC: 233AS101 Part C (Part Cparticipants) placebo-controlled period   | ABCL1: Overall 233AS101 and 233AS102 (Parts A, B and C participants) tofersen-treated period   |
|--------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
|                                      | tofersen 100 (N=72) n (%)                                            | mg                                                                   | placebo (N=36) n (%)                                                 | Total tofersen 100 mg (N=147) n (%)                                                            |
| Nausea                               | 9 (12.5)                                                             |                                                                      | 6 (16.7)                                                             | 34 (23.1)                                                                                      |
| COVID-19                             | 1 (1.4)                                                              |                                                                      | 1 (2.8)                                                              | 31 (21.1)                                                                                      |
| Myalgia                              | 10 (13.9)                                                            |                                                                      | 2 (5.6)                                                              | 28 (19.0)                                                                                      |
| CSF white blood cell count increased | N                                                                    |                                                                      | N                                                                    | 24 (16.3)                                                                                      |
| Contusion                            | 3 (4.2)                                                              |                                                                      | 1 (2.8)                                                              | 24 (16.3)                                                                                      |
| Muscle spasms                        | 5 (6.9)                                                              |                                                                      | 2 (5.6)                                                              | 27 (18.4)                                                                                      |
| Dizziness                            | 4 (5.6)                                                              |                                                                      | 3 (8.3)                                                              | 26 (17.7)                                                                                      |
| Constipation                         | 6 (8.3)                                                              |                                                                      | 4 (11.1)                                                             | 26 (17.7)                                                                                      |
| Nasopharyngitis                      | 2 (2.8)                                                              |                                                                      | 7 (19.4)                                                             | 24 (16.3)                                                                                      |
| Pyrexia                              | 3 (4.2)                                                              |                                                                      | 1 (2.8)                                                              | 23 (15.6)                                                                                      |
| Dyspnoea                             | 4 (5.6)                                                              |                                                                      | 5 (13.9)                                                             | 19 (12.9)                                                                                      |
| Respiratory failure                  | N                                                                    |                                                                      | N                                                                    | 20 (13.6)                                                                                      |
| Upper respiratory tract infection    | 5 (6.9)                                                              |                                                                      | 2 (5.6)                                                              | 15 (10.2)                                                                                      |
| Muscular weakness                    | 4 (5.6)                                                              |                                                                      | 4 (11.1)                                                             | 19 (12.9)                                                                                      |
| Urinary tract infection              | 2 (2.8)                                                              |                                                                      | 2 (5.6)                                                              | 17 (11.6)                                                                                      |
| Diarrhoea                            | 1 (1.4)                                                              |                                                                      | 5 (13.9)                                                             | 16 (10.9)                                                                                      |
| Salivary hypersecretion              | 4 (5.6)                                                              |                                                                      | 1 (2.8)                                                              | 15 (10.2)                                                                                      |
| Pleocytosis                          | N                                                                    |                                                                      | N                                                                    | 13 (8.8)                                                                                       |
| Pain                                 | N                                                                    |                                                                      | N                                                                    | 15 (10.2)                                                                                      |
| Paraesthesia                         | 6 (8.3)                                                              |                                                                      | 6 (16.7)                                                             | 14 (9.5)                                                                                       |
| Neck pain                            | 4 (5.6)                                                              |                                                                      | 4 (11.1)                                                             | 12 (8.2)                                                                                       |
| Pneumonia aspiration                 | N                                                                    |                                                                      | N                                                                    | 12 (8.2)                                                                                       |
| Post procedural complication         | 3 (4.2)                                                              |                                                                      | 4 (11.1)                                                             | 6 (4.1)                                                                                        |

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

## TEAEs considered treatment related by the investigator

In  Study  101  Part  C,  related  AEs  with  an  incidence  of  ≥5%  in  tofersen -treated  participants  were undisclosed information to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102.

In the tofersen 100 mgtreated group (ABCL1), related AEs with an incidence of ≥5% (as of 28 Feb 2023) were CSF protein increased (22.4%), pain in extremity  (17.7%),  CSF  white  blood  cell  count

<div style=\"page-break-after: always\"></div>

increased (14.3%), headache (13.6%), myalgia (10.2%), pleocytosis (8.2%), procedural pain (6.8%), paraesthesia and back pain (6.1% each), and fatigue (5.4%).

The  approach  to  identify  ADRs  used  by  the  applicant  took  into  consideration  differences  in  the  AE incidence to placebo from study 101 Part C, using a &gt;5% threshold and causality assessment including risk factors/confounders, alternative explanations and general biological plausibility. Medical review of additional AEs from integrated study 101 and study 102 safety data complemented this assessment to identify other potential ADRs, based on events that may be related to nonclinical findings, on investigator evaluation of relatedness to study treatment or the LP procedure, on timing of events relative to drug exposure and the presence of a positive rechallenge.

The ADRs identified in the CDP for tofersen with incidences derived from Pool ABCL1 are given in Table 37.

Table 37: Adverse reactions for pooled group ABCL1 - safety population (cut-off 28 Feb 2023)

| ADRs (PTs)                     | Frequency of ADRs n/N (%)   | Frequency Category (a)   |
|--------------------------------|-----------------------------|--------------------------|
| Pain                           | 97/147 (66.0)               | Very common              |
| Fatigue                        | 42/147 (28.6)               | Very common              |
| Arthralgia                     | 50/147 (34.0)               | Very common              |
| Myalgia                        | 28/147 (19.0)               | Very common              |
| CSF white blood cell increased | 39/147 (26.5)               | Very common              |
| CSF protein increased          | 39/147 (26.5)               | Very common              |
| Pyrexia                        | 27/147 (18.4)               | Very common              |
| Musculoskeletal stiffness      | 10/147 (6.8)                | Common                   |
| Neuralgia                      | 7/147 (4 . 8 )              | Common                   |
| Myelitis                       | 4/147 (2 . 7 )              | Common                   |
| Radiculitis                    | 4/147 (2 . 7 )              | Common                   |
| Aseptic meningitis             | 6/147 (4 . 1 )              | Common                   |
| Papilloedema                   | 7/147 (4 . 8 )              | Common                   |

NOTE 1: Myelitis includes preferred term of myelitis, myelitis transverse and neurosarcoidosis. Radiculitis includes preferred term of radiculopathy  and  lumbar  radiculopathy.  Aseptic  meningitis  includes  preferred  term  of  meningitis  chemical,  meningitis  aseptic. Papilloedema includes preferred term of papilloedema, intracranial pressure increased.

NOTE 2: Pain includes preferred term of pain, back pain, and pain in extremity.

NOTE 3: CSF white blood cell increased includes preferred term of CSF white blood cell count increased and Pleocytosis.

## Cerebrospinal fluid (CSF) findings

## TEAEs related to CSF abnormalities

In Study 101 Part C, 12 patients (16.7%) in the tofersen 100 mg-treated group had AEs related to CSF laboratory abnormalities compared to 1 participant (2.8%) in the placebo-treated group. AEs (PT) related to  abnormal  CSF  laboratory  parameters  reported  in  &gt;4%  of  tofersen-treated  participants  were  CSF protein increased, CSF white blood cell count increased, and pleocytosis. The AE related to abnormal CSF laboratory parameters reported in the 1 participant receiving placebo was undisclosed information to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102. .

In the integrated dataset of tofersen 100 mg-treated participants (ABCL1), 26.5% patients each had AEs of CSF white blood cell increased (including the PTs CSF white blood cell count increased and pleocytosis) and CSF protein increased. Many of the events of CSF white blood cell count increased and CSF protein increased in the tofersen 100 mg-treated participants (ABCL1) were assessed by the Investigator as treatment related.

## CSF laboratory results

In Study 101 Part C, 78.3% tofersen vs. 25.0% placebo subjects had a shift to high CSF leukocytes, and 67.4% tofersen vs. 30.0% placebo subjects had a shift to high CSF protein. As of 28 Feb 2023, a total of 90.8% and 90.6% of the participants who received tofersen 100 mg (Pool ABCL1) had shifts to high

<div style=\"page-break-after: always\"></div>

in  their  CSF  leukocytes  and  CSF  protein,  with  nearly  all  participants  (91.2%)  having  at  least  1  CSF leukocytes value &gt;5 × 10 6 /L and 80.3 % of participants having at least 1 value &gt;10 × 10 6 /L.

In pool ABCL1 an increase in mean CSF leukocytes and mean CSF protein was found, which appeared to stabilize each with continued tofersen, i.e. at above 20 leukocytes x 10 6 /L after approx. 425 days and at approx. 1000 mg protein/L after approx. 500 days, respectively (analysis performed as of 15 Jul 2022).

## Adverse Events that occurred within 24 hours of dosing

In  study  101 Part C, the AEs of pain in extremity (15.4% vs. 8.3%), back pain (13.9% vs. 2.8%), myalgia (8.3% vs. 2.8%), and fatigue (12.5% vs. 2.8%) more commonly occurred within 24 hours in the tofersen 100 mg treatment group than in the placebo group (≥ 5% difference between groups).

## 90 Day intervals

Evaluation of AEs over time by 90 Day intervals revealed no pattern in AEs or SAEs over time and no indication for an increase in specific AEs over time, respectively (as of 15 Jul2022).

## Adverse events of special interest (AESIs)

The  following  safety  topics  were  considered  of  interest  by  the  applicant  (although  not  explicitly prespecified as AESIs in the study protocols).

· Since tofersen is administered intrathecally via LP, an investigator assessment of relatedness of AEs to the LP procedure was performed.

In study 101 Part C, 80.6% of participants each in the tofersen and placebo groups reported at least one AE assessed as related to the LP by the investigator. The most common AEs with an incidence of ≥5% in tofersen-treated participants were procedural pain, post lumbar puncture syndrome, headache, back pain, pain in extremity, nausea, and CSF white blood cell count increased. According to the submitted data, LP related AEs, that occurred with a higher frequency in tofersen vs. placebo subjects (and in at least 2 tofersen subjects) were: undisclosed information to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102. In the tofersen 100 mg-treated group (Pool ABCL1), 85.7% of the participants reported AEs that were considered related to the LP by the investigator. LP related AEs with an incidence of ≥10% were procedural pain (57.8%), headache (44.9%), back pain (32.7%) and post lumbar puncture syndrome (24.5%).

·  Because thrombocytopenia, coagulation abnormalities, and renal toxicity have been observed with other subcutaneously or intravenously administered ASOs, the applicant reviewed all AEs reported in the clinical program to identify any relevant AEs for the original submission.

## Thrombocytopenia

In the CDP, no AEs of thrombocytopenia or any cases of sustained or severe thrombocytopenia were identified in tofersen-treated participants and 6 participants (4.1%) in pool ABCL1 experienced shifts to low platelet count (as of 28 Feb 2023). In study 101 Part C, there was no difference in platelet counts over time between the placebo and tofersen-treated participants. The proportion of participants with shifts from normal or high platelet count at baseline to low value during treatment was similar in the tofersen and placebo group. As of 15 Jul 2022, across studies 101 and 102, 2 participants had a platelet value below 100 × 10 9 /L (1 participant from study 101 Part B and 1 participant from study 101 Part C) and both had a repeat result within close proximity to the abnormal result that showed normal platelet counts. No bleeding events were reported during these transient episodes, and none of the low platelet values in the clinical studies were reported as AEs. Resolution of low platelet counts were observed.

## Coagulation abnormalities

<div style=\"page-break-after: always\"></div>

There was a high incidence of abnormal coagulation test results in all treatment groups across studies. The central laboratory frequently reported results outside of their laboratory normal ranges, while local laboratories of multiple study sites reported normal results. In addition, abnormal coagulation values were queried by the medical monitors and were confirmed to be considered not clinically significant. An investigation of the issue led to corrective actions. All results collected in the electronic case record forms were included in the analysis tables for coagulation, including shift tables.

Overall, treatment with tofersen was not associated with any clinically meaningful changes or percent changes over time for coagulation parameters, and the values were similar to placebo in study 101 Part C. A shift from baseline to high values was measured for activated partial thromboplastin time (aPTT) in 19.4% tofersen vs. 28.6% placebo subjects, for INR in 31.3% tofersen vs. 19.4% placebo subjects, and for PT (prothrombin time) in 50.0% tofersen and 51.9% placebo subjects, respectively. As of 28 Feb 2023, a total of 4 participants had coagulation panel-related AEs in the Investigations SOC reported: aPTT prolonged in 2, prothrombin time prolonged in one, and coagulation test abnormal in one patient. One event of aPTT prolonged in a tofersen treated participant was assessed as treatment related by the Investigator. All of these AEs were mild, self-limiting, and none were treatment limiting. None of these AEs was reported during the placebo-controlled study 101 part C.

## Renal toxicity

In study 101 part C, patterns of creatinine and blood urea nitrogen (BUN) over time were similar between groups, shifts to high creatinine occurred in 1.4% tofersen versus 5.9% placebo subjects and shifts to high BUN values occurred in 23.5% tofersen versus 28.1% placebo subjects. However, AEs related to abnormal renal function or abnormal renal laboratory values were infrequent in both groups at a rate of &lt;3%. There have been no reports of glomerulonephritis or nephrotic syndrome or other relevant renal toxicity in participants exposed to tofersen.

·  Given  tofersen's  mechanism  of  action,  there  exists  the  hypothetical  potential  for  adverse  effects attributable to SOD1 deficiency; however, a 'toxic' threshold for reduced SOD1 protein and/or SOD1 enzymatic activity has not been identified. To date, findings in nonclinical and clinical studies of tofersen do not clearly indicate any AEs attributable to SOD1 deficiency.

## 2.6.8.3. Serious adverse event/deaths/other significant events

## Deaths

Overall, 25 tofersen treated subjects died during the CDP, no death has been assessed as treatment related by the investigator (as of 28 Feb 2023). During the controlled study parts, no death occurred in study 101 part A; in study 101 part B, 1/12 (8.3%) placebo subjects vs. 2/38 (5.6%) tofersen subjects died; in study 101 part C 1/72 (1.4%) tofersen subjects vs. 0/36 placebo subjects died.

In Study 101 Part B, 1 participant in the tofersen 20mg group with a history of obesity and sleep apnoea died due to an event of cardiovascular disorder, and 1 participant in the tofersen 60mg group died due to respiratory failure secondary to ALS.

In Study 101 Part C, 1 participant with a past medical history including longstanding coronary artery disease and other comorbidities died due to cardiac failure congestive (Day 114).

As of 15 Jul 2022, in Study 102, 12 participants died due to respiratory failure (among whom 1 participant also had a fatal event of ALS) and 2 died of respiratory arrest which were assessed as associated with ALS disease progression. Some of these events were associated with either the voluntary withdrawal of non-invasive  ventilation  or  the  participant  declining  to  initiate  noninvasive  ventilation.  Other  deaths occurred in participants that had been dependent on noninvasive ventilation for several months and/or

<div style=\"page-break-after: always\"></div>

were receiving hospice or palliative care due to advanced ALS disease. One additional participant died due to pneumonia aspiration.

One participant each in Study 102 died due to fatal events of sudden death and cardiac arrest. Both participants had a history of coronary artery disease, prior myocardial infarction, and other medical comorbidities. One participant each died due to fatal events of ALS and euthanasia. Finally, 1 participant died  due  to  a  fatal  event  of  septic  shock.  The  participant  had  additional  SAEs,  specifically  acute respiratory  distress  syndrome,  encephalopathy,  pneumonia  aspiration,  pulmonary  embolism,  and respiratory failure, all starting on Study Day 908 with death on Study Day 917 in Study 102. Septic shock was suspected to be secondary to a polymicrobial infection. Three further participants of study 102 died between 15 Jul 2022 and 28 Feb 2023, with fatal AEs of respiratory failure, cardio-respiratory arrest and pneumonia aspiration in one subject each, none of which was considered related to tofersen.

## SAEs

In study 101 part C, the incidence of SAEs was higher in the tofersen group (13/72 participants [18.1%]) compared with the placebo group (5/36 participants [13.9%]). SAEs were most frequently reported (≥ 4%) in the SOCs respiratory, thoracic and mediastinal disorders (5/72 participants [6.9%] in the tofersen group and 4/36 participants [11.1%] in the placebo group); general disorders and administration site conditions undisclosed information to avoid unblinding of treatment allocation from Study 101 in the context  of  the  ongoing  open-label  extension  Study  102;  and  nervous  system  disorders  undisclosed information to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102.

## SAEs considered related to study drug by the investigator are presented in Table 38.

Table 38: Related serious adverse events by system organ class and preferred term - safety population (cut-off: 28 Feb 2023)

|                                                                   | 233AS101 Part C (Part C subjects) placebo-controlled period   | 233AS101 Part C (Part C subjects) placebo-controlled period   | Overall 233AS101 and 233AS102 (Parts A, B and C subjects) tofersen treated period   | Overall 233AS101 and 233AS102 (Parts A, B and C subjects) tofersen treated period   |
|-------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                                                                   | Tofersen 100 mg, Pool RC1 (N=72) n (%)                        | Placebo Pool RC2 (N=36) n (%)                                 | Total tofersen 100 mg Pool ABCL1 (N=147) n (%)                                      | Total tofersen all doses Pool ABCL2 (N=166) n (%)                                   |
| Number of subjects with any related serious event                 | N                                                             | N                                                             | 10 (6.8)                                                                            | 11 (6.6)                                                                            |
| Nervous system disorders Intracranial pressure increased Headache | N 0 0 N                                                       | N 0 0 N                                                       | 7 (4.8) 3 (2.0) 1 (0.7) 1 (0.7) 1 (0.7)                                             | 6 (3.6) 3 (1.8) 1 (0.6) 1 (0.6)                                                     |
| Lumbar radiculopathy                                              |                                                               |                                                               |                                                                                     |                                                                                     |
| Myelitis transverse                                               | N0                                                            | N                                                             |                                                                                     | 1 (0.6)                                                                             |
| Radiculopathy                                                     |                                                               | 0                                                             | 1 (0.7)                                                                             | 1 (0.6)                                                                             |
| Infections and infestations                                       | N                                                             | N                                                             | 3 (2.0)                                                                             | 3 (1.8)                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                                    | 233AS101 Part C (Part C subjects) placebo-controlled period   | 233AS101 Part C (Part C subjects) placebo-controlled period   | Overall 233AS101 and 233AS102 (Parts A, B and C subjects) tofersen treated period   | Overall 233AS101 and 233AS102 (Parts A, B and C subjects) tofersen treated period   |
|--------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                                                                    | Tofersen 100 mg, Pool RC1 (N=72) n (%)                        | Placebo Pool RC2 (N=36) n (%)                                 | Total tofersen 100 mg Pool ABCL1 (N=147) n (%)                                      | Total tofersen all doses Pool ABCL2 (N=166) n (%)                                   |
| Myelitis Meningitis aseptic                                        | N 0                                                           | N 0                                                           | 2 (1.4) 1 (0.7)                                                                     | 2 (1.2) 1 (0.6)                                                                     |
| Eye disorders Papilloedema                                         | 0 0                                                           | 0 0                                                           | 1 (0.7) 1 (0.7)                                                                     | 1 (0.6) 1 (0.6)                                                                     |
| Gastrointestinal                                                   | 0 0                                                           | 0 0                                                           | 1 (0.7) 1 (0.7)                                                                     | 1 (0.6) 1 (0.6) 1 (0.6)                                                             |
| disorders Gastritis Pancreatitis                                   | 0                                                             | 0                                                             | 1 (0.7)                                                                             |                                                                                     |
| Injury, poisoning and procedural complications Meningitis chemical | NN                                                            | NN                                                            | 1 (0.7) 1 (0.7)                                                                     | 1 (0.6) 1 (0.6)                                                                     |
| Investigations CSF protein increase CSF WBC count increased        | 0 0 0                                                         | 0 0 0                                                         | 0 0 0                                                                               | 1 (0.6) 1 (0.6) 1 (0.6)                                                             |

NOTE 1: Only treatment emergent adverse events are summarized. A subject was counted only once within each system organ class and preferred term (MedDRA version 25.1).

NOTE 2: System organ class and preferred term are presented in decreasing frequency of the table's rightmost column.

NOTE 3: Relationship to study drug per investigator assessment.

WBC: white blood cell

N: Numbers removed to avoid unblinding of treatment allocation from Study 101 in the context of the ongoing open-label extension Study 102, as per the Unblinding Plan.

## Additional information on related SAEs:

## Myelitis and radiculitis

According to the referenced publication by Li 2021, studies have reported overall incidence rates of transverse myelitis ranging from 0.4 to 4.6 per 100,000 persons per year. A Canadian study (Klein 2010) reporting a higher incidence of 18.3 cases per 100,000 persons per year in Albuquerque may be an outlier.

A total of 6 participants experienced SAEs of myelitis or radiculitis as of 28 Feb 2023. The Investigator considered the events related to tofersen in 5 of 6 cases. Four participants reported SAEs of myelitis (PTs myelitis, myelitis transverse, and neurosarcoidosis), and 2 participants reported SAEs of radiculitis (PTs  radiculopathy  and  lumbar  radiculopathy).  The  number  of  doses  of  tofersen  that  a  participant received prior to SAE onset varied between 1 and 24, and each SAE was associated with a CSF pleocytosis and elevated CSF protein.

<div style=\"page-break-after: always\"></div>

Cases involving events consistent with myelitis are briefly summarized below.

·  One  SAE  of  neurosarcoidosis  (verbatim  term  'neurosarcoid  transverse  myelitis')  occurred  in  a participant with a comorbid history of sarcoidosis and was assessed by the Investigator as unrelated to tofersen. This participant continued treatment with tofersen while receiving immunomodulatory therapy for their sarcoidosis. The participant additionally reported a nonserious AE of thoracic radiculopathy which was assessed by the Investigator as mild and unrelated to study treatment.

· One participant with an event of myelitis, developed bilateral lower extremity numbness and weakness, MRI demonstrated extensive T2-hyperintense lesions and associated enhancement and CSF pleocytosis and  elevated  CSF  protein  was  found.  This  participant  required  immunomodulatory  therapy  and rehabilitation,  and  tofersen  treatment  was  discontinued.  The  event  resolved  without  sequelae  after approximately 3 months.

· One event of myelitis was asymptomatic; diagnosis was based on MRI contrast enhancement in the lower thoracic medulla and conus medullaris as well as CSF pleocytosis and elevated CSF protein. The participant continued treatment with tofersen despite a persistent CSF pleocytosis and elevated CSF protein.

· One event of myelitis occurred in a participant with a preceding nonserious event of aseptic meningitis and a preceding serious event of intracranial hypertension. The myelitic lesion was found on an MRI of the spine without associated symptoms, and approximately one month later the lesion was diminished in size with disappearance of enhancement. Tofersen was temporarily discontinued.

The two SAEs of radiculitis are briefly summarized below.

· One participant with an event of lumbar radiculopathy had symptoms of back pain and gait abnormality secondary to sensory changes associated with a mild CSF pleocytosis and elevated CSF protein but unremarkable MRI. Symptoms related to this event resolved within days, the participant continued on tofersen. The participant had 3 subsequent transient non-serious AEs of lumbar radiculopathy, which were assessed by the Investigator as tofersen related; all resolved within days, and the participant remains in Study 102.

· One event of radiculopathy was associated with of symptoms of back and thigh pain and subjective and objective sensory changes in the bilateral lower extremities. MRI examination demonstrated cauda equina enhancement. The event was considered resolved after approximately 9 months with sequelae of bilateral foot sensory loss, and loss of ankle jerk reflexes.

· In addition, nonserious AEs of lumbar radiculopathy (2 participants), and radiculopathy (1 participant) have been reported in the clinical trials. These non-serious events were assessed as mild to moderate and treatment related by the Investigator and did not lead to tofersen discontinuation.

## Papilloedema/increased intracranial pressure.

The incidence of papilloedema in the general population is reported as 0.9 per 100,000 in the US and 1.56 per 100,000 in the UK [Rigi 2015].

In the CDP, four SAEs involving elevated intracranial pressure and/or papilloedema occurred (3 events with  PT  intracranial  pressure  increased,  1  event  with  PT  papilloedema).  All  4  SAEs  were  considered related to treatment by the investigator and medical review demonstrated papilloedema as a feature in each of these SAEs. Additionally, 2 participants had preceding AEs or SAEs of aseptic meningitis which could have affected CSF outflow and thereby increased their risk of development of papilloedema. All AEs and SAEs related to papilloedema/intracranial pressure increased were reported in participants who received tofersen 100 mg; no such events were reported in the placebo group].

<div style=\"page-break-after: always\"></div>

These four SAEs are described below:

· One SAE of intracranial pressure increased was reported in a participant, who additionally reported an SAE  of  myelitis.  The  participant  developed  headaches  and  deterioration  in  their  eyesight,  bilateral papilloedema, and an elevated LP CSF opening pressure of 38 cm H2O, CSF pleocytosis, and elevated CSF  protein.  Approximately  8  months  after  onset  the  papilloedema  was  markedly  regressed,  and headaches and blurred vision had disappeared. As of the 28 Feb 2023 data cut, the event of intracranial pressure  increased  is  ongoing,  and  treatment  with  tofersen  remains  ongoing.  The  most  recent  CSF opening pressure was + 25 cm H2O, and ophthalmological examination was normal with no papillary oedema.

· One SAE of intracranial pressure increased was reported after approximately 18 doses of tofersen, symptoms included headache, nausea, fever, photophobia, visual obscurations, and auditory distortions. Initial examination showed no papilloedema. LP was obtained and demonstrated an elevated CSF opening pressure, CSF pleocytosis, and elevated CSF protein. After initial improvement, symptoms recurred after a subsequent dose, and further evaluation showed papilloedema. The event was reported resolved after 27 days with sequelae (ongoing headache and visual disturbance). The participant continued to receive tofersen for approximately 6 months with doses alternating every other month and finally withdrew tofersen, because the patient still had some symptoms, he thought might be related to study drug.

·  One  SAE  of  papilloedema  was  reported  after  receiving  7  doses  of  tofersen  100  mg.  Following  a preceding  SAE  of  aseptic  meningitis  treated  with  prednisone,  the  participant  developed  intermittent headache, visual acuity loss in the eye, peripheral visual field loss and visual floaters. Ophthalmological examination noted bilateral blind spot enlargement and optic nerve edema with hemorrhage as well as vitreous hemorrhage in the eye. The LP opening pressure was not elevated, and CSF pleocytosis and elevated CSF protein was found. The participant was started on acetazolamide, furosemide as well as IV methylprednisolone with tofersen dosing visits. The SAE of papilloedema was reported as resolved after 191  days,  but  Neuro-ophthalmology  recommended  continued  IV  methylprednisolone  around  study treatment infusions and continued acetazolamide. This participant additionally experienced another SAE as unrelated to study treatment but in the setting of treatment with acetazolamide and glucocorticoids as  well  as  an  SAE  of  headache  assessed  as  rebound  of  intracranial  hypertension  associated  with acetazolamide withdrawal.

· One SAE of intracranial pressured increased was reported after receiving 9 doses of tofersen 100 mg, symptoms included headaches and pulsatile tinnitus. LP demonstrated an elevated opening pressure, and prior CSF analyses found elevated CSF WBC and elevated CSF protein. 5 days after the SAE of intracranial  pressured  increased  was  reported,  a  coinciding  nonserious,  treatment  related  AE  of papilloedema was reported, that resolved after 37 days. These events did not lead to study treatment interruption or withdrawal. Two to 3 days after beginning acetazolamide, the participant's headaches and pulsatile tinnitus resolved completely. The participant has continued treatment with acetazolamide, and  the  SAE  was  reported  resolved  after  247  days.  As  of  28  Feb  2023,  the  patient  continued acetazolamide, and the most recent visual examinations noted VA 20/25+2 OD and 20/25 OS without disc  edema,  peripapillary hemorrhage,  or  pallor.  A new  nonserious,  mild  AE  of  intracranial  pressure increased was reported then in this patient, that was ongoing as of 28 Feb 2023.

In  addition,  overall,  5  patients  reported  nonserious  events  of  papilloedema. Of  those,  3  participants reported only non-serious events of intracranial pressure increased (with or without additional AEs of papilloedema) and 2 participants reported nonserious AEs of papilloedema concurrent to serious AEs of papilledema/ intracranial pressure increased. In addition, one nonserious AE of 'CSF pressure increased' assessed as tofersen related, mild and ongoing as of 28 Feb 2023 was reported.

<div style=\"page-break-after: always\"></div>

## Aseptic meningitis

Aseptic meningitis is seen at a rate of 2.9 to 7.6 cases per 100,000 persons in the general population [Mount and Boyle 2017].

During the CDP, two SAEs of aseptic meningitis (with the PTs meningitis chemical and meningitis aseptic, respectively in one subject each) were reported and are briefly described below:

· One participant with an SAE of meningitis chemical had symptoms of headache, neck pain, stiffness, and body aches, and a LP demonstrated CSF pleocytosis and elevated CSF protein but negative microbial studies. Study treatment was permanently discontinued, and the event resolved after 11 days.

· An SAE of aseptic meningitis occurred in one patient who also had an SAE of papilloedema. Symptoms included  headache,  neck  stiffness,  nausea,  visual  disturbances,  and  episodes  of  confusion.  LP demonstrated a CSF pleocytosis and elevated protein but negative microbial studies. The participant was treated symptomatically with NSAIDS, steroids, and Benadryl; tofersen dosage was maintained, and the event resolved after 25 days.

Further review of clinical trial data identified 4 participants reporting nonserious AEs of aseptic meningitis with  PTs  of  meningitis  chemical  (2)  and  meningitis  aseptic  (2),  all  of  which  were  assessed  by  the Investigator as tofersen related and remained ongoing as of 28 Feb 2023. Of those, one event was previously reported with a VT of meningitis and the study site updated the event of VT to meningitis aseptic  after  query  from  the  applicant.  Two  of  the  nonserious  events  of  meningitis  occurred  in participants with AEs/SAEs of intracranial pressure increased/papilloedema.

In addition to the PTs included in the event of aseptic meningitis, there was 1 nonserious AE of meningism (resolved). This event was mild and study treatment related.

SAEs of gastritis and pancreatitis were reported in a single participant during study 102. . The SAEs of gastritis and pancreatitis were assessed as related to tofersen by the investigator given no alternative explanation. However, in reviewing AEs for the total tofersen population at all doses (ABCL2), no pattern of similar AEs was identified, and there were no other AEs of pancreatitis and no AEs in the Investigations SOC of elevated amylase and lipase. Two participants in Study 101 Part C reported AEs of gastritis, and 1 additional participant in Study 102 reported a mild AE of gastritis that was assessed as unrelated.

## 2.6.8.4. Laboratory findings

## Haematology

In the integrated safety data set, there were no significant trends appreciated in hematology values, including hemoglobin, haematocrit, white blood cells, neutrophils, and lymphocytes. As of 28 Feb 2023, in pool ABCL1, AEs reported in the Investigations SOC or the Blood and lymphatic system disorders SOC that were related to hematology results were infrequent at rates of ≤3 % for each PT, none of these AEs was assessed as tofersen related by the investigator.

## Chemistry

## Hepatic function (as of 15 Jul 2022 unless indicated otherwise)

In study 101 part C, treatment with tofersen was not associated with any clinically meaningful changes or  percent changes over time in liver function tests (LFT), and the values were similar to those for placebo. Shifts to high alanine transaminase (ALT) were less frequent in tofersen 100 mg than in placebotreated participants (34.8% vs. 44.0%) but shifts to high aspartate transaminase (AST) (30.4% vs. 21.9%), alkaline phosphatase (7.1% vs. 2.8%), and gamma-glutamyl transferase (GGT) (12.6% vs. 5.9%) were more frequent in tofersen 100 mg-treated participants than in placebo-treated participants.

<div style=\"page-break-after: always\"></div>

There were no Hy's Law cases in the integrated safety set.

Study 101 Part C had 1 participant with an ALT &gt; 5 x the upper limit of normal (ULN), 1 participant with an AST &gt; 3x ULN, 1 participant with a total bilirubin &gt; 1× (≤ 1.5 x) ULN, and 1 participant with an alkaline phosphatase &gt; 1.5x ULN. In all other instances, changes in liver function parameters, including bilirubin,  were  mild  and  generally  similar  between  the  tofersen  100  mg-treated and placebo-treated participants. In the overall tofersen 100 mg-treated participants (ABCL1), 5.4% of participants had AST &gt; 3 x ULN, and 10.9% had ALT &gt; 3 x ULN.

As of 28 Feb 2023, in all tofersen 100mg treated participants, AEs related to LFT parameters in the SOC Investigations of ALT increased (5.4%), AST increased (4.1%), hepatic enzyme increased (4.1%), GGT increased (1.4 %), transaminases increased (1.4 %), blood alkaline phosphatase increased (1.4%), and liver function test abnormal (0.7%) each occurred in &lt;6% of participants. According to ISS Addendum 2023, Appendix 2.3, one event each of ALT increased, AST increased, and blood alkaline phosphatase increased,  respectively  was  considered  treatment  related  by  the  investigator.  AEs  in  the  SOC Hepatobiliary disorders were reported in ≤ 6 % of tofersen 100 mg -treated participants and included PTs of hepatic steatosis, cholelithiasis, cholecystitis, bile duct stone, hepatic function abnormal, and hypertransaminasaemia; none of these events were assessed by the Investigator as related to study treatment.

The following hepatic and biliary laboratory abnormalities of note are presented in the SCS:

· One participant had events of increased ALT and AST that were assessed by the Investigator as related to study treatment and mild in severity. This participant used confounding concomitant medication and LFT values fluctuated throughout the study including baseline abnormalities and frequent normalisation despite uninterrupted study treatment dosing.

· One participant in study 101 Part C had events of ALT increased and AST increased which were grade 3 severity and assessed as unrelated to study treatment. This participant had an elevated ALT (1.7 x ULN) and AST (1.1 x ULN) on Day 1 which on Day 15 increased to ALT 5.2 x ULN and AST (3.7 x ULN), corresponding with the time that the AEs were reported (Day 14). While the AEs did not resolve over the course of the study, Day 29 values improved to ALT 3 x ULN and AST 1.1 x ULN and remained &lt;1.5 x ULN for ALT and &lt;1.6 x ULN for AST for the remainder of their participation in Study 101 Part C. ALT in Study 102 ranged from approximately 1.2 x ULN to 2.0 x ULN, while AST was largely within normal limits.

· One participant in study 101 Part C and the LTE experienced an AE of blood alkaline phosphatase increased, which was assessed as study treatment related. This participant had no other abnormal LFT parameters throughout the study. This AE was assessed as moderate in severity, led to study treatment interruption, and was not resolved as of the 15 July 2022 data cut. AP levels were normal throughout study 101 Part C and before Week 60 in the LTE, when the value was 1.8203 µkat/L (&lt;1.04 x ULN); it reached 1.3 x ULN at Week 80, and 3.3 x ULN at Week 104, leading to tofersen withdrawal. AP levels remained stably elevated thereafter despite no tofersen administration since approx. 11 months (as of 28 Feb 2023). No other study participants have reported a related AE of blood alkaline phosphatase increased.

## Urinalysis

As of 15 Jul 2022, treatment with tofersen was not associated with any clinically meaningful changes over time in urinalysis parameters and there were no clear patterns of treatment-emergent abnormalities in urinalysis. In the SOC Investigations, AEs of blood urine present, cells in urine, protein urine, protein urine present, white blood cells urine positive, glucose urine present, and nitrite urine present each occurred in 1 subject of all tofersen 100 mg-treated participants (ABCL1). In the SOC Renal and urinary disorders, AEs of undisclosed AE (undisclosed to avoid unblinding of treatment allocation from Study 101

<div style=\"page-break-after: always\"></div>

in the context of the ongoing open label extension Study 102) and haematuria each occurred in ≤2% of all tofersen 100 mg-treated participants (ABCL1). None of these AEs were assessed as treatment related by the Investigator.

## Vital signs

Overall,  treatment  with  tofersen  was  not  associated  with  changes  over  time  for  the  vital  sign measurements (body temperature, heart rate, blood pressure, weight and respiratory rate) during study 101 part C and study 102 (according to the Interim 2 Report of study 102, cut-off date: 16 Jan 2022). In study 101 Part C, weight gain ≥ 7% occurred at an increased incidence in the tofersen vs. the placebo group (14.3% vs. 5.6%), while weight loss occurred at a lower incidence in the tofersen vs. the placebo group (12.9% vs. 19.4%). Across pool RC1 and ABLC1 a similar proportion of subjects experienced weight gain and weight loss, respectively. Apart from pyrexia and related PTs of chills, feeling hot, and feeling cold, respectively AEs of vital sign abnormalities were infrequent, and (apart from temperature related AEs) none were assessed by the Investigator as related to tofersen (as of 15 Jul 2022).

Overall, treatment with tofersen was not associated with changes over time for the electrocardiogram (ECG) measurements (according to the Report of study 101 part C and the Interim 2 Report of study 102, cut-off date: 16 Jan 2022). In study 101 part C, a higher incidence of increase in QTc &gt;30 ms to 60 ms was found in tofersen vs. placebo subjects (11.3% vs. 5.6%). An increase in QTc &gt; 60 ms, or QTc values &gt; 480 ms or &gt; 500 ms was not reported in this study part and was each reported in single subjects only of the total tofersen 100 mg population (pool ABCL1, as of 15 Jul 2022). As of 28 Feb 2023, in pool ABCL1, AEs reported in the cardiac disorders SOC and in the investigations SOC related to ECG  abnormalities,  respectively  were  generally  infrequent  (&lt;4%  by  PT)  and  were  all  considered unrelated to treatment. AEs were further evaluated for events consistent with potential pro-arrhythmic effects  using  the  MedDRA  Standardized  Medical  Dictionary  for  Regulatory  Activities  Query  (SMQ) 'Torsade de pointes/QT Prolongation' and PT 'Seizure.' During study 101 part C, respective events were reported in 1 (1.4%) tofersen and 2 (5.6%) placebo subjects.

In study 101 part C, shifts in ECG to abnormal, clinically significant AE values were low and similar between the tofersen and placebo group.

In study 101 Part C, treatment-emergent suicidal ideation occurred at similar rates between the tofersen (6.9%) and placebo-treated participants (5.6%) and suicidal behaviour did not occur (measured by CSSRS). There were no clinically significant differences or trends in the Mini-Mental State Exam between the tofersen 100 mg-treated participants (RC1) and the placebo participants (RC2) in Study 101 Part C.

## 2.6.8.5. Safety in special populations

## Intrinsic and extrinsic factors (as of 15 Jul 2022):

## Disease progression status

The most common AEs in participants in the 'enriched' subgroup of SOD1-ALS participants (i.e., deemed most  likely  to  have  faster  disease  progression  based  on  the  original  protocol  defined  enrichment definition) were generally similar to those in the 'other' subgroup of SOD1-ALS participants. Participants in the 'enriched' subgroup were noted to have a higher frequency of AEs ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 3. Within the 'enriched' subgroup, the incidence of SAEs was higher in the tofersen group (11/39 participants [28.2%]) compared with the placebo group (4/21 participants [19.0%]) whereas SAEs in the 'other' subgroup occurred less frequently (in 2/33 [6.1%] tofersen vs. 1/15 [6.7%] placebo subjects). In particular, participants in the 'enriched' subgroup who received either tofersen or placebo in Study 101 had more events in the SOC of Respiratory, thoracic, and mediastinal

<div style=\"page-break-after: always\"></div>

disorders than did participants in the 'other' subgroup. Of note, serious neurologic events occurred in participants in both the 'enriched' and the 'other' subgroup.

## Age

The total tofersen population in both the RC and ABCL1 pools ranged in age from 23 to 78 years. Study 101 part C included nine tofersen and 5 placebo patients ≥ 65 years, and 20 (13.6%) patients of pool ABCL1 were ≥ 65 years. Evaluation of the overall summ ary of AEs showed that in the RC and ABCL1 pools,  both  subgroups  (&lt;65  and  ≥65  years)  generally  had  similar  proportions  of  participants experiencing AEs in each AE category. Review of individual AEs (incidence ≥ 5% in the RC pool and ABCL1 groups) showed that the incidence and type of AEs for tofersen versus placebo subjects in study 101 part C and in the ABCL1 pool within both age subgroups were generally consistent with those of the overall population and did not reveal any notable concerns in any subgroup.

## Sex

In  the  RC  and  ABCL1  pools,  there  were  more  male  (57.4%  and  55.8%,  respectively)  than  female participants.  In  the  overall  summary  of  AEs,  both  subgroups  had  similar  proportions  of  participants experiencing AEs in each AE category. Review of individual AEs ( incidence ≥ 5% in the RC and ABCL1 groups) showed that the incidence and type of AEs were generally consistent with those of the overall population and did not reveal any notable concerns in either subgroup.

## Race

Most participants in studies 101 and 102 were white, or race was not reported (e.g. in Pool ABCL1 the respective numbers were 59.9% and 30.6% respectively), limiting the AE comparison across race.

Site of onset was specified as a subgroup of interest; however, only a small number of participants was enrolled in study 101 Part C with bulbar onset (3 tofersen, 3 placebo) compared to other regions of onset (69 tofersen, 33 placebo).

Participants with hepatic or renal impairment were not included in the clinical studies with tofersen.

## Geographic region

Study  101  Part  C  included  participants  from  North  America  (48  tofersen,  25  placebo),  Europe  (21 tofersen,  7  placebo),  and  Asia-Pacific  (3  tofersen,  4  placebo).  No  differences  were  identified  by  the applicant  when  comparing  AEs  in  participants  who  received  tofersen  100  mg  (RC1)  against  those receiving placebo (RC2) across geographical regions, and review of all participants who received tofersen 100 mg (group ABCL1) did not identify any regional differences in commonly reported AEs or serious neurological  adverse  events.  However,  according  to  ISS3  Appendix  2.3.2,  Output  13,  in  the  overall tofersen 100 mg population (pool ABCL1), CSF protein increased was reported as AE in 46.7% European vs.  only  12.6% North American patients, and CSF WBC count increased was reported as AE 26.7% European vs. 11.6% North American patients.

There are no data from clinical studies on the use of tofersen during pregnancy and lactation.

## 2.6.8.6. Overdose and abuse potential

No cases of overdose associated with tofersen have been reported in clinical studies (as of 15 Jul 2022).

Given the targeted mechanism of action and intrathecal route of administration (necessitating in-clinic dosing), it is anticipated that tofersen would have a negligible potential for drug abuse. The dependence potential of tofersen has not been studied.

<div style=\"page-break-after: always\"></div>

## 2.6.8.7. Immunological events

As of 15 Jul 2022, in the total 100 mg tofersen population (pool ABCL1), 93/147 (63.3%) subjects developed positive ADAs in plasma, and ADAs were found to be persistent in the majority of ADA positive subjects (76/93; 81.7%). Neutralizing ADAs or ADA status in CSF was not examined.

## Impact of ADAs on PK

The presence of ADAs appeared to decrease plasma clearance by 32.2%.

## Impact of ADAs on efficacy

According to the applicant, given the relatively small number of participants in each group and individual disease heterogeneity, no clear conclusions regarding the comparison of ALSFRS-R in participants with persistent positive ADAs and other participants can be drawn (and no comprehensive evaluation has been provided). However, the applicant expects no impact on efficacy, as large molecules such as ADAs have limited penetration through the blood brain barrier and ADAs were not found to be a significant covariate for either the SOD1 protein or NfL in the PK/PD models.

## Impact of ADAs on safety (as of 15 July 2022, unless stated otherwise)

In order to explore the impact of tofersen ADA response on safety, the incidence of AEs selected by SMQs (of hypersensitivity, anaphylactic reaction, and angioedema) was evaluated by ADA status. In study 101 Part C, the frequency of AEs identified by these SMQs was lower in ADA positive tofersen subjects (22.7%) compared to both, ADA negative tofersen subjects (28.0%) and ADA negative placebo subjects (32.4%); one of 2 (50%) ADA positive placebo subjects had an AE in these SMQs (PT dyspnoea). In the total 100 mg of tofersen safety population (ABCL1), AEs identified by these SMQs were reported in 60 (64.5%) ADA positive and 31 (57.4%) ADA negative participants. As of 28 Feb 2023, 4 subjects in pool ABCL1 had multiple pyrexia events that were considered tofersen related by the investigator. Two of these patients had positive and two had negative ADA status.

As  of  15  July  2022  data  cut,  no  impact  of  tofersen  ADA  was  observed  on  the  incidence  of  serious neurological ADRs (myelitis, radiculitis, papilloedema, aseptic meningitis). In the overall tofersen 100 mg-treated group (ABCL1), 4 participants (2.7%) with serious neurologic ADRs had positive ADA status, while 6 (4.1%) had negative ADA status. No further serious neurological ADRs were reported between 15 July 2022 and 28 Feb 2023.

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

The DDI potential for ASOs is low. In-vitro studies in human biomaterials did not provide any indication for a potential DDI of tofersen with common drug metabolising enzymes or drug transporters. Therefore, no dedicated human DDI studies with tofersen have been performed.

## 2.6.8.9. Discontinuation due to adverse events

AEs  leading  to  treatment  discontinuation  were  reported  in  4/72  (5.6%)  tofersen  vs.  0/36  placebo subjects in Study 101 part C. In the total tofersen 100 mg population, 30 reported AEs that led to study treatment discontinuation, most of which were associated with the underlying ALS disease (including the death cases). With regard to the identified serious ADR of tofersen, the events of myelitis, meningitis chemical,  and  neurosarcoidosis  led  to  tofersen  withdrawal  in  one  subject  each.  Also,  one  SAE  of intracranial pressure increased finally led to tofersen withdrawal.

AEs leading to study treatment interruption occurred in 28 of tofersen 100 mg-treated patients. Each AE (by PT) that led to study treatment interruption occurred in only 1 participant apart from AEs of COVID-

<div style=\"page-break-after: always\"></div>

19 (in 10 participants) and deep vein thrombosis, nasopharyngitis and headache (in 2 participants each), respectively.  Respective  events  (by  PT),  which  occurred  in  single  subjects  only,  included  (amongst others), myelitis, papilloedema, back pain, procedural pain and post lumbar puncture syndrome.

## 2.6.8.10. Post marketing experience

N/A (Tofersen was approved by the FDA only after the safety data cut of 28 Feb 2023).

## 2.6.9. Discussion on clinical safety

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics

As of the 28 Feb 2023, safety data are available from 166 ALS patients who received tofersen in the placebo controlled multi-part study 101 and open-extension study 102 and who were SOD1-ALS patients with the exception of 4 subjects in the single dose study 101 part A. Of these, 147 SOD1-ALS subjects have received at least 1 dose of 100 mg tofersen (the intended dose), 116 SOD1-ALS subjects have received 100 mg tofersen for at least one year and 95 subjects for at least two years. The maximum total duration of exposure for 100 mg (any dose of) tofersen is 245 (316) weeks. The number of overall tofersen exposed subjects and in particular the controlled exposure in study 101 part C which is pivotal for this application (i.e. 72 tofersen and 36 placebo subjects treated for 24 weeks) is rather limited, taking into consideration that the underlying disease can lead to a broad spectrum of symptoms including extra-motor symptoms, e.g. dysfunction of the autonomic system, cognitive and behavioural changes, and complications of malnutrition and restricted mobility, respectively. Therefore, TEAEs derived from uncontrolled ALS studies are often difficult to interpret with regard to causality. Nevertheless, taking into consideration that SOD1-ALS is an ultra-orphan disease, the safety exposure is considered sufficient for a benefit risk evaluation. As the general cut-off date for the safety data of the original submission was the 15 July 2022, updated safety data focusing on key safety analyses from ongoing long-term extension study 102 (including updated pooled safety analyses) as of 28 Feb 2023 were provided by the applicant in order to further inform long-term safety of tofersen.

The applicant's discussion of safety focuses on the comparison of safety in the active treatment group of 'pivotal' study 101 part C, receiving 100 mg tofersen (Pool RC1), with the respective placebo group (Pool RC2) as well as on Pool ABCL1, which includes all participants receiving 100 mg tofersen during study 101 and/or 102. This is considered appropriate, as 100 mg is the intended tofersen dose, constitutes the highest tofersen dose evaluated in the clinical studies and also the dose that the majority of patients received.

The vast majority (&gt;94%) of participants across the tofersen and placebo group of study 101 part C reported at least one TEAE, many of which were consistent with ALS or the LP procedure. However, the overview of safety revealed a higher incidence of AEs considered treatment related by the investigator in tofersen vs. placebo treated subjects (38.9% vs. 5.6%) and the severity of TEAEs by CTCAE grading tended to be higher in the tofersen 100 mg compared to the placebo group. In line with this, SAEs occurred with a somewhat higher frequency in tofersen vs. placebo subjects (18.1% vs. 13.9%). During longer exposure 66.7% subjects treated with tofersen 100 mg experienced treatment related AEs (Pool ABCL1) and the incidence of SAEs assessed as related by investigator in the overall 100 mg tofersen treated subjects (Pool ABCL1) was 6.8%.

The approach used by the applicant to identify adverse drug reactions (ADRs) is generally considered acceptable and took into consideration differences to placebo in the AE incidence from the 'pivotal' study, using a &gt;5% threshold based on the 2:1 randomisation and population size and causality assessment.

<div style=\"page-break-after: always\"></div>

In addition, medical review of additional AEs from the integrated safety data from Study 101 and Study 102 was performed to identify other potential ADRs, based on events related to nonclinical findings, investigator assessment of relatedness to study treatment and the LP procedure, the timing of events and the presence of a positive rechallenge.

The most common identified ADRs are pain (including the PTs pain, back pain, and pain in extremity; reported  in  66.0%  subjects  in  the  total  tofersen  Pool  ABCL1),  fatigue  (28.6%),  arthralgia  (34.0%), myalgia (19.0%), and CSF abnormalities (white blood cell increased and protein increased, reported in 26.5% subjects each) and these were all identified based on a &gt; 5% higher incidence in tofersen vs. placebo subjects in study 101 part C. In addition, pyrexia has been identified as an ADR due to positive rechallenge experiences in participants receiving tofersen and as pyrexia occurred in close proximity to timing of exposure in some subjects (i.e. pyrexia within 24 hours of tofersen administration occurred in 9.1% subjects in Pool ABCL1). Pyrexia was reported in 18.4% subjects in the total tofersen 100 mg population  (Pool  ABCL1),  overall,  no  pyrexia  event  was  severe  or  serious,  and  no  increase  in  the incidence of pyrexia with longer treatment duration was recognizable. Pyrexia is an ADR that is shared by multiple ASO drugs and may be mediated by an immune response to the ASO. Overall, 70 AEs related to pyrexia, that were considered treatment related by the investigator, were reported in 8 participants in the clinical trial database. In half of these latter subjects (4/8), a positive rechallenge was found with 6 to 25 multiple events. Nevertheless, no increase in severity of pyrexia is recognizable, as all related pyrexia events were grade 1 in severity. Also, in all of the patients with a positive pyrexia rechallenge no action was taken with study treatment as a result of the event and no precautionary measures for tofersen related pyrexia (e.g., antipyretics) were taken around the time of any pyrexia events. As more than half of the ABCL1 population developed positive ADA titres, it is considered reassuring that of the patients with multiple tofersen related pyrexia events, only two had positive ADA titers, whereas two patients had negative ADA status.

Irrespective  of  causality,  the  incidence  of  headache  was  comparable in  tofersen  vs.  placebo  treated subjects during study 101 part C (45.8% vs. 44.4%). Further evaluation revealed, that only 3/147 (4.1 %) of these patients had headache events considered related to tofersen treatment but not to the LP. Two of these subjects had a confounding medical history, in none of these subjects the tofersen dose was changed due to the event. Irrespective of headache as a frequent event after LP procedures or as a possible  symptom  of  the  identified  neuroinflammatory  adverse  reactions,  a  causal  relationship  of headache  with  tofersen  cannot  clearly  be  derived  from  the  available  data  and  separate  labelling  of headache as a tofersen related ADR is currently not warranted. Procedural pain was reported in more than half of the subjects of study 101 part C in both treatment groups (56.9% RC1 vs. 58.3% RC2). While  lumbar  punctures  are  frequently  associated  with  procedural  pain,  further  evaluation  of  the applicant  did  not  allow  for  firm  conclusions  regarding  a  causal  relationship  between  tofersen  and procedural pain, e.g. via local irritation.

Analyses of TEAEs, that occurred ≥ 5% more frequently within 24 hours of dosing in the tofersen vs. placebo group of study 101 part C indicate, that the identified ADRs of pain in extremity, back pain, myalgia, and fatigue, respectively frequently occur within 24 hours of tofersen administration. It is stated in the Clinical overview, that an analysis of events reported within 24 hours after dosing was performed to examine possible acute toxicities and revealed no safety concerns. However, a rather small imbalance was also found with regard to pruritis reported within 24 hours of study drug administration. As of the 15 Jul 2023, in the overall tofersen 100 mg pool (ABCL1), eight participants reported 15 AEs related to pruritus, rash, rash pruritic, dermatitis, and/or blister occurring within 24  hours  of tofersen administration. None of the 15 events was serious. Eight of these 15 AEs had no exact day of onset specified  and,  using  a  conservative  approach,  were  considered  of  onset  within  24  hours  of  tofersen dosing. Seven of the 15 events were considered related to treatment, however, none of these events let to tofersen discontinuation or dose modification. Overall, relevant AEs considered related to tofersen by

<div style=\"page-break-after: always\"></div>

the investigator with known onset within 24 hours of tofersen occurred only in a single subject and concerned pruritus at different locations of the lower body after the second last dose before the data cut with mild severity each.  A clear risk of tofersen for hypersensitivity reactions cannot be concluded at present. The applicant will continue to monitor for hypersensitivity reactions in the ongoing tofersen trial, EAP and in the post-marketing setting, which is endorsed.

It is considered reassuring, that analyses by 90 Day intervals revealed no apparent pattern in AEs or SAEs over time and no indication for an increase in specific AEs over time, respectively (as of 15 July 2022). Nevertheless, results need to be interpreted with caution due to considerably decreasing subject numbers with time in pool ABCL1.

Overall, as of 28 Feb 2023, 25 tofersen treated subjects died during the CDP, no death was assessed as treatment related by the investigator. During the controlled study parts, there was no clear imbalance in  fatal  events  between  tofersen  and  placebo  treated  subjects.  From  the  information  provided,  the majority of deaths in tofersen treated subjects during the CDP was consistent with and considered related to the known course of ALS. As of the 15 Jul 2022, 14 of 22 fatal AEs were in the respiratory, thoracic and mediastinal disorders SOC, including 12 cases of respiratory failure and 2 cases of respiratory arrest which were associated with ALS disease progression. Other fatal AEs by PT attributable to the underlying disease, or consequences thereof, included pneumonia aspiration, ALS, euthanasia, and septic shock. Of note,  regarding  this  latter  case,  the  fatal  event  occurred  more  than  one  month  after  the  last  IMP administration and the narrative is not indicative of an infection due to the LP. The cause of a fatal event of 'cardiopulmonary event' (PT) is also compatible with advanced ALS. Three subjects with fatal events of cardiac arrest, cardiac failure congestive, or sudden death, each had an increased risk of cardiac death based on their medical history and cardiovascular risk factors. From the available information on death cases, no safety signal arises. Three further participants of study 102 died between 15 Jul 2022 and 28 Feb 2023, with fatal AEs of respiratory failure, cardio-respiratory arrest and pneumonia aspiration in one subject each, none of which was considered related to tofersen.

Serious ADRs of myelitis and radiculitis, papilloedema and aseptic meningitis have been identified based on a higher incidence than would be expected in the study population, biological plausibility, and apart from papilloedema also correlation with non-clinical findings. All of these events occurred during the placebo-controlled study parts and were associated with CSF WBC and protein increase. These serious ADR are all consistent with nervous system inflammation that may be secondary to the proinflammatory effect of the ASO tofersen and may fall within the same spectrum of neuroinflammation, which is also supported by the finding, that some patients had more than one type of these serious ADRs. As of 28 Feb 2023, overall, 12 neuroinflammatory SAE were reported in 10 patients. However, although all of these serious ADR appear to involve the central nervous system (CNS), the neuroinflammation is not limited to the CNS in all events, as radiculitis would be considered a disorder of the peripheral nervous system.

Myelitis (including the PTs myelitis myelitis transverse, and neurosarcoidosis), radiculitis (including the PTs  radiculopathy,  and  lumbar  radiculopathy),  papilloedema  (including  the  PTs  papilloedema,  and intracranial  pressure  increased)  and  aseptic  meningitis  (including  the  PTs  aseptic  meningitis,  and meningitis chemical) are each proposed to be given in SmPC section 4.8 as common adverse events, which is endorsed. The incidences have been clarified as requested.

Each of these serious ADRs was associated with CSF pleocytosis and increased CSF protein, however, with  varying  degrees.  Since  the  vast  majority  of  subjects  in  pool  ABCL1  had  CSF  pleocytosis  and increased CSF protein, these CSF abnormalities are considered of less value for identifying patients at risk for serious neurological ADRs. The requested evaluation performed by the applicant did not identify any risk factors for these events, including (but not limited to) no clear association with duration of exposure, ADA status or titre, or age. In three of the 12 neuroinflammatory SAEs reported in the clinical

<div style=\"page-break-after: always\"></div>

studies, study treatment was interrupted, in two events study treatment was permanently discontinued. Two of  the  12  neuroinflammatory  SAEs  resolved  with  sequelae:  One  event  of  intracranial  pressure increased  (ICP)  had  ongoing  headache  and  visual  disturbance,  which  finally  led  to  study  treatment withdrawal. One event of radiculopathy resolved with continued study treatment after approximately 9 months with sequelae of CSF pleocytosis, elevated CSF protein, bilateral foot sensory loss, and loss of ankle jerk reflexes. A further SAE with the PT ICP increased was reported not resolved as of 28 Feb 2023, however, the clinical symptoms and papillary oedema had disappeared, while the CSF opening pressure was 25 cm H2O as of the most current value reported in Table 1 of the applicant's Response; no action was taken with study treatment in this event. The other 9 neuroinflammatory SAEs resolved (without clinical sequelae) despite no action taken with study treatment in 5 of these events. In studies 101 and 102, overall, five patients with SAEs associated with myelitis and radiculitis, respectively had inflammatory findings in the spinal MRI. In two of these patients, study treatment was administered while inflammatory findings were present, in two subjects, study treatment was discontinued or only resumed after imaging was improved, respectively, in one subject it remains unclear, whether study treatment was administered while inflammatory imaging findings were present.

As there was high variability in manifestations, courses and required action in these SAE cases, the applicant's position not to make specific recommendations in the SmPC in case of neuroinflammatory ADRs  can  be  agreed.  Instead,  diagnostic  evaluation  and  clinical  management  should  be  performed according  to  standard  of  care  and  the  consequences  regarding  tofersen  treatment  (i.e.,  treatment discontinuation, interruption or continuation) in case of neuro-inflammatory adverse reactions should be decided upon by the treating physician at the individual patient level.

All four patients with SAEs of papilloedema/increased ICP had typical symptoms such as headache or visual  disturbance  which  are  clinically  monitorable.  Therefore,  routine  measurement  of  the  opening pressure is  not  generally recommended with tofersen treatment. Nevertheless, an evaluation of the fundus of the eye before any LP is considered standard.

Irrespective of tofersen or placebo administration, the majority of study subjects experienced LP related events, i.e. 80.6% in either treatment group of study 101 part C. While some of the events considered 'LP procedure related events'  by the Investigators were reported only in the tofersen but not in the placebo group and have actually been identified as tofersen related events, established adverse events of  an  LP  procedure  (e.g.  procedural  pain,  post-lumbar  puncture  syndrome,  and  headache)  were frequently reported across both treatment groups, as expected, but are currently still not addressed in the proposed SmPC and should be implemented (see also attached documents).  During the clinical study program, one event of propionibacterium infection of the CSF was reported, that was related to the LP. The event was moderate and non-serious, however required intravenous antibiotic treatment for two weeks. Limited data on the event are available, however, no AEs suggestive of infectious complications (e.g. no meningitis) were reported in this subject. Apart from this, no events suggestive of a serious CNS infection and no SAE of (CNS) infection due to the LP was reported in the CDP. SmPC Section 4.4 has been amended to warn about the risk of CNS infection (amongst other established AEs of an LP procedure) and lumbar puncture related adverse reactions are also adequately presented in section 4.8 of the SmPC.

In tofersen treated patients, an increase in mean cerebrospinal fluid (CSF) leukocytes and mean CSF protein  was  found,  which  appeared  to  stabilize  at  greater  than  4  times  the  upper  normal  value  for leukocytes (i.e. at above 20 leukocytes x 10 6 /L after approx. 425 days) and at nearly twice the upper normal value for protein (i.e. at approx. 1000 mg protein/L after approx. 500 days) after approx. 500 days of continued tofersen exposure in each case. Although the vast majority of subjects in pool ABCL1 had upward shifts of CSF protein (90.6%) or leukocytes (90.8%), respectively, these were reported as TEAEs in less than half of the cases (as of 28 Feb 2023). While the serious neuroinflammatory ADRs were  all  associated  with  increased  CSF  leukocytes  and  protein,  CSF  abnormalities  per  se  were  not

<div style=\"page-break-after: always\"></div>

treatment limiting. An increase in CSF white blood cell counts and CSF protein, respectively was also found in the 9-months non-human primate studies.

As of 15 Jul 2022, no clear safety signals arose from other laboratory evaluations. With the absence of findings as of this date the applicant did not pursue focused investigations in the updated safety data as of 28 Feb 2023. There may be a minor imbalance with regard to clinically significant abnormalities in LFT parameters in tofersen vs. placebo treated subjects in study 101 part C, however these concerned total bilirubin &gt;1x ULN (but ≤ 1.5x ULN), ALT &gt;5 x ULN, AST &gt; 3x ULN and alkaline phosphatase &gt; 1. 5x ULN .  Similarly,  TEAEs, related to LFT parameters in the Investigations SOC occurred more commonly in tofersen subjects during study 101 part C. However, taking the overall data concerning LFT parameters into consideration, as well as low subject numbers and 2:1 randomisation, this may be due to a chance finding. In particular there were no meaningful mean or percent changes in LFT parameters over time, and across different LFT parameters there was no consistent higher incidences in shifts towards higher values in tofersen vs. placebo treated subjects. There were no cases of Hy's law, and apart from one SAE of cholecystitis (considered not related to treatment by Investigator), none of the AEs related to LFT parameters in the investigations SOC and of the AEs in the hepatobiliary disorders SOC was serious.

As of the 28 Feb 2023, the incidence of TEAEs related to LFT parameters in the investigations SOC as well as TEAEs in the hepatobiliary disorders SOC remained low and apart from one AE of mild AST and mild ALT increased as well as one moderate event of alkaline phosphatase increased, respectively, these were not considered related to treatment. Also, follow-up information and a causality assessment of these cases do not clearly indicate a causal relationship with tofersen. Ambiguities regarding LFT units were clarified and corrected during the procedure.

The available data derived from the tofersen CDP do not indicate a clear risk of thrombocytopenia, coagulation  abnormality  or  bleeding,  or  renal  toxicity.  However,  thrombocytopenia  and  coagulation abnormalities as well as renal toxicity have been observed after administration of some subcutaneously and intravenously administered ASOs. Based on class effects data, these risks can therefore not be excluded for tofersen and should be further followed. A respective warning has been added to SmPC section 4.4.

The significance of an imbalance found with regard to increases in QTc &gt;30 to 60 ms in tofersen vs. placebo subjects (11.3% vs. 5.6%) in study 101 part C is unclear. There was no increase in relative to placebo  control  in  the  incidence  of  cardiac  AEs  associated  with  delayed  ventricular  repolarisation  in tofersen treated patients. In routine ECG monitoring, an increase in QTc &gt; 60 ms, or QTc values &gt; 480 ms or &gt; 500 ms was not reported in this study part and was each reported in single subjects only of the total tofersen 100 mg population, and no AEs associated with these outlier values were reported (pool ABCL1, as of 15 Jul 2022). Also, in pool ABCL1 (as of 28 Feb 2023), AEs reported in the cardiac disorders SOC and in the investigations SOC related to ECG abnormalities, respectively were generally infrequent (&lt;3% by PT, apart from tachycardia reported in 3.4%) and were all considered unrelated to treatment. A hERG assay as well as the provided PK/PD modelling of QTc data from the clinical studies was not indicative of a proarrhythmic potential of tofersen, however the PK/PD modelling data are of limited value (as discussed in the Clinical pharmacology section).

Immunotoxicology  has  not  been  evaluated  in  the  preclinical  development  program.  However,  it  is acknowledged, that immune reactions in animals may be of questionable relevance for humans. As of 15 Jul 2022, approx. two thirds (63.3%) of the total tofersen 100 mg safety population (pool ABCL1) developed positive ADAs in plasma, the majority of which remained persistent (in 81.7% of ADA positive subjects). Analyses of TEAEs in selected SMQs (hypersensitivity, anaphylactic reaction, and angioedema) by  ADA  status  revealed  no  clearly  increased  risk  in  ADA  positive  patients.  These  data  need  to  be interpreted cautiously though, as the evaluated SMQs include several PTs, which frequently occur in ALS patients. Nevertheless, it is considered reassuring that of the patients with multiple tofersen related

<div style=\"page-break-after: always\"></div>

pyrexia events, only two had positive ADA titers, whereas two patients had negative ADA status. No impact of plasma anti-tofersen antibodies on the incidence of the serious neurological ADRs (myelitis, radiculitis, papilloedema, or aseptic meningitis) was observed, which occurred in 4 (2.7%) patients with ADA positive status and in 6 (4.1%) with negative ADA status in Pool ABCL1. There appears to be no documented evidence that ADAs are produced intrathecally. Consequently, any ADAs measured in CSF would require either very high plasma ADA titres or disruption of the BBB. Additional measurement of ADAs in CSF would therefore be of questionable value regarding safety. The applicant did not identify an impact of ADAs in plasma on tofersen efficacy based on limited data. Since ASOs bind to their RNA substrate within cells and thus will not compete with circulating antibodies, neutralising ADA assays are not relevant for ASOs in simple saline formulation and have not been developed. Nevertheless, circulating ADAs have the potential to alter the distribution and clearance of tofersen, which could further impact effectiveness. However, the finding of a 32.2% decrease of tofersen plasma clearance in the presence of ADAs is somewhat questionable because of unlikely results. Due to the high prevalence of ADAs, an additional safety analysis of overall safety (and not only of safety topics of interest) by ADA status is therefore not anticipated to provide relevant new safety insights.  The applicant plans to further evaluate the impact of ADAs on efficacy, on the incidence of serious neurological events and other areas of interest which may arise, in the ongoing clinical studies, which is endorsed.

In the provided subgroup analyses, it is striking, that in the overall tofersen 100 mg population (Pool ABCL1), CSF protein increased was reported as AE in 21/45 (46.7%) European vs. only 12/95 (12.6%) North American patients, and CSF WBC count increased was reported as AE in 12/45 (26.7%) European vs. 11/95 (11.6%) North American patients. Further evaluation indicates that this imbalance could be explained by differences in interpretation of CSF abnormalities, as the mean and median CSF WBC and protein values at baseline and across study visits were generally similar in European vs. North American patients. No clear differences in the risk of neuro-inflammatory SAEs by region were found. The provided subgroup analyses did not reveal any apparent differences in tofersen safety by age, sex, or ALS disease progression status, although subgroup analyses were generally limited due to the small subject numbers, and a higher risk of tofersen for more severe AEs (i.e. CTCAE grade ≥ 3 AEs, SAEs) in subjects with faster ALS progression cannot be excluded with absolute certainty. Also, data in older subjects is limited: The 'pivotal' study included only 9 tofersen and 5 placebo subjects ≥ 65 years, 20 subjects in the total tofersen 100 mg population were ≥ 65 years old, 2 of whom were ≥75 -78 years; and 22 subjects ≥ 65 years were exposed with any dose of tofersen. Further evaluation of older tofersen treated patients by additional age categories is therefore not anticipated to provide meaningful results. As use of tofersen is also considered relevant in patients ≥ 65 years given the underlying disease, appropriate information on the data limitations in older patients has been included in SmPC section 4.2. No meaningful subgroup analyses by race or site of ALS onset could be provided.

No dedicated human interaction studies with tofersen have been performed. The applicant's statement in  the  SCS  regarding  absence  of  noticeable  potentiation  of  common  side  effects  of  concomitant medications and absence of AEs suggestive of a potential drug-drug interaction is somewhat difficult to follow, as no details on these conclusions have been provided. Nevertheless, relevant interactions with concomitant medications used for sedation during the LP procedure would presumably occur with close temporal  relationship  of  tofersen  administration.  In  this  context  it  is  considered  reassuring,  that evaluation of AEs which occurred more frequently (≥ 5%) during the first 24 hours in the tofersen vs. placebo group of study 101 part C (pain in extremity, back pain, myalgia, and fatigue) does not raise clear concerns in this regard. 62% of the population of study 101 part C used concomitant riluzole, which is also associated with pain (common). Analyses of pain related AEs reported during study 101 part C did not clearly show a potentiation of pain related events in tofersen patients with concomitant riluzole.

A hypothetical potential for adverse effects attributable to SOD1 deficiency is derived from tofersen's mechanism of action. To date, findings in nonclinical and clinical studies of tofersen did not identify clear

<div style=\"page-break-after: always\"></div>

risks attributable to SOD1 deficiency. However, a 'toxic' threshold for reduced SOD1 protein and/or SOD1 enzymatic activity has not been identified and knowledge on SOD1 deficiency is sparse. Published case reports referenced by the applicant concern young children presenting with a neurodegenerative disorder  involving  progressive  loss  of  motor  function  and  spastic  tetraplegia.  Consequently,  there  is uncertainty, how SOD1 deficiency would present in (adult) ALS patients.

The updated data derived from the ongoing EAP (EAP; as of 28 Feb 2023) with an estimated number of up to 287 ALS patients treated with tofersen (of whom 67 may have been treated for one to two years) appear to be generally consistent with the safety profile derived from the clinical studies. In line with the serious ADRs of tofersen identified in the clinical studies, two related SAEs of myelitis ( one leading to permanent tofersen withdrawal and resolved with sequelae [weakness], one ongoing as of 28 Feb 2023), one related SAE of radiculopathy (outcome unknown as of 28 Feb 2023), 2 related SAEs of aseptic meningitis,  2  related  SAE  of  papilloedema  and  one  related  nonserious  AE  of  lumbar  radiculopathy (leading to permanent tofersen discontinuation, resolved within days) were reported. Among the AEs related to tofersen reported during the EAP, three events of 'intercept product dispensing error' are listed. The applicant clarified that the product dispensing errors occurred at the warehouse level due to a failure of the internal labeling procedures but not due to any similarity in the name, packaging, or appearance of the drugs concerned tofersen and anifrolumab, respectively. Therefore, changes to the packaging or labelling of the marketed version of tofersen are not considered warranted at present. Apart from this no clear new safety signal arises from the EAP. One SAE (PT) of intervertebral discitis was considered possibly related to tofersen by the HCP. A causal relationship of the event of intervertebral discitis with tofersen cannot be fully excluded, although the inflammatory process did not concern the nervous system. However, based on the patient's confounding medical history, the course of the event (resolved without sequelae) as well as the fact, that this was the only event of discitis in the EAP or the CDP, the applicant's proposal not to include intervertebral discitis at the present time but to monitor for additional events can be agreed. The patient in whom an SAE of visual hallucination was reported one day after the first tofersen administration, experienced further episodes within 30 hours of subsequent doses.  All  episodes  resolved  within  24  hours,  apparently  decreased  in  severity  with  subsequent administrations, improved  with anxiolytics and were  rather considered suggestive of anxious manifestations  and  assessed  as  probably  unrelated  to  tofersen  by  the  HCP.  A  single  event  of hallucination was reported in the CDP (cutoff date 28 Feb 2023), however this event was considered as mild, unrelated, and did not occur within 24 hours of dosing. Therefore, labelling of hallucination is currently not considered warranted by the CHMP.

## Additional safety data needed in the context of a MA under exceptional circumstances

The number of tofersen exposed subjects in the clinical studies (N=166) and, taking the difficulties of causality assessment in uncontrolled ALS studies into consideration, in particular the controlled exposure in the pivotal study (72 tofersen and 36 placebo patients) is rather limited.

The CHMP agreed on a data generation plan / SOBs so additional safety data could be generated during the post-authorisation phase (see also section 2.6.6 Discussion on clinical efficacy, Additional efficacy data needed in the context of MA under exceptional circumstances).

## 2.6.10. Conclusions on the clinical safety

Taken together, the safety profile of tofersen is considered acceptable.

The CHMP considers the following measures (SOB) necessary to address the missing safety data in the context of a MA under exceptional circumstances:

- 233AS102 An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics,

<div style=\"page-break-after: always\"></div>

and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation.

- 233AS401 An observational registry-based study to evaluate the long-term safety of tofersen in patients with SOD1-ALS.
- Submission of yearly  updates on any new information concerning the safety and efficacy of tofersen

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table 39: Summary of safety concerns

| Important identified risks   | • Myelitis and/or radiculitis • Increased intracranial pressure and/or papilloedema   |
|------------------------------|---------------------------------------------------------------------------------------|
| Important potential risks    | • None                                                                                |
| Missing information          | • None                                                                                |

## 2.7.2. Pharmacovigilance plan

Table 40: Summary of ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                              | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Safety concerns addressed                                                                                                                                                                                                 | Milestones                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                               | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 |
| • None                                                                                                                                                                                                                    | • None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | • None                                                                                                                                                                                                                    | • None                                                                                                                                                                                                                    | • None                                                                                                                                                                                                                    |
| Category 2 - Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                                                                                                                                                                               | Category 2 - Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| 233AS401 An observational registry- based study to evaluate the long-term safety of tofersen in patients with SOD1 ALS Status: Planned                                                                                    | Primary Objective: • Describe demographic and clinical characteristics of SOD1-ALS participants at baseline, and stratified by tofersen treatment status • Estimate the incidence of SAEs among all participants and stratified by tofersen treatment status, including serious neurologic events previously reported in clinical trial participants (e.g., myelitis, radiculitis, aseptic meningitis, increased intracranial pressure and/or papilloedema) Secondary Objectives: • Disease progression measured by the | • Myelitis and or radiculitis • Increased intracranial pressure and/or papilloedema                                                                                                                                       | • Protocol submission • Interim progress report* • Continued evaluation                                                                                                                                                   | Within 6 months after the EC decision on this MAA 12 months after the Agency's approval of the final protocol and annually thereafter. With annual reassessmen t                                                          |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                                    | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                       | Safety concerns addressed                                                           | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                 | ALSFRS-R as rate of change over time in total scores • Occurrence of relevant clinical outcomes including permanent ventilation and feeding tube placement as well as changes in pulmonary function measured by FVC and SVC • Variant-specific survival • Reports of new comorbid conditions, pregnancy and pregnancy outcome, and hospitalisations (including reason for hospitalisation) not reported as SAEs • Treatment discontinuation |                                                                                     |                                                               |                                                               |
| 233AS102 An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation Status: Ongoing | Primary Objective: • Evaluate the long-term safety and tolerability of BIIB067 in participants with SOD1-ALS. Secondary Objectives: • Evaluate the PK, PD, biomarker effects, and efficacy of BIIB067 administered to participants with ALS and confirmed SOD1 mutation.                                                                                                                                                                    | • Myelitis and or radiculitis • Increased intracranial pressure and/or papilloedema | • Final report                                                | 30 September 2025                                             |
| Yearly updates on any new information concerning safety and efficacy of tofersen Status: Planned                                                                                                                                                                                | In order to ensure adequate monitoring of safety and efficacy of tofersen in the treatment of patients with SOD1-ALS, the MAH shall provide yearly updates on any new information concerning the safety and efficacy of tofersen.                                                                                                                                                                                                           | • Any new information concerning safety and efficacy of tofersen                    | Annual report                                                 | Annually (with annual reassessmen t)                          |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                               | Category 3 - Required additional pharmacovigilance activities                       | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| • None                                                                                                                                                                                                                                                                          | • None                                                                                                                                                                                                                                                                                                                                                                                                                                      | • None                                                                              | • None                                                        | • None                                                        |

## 2.7.3. Risk minimisation measures

Table 41: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern              | Risk minimisation measures                                                                                                                                                  | Pharmacovigilance activities                                                                                                                                                                            |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks  | Important identified risks                                                                                                                                                  | Important identified risks                                                                                                                                                                              |
| Myelitis and/or radiculitis | Routine risk minimisation measures: • SmPC Sections 4.4 and 4.8. • PIL Sections 2 and 4. • Legal status: Prescription only medicine. Additional risk minimisation measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • DCT for collection of additional information relating to reported events of myelitis and/or radiculitis |

<div style=\"page-break-after: always\"></div>

| Safety concern                                      | Risk minimisation measures                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                                                                                                                        |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                     | • None                                                                                                                                                                            | Additional pharmacovigilance activities: • Study 233AS102 • Study 233AS401                                                                                                                                                                                          |
| Increased intracranial pressure and/or papilloedema | Routine risk minimisation measures: • SmPC Sections 4.4 and 4.8. • PIL Sections 2 and 4. • Legal status: Prescription only medicine Additional risk minimisation measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • DCT for collection of additional information relating to reported events of papilloedema Additional pharmacovigilance activities: • Study 233AS102 • Study 233AS401 |
| Important potential risks                           | Important potential risks                                                                                                                                                         | Important potential risks                                                                                                                                                                                                                                           |
| None                                                | None                                                                                                                                                                              | None                                                                                                                                                                                                                                                                |
| Missing information                                 | Missing information                                                                                                                                                               | Missing information                                                                                                                                                                                                                                                 |
| None                                                | None                                                                                                                                                                              | None                                                                                                                                                                                                                                                                |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

The applicant is reminded that in case of a Positive Opinion, the body of the RMP and Annexes 4 and 6 (as applicable) will be published on the EMA website at the time of the EPAR publication, so considerations should  be  given  on  the  retention/removal  of  Personal  Data  (PD)  and  identification  of  Commercially Confidential Information (CCI) in any updated RMP submitted throughout this procedure.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 25 April 2023

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Labelling exemptions

A request to omit certain particulars from the labelling as per Art.63.3 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable by the QRD Group for the following reasons:

- Due to the limited space on the immediate label (vial of 20ml size), the QRD group accepted the omission of the full and allowed the use of minimum particulars applicable for small immediate packaging units.

## 2.9.3. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Qalsody (tofersen) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

ALS is a relentlessly progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death, with a median survival of three to five years.

Historically, ALS was identified as a clinical syndrome distinguishable from other motoneuron diseases such as primary lateral sclerosis, primary muscular atrophy, and progressive bulbar palsy, based upon the location of first symptom and the extent to which anterior horn cells or corticomotor neurons are initially  involved.  However,  it  is  increasingly  evident  that  ALS  is  clinically  and  pathophysiologically diverse.

Since 1993, mutations in more than forty genes are linked to ALS, the most frequent are those in the SOD1 gene encoding the essential antioxidant enzyme copper zinc superoxide dismutase. SOD1-ALS is a primarily autosomal-dominant disorder representing approximately 2% of the ALS population. The distribution  of  SOD1  mutations  differs  markedly  even  among  apparently  similar  populations  (i.e., Netherlands and Belgium, Ireland and England) and the same mutations in different populations can be associated with distinct clinical presentations. The clinical phenotype is highly variable and patients with

<div style=\"page-break-after: always\"></div>

a particular SOD1 mutation show intrafamilial differences in the severity of symptoms and the speed of disease progression. The median survival time appears to be 2.3 years (Opie-Martin 2022).

## 3.1.2. Available therapies and unmet medical need

A treatment for SOD1-ALS has not been approved yet. Also, for ALS in general, the only treatment approved in Europe is riluzole, which was shown in 1996 (EU) to prolong survival based on 2 studies that demonstrated that the time to tracheostomy or death was prolonged for approximately 2 months in participants receiving riluzole compared to those receiving placebo.

The intended patient population for treatment with tofersen is SOD1-ALS.

## 3.1.3. Main clinical studies

The applicant has completed study 233AS101, consisting of phase 1/2 parts A and B and phase 3 part C. Part C of study 101 is intended to support the efficacy and safety of tofersen together with the OLE study 233AS102 (further referred to as study 102).

Study 101 Part C was a Phase 3, randomized, double-blind, placebo-controlled study comparing tofersen 100  mg  administered  by  intrathecal  bolus  injection  with  placebo.  A  total  of  108  participants  with weakness attributable to ALS and a confirmed SOD1 mutation were randomized 2:1 to receive tofersen or placebo for approximately 28 weeks (3 loading doses followed by 5 maintenance doses).

Study 102 is an ongoing, multicenter, open-label, long-term extension study to assess the long-term safety, tolerability, PK, PD, and efficacy of tofersen administered by IT injection to participants with SOD1-ALS who completed Part C of Study 233AS101. Of the 159 eligible participants who completed Study 101, a total of 139 participants enrolled from Study 101 Parts A, B, and C: 44 participants enrolled from Study 101 Parts A and B and 95 participants enrolled from Part C.

## 3.2. Favourable effects

In study 101 Part C, a robust reduction in total CSF SOD1 protein was observed at Week 28 in the tofersen  group  compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 38% and nominal p &lt;0.0001) in the mITT population. Also, in the ITT population, a reduction in total CSF SOD1 protein was observed at Week 28 in the tofersen group compared to the placebo group (difference in geometric mean ratios for tofersen to placebo of 34% and post-hoc nominal p &lt; 0.0001).

Reduction in plasma NfL levels from baseline to Week 28 was observed in both populations (mITT and non-mITT), with a 67% reduction (difference in geometric mean ratios for tofersen to placebo) and nominal p &lt; 0.0001 in the mITT population. In the ITT population this difference in geometric mean ratios for tofersen to placebo was 60% ( post hoc nominal p &lt; 0.0001). Robust reductions (60-70%) in plasma and CSF NfL from baseline were maintained up to week 104.

With respect to the primary analysis for the change in ALSFRS-R total score over 28 weeks as the primary endpoint, a statistically non-significant difference of 1.2 points was found in favour of tofersen in the mITT population using JRT in conjunction with MI for withdrawals other than death (p=0.9689). Post hoc analyses performed in the overall ITT population, adjusting for baseline NfL as a covariate rather than disease duration and including it also as part of the imputation model, showed a 2.1-point treatment difference in favor of tofersen with greater statistical differentiation, but without reaching significance (95% CI: -0.33, 4.54; JRT+MI nominal p = 0.5015; ANCOVA+MI nominal p = 0.0904).

<div style=\"page-break-after: always\"></div>

Similar trends favouring tofersen treatment at week 28 were observed for SVC, HDD megascore and PROs such as ALSAQ-5, FSS, ED-5D-5L.

With respect to survival, time to death or PV and time to death were assessed as key secondary endpoints in  Study 101  Part C.  In  the  mITT  population,  a  similar  proportion  of  participants  in  the  placebo  (2 participants [9.5%] with events of permanent ventilation) and tofersen groups (4 participants [10.3%] - 1 death due to congestive heart failure and 3 events of permanent ventilation) experienced events of death or permanent ventilation. No events occurred in the non-mITT population.

The analysis of the pooled double-blind data from study Part C and the open-label data from study 102 LTE at week 52 and 104 showed consistent results. Numerical differences favoring early-start tofersen (as  compared  with  delayed-start  tofersen)  were  also  observed  by  week  52  across  clinical  outcome measures.  For function on ALSFRS-R there was a difference of 2.3 points (95% CI -1.26, 5.82, nominal p=0.21) not adjusted for NfL (but for disease duration as originally prespecified). Values adjusted for NfL using a post-hoc analysis were: ALSFRS-R: 3.5-point difference (95% CI 0.40, 6.69; nominal p = 0.0272).

Nominally  statistically  significant  differences  between  early  treatment  tofersen  and  placebo/delayed treatment tofersen were also observed for SVC and HDD megascore to week 52 for the ITT population using a post-hoc analysis with baseline plasma NfL as a covariate. Results were for respiratory strength SVC:  9.2  percent-predicted  difference  (nominal  p  =  0.0159),  for  muscle  strength  HHD  megascore: 0.28 difference (nominal p = 0.0186) and for PROs of disease severity and quality of life ALSAQ-5: -10.3 difference (nominal p = 0.0044); FSS: -3.8 difference (nominal p = 0.1493); EQ-5D-5L: 0.2 difference (nominal p &lt; 0.0001).

The applicant presented an analysis (3 rd  interim) with an additional year of follow-up (28 February 2023 data cut, 104 weeks), comparing early start tofersen with delayed start. For the change from baseline in ALSFRS-R at week 104, the difference between groups was 3.7 (CI 95% -0.7, 8.2 and nominal p value of 0.1004), i.e. almost the same difference as observed after 52 weeks. A high percentage of tofersentreated participants experienced sustained stabilisation or even improvement in function, which is clearly inconsistent with the natural history of the progressive disease.

Although the decline in ALSFRS-R is not always linear, it is estimated that people living with ALS decline by an average of approximately 1 point per month. Participants in Studies 101 Part C and 102 lost 9.5 and  13.2  points  (adjusted  mean  on  ANCOVA+MI)  over  24  months  in  the  tofersen  early-start  and placebo/delayed-start groups, respectively, which is not consistent with the natural course of the disease.

These data in the CL population (Study 101 Part C and Study 102) appear consistent with observations for the patients from the Study 101 Parts A and B, who continued in Study 102, received at least 1 dose of tofersen (N=40) (ABL Cohort) and for whom disease progression has essentially been stabilized for over 3 years of follow-up. These participants experienced a mean change from Study 102 baseline to Week 168 (~3.2 years) of -2.3 points on ALSFRS-R, -2.4 on percent-predicted SVC, and -0.1 on HHD megascore.

In the early-start tofersen group, 19.5% of participants experienced improvement on the ALSFRS-R and 29.3% had stabilisation  or  improvement  over  104  weeks.  In  the  case  of  the  placebo/delayed  start tofersen treatment group, 11.6% showed improvement and 22.7% had stabilisation or improvement over 104 weeks.

Under the Raw Data Pilot project, a new event analysis was defined as change from baseline in ALSFRSR total score with a deterioration greater than 10 points (&lt; -10), 21 days of permanent ventilation assistance or death at any time point up to Week 124 (~17 months). A hazard ratio for this event analysis was calculated 0.70 (0.375-1-.309) and when adjusted for log(baseline NfL), the HR was 0.46 (0.241-0.883). The HR calculated by the applicant for time to death or PV was 0.47 and for time to

<div style=\"page-break-after: always\"></div>

death, PV, or withdrawal due to disease progression HR was 0.50. These analyses indicated a better outcome  for  the  patients  with  early  tofersen  treatment,  especially  when  baseline  NfL  is  taken  into account, indicating an association of NfL and detrimental effect in patients' condition.

Survival  was  numerically  in  favour  for  early  start  tofersen.  An  extended  duration  of  follow-up  from baseline to 3.4 years showed that the majority of patients remain alive on-study, since the number of death-equivalent events were limited. The range of follow-up from 2.2 to 3.9 years exceeds the 2.3 years median survival for SOD1-ALS characterized in the literature. The survival benefit in the earlystart participants, relative to the delayed-start participants, is unlikely to be attributed to enrolment of individuals with more slowly progressing disease.

A5V variant carriers, albeit being well studied and well characterised, are known to be associated with a median disease duration of approximately 1 to 1.2 years [Bali 2017; Opie-Martin 2022]. From a small subset of the participants in study 101 Part C and 102 who are A5V carriers (n=17), the median duration from ALS symptom onset to death or censoring was 1.9 years (range: 0.9 to 4.8 years) in the earlystart group and 1.3 years (range: 0.7 to 2.9) in the delayed-start group, with 3 A5V carriers ongoing as of the data cut off. This is not in line with the usual disease progression course of A5V carriers and indicates  a  potential  tofersen  treatment  benefit,  but  uncertainties  due  to  small  sample  size  and limitations of comparisons against historical controls should be also taken into account.

Cumulative  distribution  function  analysis  of  ALSFRS-R  changes  from  baseline  at  Weeks  52  and  104 reflects the probability of worsening defined by change from baseline in ALSFRS-R being less than the cut-off value, taking into consideration treatment discontinuation due to death, progressive disease, AE, and other subject withdrawal as the worst outcome. For a cutoff of -12, the rates of worsening in ALSFRSR are approximately 32% and 44% for the early-start tofersen group and the placebo/delayed-start tofersen group, respectively. These show that participants in the placebo/delayed-start group tend to have a higher  rate  of  worsening  in  ALSFRS-R  at  Week  52.  Overall,  the  CDF  analysis  for  ALSFRS-R supports the tofersen treatment effect with regards to a higher responder proportion at Weeks 52 and 104. However, the post hoc and descriptive nature of the analysis (including not showing uncertainty such as confidence intervals) need to be taken into account.

A consistency in the clinical measures results with trends in favour of tofersen treatment over time, over 104 weeks, is clearly observed. Even if some of the analyses rely heavily on strong assumptions, the results are not contradictory to the tofersen treatment effect.

The results from the Part A/B participants (ABL) should be interpreted with caution due to the significant washout  periods,  variable  dosing  history,  and  the  more  slowly  progressing  nature  of  their  disease. However, even in slower-progressing SOD1 -ALS patients, the disease is associated with progressive declines  in  strength  and  function.  These  participants  have  experienced  an  apparent  stabilisation  of function and strength over more than 3 years of follow-up, with a reduction of only 2.3 in ALSFRS-R total score over 168 weeks (approximately 39 months).

The applicant has submitted a supportive data generation plan and specific obligations for a MAUEC, which includes the conclusion of studies 102 LTE and 303 (ATLAS), registry-based study 233S401 and collaboration  with  ALS-NHC  (primarily  US-based)  and  TRICALS  /European  sites).  The  applicant  has provided all information on study 303 available up to 26 June 2023. Study 303 is well in progress with over 68% of the planned presymptomatic at-risk carriers of SOD1 mutation already enrolled.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

No statistically significant difference between tofersen and placebo groups was observed on the primary analysis of ALSFRS-R change from baseline to Week 28 in the primary analysis (mITT) population. Hence, study 101 Part C failed to provide confirmatory evidence of efficacy in SOD1-ALS.

There  is  large  heterogeneity  with  several  variants  with  very  diverse  characteristics  in  a  very  small proportion (~2%) of ALS patients with the SOD1 mutation. However, baseline characteristics regarding variants are not considered to have favoured the tofersen group.

It is acknowledged that the prognostic and predictive value of NfL in ALS is not fully established yet and NfL cannot be considered as a validated surrogate endpoint for predicting efficacy. However, NfL is being used in most of the clinical trials in ALS and it is currently recognised as an important and reliable biomarker for neurodegeneration in ALS (Thompson et al 2022, Brousse et al 2023, Jiang et al 2022, Mead et al 2023, McCluskey et al 2023 and Sanchez-Tejerina et al 2023). The clinical relevance of treatment-driven reductions in neurofilament is supported by a significant body of literature. NfL may not only be a prognostic marker in ALS but also a marker for prediction of clinical response. The majority of the SAG-N experts considered that NFL levels can be used for predicting a clinical effect in patients with ALS at least on a cohort level. There is uncertainty in this prediction mainly due to the timelines time since the NFL change to the occurrence of the clinical effect - and the potential of  prediction of a clinically relevant effect because there is no clear definition on what constitutes a clinically relevant effect in ALS (e.g., a threshold of change in a clinical scale) besides a change in survival which is considered as clinically relevant by all SAG-N experts.

NfL cannot be considered as a validated surrogate endpoint for predicting efficacy in ALS for the time being. However, there is a strong biological plausibility (supported by nonclinical data), that the lowering of toxic SOD1 exerts disease-modifying effects of tofersen, which can be pharmacodynamically measured by an appropriate neurodegeneration biomarker, NfL. A number of literature publications consistently show  that  neurofilament  levels  are  prognostic  for  disease  progression  and  survival  in  ALS.  These reductions  in  SOD1  protein  and  consequently  NfL  could  not  be  translated  immediately  into  clear differences  in  ALSFRS-R  and  other  clinical  outcome  measures,  indicating  a  potential  delay  in  the treatment effect. Similar observations have been made in cases with other ASOs (milasen and jacifusen). It should be pointed out that baseline plasma NfL levels were approximately 23% higher in the early-start group than in the placebo/delayed-start group. This suggests that the early-start tofersen group was at a higher risk for faster disease progression and shorter survival compared to the placebo/delayed-start tofersen treatment group. These higher plasma NfL levels in the early start group were not in favour of tofersen treatment.

After the analysis FDA performed with the difference between groups in the change from baseline to week 28 in ALSFRS-R and plasma NfL levels, a correlations exploration was performed in the EMA Raw Data Pilot Project. In this exploration weak correlations were observed between the change from baseline to week 28 in ALSFRS-R and plasma NfL levels at certain tome points. Clarifications for the correlations between  NfL  and  clinical  function  and  potential  discrepancies  have  been  provided.  The  relationship between  the  reduction  in  NfL  and  clinical  function  cannot  be  adequately  assessed  using  correlation coefficients without adjustment for baseline NfL, as this approach does not take into account variable natural disease progression across participants. It is acknowledged that the partial correlations presented by the applicant are in line with the hypothesis of a relationship between changes in NfL and clinical outcomes.

The  observed  effects  in  important  secondary  endpoints  in  study  101  Part  C  were  statistically  nonsignificant, but showed consistency over a period of time at weeks 28, 52 and 104.

<div style=\"page-break-after: always\"></div>

With respect to survival the numbers are too low for the duration of the placebo-controlled study 101 Part C (28 weeks) to allow any firm conclusions.

When combining double-blind data from study 101 Part C and uncontrolled data from study 102 LTE, a nominally statistically significant difference of 3.5 (p=0.0272) in the change of ALSFRS-R from baseline to  week  52  between  early  and  placebo/delayed  start  tofersen  group  was  observed  with  a  post-hoc analysis after baseline NfL adjustment. However, there is considerable uncertainty on the size of the potential treatment effect, which cannot be reliably quantified based on the available controlled and uncontrolled data.

At week 104 there were 5 (13.9%) deaths in the placebo/delayed start tofersen group and 8 (11.1%) in the early start tofersen group, leading to comparable percentages. The applicant has performed analyses for three different time to event endpoints: Time to death or PV, Time to death, Time to death or PV or withdrawal due to disease progression and calculated the respective Hazard ratios. For time to event endpoints with events 'death or PV', 'death' and 'death, PV or withdrawal due to disease progression', Cox regression including NfL as covariate showed HRs of 0.47 (95% CI (0.20,1.11)), 0.36 (95% CI (0.13,1.02)) and 0.50 (95% CI (0.25,0.99)), respectively, at the latest data cut-off. However, the overall number of events (deaths or PV) at the latest data cut-off (28 February 2023) is small, despite that strong assumptions were made for analysis.

It is acknowledged that comparisons to natural history or the natural course of the disease are difficult to interpret because this requires that natural history is characterized with high certainty, which may not be the case in this heterogeneous population.

## 3.4. Unfavourable effects

Immunostimulatory and proinflammatory effects have been associated with ASOs in multiple preclinical species and in humans. In the tofersen CDP, serious neuroinflammatory adverse reactions were identified with no occurrence in the placebo group of study 101 Part C. The incidence was higher than would have been expected for the study population and the biological plausibility.  Some patients experienced more than one type of neuroinflammatory ADR. Apart from papilloedema, the identified neuroinflammatory events correlated with non-clinical findings. All these events were associated with increased CSF white blood cells and CSF protein of varying degrees and included:

## Myelitis and radiculitis

Myelitis (PTs myelitis, myelitis transverse, and neurosarcoidosis) and radiculitis (PTs radiculopathy and lumbar radiculopathy) occurred in 6 participants. All events of myelitis were SAEs. No pattern with regard to number of tofersen doses received before the onset of these SAEs was found (range after 1st to 24th dose). Two subjects with ADRs of myelitis received immunomodulatory therapy, however, one subject had a history of neurosarcoidosis. Two events of myelitis were asymptomatic and diagnosed based on imaging  and  or  laboratory  findings.  Overall,  five  patients  with  SAEs  of  myelitis  or  radiculitis  had inflammatory  findings  in  the  spinal  MRI.  In  two  of  these  patients,  tofersen  was  administered  while inflammatory findings were present, in two subjects, tofersen was discontinued or only resumed after imaging was improved, respectively, in one subject no information was available in this regard. In two of  four  SAEs  of  myelitis  and  in  both  SAEs  of  radiculopathy,  tofersen  was  maintained.  Associated symptoms of all SAES of myelitis/radiculitis resolved within days to months, although in one subject the SAE of radiculopathy was considered resolved with sequelae of bilateral foot sensory loss after a long period (9 months).

<div style=\"page-break-after: always\"></div>

## Papilloedema

In pool ABCL1 (as well as in the total CDP) 4/147 subjects reported SAEs related to papilloedema (PTs papilloedema, and intracranial pressure increased); in addition, non-serious events of papilloedema, ICP increased and CSF pressure increased were reported with an overall incidence of papilloedema of 8/147 subjects (5.4%). All four SAEs were symptomatic with headache in all and visual disturbances in three subjects concerned, and all four SAEs demonstrated papilloedema as a feature, which however was not always present at the beginning of the event. One SAE of papilloedema/increased ICP resolved with sequelae of improved but ongoing symptoms, which led to permanent tofersen discontinuation (after tofersen interruption and subsequent bimonthly dosing). One SAE was not resolved as of 28 Feb 2023 with  unchanged  tofersen  treatment;  however,  the  clinical  symptoms  and  papillary  oedema  had disappeared. Two SAEs resolved without sequelae after approx. 7 and 8 months, respectively, in one case  no  action  was  taken  with  tofersen,  in  the  other,  treatment  with  tofersen  was  interrupted. Treatment of SAEs of papilloedema/ICP increased included amongst others long-term treatment with acetazolamide in several subjects, and IV methylprednisolone with tofersen dosing visits in one subject.

## Aseptic meningitis

In the CDP, 6 patients experienced aseptic meningitis (PTs meningitis chemical or aseptic meningitis), these events were serious in 2 and non-serious in 4 subjects. Both SAEs of aseptic meningitis were associated with typical symptoms and negative microbial studies. Both SAEs resolved, after 10 days in a subject, in whom study treatment was permanently discontinued, and after less than 4 weeks in a subject, in whom study treatment was maintained.

In  tofersen  treated  patients,  a  mean  increase  in  CSF  leukocytes  and  CSF  protein  was  found,  which appeared to stabilize each after approx. 500 days of treatment with continued tofersen exposure at above the four-fold of the upper normal value for leukocytes (i.e. at above 20 leukocytes x 106/L after approx. 425 days) and at nearly twice the upper normal value for protein (i.e. at approx. 1000 mg protein/L after approx. 500 days). In the total tofersen 100 mg population (Pool ABCL1), 26.5% subjects each reported AEs of CSF WBC increased or CSF protein increased, respectively. Per se these were not treatment limiting.

Apart from CSF abnormalities, the most common adverse drug reactions are pain (including the PTs pain, back pain, and pain in extremity; reported in 66.0% subjects in the total tofersen pool ABCL1), fatigue (28.6%), arthralgia (34.0%), and myalgia (19.0%), respectively, which were all identified based on a &gt; 5% higher incidence in tofersen vs. placebo subjects in study 101 part C. Analyses of TEAEs reported ≥ 5% more frequently within 24 hours of dosing in the tofersen vs. placebo group of study 101 part C indicate, that the identified ADRs of pain in extremity, back pain, myalgia, and fatigue, respectively frequently occur within 24 hours of tofersen administration.

In addition, pyrexia was identified as an adverse reaction due to positive rechallenge experiences in participants receiving tofersen and as pyrexia occurred in 9.1% subjects within 24 hours of tofersen administration in Pool ABCL1. Pyrexia was reported in 18.4% subjects in the total tofersen 100 mg population (Pool ABCL1), overall, no pyrexia event was severe or serious, and no increase in the severity of pyrexia with longer treatment duration was recognizable. In all of the patients with a positive pyrexia rechallenge no action was taken with study treatment as a result of the event and no precautionary measures for tofersen related pyrexia (e.g., antipyretics) were taken around the time of any pyrexia events. Of the patients with multiple tofersen related pyrexia events, only two had positive ADA titers, whereas two patients had a negative ADA status. Pyrexia is an ADR that is shared by multiple ASO drugs and may be mediated by an immune response to the ASO.

<div style=\"page-break-after: always\"></div>

Lumbar puncture (LP) procedures are associated with known risks (e.g. procedural pain, post-lumbar puncture syndrome, and headache) and 80.6% of subjects in either treatment group of study 101 part C experienced LP related events. During the clinical study program, one LP related, non-serious event of propionibacterium  infection  of  the  CSF  was  reported,  that  was  of  moderate  severity  and  required intravenous antibiotic treatment for two weeks. Apart from this, no events suggestive of a serious CNS infection and no SAE of (CNS) infection due to the LP was reported in the CDP. SmPC Section 4.4 was amended to warn about the risk of CNS infection (amongst other established AEs of an LP procedure) and lumbar puncture related adverse reactions have been adequately implemented in section 4.8 of the SmPC.

As of 15 Jul 2022, 63.3% of the total tofersen 100 mg safety population (pool ABCL1) developed positive ADAs in plasma, the majority of which remained persistent (in 81.7% of ADA positive subjects). Serious neurological  ADRs  (myelitis,  radiculitis,  papilloedema,  or  aseptic  meningitis),  occurred  in  4  (2.7%) patients with ADA positive status and in 6 (4.1%) with negative ADA status (Pool ABCL1).

As of the updated cut-off date of 28 Feb 2023, an estimated number of 287 patients have been treated with tofersen during an ongoing EAP, 67 of whom may have received tofersen for at least one year. The data derived from the EAP appear to be generally consistent with the safety profile derived from the clinical studies. Among the AEs related to tofersen reported during the EAP, three events concerned 'intercept product dispensing error'. However, the applicant clarified, that the product dispensing errors occurred at the warehouse level due to a failure of the internal labelling procedures but not due to any similarity  in  the  name,  packaging,  or  appearance  of  the  drugs  concerned  tofersen  and  anifrolumab, respectively. Therefore, changes to the packaging or labelling of the marketed version of tofersen are not considered warranted at present.

## 3.5. Uncertainties and limitations about unfavourable effects

The safety profile of tofersen is based on a limited number of exposed patients (147 SOD1-ALS patients have received at least 1 dose of 100 mg tofersen, the intended and highest evaluated dose), and on a limited controlled exposure in study 101 part C considered pivotal for this application (i.e. 72 tofersen and 36 placebo subjects treated for 24 weeks). However, with the updated safety data as of 28 Feb 2023, long-term treatment is nevertheless available from 116 (95) patients having received 100 mg tofersen for at least one (two) year(s) with a maximum treatment duration of 245 weeks.

A clear risk of tofersen for hypersensitivity reactions cannot be concluded at present. The applicant will continue to monitor for hypersensitivity reactions in the ongoing tofersen trial, EAP and in the postmarketing setting.

The significance of an imbalance found with regard to increase in QTc &gt;30 to 60 ms in tofersen vs. placebo subjects (11.3% vs. 5.6%) in study 101 part C is unclear. There was no increase in relative to placebo  control  in  the  incidence  of  cardiac  AEs  associated  with  delayed  ventricular  repolarisation  in tofersen treated patients. In routine ECG monitoring, an increase in QTc &gt; 60 ms, or QTc values &gt; 480 ms or &gt; 500 ms was not reported in this study part and was each reported. Also, in pool ABCL1 (as of 28 Feb 2023), AEs reported in the cardiac disorders SOC and in the investigations SOC related to ECG abnormalities, respectively were generally infrequent (&lt;3% by PT, apart from tachycardia reported in 3.4%) and were all considered unrelated to treatment. A hERG assay as well as the provided PK/PD modelling of QTc data from the clinical studies was not indicative of a proarrhythmic potential of tofersen.

Analyses of TEAEs in selected SMQs (hypersensitivity, anaphylactic reaction, and angioedema) by ADA status revealed no clearly increased risk of these events in ADA positive patients. However, these data are limited as there is overlap between the PTs of the evaluated SMQs and frequent ALS symptoms. Limited data (including PK/PD modelling of SOD1 protein and NfL) also did not identify an impact of ADAs

<div style=\"page-break-after: always\"></div>

in plasma on tofersen efficacy. The applicant plans to further evaluate the impact of ADAs on efficacy as well as on the incidence of serious neurological events and other areas of interest, which may arise in the  ongoing  clinical  studies,  which  is  endorsed.  The  provided  subgroup  analyses  did  not  reveal  any apparent  differences  in  tofersen  safety  by  age,  sex,  or  ALS  disease  progression  status,  although subgroup analyses were generally limited due to the low subject numbers, and a higher risk of tofersen for more  severe  AEs  (i.e.  CTCAE  grade  ≥  3  AEs,  SAEs)  with  tofersen  in  subjects  with  faster  ALS progression cannot be excluded with absolute certainty. A higher reporting rate of AEs of CSF protein increased in  European vs. North American patients (46.7% vs. 12.6%) and also of CSF WBC count increased (26.7% vs. 11.6%) could be explained by differences in interpretation of CSF abnormalities, as the mean and median CSF WBC and protein values at baseline and across study visits were generally similar in European vs. North American patients. No clear differences in the risk of neuro-inflammatory SAEs by region were found.

A causal relationship of one event of intervertebral discitis, that was reported during the Expanded Access Program, with tofersen cannot be fully excluded, although the inflammatory process did not concern the nervous system. However, the patient had a confounding medical history, the event resolved without sequelae  and  based  on  the  fact,  that  this  was  the  only  event  of  discitis  in  the  EAP  or  the  CDP, intervertebral discitis is not included to SmPC section 4.8 at the present time and the applicant will monitor for additional events.

The available data for tofersen do not indicate a clear risk of thrombocytopenia, coagulation abnormality or bleeding, or renal toxicity. However, thrombocytopenia, coagulation abnormalities as well as renal toxicity have been observed after administration of some subcutaneously and intravenously administered ASOs. Based on class effects data, these risks cannot be excluded for tofersen and should be further followed. A respective warning has been added to SmPC section 4.4.

Hydrocephalus was not reported during the tofersen  CDP so far.  However,  hydrocephalus has been reported with intrathecally administered ASOs  (nusinersen and tominersen) and the risk of hydrocephalus should be further followed.

## 3.6. Effects Table

Table  42:  Effects  table  for  Qalsody;  treatment  of  adults  with  amyotrophic  lateral  sclerosis  (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene] (data cut-off:28 Feb 2023).

| Effect                                | Short Description                                                                                                                                        | Unit               | Treatment             | Control              | Uncertainties/ Strength of evidence                                          | Referenc es        |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------|----------------------|------------------------------------------------------------------------------|--------------------|
| Favourable Effects                    | Favourable Effects                                                                                                                                       | Favourable Effects | Favourable Effects    | Favourable Effects   | Favourable Effects                                                           | Favourable Effects |
| Predefined ALSFRS-R change to week 28 | ALSFRS-R change from baseline to week 28 for the predefined mITT (faster progressing subgroup)                                                           | point              | Tofersen (n=72) -6.98 | Placebo (n=36) -8.14 | UnCert: difference 1.2 (CI - 3.2, 5.5), p-value (Joint rank+MI) 0.9689       | Study 101 Part C   |
| ALSFRS-R change to week 28 Post hoc   | ALSFRS-R change from baseline to week 28 - Post hoc analyses with baseline plasma NfL as a covariate (from Study 101 Part C Baseline - I Τ T population) | point              | Tofersen (n=72) -4.10 | Placebo (n=36) -6.20 | UnCert: difference 2.1 (CI - 0.3, 4.5), Nominal p-value (ANCOVA + MI) 0.0904 | Study 101 Part C   |

<div style=\"page-break-after: always\"></div>

| Effect                                         | Short Description                                                                                                                                        | Unit                 | Treatment                         | Control                                                      | Uncertainties/ Strength of evidence                                                                                                                                                                                                  | Referenc es                               |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| ALSFRS-R change to week 52 Post hoc            | ALSFRS-R change from baseline to week 52 - Post hoc analyses with baseline plasma NfL as a covariate (from Study 101 Part C baseline - I Τ T population) | Point                | Tofersen early start (n=72) -6.00 | Placebo/D elayed start tofersen (n=36) -9.50                 | SoE: difference 3.5 (95% CI 0.4, 6.7), p-value (ANCOVA+MI) 0.0272 UnCert: pooling of double blind and uncontrolled data                                                                                                              | Studies 101 Part C and 102 (ISE SAP V3.0) |
| ALSFRS-R change to week 104 Post hoc           | ALSFRS-R change from baseline to week 52 - Post hoc analyses with baseline plasma NfL as a covariate (from Study 101 Part C baseline - I Τ T population) | Point                | -9.5                              | -13.2                                                        | SoE: Adjusted mean difference (95% CI): 3.7 (- 0.7, 8.2), ANCOVA+MI: p=0.1004, Original JRT: p=0.0835, Alternative JRT: p=0.0335                                                                                                     | Responses to Day 120 LoQ                  |
| Responder- like analyses                       | Cumulative probability of failure at week 52§                                                                                                            |                      | Tofersen early start (n=72) 35%   | Placebo/D elayed start tofersen (n=36) 47%                   | SoE: cumulative probability of failure for a cut-off of -10 in ALSFRS-R, PV or death, a rate of about 35% and 47% for the failure rates corresponds to early start and placebo delayed start tofersen treatment group, respectively. | Raw Data Pilot Project                    |
| Unfavourable Effects                           | Unfavourable Effects                                                                                                                                     | Unfavourable Effects | Unfavourable Effects              | Unfavourable Effects                                         | Unfavourable Effects                                                                                                                                                                                                                 | Unfavourable Effects                      |
|                                                |                                                                                                                                                          |                      | Tofersen 100 mg                   | Placebo                                                      |                                                                                                                                                                                                                                      |                                           |
| Myelitis                                       | Incidence                                                                                                                                                | (%)                  | ABCL1: 2.7                        | not reported in placebo group of study 101 part C (pool RC2) | Higher incidence than expected; always associated with CSF abnormalities of varying degrees; mononuclear cell infiltrates in the spinal cord and nerve roots in toxicology studies                                                   | (1), (2)                                  |
| Radiculitis                                    | Incidence                                                                                                                                                | (%)                  | ABCL1: 2.7                        | Not reported in pool RC2                                     | (see myelitis)                                                                                                                                                                                                                       | (1), (2)                                  |
| Papilloedem a/ intracranial pressure increased | Incidence                                                                                                                                                | (%)                  | ABCL1: 5.4*                       | Not reported in pool RC2                                     | Higher incidence than expected reported in tofersen patients only; always associated with CSF abnormalities of varying degrees; postulated to be caused by CNS inflammation; no corresponding pre-clinical findings;                 | (1), (3)                                  |
| Aseptic meningitis                             | Incidence                                                                                                                                                | (%)                  | ABCL1: 4.1                        | No reported in pool RC2                                      | Associated with several intrathecally administered Active substances; (high incidence of CSF WBC/protein increased with                                                                                                              | (1), (3)                                  |

<div style=\"page-break-after: always\"></div>

| Effect                                                 | Short Description                            | Unit   | Treatment                        | Control           | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                         | Referenc es   |
|--------------------------------------------------------|----------------------------------------------|--------|----------------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| CSF WBC increased                                      | Incidence of AE Any shift to high            | (%)    | ABCL1: 26.5 ABCL1: 91.2          |                   | Gradual rise in mean CSF WBC (to ~ 4xULN; stabilisation after ~ 500 days)**; increase in CSF WBC in 9- months non-human primate studies;                                                                                                                                                                                                                    | (1), (3)      |
| CSF protein increased                                  | Incidence of AE Any shift to high            | (%)    | RC1: 8.3 ABCL1: 26.5 ABCL1: 80.3 | RC2: 2.8          | Gradual rise in mean CSF protein ( to ~ 2xULN; stabilisation after ~ 500 days)**; increase in CSF protein in 9- months non-human primate studies;                                                                                                                                                                                                           | (1), (3)      |
| Pain (including PT pain, back pain, pain in extremity) | Incidence                                    | (%)    | RC1: 41.7                        | RC2: 22.2         | >5% higher incidence vs. pbo (also for associated PTs each);                                                                                                                                                                                                                                                                                                | (1)           |
| Fatigue                                                | Incidence                                    | (%)    | RC1: 16.7                        | RC2: 5.6          | >5% higher incidence vs. pbo;                                                                                                                                                                                                                                                                                                                               | (1)           |
| Pyrexia                                                | Incidence                                    | (%)    | RC1: 4.2 Pool ABCL1: 18.4        | RC2: 2.8          | Pyrexia within 24 hrs of dosing in 9.1% ABCL1 patients; Positive rechallenge in multiple patients;                                                                                                                                                                                                                                                          | (1), (3)      |
| Arthralgia/M yalgia/ Neuralgia                         | Incidence                                    | (%)    | RC1: 13.9 RC1: 13.9              | RC2: 5.6 RC2: 5.6 | >5% higher incidence vs. pbo;                                                                                                                                                                                                                                                                                                                               | (1)           |
| Immuno- Genicity                                       | Incidence in plasma - ADAs - persistent ADAs | %      | ABCL1: 63.3 51.7                 |                   | No apparent increase in events identified by SMQs (hypersensitivity, anaphylactic reaction, and angioedema) in ADA positive group; No apparent higher risk of serious neuroinflammatory ADRs in ADA positive group;                                                                                                                                         | ISI, (2)      |
| Risk related to the LP                                 |                                              |        |                                  |                   | Known risk of adverse reactions to LP procedures (e.g. headache, procedural pain, post-lumbar puncture syndrome); One propinoibacterium infection of CSF (moderate, non-serious, requiring antibiotic treatment) Risk of serious infection? (bacterial meningitis is known, very infrequent complication of LP)                                             |               |
| ASO class related risks                                |                                              |        |                                  |                   | Thrombocytopenia and coagulation abnormalities, including acute severe thrombocytopenia, have been observed after administration of other subcutaneously or intravenously administered antisense oligonucleotides. Renal toxicity has been observed after administration of other subcutaneously and intravenously administered antisense oligonucleotides. |               |
| Risk of Hydrocephal us                                 |                                              |        |                                  |                   | Reported with intrathecally administered ASOs, i.e. tominersen (secondary to aseptic meningitis), nusinersen                                                                                                                                                                                                                                                |               |

Abbreviations: ASO - antisense oligonucleotide, ADA - antidrug antibody, CSF - cerebrospinal fluid, ICP - intracranial pressure; pbo - placebo; ISI - integrates summary of immunogenicity; LP - lumbar puncture; WBC - white blood cell;

<div style=\"page-break-after: always\"></div>

Notes: (1) Study 101 part C evaluating tofersen 100 mg (Pool RC1) and placebo group (Pool RC2);

(2) Total tofersen 100 mg population from study 101 and 102 (Pool ABCL1, cut-off date: 15 Jul 2022).

(3) Total tofersen 100 mg population from study 101 and 102 (Pool ABCL1, cut-off date: 28 Feb 2023).

*including one patient with 'CSF pressure increased'

** as of 15 Jul 2022

§ cumulative distribution functions of the change from baseline in the ALSFRS-R total score were generated for both treatment groups indicating  the  probability  of  failure  (y  axis)  projected  versus  change  from  baseline  as  cut-off  value  defining  failure,  taking  into consideration treatment discontinuation due to death, progressive disease, AE and other subject withdrawal as failure expressed as a decrease from baseline of -40 being lower than any other change from baseline.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The applicant has developed an ASO, tofersen, to target the increase and accumulation of toxic SOD1 in ALS. The mechanism of action is plausible and relevant and sustained reductions in SOD1 in CSF could be demonstrated with IT administration of tofersen. Indications of subsequent slowing of axonal injury and neurodegeneration derive from non-clinical and clinical pharmacology data by clear reductions in the neurodegeneration biomarker NfL. NfL is being increasingly acknowledged as an important biomarker for neurodegeneration in ALS.

However, the pivotal trial 101 Part C which used appropriate scales, did not confirm efficacy of tofersen in  patients with SOD1 ALS. The observed effects were small and neither statistically significant, nor clinically relevant. Assay sensitivity was low probably for several reasons including study design with a too short placebo-controlled phase of only 28 weeks, suboptimal selection of variables for enrichment purposes, and large heterogeneity of the SOD1 ALS population.

However,  consistent  trends  in  favour  of  tofersen  compared  to  placebo  were  observed  at  week  28. Furthermore, longer term data comparing early vs delayed start tofersen suggest a treatment effect of tofersen. These favourable trends continued up to week 104 in the CL-ITT group. Numerical differences consistently in favour of tofersen across several assessment scales in the context of sustained SOD1 and NfL decreases should be taken into consideration for a potential benefit in SOD1-ALS, which is an ultrarare disease with a high unmet medical need. The data suggest that these reductions in SOD1 protein and consequently NfL result in a delayed effect on function as measured by ALSFRS-R and other clinical outcome  measures,  which  is  considered  biologically  plausible.  The  majority  of  the  SAG-N  experts considered that NFL levels can be used for predicting a clinical effect in patients with ALS at least on a cohort level. However, NfL is not an established biomarker with a predictive value in ALS. Explanations for the lack of strong correlations between changes in NfL and ALSFRS-R across the pairs of timepoints considered in the Raw Data Pilot Project were provided and these are acceptable.

Survival data are too limited to allow robust conclusions.

The main methodological concerns on tofersen efficacy are the lack of confirmatory evidence at week 28 and the difficulty to interpret post hoc analyses of pooled data across study 101 and its OLE study 102.

However,  in  agreement  with  the  applicant's  argumentation,  comparison  of  the  early-start  and placebo/delayed-start groups can be considered reliable. The reasons are: 1) Study 101 Part C treatment assignments remain blinded such that any bias introduced by the open-label nature of the study would apply equally to both arms and 2) baseline disease characteristics were generally balanced between these groups by way of SOD1 variant type, use of riluzole and/or edaravone, and characteristics reflective of the stage of disease (time from symptom onset, total ALSFRS-R score, and percent-predicted SVC). Therefore, any survival benefit in the early-start participants relative to the delayed-start participants is unlikely to be attributed to enrolment of individuals with more slowly progressing disease.

'Responder-like' analysis with a cumulative probability of response also suggest that tofersen may have a disease modifying effect.

<div style=\"page-break-after: always\"></div>

Although  efficacy  of  tofersen  in  SOD1  ALS  has  not  been  proven  in  a  confirmatory  sense  and  that methodological uncertainties related to interpretation of pooled post hoc analyses remain, the clinical results support that there is a favourable trend of effect of tofersen treatment, which eventually could lead to at least a slowing or a stabilisation of the disease and, in some cases, even to an improvement in function. An additional, adequately powered, placebo-controlled study in SOD1 -ALS is not considered operationally feasible, given the ultra-rare nature of the disease (see also discussion on clinical efficacy).

The main safety concern of tofersen relates to the serious neuroinflammatory ADRs of myelitis and radiculitis, papilloedema/increased intracranial pressure and aseptic meningitis, respectively, which were commonly  reported  each  and  all  appear  to  involve  the  central  nervous  system.  These  ADRs  were predominantly associated with typical symptoms of the respective type of adverse reaction but were sometimes asymptomatic and led to study treatment discontinuation or treatment interruption in some cases. Treatment applied for myelitis involved (amongst others) immunomodulatory treatment in single patients,  treatment  of  SAEs  of  papilloedema/ICP  increased  included  long-term  treatment  with acetazolamide in several subjects (which is regularly used for the treatment of papilloedema in clinical practice but not approved), as well as IV methylprednisolone with tofersen dosing visits in one subject. Treatment of aseptic meningitis involved symptomatic NSAIDS and steroids. Associated symptoms of SAEs  of  myelitis/radiculitis  all  resolved  within  days  to  months,  although  one  SAE  of  radiculopathy resolved with sequelae (bilateral foot sensory loss) after 9 months. As of 28 Feb 2023, one of the 4 SAEs relating  to  papilloedema  was  reported  ongoing,  while  accompanying  symptoms  appeared  mainly resolved. Both SAEs of aseptic meningitis resolved.

The serious neuroinflammatory ADRs are considered manageable with standard of care diagnostics and treatment as proposed by the applicant. As there was high variability in manifestations, courses and required action in these SAE cases, and as no discernible risk factors for development of these ADRs were identified, the applicant's position not to make more specific recommendations in the SmPC can in general be agreed. The consequences regarding tofersen treatment (i.e., treatment discontinuation, interruption or continuation) in case of neuro-inflammatory adverse reactions should be decided upon by the treating physician at the individual patient level. All four patients with SAEs of papilloedema/increased ICP had typical symptoms such as headache or visual disturbance, which are clinically  monitorable.  Therefore,  routine  measurement  of  the  opening  pressure  is  not  generally recommended with tofersen treatment. Nevertheless, an evaluation of the fundus of the eye before any LP is considered standard clinical practice.

Myelitis and/or radiculitis and papilloedema are included in the RMP as important identified risks, which is  agreed  as  these  are  clinically  serious  events  with  potentially  serious  outcomes.  Symptoms  of myelitis/radiculitis can imitate or worsen typical ALS motor symptoms but also include sensory disorders and pain.  Papilloedema  is  associated  with  increased  intracranial  pressure  and  usually  presents  with headache and visual disturbance, which can lead to vision loss, if untreated. In line with nusinersen, for which aseptic meningitis is also an identified risk, the applicant considers the risk of aseptic meningitis as not important, mainly because drug-induced meningitis is generally monitorable, transient, and does not lead to permanent sequelae, which could be agreed. Nevertheless, hydrocephalus has been reported with  nusinersen  and  a  case  of  hydrocephalus  secondary  to  a  sterile  meningitis  induced  by  the intrathecally  administered  ASO  tominersen  has  been  reported  in  literature.  Although  no  events  of hydrocephalus were reported in the CDP so far, this risk cannot be excluded for tofersen and should be followed further.

In  addition,  the  safety  profile  of  tofersen  is  mainly  characterised  by  very  common  events  of  pain (reported in 41.7% tofersen vs. 22.2% placebo patients), fatigue (16.7% vs. 5.6%), arthralgia, myalgia, and pyrexia.

<div style=\"page-break-after: always\"></div>

Adverse events known to be frequently associated with lumbar puncture (LP) procedures like headache, procedural pain, and post-lumbar puncture syndrome also occur with tofersen treatment due to the mode of administration. A burden is certainly imposed on the patients during treatment with tofersen due  to  the  repeated  LP  procedures  (with  bi-weekly  intervals  between  the  three  loading  doses  and monthly intervals thereafter), however this was not quantifiable in the clinical studies, as LPs were also administered to placebo subjects.

Based on class effects data, the risks of thrombocytopenia, coagulation abnormalities and of renal toxicity cannot be excluded for tofersen and should be further followed.

## 3.7.2. Balance of benefits and risks

A  mechanistic  basis  for  the  potential  treatment  effect  of  tofersen  exists  and  has  been  described  in sufficient detail. There is target engagement and a strong biological plausibility that the lowering of toxic SOD1 exerts a disease-modifying effect of tofersen, which can be pharmacodynamically measured by an appropriate  neurodegeneration  biomarker,  increasingly  used  in  ALS,  i.e.  NfL.  However,  at  week  28 (placebo-controlled data) there was no statistically significant difference in the change from baseline on the ALSFRS-R between tofersen and placebo regardless of the analyses conducted. However, follow-up data up to at least week 104 showed results for all endpoints consistently favouring tofersen. Survival data and analyses with a cumulative probability of response also suggest that tofersen has the potential to modify the clinical course of SOD1 ALS.

Risks associated with tofersen treatment are not negligible but considered manageable.

The benefit/risk balance of tofersen for the treatment of patients with SOD1-ALS, a serious, relentlessly progressive  and  invariably  fatal  disease,  is  considered  favourable  based  on  the  totality  of  evidence provided.

The CHMP did not consider the available data to be comprehensive to support a full MA as initially requested by the applicant but considered a MAUEC to be the most appropriate approach because of the rarity of the disorder and the improbability that comprehensive data can be generated.

The SOBs suggested by the applicant were accepted. In addition to the open-label long-term extension of Study 102 and ATLAS, the applicant confirmed their indefinite collaboration with two disease registries (ALS/MND-NHC and Precision ALS) and proposed an observational registry-based Study 233AS401 to evaluate the long-term safety of tofersen in patients with SOD1-ALS. The applicant has already provided a draft synopsis of the proposed Study 233AS401, which will also follow patients' disease progression measured by the ALSFRS-R as rate of change over time in total scores. Occurrence of relevant clinical outcomes, including permanent ventilation and feeding tube placement as well as changes in pulmonary function measured by FVC and SVC will also be measured.

## 3.7.3. Additional considerations on the benefit-risk balance

## Patient representatives

The contribution of patient representatives was acknowledged and welcomed by CHMP. The points raised by  one  person  receiving  tofersen  with  'fluctuating  effects'  were  considered  interesting.  This  person received a total of 50 IT injections (placebo and then tofersen). An effect was not immediately detectable, but over some months, the patient noticed a stabilisation of an otherwise relatively rapidly evolving disease. The patient also reported significant improvement in using one of the hands, with the capacity to now move fingers and hold objects, which was no longer the case before. However, the patient noticed the effect to be fluctuating, as the ability of using the hand varies from one injection to the next. It was

<div style=\"page-break-after: always\"></div>

noted by CHMP that, although helpful, the above case corresponds to a single case. Another interesting point raised was the adequacy of the dose (whether 100 mg was the highest tolerated dose or whether testing of a higher dose was limited by a volume too high for intrathecal injection).

In  the  view  of  CHMP,  from  a  clinical  point  of  view,  prescription  of  tofersen  should  be  restricted  to physicians  experienced  in  the  management  of  ALS  and  administered  by,  or  under  the  direction  of, healthcare professionals experienced in performing lumbar punctures. Feedback from patient organisations included the question whether follow up administrations of tofersen could be performed in neurology departments, which are not specialised ALS centres in order to reduce the burden of longdistance travelling for patients if administration is restricted to specialised centres. However, as serious neuroinflammatory  ADRs  have  been  identified  which  partly  overlap  with  ALS  symptoms,  a  cautious approach is indicated.

## Comprehensiveness of the data package

## 1. Quality of evidence (including feasibility considerations)

Despite  the  rarity  of  the  disease,  a  randomised  placebo-controlled  trial  was  performed,  which  is supported. The main study was adequately designed and aimed to demonstrate superiority to placebo in the change from Study 101 Part C baseline ALSFRS-R to week 28. The duration of the study, however, was too short to confirm efficacy of tofersen treatment, also given the inherent heterogeneity in SOD1ALS with more than 200 variants. The study failed to demonstrate a statistically significant effect in the pre-specified primary analysis such that there is no confirmatory proof of efficacy.

## 2. Efficacy: precision of effect size

The precision of the effect size of tofersen on the mean change from baseline in ALSFRS-R compared to placebo could not be adequately estimated. At week 28, the difference was neither statistically significant nor  clinically  compelling.  A  trend  in  favour  of  tofersen  treatment  was  consistently  shown  across  all endpoints. However, the size of the effect depended on what covariates were included in the analysis and what methods for missing data imputation were used. Confidence intervals were generally wide. Overall, the size of the potential treatment effect could not be precisely estimated. The effect size can also not be precisely estimated from the available long-term data due to the uncontrolled nature of these data and the increasing number of missing data over time.

## 3. Efficacy: clinical meaningfulness of the endpoint

Robust reductions from baseline of 60-70% in plasma and CSF NfL at week 28 though to week 104 were statistically significant. Although, neurofilament is not a validated surrogate endpoint for efficacy, it is increasingly recognised as an important biomarker in ALS and may be considered a reasonably likely surrogate endpoint in early established ALS (Benatar M et al. Brain 2023). Also, the majority of the SAGN experts considered that NfL levels can be used for predicting a clinical effect in patients with ALS, at least on a population level.

ALSFR-R is an appropriate and validated scale to assess effects on functional aspects in patients with ALS. At week 28, the difference between tofersen and placebo in the change from baseline in ALSFRS-R total score was small and not statistically significant. Based on the knowledge for ALS in general, a decrease in ALSFRS-R total score is approximately 1.0 point per month and the difference observed with placebo-controlled  trial  was  1.2  in  the  prespecified  mITT  population  and  2.1  points  after  post  hoc analyses with baseline plasma NfL as a covariate. This small slowing of decline in clinical function is not considered clinically meaningful.

Using the data from OLE study, there were consistent trends in favour of tofersen in function, strength and QoL up to week 104.

<div style=\"page-break-after: always\"></div>

## 4. Efficacy: duration of efficacy

The disease has a variable progression. It is not always a linear decline in function, but it is estimated that people living with ALS decline by an average of ~1 point per month. All participants enrolled in Study 101 Part C had a median opportunity for follow-up from baseline of 3.4 years (range: 2.2 to 3.9 years), extending beyond the 2.3-year median survival for SOD1-ALS characterized in the literature. The data suggest stabilisation or even improvement of disease in the long-term. However, the interpretation of the data beyond week 28 is challenging.

## 5. Safety: exposure

There was limited controlled safety exposure. The number of tofersen exposed subjects in the clinical studies (N=166) and, taking the difficulties of causality assessment in uncontrolled ALS studies into consideration, in particular the controlled exposure in the pivotal study (72 tofersen and 36 placebo patients) is rather limited.

## 6. Safety: length of follow-up

As of 28 February 2023, a total of 166 participants from Studies 101 and 102 were exposed to any dose of  tofersen  for  408.82  participant-years.  The  median exposure to tofersen for this group was 131.7 weeks. Participants from Parts A and B of Study 101 who received at least 1 dose of tofersen 100 mg in Study 102 have had the opportunity for a median follow-up of 4.7 years (range: 3.1 to 5.8 years) in Study 102. The length of safety follow-up is considered appropriate.

## 7. Target population vs study population

The study population was SOD1-ALS, which corresponds to 2% of all ALS patients. For inclusion in the study, the SOD1 mutation was confirmed, and the weakness was attributable to ALS. However, over 200 SOD1 mutations associated with ALS have been identified to date, with varying degrees of evidence about pathogenicity, disease progression rate and variable prognosis for survival. The indication is aiming for all SOD1-ALS patients, but it acknowledged that not all SOD mutations can be studied. The study population is considered sufficiently representative of the target population.

## 8. Pharmacological rationale

The antisense oligonucleotide, tofersen, has been developed to target the increase and accumulation of toxic SOD1 in SOD1 ALS. The hybridisation of tofersen to the cognate mRNA results in RNase-H-mediated degradation  of  the  mRNA  for  SOD1,  which  reduces  the  amount  of  SOD1  protein  synthesis  and accumulation. In nonclinical studies, dose-dependent reductions in SOD1 mRNA and SOD1 protein were observed with administration of tofersen in rodents and NHPs [McCampbell 2018]. In the SOD1 G93A mouse model (i.e., with transgenic expression of G93A mutant form of human SOD1 driven by the human SOD1 promoter), tofersen drove reductions in serum pNfH, improvement in motor performance and weight loss, reversal of muscle action potential loss, and prolongation of survival.

Also, in patients with SOD1 ALS, relevant and sustained reductions in SOD1 and NfL were demonstrated. Therefore, indications of slowing of axonal injury and neurodegeneration derive from non-clinical and clinical pharmacology data.

## 9. Natural history/ course of the disease

Data from the literature on SOD1-ALS are limited and are continuously being generated. The applicant has provided some publications available for the natural disease course, as well as for the broader ALS condition.

In conclusion, the data are not considered comprehensive to justify a full MA.

## Marketing authorisation under exceptional circumstances

<div style=\"page-break-after: always\"></div>

As comprehensive data on the product is not available (see above), a marketing authorisation under exceptional circumstances was proposed by the CHMP during the assessment, after having consulted with the applicant.

The CHMP considers that the conditions for a marketing authorisation under exceptional circumstances are fulfilled.

Firstly,  the  CHMP  considered  that,  based on  the  totality  of  the  evidence,  the  benefit-risk  balance  is positive (see above).

Secondly, the CHMP considered that the applicant has sufficiently demonstrated that it is not possible to provide comprehensive data on the efficacy and safety under normal conditions of use, because the applied  for  indication  is  encountered  so  rarely  that  the  applicant  cannot  reasonably  be  expected  to provide  comprehensive  evidence.  In  this  respect,  the  CHMP  is  of  opinion  that,  in  order  to  provide comprehensive  evidence  on  the  efficacy  of  the  medicinal  product  under  normal  conditions  of  use, confirmatory evidence of efficacy would be needed, generated by additional placebo-controlled study(ies) in symptomatic SOD1-ALS patients. However, it is agreed that such studies are not feasible, mainly due to the rarity of the disease (the condition to be treated, i.e. SOD1-ALS is only a small subset of ~2% of ALS and very rare) and due to the impact of tofersen's approval on patient recruitment.

Furthermore, the data that are expected to be feasible to collect (which form the basis of the imposed specific  obligations),  are  unlikely  to  fully  address  the  uncertainties  above  described,  in  particular regarding the medicine's efficacy and thus, to generate a comprehensive dataset. The main reasons are summarised below, and additional details can be found in the section 'Additional data needed in the context of MA under exceptional circumstances', in section '2.6.6 Discussion on clinical efficacy' above:

- The data expected to be generated by study 233AS303 conducted with presymptomatic carriers of selected variants of SOD1 mutation is unlikely to provide confirmatory evidence of efficacy for the following reasons/limitations: (1) the sample size of 28 patients in the placebo-controlled part B is considered too small for a  robust demonstration of a treatment effect; increasing the sample size is not considered feasible (please see also 'Additional efficacy data needed in the context of a MA under exceptional circumstances' in section 2.6.6 of this assessment report); (2) the data collected  from  the  remaining  participants  in  study  303  will  be  uncontrolled,  open-label;  (3) heterogeneity in study population is still  likely  to be  considerable  although  an  enriched  SOD1 population with the aim to increase sensitivity has been selected with a subset of 17 SOD1 variants being pre-specified for inclusion that are thought to have high or complete penetrance, informed by the scientific literature,  genetic  databases, and clinical experience; (4) there is uncertainty about  the  specific  threshold  of  NfL  for  being  prognostic  to  becoming  symptomatic,  with  the trajectory model as the basis for the threshold being exploratory and probably lacking robustness; (5) there is also uncertainty regarding the time between meeting the threshold and developing symptoms. Hence, the design of study 303 is based on many assumptions, especially the one underlying  the  NfL  trajectory  model,  and  the  high  uncertainties  regarding  the  validity  of  the assumptions mean that the study cannot be expected to be conclusive. Finally, the results of study 233AS303  in  an  enriched  population  of  presymptomatic  SOD1-ALS  carriers  cannot  simply  be extrapolated to  the  broad  SOD1-ALS  patient  population  with  symptomatic  disease,  the  target population of the indication.
- Study 233AS102 is expected to provide meaningful data in further characterising the benefits and the risks of tofersen, in particular with regard to long-term safety (primary aim) and also additional information on survival. However, due to the limitations of the design (the study is not a placebocontrolled trial; all patients will be treated (open label)), this would not generate data that would allow to provide confirmatory evidence of clinical benefits of tofersen treatment. Therefore, the results of this study are not expected to lead to a comprehensive confirmatory dataset.

<div style=\"page-break-after: always\"></div>

- Study 233AS401 is an observational registry-based study. While the primary aim is to evaluate the long-term safety of tofersen in patients with SOD1-ALS, some efficacy data are expected to be collected as part of the secondary objective of the study (in particular disease progression measured by the ALSFRS-R, outcomes related with respiratory function and survival). However, as this is an observational, registry-based study lacking randomisation and blinding, it would not likely generate data that would allow to provide confirmatory evidence of efficacy. Therefore, CHMP concluded it is  unlikely  that  the  data  generated  from  this  study  will  provide  a  comprehensive dataset.

The CHMP acknowledged the challenges to be able to generate new data during the post-authorisation phase. It is considered that this evidence generation plan will likely provide meaningful data to further characterise  the  efficacy  and  the  safety  in  addition  to  the  already  available  information.  However, because of the mentioned uncertainties and limitations of the above-described studies, the CHMP is of the opinion that the amount and the quality of the data expected to be generated is unlikely to be considered as comprehensive.

Therefore, recommending a marketing authorisation under exceptional circumstances was considered appropriate.

## 3.8. Conclusions

The  overall  benefit/risk  balance  of  Qalsody  is  positive,  subject  to  the  conditions  stated  in  section 'Recommendations'.

Divergent position(s) are appended to this report.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by majority decision that the benefit-risk balance of Qalsody is favourable in the following indication(s):

The treatment of adults  with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

The  CHMP  therefore  recommends  the  granting  of  the  marketing  authorisation  under  exceptional circumstances subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- Obligation to conduct post-authorisation measures

## Specific Obligation to complete post-authorisation measures for the marketing authorisation under exceptional circumstances.

This being an approval under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measures:

| Description                                                                                                                                                                                                                                                                                                                                    | Due Date                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| To further investigate the long-term efficacy and safety of tofersen in the treatment of SOD1-ALS, the MAH shall submit the final results of the long-term extension study (Study 233AS102).                                                                                                                                                   | by 30 September 2025                |
| -To further investigate if initiation of tofersen in presymptomatic SOD1ALS patients can delay or even prevent emergence of clinically manifested ALS (CMALS), the MAH shall submit the final results of the phase 3 study in patients with clinically presymptomatic SOD1-ALS (Study ATLAS 233AS303).                                         | by 31 December 2028                 |
| To further characterise variant-specific survival, the MAH will provide the final results of the descriptive integrated analyses of disease duration (survival) by SOD1 variant-type in tofersen-treated (Studies 101/102; disease registries) vs. patients untreated with tofersen (disease registries, natural history datasets/literature). | by 30 June 2027                     |
| To further evaluate the long-term safety of tofersen in patients with SOD1-ALS, the MAH shall conduct and submit the results of an observational registry-based study 233AS401 according to the agreed protocol.                                                                                                                               | Annually (with annual reassessment) |
| In order to ensure adequate monitoring of safety and efficacy of tofersen in the treatment of patients with SOD1-ALS, the MAH shall provide yearly updates on any new information concerning the safety and efficacy of tofersen.                                                                                                              | Annually (with annual reassessment) |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that tofersen is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.

Refer to Appendix on new active substance (NAS).

## Divergent position(s)

Divergent position(s) to the majority recommendation are appended to this report.

<div style=\"page-break-after: always\"></div>

DIVERGENT POSITION DATED 22 FEBRUARY 2024

<div style=\"page-break-after: always\"></div>

The undersigned member(s) of the CHMP did not agree with the CHMP's positive opinion recommending the granting of the marketing authorisation under exceptional circumstances of Qalsody (tofersen) for the following indication:

Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

The reasons for the divergent opinion were the following:

The pivotal study 101 was a failed study.  Efficacy results from part C (phase 3 part) of study 101 did not meet the primary study objective.  While a reduction of cerebral spinal fluid SOD1 protein, implying target engagement, and a reduction in plasma neurofilament (NfL) levels, a PD marker of axonal damage, were observed, the study was not appropriately designed to demonstrate clinical efficacy (ALSFRS-R). The change in ALSFRS-R total score over 28 weeks was statistically non-significant (p=0.9689).  The Company had disregarded previous EMA scientific advice that strongly recommended to extend the study duration beyond 28 weeks to allow capturing a meaningful change in clinical outcomes as measured by ALSFRS-R.  NfL´s ability to predict clinical benefit still needs to be demonstrated (unvalidated surrogate endpoint biomarker, for which the link with clinical outcomes was and is not fully established).  The results of the open label long term extension data from study 102, are difficult to interpret.  Post hoc analyses of clinical efficacy in subgroups corrected for baseline NfL levels were not alpha corrected nor did they lead to convincing (not even nominal significant) results.

Overall,  considering  the  lack  of  demonstrated  clinical  benefit  (primary  endpoint),  a  signal  of  target engagement and impact on a marker of axonal damage although its clinical relevance (i.e., surrogacy) still needs to be defined, could be grounds for granting conditional marketing authorisation (CMA) in an area of high unmet need.  The CMA should allow collecting further clinical efficacy (trial or registry) data, in a way suited to definitively conclude on the positive benefit/risk balance of Qalsody.

CHMP Member(s) expressing a divergent opinion:

Peter Mol

Paolo Gasparini

<div style=\"page-break-after: always\"></div>

DIVERGENT POSITION DATED 22 FEBRUARY 2024

<div style=\"page-break-after: always\"></div>

The undersigned member(s) of the CHMP did not agree with the CHMP's positive opinion recommending the granting of the marketing authorisation of Qalsody (tofersen) for the following indication:

Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

The reasons for the divergent opinion were the following:

In the pivotal 101 trial of Qalsody, the change in ALSFRS-R total score over 28 weeks (primary endpoint) was  statistically  non-significant  compared  to  placebo  (p=0.9689).  All  further  inferences  of  potential benefit are liable to bias and are not type 1 error controlled.

Treatment with Qalsody resulted in a reduction of CSF SOD1 protein, implying some level of target engagement. Notably, there are no external data to support what level of reduction might be required for clinical efficacy.

A treatment-dependent reduction in plasma NfL levels was demonstrated. However, the predictive value of NfL as a surrogate in ALS has not been established. The prognostic value of this biomarker may be considered limited, as instantiated by the SAG-N proceedings of Oct 30 th  2023. Notably, the 101 study itself failed to corroborate the predictive value of NfL.

In conclusion, the efficacy of Qalsody in the treatment of patients with ALS associated with a mutation in the superoxide dismutase 1 (SOD1) gene has not been established.

Qalsody may be causative of serious neuroinflammatory reactions, which is not acceptable in the absence of  established  benefit.  Moreover,  treatment  is  burdensome  for  the  patient,  requiring  repeat  lumbar punctures.

The B/R balance of Qalsody is negative.

CHMP Member(s) expressing a divergent opinion:

Kristina Dunder

Maria Concepción Prieto Yerro

Outi Mäki-Ikola

Sol Ruiz